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Antimicrobial therapy is a key factor in our success against
pathogens poised to ravage at risk or infected individuals.
However, we are currently at a watershed point as we face a
growing crisis of antibiotic resistance among diverse pathogens.
One area of intense interest is the impact of the application of
antibiotics for uses other than the treatment of patients and
the association with such utilization with emerging drug resis-
tance. This Research Topic “Low-dose antibiotics: current sta-
tus and outlook for the future” in Frontiers in Microbiology:
Antimicrobials, Resistance, and Chemotherapy details various
aspects of the wide ranging effects of antimicrobial therapy from
areas such as the regulation of host responses to modulation of
bacterial virulence factors to acquisition of antibiotic resistance
genes.
A remarkable and often overlooked fundamental of antibiotics
is that they have biological activities beyondmicrobial killing. The
host modulatory aspects of macrolides, tetracyclines, and beta-
lactams are reviewed by Aminov (2013a) underscoring how, for
example, macrolides such as azithromycin are routinely used for
immunomodulation in patients with chronic pulmonary disease
rather than for an antimicrobial effect. Azithromycin is also used
as a tool by Imperi et al. to detail how non-conventional thinking
about regulating virulence factors or modifying host inflamma-
tory cascades are useful to combating major pathogens such as
Pseudomonas aeruginosa (Imperi et al., 2014). Along this line,
Morita and colleagues carefully detail the pleotropic responses
of P. aeruginosa to sub-therapeutic levels of several antibacterials
and propose avenues to pursue to combat this pathogen, such as
developing efflux pump inhibitors (Morita et al., 2014). In their
article, Charlebois et al. show Clostridium perfringens biofilm
can be regulated by certain antibiotics at low concentrations
(Charlebois et al., 2014). For example, low dose bacitracin signif-
icantly enhances biofilm formation whereas low dose penicillin
reduces biofilm. This work underscores how there are untoward
effects that are not predictable when antimicrobials are admin-
istered at low concentrations. Providing a view on specific host
effector pathways with antimicrobials, Mihu et al. detail how
antifungal medications effectively stimulate host responses via
engagement with toll-like receptors (Mihu et al., 2014). In light
of the expanding difficulties with drug resistance and a lack of
therapeutics to combat them, Clark presents a cogent call for
pursing Ca2+ modulating strategies where by host Ca2+ home-
ostasis is modulated to block pathogens from effectively utilizing
this essential element (Clark, 2013).
An important focus in this Research Topic is the use
of antibiotics as growth enhancers in animals. Sorensen and
colleagues provide key insights into the effects of scientific
evidence on the policy decisions on the use of low-dose antimi-
crobials in livestock for growth promotion and disease preven-
tion particularly delineating how data have led to the European
Union’s ban of low-dose antimicrobials whereas their use in
the United States of America remains in flux (Sorensen et al.,
2014). The bottom line is that there is an urgent need to develop
policy based on well derived data, with this data being eas-
ily and widely available to independent parties. The articles by
Cheng et al. (2014), Chattopadhyay (2014), and Hao et al. (2014)
all further underscore critically important facets of the contin-
ued utilization of antibiotics in animal husbandry. Looft and
colleagues detail their research on how the use of the in-feed
antibiotic carbadox cases dramatic short- and long-term effects
on the composition of porcine gut microbiota (Looft et al., 2014).
Diarra and Malouin specifically describe the impact of antibi-
otics in Canadian poultry production and describe the use of
alternatives, such as bioactive molecules from cranberries, that
should not drive antibiotic resistance (Diarra andMalouin, 2014).
Similarly, Rendondo et al. provide thoughtful insights into the use
of tannins in lieu of antibiotics for improving health in poultry
(Redondo et al., 2014). Lin details that the effective of antibi-
otics as growth promoters is linked to decreased activities of bile
salt hydrolase, which thus makes targeting this enzyme directly
a promising method for removing antibiotics for use as growth
enhancers (Lin, 2014).
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You and Silbergeld critically discuss the effects of
antimicrobials as drivers of resistome expansion (You and
Silbergeld, 2014), a major secondary effect due to environmental
pollution. The effects of antibiotics permeating our environment
are highlighted by Conro and colleagues who present their
findings that the presence of antibiotics in aquatic environments
can induce co-aggregation of bacterial species as an effective
mechanism to combat the effects of the antimicrobials (Corno
et al., 2014), which can lead to extensive resistance through the
transfer of resistance genes among these aggregated bacteria. It is
a small leap for these microbes to then impact humans and other
organisms. Aminov provides the example of the rampant use of
tetracyclines for non-medical purposes as driving the penetration
of tet(X) into pathogenic microbial communities (Aminov,
2013b). Chowdhury and colleagues eloquently discuss the import
of surveillance strategies for critically elucidating the emergence
of drug resistant pathogens in the context of low-dose antibiotic
use in animal husbandry (Roy Chowdhury et al., 2014).
In summary, the articles within this Research Topic serve as
a “call to arms” for scientists, policy makers and the public to
be increasingly vigilant about the use of antimicrobials, partic-
ularly in low-dose or where they can become widespread in the
environment, in order to maintain our capacity to effectively care
for individuals with infectious diseases. The articles also provide
new concepts for approaches for the development of antimicro-
bials as well as for novel growth enhancers for the use in animal
husbandry.
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Biological functions of antibiotics are not limited to killing. The most likely function of
antibiotics in natural microbial ecosystems is signaling. Does this signaling function of
antibiotics also extend to the eukaryotic – in particular mammalian – cells? In this review,
the host modulating properties of three classes of antibiotics (macrolides, tetracyclines,
and β-lactams) will be brieﬂy discussed. Antibiotics can be effective in treatment of a broad
spectrum of diseases and pathological conditions other than those of infectious etiology
and, in this capacity, may ﬁnd widespread applications beyond the intended antimicrobial
use. This use, however, should not compromise the primary function antibiotics are used
for. The biological background for this inter-kingdom signaling is also discussed.
Keywords: tetracyclines, macrolides, β-lactam, inflammation, respiratory, cardiovascular, neuroprotection, cancer
INTRODUCTION
We are all familiar with the use of antibiotics for treatment of
infectious diseases. But antibiotics do not only kill bacteria, their
original role possibly involved signaling functions (Davies et al.,
2006; Linares et al., 2006; Yim et al., 2006, 2007; Martínez, 2008;
Aminov, 2009; Romero et al., 2011). These functions, usually per-
formed at lower concentrations, are different from those leading to
cell death, and they are realized through different sets of molecular
targets in the cell. While many aspects of this communication in
the microbial world remain elusive, there is a large body of infor-
mation regarding the signaling effects of low-dose antibiotics on
humans and animals beyond the intended antimicrobial activities.
Thus the intention of this article is to undertake an interdisci-
plinary coverage of and familiarize biologists with this aspect of
non-antimicrobial antibiotic use in clinical research and practice.
The results covered in this review have been collected in various
animal models, tissue cultures, and pre-clinical and clinical tri-
als, with little or no involvement of microbiology, and, therefore,
might have escaped the attention of microbiologists. I believe this
interdisciplinary coverage is highly important to close the gap in
non-antimicrobial use of antimicrobials for a number of reasons.
First of all, it is the speciﬁcs of this type of therapy, with the use
of low-dose antibiotics for very extended periods of time mea-
sured in weeks, months, and even years. Second, while in clinical
microbiology a great deal of attention is paid to the appearance of
antibiotic resistance as a side effect of antibiotic therapy, this aspect
has had a relatively low priority and has been largely overlooked in
the low-dose long-term antibiotic treatment trials. Another aspect
that may need more careful consideration in this type of therapy
is the role of commensal microbiota, which is also an important
player in human metabolism and physiology. Antibiotics act not
only on the targets in the human body but also on the microbiota,
which is the integral part of human metabolism and physiology.
And as we know, the role of commensal microbiota in human
health and disease is immense, affecting almost every aspect of it.
Thus the antibiotic effects have to be evaluated from both sides
of their activities, including the direct interaction of antibiotics
with the host cells as well as indirect, through the modulation of
microbiota and, correspondingly, microbial metabolites, macro-
molecules, andother biologically active components of microbiota
that affect the host. And ﬁnally, it is intriguing to recognize how
many molecular targets for antibiotics are in the human body. Is it
by chance that they have such pleiotropic properties that are affect-
ing almost every organ or system in the human body? Only three
classes of antibiotics are covered in this review because of space
restraints. These are the macrolides, tetracyclines, and β-lactams.
For the same reason, only few most important examples for each
antibiotic class and for each group of diseases are given. These are
followed by a discussion of various implications of the effects and
consequences of the non-antimicrobial antibiotic use.
MACROLIDES
There are many examples of antibiotic signaling effects on the
host beyond the intended antimicrobial activity. The use of
macrolides for treatment of non-infectious diseases has the ear-
liest history among other antibiotics. A considerable amount of
information regarding the therapeutic potential of macrolides for
non-antimicrobial use has been collected beginning from the late
1980s. Since then, a great number of animal experiments have
been performed, many representatives of this class of antibiotics
have gone through clinical trials, and a number of drugs in this
group have been approved and are currently commonly used in
clinical practice for non-antimicrobial purposes.
The use of macrolides has been especially successful in theman-
agement of various chronic respiratory diseases not only in the role
of antimicrobial agents but also due to their anti-inﬂammatory
and pro-kinetic properties. The positive effect of long-term low-
dose administration of erythromycin to patients with diffuse pan-
bronchiolitis was demonstrated by Japanese researchersmore than
two decades ago, thus suggesting other than antimicrobial nature
of erythromycin action (Kudoh et al., 1987; Nagai et al., 1991).
From this point, the use of macrolides for non-antimicrobial
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purposes has become one of the mainstream choices for treatment
of chronic respiratory diseases.
In cystic ﬁbrosis (CF), the main bacterium associated with
the pulmonary disease is Pseudomonas aeruginosa, which pro-
duces bioﬁlms resistant to antibiotic treatment within the airways
(Singh et al., 2000). Although P. aeruginosa is naturally resistant
to macrolides, these antibiotics, even at subinhibitory concentra-
tions, can suppress quorum sensing necessary for bioﬁlm forma-
tion (Tateda et al., 2007). This mechanism possibly contributes
to the heightened sensitivity of non-susceptible P. aeruginosa
toward a variety of anti-pseudomonal agents in bioﬁlms when
exposed to macrolides at subinhibitory concentrations (Lutz et al.,
2012). In addition, low-dose macrolides display immunomod-
ulatory properties inﬂuencing cytokine production and altering
polymorphonuclear cell functions (Schultz, 2004). This prevents
excessive uncontrolled inﬂammation and associated tissue dam-
age. Another beneﬁt of the macrolide use in the management of
CF is the reduced chronic airway hypersecretion (Tamaoki et al.,
1995).
Treatment of other respiratory diseases such as asthma may
beneﬁt from the dual action of macrolides because asthma is a
result of interaction of genetic and environmental factors. The
presence of Mycoplasma pneumoniae and Chlamydophila pneu-
moniae in asthmatics best identiﬁes the macrolide responsive
phenotype because of the antimicrobial and anti-inﬂammatory
properties of macrolides covering the infection and genetic
predisposition continuum (Good et al., 2012).
Chronic obstructive pulmonary disease (COPD) remains one
of the important causes of morbidity, mortality, and health-care
costs worldwide (Mannino and Buist, 2007). Although smoking
is the most important risk factor for the disease, it also has a
substantial genetic component (Wain et al., 2012). Pathogenesis in
COPD is largely driven by dysregulated responses of the innate and
adaptive immune systems to the environmental cues leading to an
exaggerated inﬂammatory response, which results in permanent
inﬂammation, tissue damage, and lung function decline (Hol-
loway and Donnelly, 2013). A well-designed, randomized, 1-year
trial of erythromycin, at a dose of 250 mg twice daily, has found
a signiﬁcant reduction in COPD exacerbations compared to the
placebo group (Seemungal et al., 2008). Long-termadministration
of azithromycin by outpatients with severe COPD has appeared to
be safe and effective, with reduced exacerbations, hospitalizations,
and improved quality of life (Blasi et al., 2010). Another trial with
a daily azithromycin for 1 year for prevention of exacerbations
of COPD has demonstrated decreased frequency of exacerbations
and improved quality of life but has caused hearing decrements
in a small percentage of subjects (Albert et al., 2011). A recent
review of controlled clinical studies focusing on the prevention of
COPD exacerbations with long-term azithromycin, erythromycin,
or clarithromycin treatment suggests that it is effective, safe, and
cost-efﬁcient (Simoens et al., 2013). Other chronic respiratory dis-
eases may also be treated by macrolides, but better designed trials
are necessary to conﬁrm their efﬁcacy (Suresh Babu et al., 2013).
Novel effects of macrolides on cardiovascular diseases have
been discovered recently. In animal models, clarithromycin has
suppressed the development of myocarditis, cardiac rejection, and
myocardial ischemia (Nakajima et al., 2010; Suzuki et al., 2012).
The positive effect of clarithromycin in cardiovascular diseases
may be due to the alteration of inﬂammatory factors and matrix
metalloproteinases (MMPs). MMPs as a part of the extracellular
matrix participate in a number of normal physiological processes,
which contribute to tissue structure, function, and remodeling,
including the myocardium (Spinale et al., 2013). Both the expres-
sion and activity of MMPs are regulated by the tissue inhibitors
of matrix metalloproteinases (TIMPs), and the MMPs/TIMPs
balance is crucial for the normal maintenance of myocardial inter-
stitial homeostasis. Misbalance and the resulting involvement of
MMPs in disease, however, have been shown for a number of
pathologies spanning from cancer to cardiovascular diseases and
to neurodegeneration (Sbardella et al., 2012). The protective effect
of clarithromycin in the case of autoimmune myocarditis appears
to be implemented through the inhibition of the MMP-9 activity
(Hishikari et al., 2010). In the long run, however, a short-term clar-
ithromycin administration in patients with coronary heart disease
for clearance of suspected infections results in increased risk of
mortality (Gluud et al., 2008).
Immunosuppressive activities of macrolides have been known
for almost four decades now. The ﬁrst macrolide with this activ-
ity, rapamycin (also called sirolimus), was discovered by Brazilian
researchers during a screening program for antifungal compounds
produced by soil bacteria (Vézina et al., 1975). But its use as an
antifungal antibiotic has been abandoned due to potent immuno-
suppressive and antiproliferative activities. Its antiproliferative
action is realized through the formation of an active complex with
its cytosolic receptor protein, FKBP12, and targeting of a puta-
tive lipid kinase termed target of rapamycin (TOR; Brown et al.,
1994; Sabers et al., 1995; Wiederrecht et al., 1995). The loss of
TOR function leads to the inhibition of G1- to S-phase progres-
sion in various sensitive cells. The immunosuppressive activity
of rapamycin is also realized via the same protein kinase inhibi-
tion pathway affecting cell-cycle proliferation of lymphoid cells
(Abraham, 1998).
The TOR complexes regulate cell growth and metabolism in
response to environmental and intracellular cues and are com-
prised of two distinct multiprotein complexes: TOR complex 1
(TORC1), which is sensitive to rapamycin, and TORC2, which
is not (Wullschleger et al., 2006). Dysregulation of these com-
plexes is associated with various pathologies, including cancer,
cardiovascular diseases, autoimmunity, metabolic disorders, and
neurodegenerative diseases. Thus rapamycin and its derivatives
can be used for treatment of a variety of diseases (Cruzado, 2008).
It is also potentially useful for treatment of substance abuse con-
ditions, alcohol abuse in particular, since inhibition of TORC1
by rapamycin disrupts alcohol-associated memory reconsolida-
tion, leading to a long-lasting suppression of relapse (Barak et al.,
2013). Currently it is approved for prevention of transplant rejec-
tion, and its latest derivative, everolimus, is widely used to prevent
the rejectionof heart, lung, kidney, or liver allografts (Gurk-Turner
et al., 2012). Since TOR complexes are evolutionary conserved
and involved in very fundamental biological processes in the
cell, pharmacological inhibition of TOR signaling by rapamycin
increases the lifespan of yeasts and higher eukaryotes (Powers
et al., 2006). The use of rapamycin in humans as an anti-aging
agent is uncertain because of side effects; this use will require the
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development of safer derivatives, termed rapalogs (Lamming et al.,
2013).
Another macrolide compound with a potent immunosuppres-
sive activity was discovered in 1984 during the screening pro-
gram of Fujisawa Pharmaceutical Company aimed at compounds
that reduce the risk of transplant rejection (Kino et al., 1987).
This 23-membered macrolide lactone, isolated from Streptomyces
tsukubaensis and called FK-506 (later also called tacrolimus or
fujimycin), was initially approved in 1994 for the prophylaxis of
liver transplant rejection, and since then the range of its use has
expanded dramatically. In fact, it is considered as a cornerstone
of modern immunosuppressive therapy and is used to treat allo-
graft rejections that are resistant to other immunosuppressants
(Rath, 2013). The effect of this class of macrolide immunosup-
pressants is also based on targeting the evolutionary conserved
signal transduction pathways but via a mechanism other than that
of rapamycin. In particular, FK506/FKBP complex inhibits the
cytosolic phosphatase calcineurin, a key enzyme regulating the
translocation of cytosolic components of various nuclear factors
into the nucleus. Thus the blocked translocation of the cytosolic
component of the nuclear factor of activated T cells (NF-AT) leads
to its inability to activate a number of genes necessary for the pro-
liferation of T cell such as IL-2 as well as for B cell help such as
IL-4 (Ho et al., 1996).
Besides the extensive use in prophylaxis of transplant rejection,
tacrolimus has demonstrated its efﬁcacy and safety for a number
of other inﬂammatory conditions. It has been successfully used
in patients with inﬂammatory bowel disease, in particular for the
treatment of severe cases (Baumgart et al., 2006) and for the induc-
tion of remission in refractory disease (Baumgart et al., 2008). In
dermatology, the success of this drug is due to its topical effective-
nesswhile cyclosporine, a drugwith a similarmechanismof action,
is topically non-responsive (Mrowietz, 1992). In general, many
macrolide immunosuppressants, due to their chemical structure,
are highly efﬁcient in the topical form and are used extensively to
treat many dermatological disorders (Mrowietz, 1999). They lack
the skin-thinning side effect of corticosteroids and, therefore, can
be used for extended periods of time and in areas with thin skin.
Macrolides are among the safest antibiotics in clinical use, with
very few severe side effects (Periti et al., 1993). The most fre-
quent manifestation is gastrointestinal disturbance occurring in
15–20% of patients on erythromycins and in 5% or fewer patients
treatedwithnovelmacrolides. Transient deafness and allergic reac-
tions are highly unusual and usually associated with the older
macrolides. Clarithromycin and erythromycin may potentiate
calcium-channel blockers by inhibiting cytochrome P450 isoen-
zyme 3A4 (Wright et al., 2011). Therefore, the concomitant use
of calcium-channel blockers and these antibiotics may result in
signiﬁcant hypotension and shock (Wright et al., 2011; Henne-
man and Thornby, 2012). Although the risk is small, it can greater
among the elderly and patients with multiple comorbidities.
In a subset of patients the use of tacrolimus for themanagement
of hematopoietic allogeneic stem cell or solid organ transplanta-
tion is associated with a rare complication, posterior reversible
encephalopathy syndrome (PRES; Wong et al., 2003; Bartynski
et al., 2008; Hodnett et al., 2009; Wu et al., 2010; Hammerstrom
et al., 2013). The main manifestations of PRES include altered
mental status, seizures, visual abnormalities, and high blood
pressure. While it is not clear how to manage the central ner-
vous system (CNS)-related side effects, PRES associated with high
blood pressure should include adequate blood pressure control
(Hammerstrom et al., 2013).
Substantial progress has been made in identiﬁcation of mam-
malian cell targets of macrolides. As discussed above, there is an
extensive variety of targets for macrolides in the human body, and
the list continues to grow. For instance, the immunomodulatory
activities of macrolides can be mediated via the inhibition of pro-
duction of many proinﬂammatory cytokines, the formation of
leukotriene B4 (a neutrophils attractant), the formation of adhe-
sion molecules necessary for neutrophil migration, and the release
of superoxide anion by neutrophils (Tamaoki et al., 2004). The
ketolide antibiotic telithromycin exerts powerful immunomodu-
latory and anti-inﬂammatory effects through NF-κB inhibition
and enhancement of inﬂammatory cell apoptosis (Leiva et al.,
2008a,b).
The macrolide antibiotic-binding human p8 protein has been
cloned and identiﬁed using the phage display library approach
(Morimura et al., 2008). This is a nuclear DNA-binding protein,
which is strongly activated in response to several stresses, and, on
the basis of functional similarity to HMG-I/Y-like proteins, it has
been suggested that p8may be involved in transcription regulation
(Encinar et al., 2001; Hoffmeister et al., 2002). It plays an impor-
tant role in such a basic biological process as ontogeny and hence is
involved in a variety of developmental processes, such as pancreatic
development in rats (Mallo et al., 1997), temporal expressionof the
beta subunit of luteinizing hormone (LHB) during gonadotroph
development in mice (Million Passe et al., 2008), and mediation
of gene expression in the diapause-destined crustacean Artemia
franciscana (Qiu and MacRae, 2007).
In pathologies, the p8 protein is crucial for tumor development
(Vasseur et al., 2002), and it is also involved in stress responses
imposed by inﬂammation, tissue damage, and remodeling. Thus
the list of pathologies includes diseases with an inﬂammatory
component, acute pancreatitis for instance (Mallo et al., 1997). In
cardiac pathology, p8 is broadly involved in cellular events leading
to cardiomyocyte hypertrophy and cardiac ﬁbroblast MMPs pro-
duction, both of which take place in heart failure (Goruppi et al.,
2007). Since clarithromycin, erythromycin, and azithromycin
inhibit the binding of recombinant p8 protein to double-stranded
DNA (Morimura et al., 2008), the anti-inﬂammatory effect of
macrolides discussed above may be explained, at least in part,
by the down-regulation of transcription of genes involved in the
proinﬂammatorynetwork. Interestingly, the same inhibitory effect
has been observed with a structurally unrelated antifungal antibi-
otic dechlorogriseofulvin (Morimura et al., 2008), suggesting a
potential overlap in recognition of structurally different antibiotic
ligands by a single human molecular target.
The important difference between the antibiotic therapy of
“classical” infectious diseases and chronic conditions such as cys-
tic CF is the duration of antibiotic treatment. With the exception
of Mycobacterium tuberculosis and few other difﬁcult-to-eradicate
infections, the antibiotic treatment period for infectious diseases
is relatively short, while the maintenance therapy for chronic
conditions is a long-term and perhaps life-long endeavor. One
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of the consequences of the maintenance therapy might be the
selection for, and maintenance of, antibiotic resistance genes.
In recent clinical trials evaluating the efﬁciency of the long-
term azithromycin and erythromycin maintenance treatments
in patients with non-CF bronchiectasis, the level of macrolide
resistance signiﬁcantly increased, despite the subinhibitory con-
centrations used (Altenburg et al., 2013; Serisier et al., 2013).
Due to the importance of other than antibacterial activities of
macrolides as well as to reduce the possibility of antibiotic selec-
tion for resistance, efforts have been made to design macrolide
molecules with better anti-inﬂammatory activities (Kobayashi
et al., 2013). Another approach to lessen the resistance burden
is the design of macrolides that have their antimicrobial activ-
ities completely abolished but have other activities retained. It
appears that the antimicrobial and anti-inﬂammatory activities of
macrolides are independent and can be separated, thus opening
the possibility of designing macrolide-based anti-inﬂammatory
drugs lacking antimicrobial activities (Bosnar et al., 2012).
Thus the recent macrolide development efforts have bifurcated
into two directions that are focused on designing and modiﬁ-
cation of macrolides better suited either for the antimicrobial
or non-antimicrobial use. Historically, antibiotics (macrolides
included), as their name implies, have been selected primarily
for their antimicrobial activities, while other activities such as
anti-inﬂammatory went unnoticed for a long time. In a recent
non-antimicrobial antibiotic development, a novel macrolide,
solithromycin, has displayed the capability to inhibit NF-κB and
demonstrated better anti-inﬂammatory activities in vitro com-
pared to more conventional macrolides used in the clinic such as
erythromycin, clarithromycin, azithromycin, and telithromycin
(Kobayashi et al., 2013). A better anti-inﬂammatory proﬁle of
this macrolide makes it a good candidate for the manage-
ment of chronic respiratory diseases. Another macrolide with
a signiﬁcantly diminished antibiotic activity, 2′-desoxy-9-(S)-
erythromycylamine, prevents neutrophil elastase-induced mucus
stasis and dehydration and, therefore, may be used for the
management of CF and COPD theoretically without affect-
ing antibiotic resistance proﬁle (Tarran et al., 2013). Synthetic
mimetics of actin-binding macrolides may provide a range of
designer compounds to treat actin-associated diseases (Perrins
et al., 2008). On the other hand, there are continuous efforts
to modify the existing macrolides to contain pathogens that
are becoming resistant to older macrolides. Recent develop-
ments, for example, have been based on the use of azalide
scaffold (Ištuk et al., 2011; Sugimoto et al., 2012), which was
originally implemented in 9-dihydro-9-deoxo-9a-methyl-9a-aza-
9a-homoerythromycin A (azithromycin), the antibiotic with
outstanding pharmacokinetic properties (Amsden, 2001; Mutak,
2007).
TETRACYCLINES
Tetracycline family of antibiotics is one of the best-studied exam-
ples of non-antimicrobial effects of antibiotics on the host.
Tetracyclines possess multiple and potent biological activities, and
minocycline, the best exemplary compound of this class, displays
anti-inﬂammatory, neuroprotective, anti-proteolytic, and anti-
apoptotic properties as well as inhibits angiogenesis andmetastatic
growth (Garrido-Mesa et al., 2013). In addition, it displays antiox-
idant activity, inhibits several enzyme activities, and regulates
immune cell activation and proliferation.
Similar to the macrolides discussed above, tetracyclines are
able to inhibit MMPs; this discovery was actually made in 1983,
i.e., before the discovery of the corresponding activity among
macrolides (Golub et al., 1983). As mentioned before, MMPs
are involved in a number of pathologies, including metastatic
growth, cardiovascular diseases, neurodegeneration, and a variety
of inﬂammatory conditions (Sbardella et al., 2012). Thus the inhi-
bition of MMPs may be a valuable option in treatment of a broad
spectrum of diseases. Interestingly, the inhibitory effect on MMPs
is realized through several targets/mechanisms ranging from indi-
rect effects of regulatorynetwork todown-regulationof expression
and to direct interference with enzymatic activity. These activi-
ties can include binding divalent cations such as Ca2+ and Zn2+,
inhibition of neutrophil migration and degranulation, and sup-
pression of synthesis of oxygen radicals (Gabler and Creamer,
1991). Administration of minocycline to diabetic rats, for exam-
ple, normalized the activity of four MMPs, while in in vitro assays
minocycline inhibited only collagenase and gelatinase activities,
with no inhibition of elastase and β-glucuronidase (Chang et al.,
1996). The inhibitory effect of tetracycline on stromelysin is medi-
ated via transcriptional inhibition involving sequences upstream
of the activating protein complex 1 binding site (Jonat et al., 1996).
But doxycycline, for example, down-regulates MMP-8 induc-
tion at both the mRNA and protein levels (Hanemaaijer et al.,
1997). It also disrupts the conformation of the hemopexin-like
domain of MMP-13 and the catalytic domain of MMP-8 (Smith
et al., 1999).
Presently the only MMPs-targeting tetracycline that has been
approved by the US Food and Drug Administration (FDA) and
other national regulatory agencies in Canada and Europe is the
low-dose formulation of doxycycline for the adjunctive treatment
of chronic periodontal disease (Gu et al., 2012). Other condi-
tions for potential application of low-dose tetracyclines to inhibit
the pathological effects of MMPs are: (i) cardiovascular diseases
such as coronary artery disease (Payne et al., 2011), hypertension
(Castro et al., 2011), atherosclerosis (Gu et al., 2011), and abdom-
inal aortic aneurysm (Abdul-Hussien et al., 2009); (ii) pulmonary
diseases such as acute respiratory distress syndrome (ARDS) for
which there is no approved medication (Roy et al., 2011), and
COPD (Dalvi et al., 2011); (iii)metastatic cancers (Lokeshwar,
2011; Richards et al., 2011); and (iv) systemic bone loss conditions
(Payne and Golub, 2011).
In many studies tetracyclines have demonstrated excellent
anti-inﬂammatory activities achieved through the inhibition of
chemotaxis, granuloma formation, nitric oxide production, and
protease activities (Weinberg, 2005;Webster and Del Rosso, 2007).
Positive effects of minocycline have been observed in animal mod-
els of rheumatoid arthritis (RA; Sewell et al., 1996), and this effect
has been conﬁrmed in several clinical trials as well (Greenwald,
2011). Tetracycline treatment of RA, however, is not widespread
because of the almost universal use of methotrexate. Based on
the results of successful clinical trials, subinhibitory concentra-
tions of doxycycline and minocycline were approved by the FDA
for the treatment of skin conditions and infections that have a
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substantial inﬂammatory component (Del Rosso, 2007). Another
FDA approval, after successful clinical trials, has been obtained
for the long-term management of chronic periodontitis by suban-
timicrobial doses of doxycycline (SDD) (Caton and Ryan, 2011).
This host modulatory therapy is directed against excessive MMPs
activities that are implicated in degradation of connective tissue
collagen surrounding and supporting the teeth. This effect may
have broader implications for other bone loss conditions (Payne
and Golub, 2011).
Following the ﬁrst reports on the neuroprotective effects of
minocycline in animal models of cerebral ischemic injury (Yrjan-
heikki et al., 1998, 1999), doxycycline was proposed as a candidate
for clinical trials of acute neurologic injury (Elewa et al., 2006).
Among other tetracyclines, the neuroprotective potential of the
second-generation antibiotic, minocycline, is remarkable. Its
effect has been conﬁrmed in experimental models of ischaemia,
traumatic brain injury and neuropathic pain, and of several neu-
rodegenerative conditions including Parkinson’s disease (Wu et al.,
2002), Huntington’s disease (Chen et al., 2000; Wang et al., 2003),
Alzheimer’s disease (Choi et al., 2007), amyotrophic lateral scle-
rosis (ALS; Tikka et al., 2002; Zhu et al., 2002), multiple sclerosis
(MS; Metz et al., 2004; Zabad et al., 2007), and spinal cord injury
(Marchand et al., 2009).
Presently, the results of several clinical trials aimed at the esti-
mation of neuroprotective effects of minocycline are available,
although with rather discouraging outcomes compared to ani-
mal studies. A phase III randomized trial of minocycline in ALS
patients actually demonstrated a harmful effect of minocycline
(Gordon et al., 2007). A futility study of minocycline in Hunt-
ington’s disease precluded proceeding with a phase III clinical
trial (Schwarz et al., 2010). A prospective study with a cohort of
multiple-system-atrophy Parkinson-type patients failed to show
a clinical effect of minocycline on severity of symptoms (Dodel
et al., 2010). Although the results of a phase II placebo-controlled
randomized trial of minocycline in acute spinal cord injury did
not establish efﬁcacy, several outcome measures had a tendency
toward improvement (Casha et al., 2012).
Treatment of a psychiatric illness relies on a combination of
psychological and biological approaches. The latter have been for
a long time focused on pharmacological interventions targeting
mainly the neurotransmitter systems, but there is a growing body
of evidence that these conditions are system-wide and include
oxidative stress, inﬂammation, changes in glutamatergic path-
ways and neurotrophins as well (Dean et al., 2012). Minocycline is
known as a modulator of glutamate-induced excitotoxicity and,
in addition, it possesses antioxidative, anti-inﬂammatory, and
neuroprotective properties. Pleiotropic properties of minocycline
targetingmultiple proteins and cellular processes implicated in the
pathoetiology of mood disorders make it a suitable candidate for
treatment of depression (Soczynska et al., 2012). It may be a valu-
able adjunctive therapeutic agent to antipsychotic medication in
patients with schizophrenia as well (Miyaoka, 2008). In a clinical
ad-on trial, minocycline treatment of early-phase schizophrenia
patients improved negative symptoms and cognitive functions
(Levkovitz et al., 2010). A recent preliminary open-label study
has suggested that minocycline, in combination with antidepres-
sants, is effective and well-tolerated in the treatment of unipolar
psychotic depression (Miyaoka et al., 2012). In a mouse model of
Fragile X syndrome (FXS), an inherited disorder with intellectual
disability and behavior at the extreme of the autistic spectrum,
minocycline showed potential to treat mental retardation and
associated behavior (Bilousova et al., 2009; Rotschafer et al., 2012).
Recent FXS clinical trials have indicated that minocycline may be
effective in treating human patients as well (Siller and Broadie,
2012). In a number of cognitive impairment models minocycline
treatment demonstrated promising results (Jin et al., 2013; Kong
et al., 2013; Li et al., 2013). In a recent clinical trial evaluating the
effect of minocycline on HIV-associated cognitive impairment,
however, no signiﬁcant improvement in cognitive functions has
been found (Nakasujja et al., 2013).
Microglia are glial cells, the only resident immune cells in the
CNS that respond to infections and brain injury and are actively
involved in brain development and function as well as in neurode-
generative disease (Miyamoto et al., 2013). In the normal brain,
these cells contribute to neuronal proliferation and differentiation,
pruning of dying neurons, synaptic remodeling, and clearance
of debris and aberrant proteins (Harry, 2013). Analogous to the
activities of immune cells, activated microglia release cytokines,
chemokines, nitric oxide, and reactive oxygen species (Harry,
2013). Dysfunctions in the homeostatic role of microglia, how-
ever, can affect neuronal functions such as cognition, personality,
and information processing (Miyamoto et al., 2013).
Minocycline is known as the only drug capable of inhibit-
ing the activation and proliferation of microglia (Tikka et al.,
2001). In pathologies such as global brain ischemia, suppres-
sion of microglial activation by tetracyclines has a neuroprotective
effect with a much better survival rate of CA1 pyramidal neu-
rons (Yrjanheikki et al., 1998). The neuroprotective effects of
tetracyclines in brain hypoxia are mainly due to the selective
down-regulation of proinﬂammatory cytokines and compounds
in the microglia (Lai and Todd, 2006). Overly rapid correction
of chronic hyponatremia can lead to a severe demyelination dis-
ease, and the inhibition of microglial activation by minocycline
prevents neurologic impairment and improves the survival rate
(Suzuki et al., 2010). Minocycline also protects against microglial
activation, neuronal death, and cognitive impairment caused by
severe hypoglycemia in diabetic patients (Won et al., 2012). In the
normal brain, the corresponding activity of minocycline modu-
lates human social behavior leading to a more situation-oriented
decision-making, possibly by suppressing the effects of personal-
ity traits (Kato et al., 2012). Minocycline also signiﬁcantly reduces
the risky trusting behavior in human economic exchange (Watabe
et al., 2013).
This, not exhaustive but still impressive, list of conditions
and diseases that can be treated with tetracyclines suggests the
pleiotropic effects and the presence of multiple targets and
receptors for which tetracyclines are ligands. In addition to
the discussed above, the known anti-inﬂammatory activities of
minocycline are achieved through the inhibition of expression of
nitric oxide synthases (Amin et al., 1996), suppression of B and T
cell function (Sewell et al., 1996), reduction of cyclooxygenase-2
expression and prostaglandin E(2) production (Yrjanheikki et al.,
1999), and up-regulation of IL-10 (Ledeboer et al., 2005). Anti-
apoptotic effects are believed to be due to inhibition of activity
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of caspase-1 and caspase-3 (Chen et al., 2000), inhibition of the
phosphorylationof p38mitogen-activatedprotein kinase (MAPK)
(Du et al., 2001; Joks and Durkin, 2011), and inhibition of mito-
chondrial permeability-transition-mediated cytochrome c release
(Zhu et al., 2002). By virtue of itsmolecular structure,minocycline
is also an effective antioxidant with a radical scavenging potency
similar to vitamin E thus providing excellent protection against
oxidative stress (Kraus et al., 2005).
Tetracyclines are generally well-tolerated but under particu-
lar environmental conditions and in a subset of certain age and
disease cohorts may provoke adverse reactions. One of the most
known and well-studied side effects of tetracycline administration
are cutaneous adverse events due to the increased photosensitivity
of the skin, typically to the UVA spectrum of light (Drucker and
Rosen, 2011; Glatz and Hofbauer, 2012). Clinically these effects
can be divided into two groups, phototoxic and photoallergic
reactions. The former is due to the formation of reactive oxygen
species, with the impairment of many cellular macromolecules,
thus leading to inﬂammation and apoptosis, while the latter is
a type IV hypersensitivity reaction resembling eczema. The pre-
ventive measures include avoiding direct sunlight and the use of
sunscreens. The culprit drug can be withdrawn if the reactions
persist (Glatz and Hofbauer, 2012).
Tetracyclines are generally not recommended for pediatric
patients because these compounds chelate calcium ions, which are
incorporated into teeth, resulting in discoloration of both the pri-
mary and permanent dentitions (Sánchez et al., 2004). There are
many case reports on the association of tooth, bone, nail, and scle-
ral pigmentation following minocycline administration in adults
as well but no systematic studies have been done in this area.
Many inﬂammatory diseases such as Alzheimer’s, Parkinson’s,
Huntington’s, familial Mediterranean fever, and others tend to
display a substantial protein deposition bias, where a normally
soluble protein is deposited in an insoluble amyloid form (Carrell
and Lomas, 1997). The deposits interfere with cellular functions,
eventually leading to the cell death (Thomas et al., 1995). Tetracy-
clines are known to inhibit the deposition process (Sirangelo and
Irace, 2010) but at the cost, by keeping the amyloid protein in a
pre-ﬁbrillar, highly cytotoxic state (Malmo et al., 2006). So care
should be exercised to avoid the toxic effects of oligomeric species
during tetracycline therapy.
In adevelopment analogous to the search for non-antimicrobial
macrolides there have been a series of works aimed at designing
tetracycline derivatives with diminished antimicrobial activities
while retaining or enhancing other activities important for their
non-antimicrobial use. It needs to be noted here that the works
with non-antimicrobial tetracycline derivatives have been actually
initiated earlier than those with macrolides, i.e., shortly after the
discovery of the host modulating properties of low-dose tetracy-
clines 30 years ago (Golub et al., 1983). However, a closer look
into literature shows that the host modulating effects of antibiotic
derivatives were detected even earlier, in 1950 (Stokstad and Jukes,
1950). In one of their experiments, the discoverers of growth-
promoting antibiotics found that the cultural supernatant of S.
aureofaciens, in which the antibiotic activity of aureomycin is
destroyed by alkaline hydrolysis, still enhanced the growth and
improved survival of chicks when added to feed (Stokstad and
Jukes, 1950). Thus, the loss of antimicrobial activity of aureomycin
has not compromised its other biological activities such as growth
promotion. It is unfortunate that this interesting observation has
been left without attention it deserves for so many years.
Chemically modiﬁed tetracyclines with no antimicrobial activ-
ity may have numerous applications without the associated
risk of selecting for antibiotic resistance. For example, chemi-
cal conversion of tetracycline hydrochloride to the analog with
no antimicrobial activity, de-dimethylaminotetracycline, has not
compromised the collagenase inhibitory activity of the original
molecule (Golub et al., 1987), while not affecting the tetracy-
cline resistance proﬁles of gut and oral microbiota (Golub et al.,
1991). COL-3, a chemically modiﬁed tetracycline with a MMP
inhibitor activity, has showed promising results in the treatment
of AIDS-related Kaposi’s sarcoma (Dezube et al., 2006). More-
over, the use of modiﬁed tetracyclines has showed promising
results inmanyﬁelds, includingophthalmologic diseases (Federici,
2011), dentistry (Grenier et al., 2002; Gu et al., 2012), cardio-
vascular pathologies (Salo et al., 2006; Gu et al., 2011), various
types of cancer (Lokeshwar, 1999, 2011; Syed et al., 2004; Zhao
et al., 2013a), and other conditions with excessive MMPs activities
(Golub, 2011).
Another direction in the development of tetracyclines is under-
standably focused on the design of drugs with better antimicrobial
activities and pharmacokinetic properties. Despite being highly
efﬁcient upon introduction in the clinical practice in the 1950s, the
widespread resistance to the ﬁrst- and second-generation tetra-
cyclines made them essentially useless for treatment of many
serious infectious diseases. One of the successful drug discov-
ery programs resulted in a third-generation tetracycline called
tigecycline (the minocycline derivative 9-tert-butyl-glycylamido-
minocycline). The antibiotic is highly efﬁcient against a broad
range of pathogenic bacteria, including those resistant to the
ﬁrst- and second-generation tetracyclines (Bertrand and Dowz-
icky, 2012). Although it is on the list of reserve drugs, its use is
steadily increasing (Huttner et al., 2012). Regrettably, similar to
the fate of other antibiotics, the efﬁciency of tigecycline may start
to deteriorate due to the penetration of tigecycline resistance into
pathogenic microbiota (Aminov, 2013).
β-LACTAMS
One of the most remarkable breakthroughs in the search for the
therapy of neurodegenerative diseases has identiﬁed β-lactams
as a very promising group of drugs. In a large screening effort
involving 1,040 FDA-approved drugs and nutritionals, it has been
discovered that the only drugs capable of regulating the expression
and modulating the activity of the glutamate transporter subtype
1 (GLT-1) are β-lactams (Rothstein et al., 2005). Glutamate is a
principal excitatory neurotransmitter in the CNS and contributes
to learning and memory (Shigeri et al., 2004). The concentration
of glutamate is mainly handled by GLT-1 (excitatory amino-acid
transporter 2, EAAT2, responsible for 90% of glutamate uptake;
Danbolt, 2001). Impairment of EAAT2 function leads to excess
of glutamate and associated glutamate excitotoxicity destroying
neurons and leading to neurodegenerative diseases such as ALS,
epilepsy, and others (Maragakis and Rothstein, 2001). No prac-
tical pharmaceuticals modulating EAAT2 expression and activity
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were known until the discovery of such activity among β-lactams
(Rothstein et al., 2005). A multi-phase randomized trial of ceftri-
axone for treatment of ALS has been recently ﬁnalized (Berry et al.,
2013).
Similar to other antibiotics, β-lactams can target many com-
ponents of the eukaryotic cellular machinery, and the effects of
β-lactams are not limited solely to the modulation of expression
and activity of EAAT2. In a recent investigation of ceftriaxone as a
potential therapy using a murine model of spinal muscular atro-
phy, the effects, in addition to the increase of EAAT2, also included
the increase of the nuclear factor (erythroid-derived 2)-like 2,
Nrf2, and the spinal muscular atrophy protein SMN (Nizzardo
et al., 2011). The treatment resulted in signiﬁcant amelioration of
the neuromuscular phenotype and increased survival consistent
with the protection of neuromuscular units through the activa-
tion of antioxidant response pathway governed by Nrf2. Another
work has pointed to this target of ceftriaxone as well: together
with the induction of the cystine/glutamate transporter SLC7A11
(formerly xCT), the neuroprotective effect of ceftriaxone in vitro
is combined with the induction of Nrf2 consistent with the activa-
tion of the antioxidant defense system of the cell (Lewerenz et al.,
2009).
In various models of brain injury ceftriaxone demonstrates
strong neuroprotective effects, mainly via the up-regulation of
GLT-1. In an experimental model of focal cerebral ischemia, the
administration of ceftriaxone induces ischemic tolerance result-
ing in a better functional recovery of animals (Chu et al., 2007).
A dramatic survival improvement can be seen in a rat model of
stroke, if the animals are treated by a single injection of ceftriaxone
90 min after the middle cerebral artery occlusion (Thöne-Reineke
et al., 2008). Pre-treatment with ceftriaxone also confers a signif-
icant neuroprotection in a cerebral ischemia/reperfusion injury
(Verma et al., 2010). In a neonatal rat model of hypoxic–ischemic
encephalopathy, pre-treatment with the antibiotic signiﬁcantly
reduces the brain injury scores and apoptotic cells in the hip-
pocampus, restores myelination in the external capsule, and
improves the posttraumatic learning and memory deﬁcits (Lai
et al., 2011). The neuroprotective effects of ceftriaxone are real-
ized not only through the regulation of expression and activity
of GLT-1, SLC7A11, and Nrf2. In a rat model of traumatic brain
injury the antibiotic also signiﬁcantly reduces the level of proin-
ﬂammatory cytokines (Wei et al., 2012). Thus the improvement
of cognitive functions and mitigation of brain edema after a
brain injury, which is treated by posttraumatic administration
of ceftriaxone, is a combined effect of reduced excitotoxicity and
suppressed inﬂammation.
The potent immunomodulatory properties of β-lactam antibi-
otics, including inﬂammation control, are not limited to the sole
example given above (Wei et al., 2012). In a mouse model of MS,
ceftriaxone treatment indirectly hampered T cell proliferation and
secretion of proinﬂammatory cytokines thus attenuating the dis-
ease course and its severity in this model of autoimmune CNS
inﬂammation (Melzer et al., 2008). Interestingly, ceftriaxone has
had no impact on the EAAT2 protein expression levels in sev-
eral brain areas as well as on the glutamate uptake rate suggesting
that in this model the positive effects of the antibiotic are not
mediated through the modulation of glutamate concentration.
Moreover, it seems that even the individual antibiotics within
the β-lactam group may display differential immunomodulatory
properties (Mor and Cohen, 2013). This mechanism operates via
covalent binding of various β-lactams to cellular albumin and
subsequent modulation of T cell function and gene expression.
β-lactams may be considered as valuable candidates for treat-
ment of alcohol and other drug dependencies due to the capability
of normalizing glutamate transmission, which is affected in addic-
tion (Kalivas et al., 2009). To start with the simplest model:
in planarians, ceftriaxone attenuates both the development of
physical dependence and abstinence-induced withdrawal from
cocaine, amphetamine, methamphetamine, and benzodiazepine
(Rawls et al., 2008). In rats, the administration of ceftriaxone may
suppress cue- and cocaine-induced relapses to cocaine-seeking
behavior via up-regulation of GLT-1 and SLC7A11 (Sari et al.,
2009; Knackstedt et al., 2010). Ceftriaxone also precludes cocaine
sensitization and provides a long-term attenuation of cue- and
cocaine-primed reinstatement of cocaine-seeking behavior, even
after the cessation of antibiotic administration (Sondheimer and
Knackstedt, 2011). In general, the antibiotic normalizes many
aspects of glutamate homeostasis disrupted by the use of cocaine
and, therefore, has the potential to lessen relapse episodes in
human cocaine addicts (Trantham-Davidson et al., 2012). Cur-
rently there is no approvedmedication for the treatment of cocaine
addiction, and the promising results obtained in the animal model
experiments described above suggest that ceftriaxone (and possi-
bly other β-lactams) can be considered as good candidates for
clinical trials.
The biggest substance abuse problem is associated with exces-
sive ethanol consumption, and β-lactams hold the potential to
contribute to this problem as well. The biochemistry of ethanol
addiction is more complicated compared to other drug depen-
dencies, but one of its components discussed above, i.e., changes
in glutamate transmission, is affected analogous to other drug
addictions (Rao and Sari, 2012). Possibly the same mechanism
of normalization, through the activation of GLT-1 by ceftriax-
one, contributes to reduced ethanol consumption as well as to
attenuation of relapse-like ethanol-drinking behavior in male
alcohol-preferring rats (Sari et al., 2011; Qrunﬂeh et al., 2013).
Reduction in the acquisition andmaintenance of ethanol-drinking
habit by ceftriaxone has also been veriﬁed for adolescent and adult
female alcohol-preferring rats (Sari et al., 2013).
Enhanced glutamatergic transmission is a primary mediator
of opiate dependence, and the counteractive effect of ceftriax-
one prevents the development of morphine physical dependence
in rats (Rawls et al., 2010a). Through the same remedial mecha-
nism, the antibiotic reduces morphine analgesic tolerance (Rawls
et al., 2010b) and suppresses opioid-induced hyperalgesia (Chen
et al., 2012). The efﬁcacy of ceftriaxone against drug dependence-
related behavior extends to amphetamine (Rasmussen et al., 2011)
and nicotine (Alajaji et al., 2013), as well as to the prevention of
cannabinoid tolerance (Gunduz et al., 2011).
In general even the higher doses of ceftriaxone are tolerated
well but care should be taken in neonates, especially those with
hyperbilirubinemia and those receiving intravenous calcium solu-
tions (Monte et al., 2008). There is no support for such restrictions
in patients >28 days old (Steadman et al., 2010). The adverse
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reactions to ceftriaxone are caused by rapid intravenous injec-
tion, unlabeled use, and past history of allergic reactions to
cephalosporins or penicillins (Shalviri et al., 2012). These risk
factors can be easily managed under the normal clinical settings.
The host modulating properties of β-lactams have been discov-
ered recently, and there is yet no data regarding the development
of β-lactams with abolished antimicrobial activity. Unlike the
macrolides and tetracyclines, the non-antimicrobial effects of
β-lactams have been studied mostly with a single representative,
ceftriaxone, and it is not clear if other representatives of this
class of drugs possess similar properties. Another problematic
area in ceftriaxone application for non-antimicrobial purposes is
the concentrations used. The concentrations may be even higher
than those for infectious disease treatment thus exerting potent
selective pressure on commensal and pathogenic microbiota. This
third-generation cephalosporin still remains a valuable therapeu-
tic option for treatment of pneumonia, bacterial meningitis, Lyme
disease, typhoid fever, and gonorrhea. Although the drug is los-
ing its position as the last remaining option for ﬁrst-line empiric
treatment of, for example, Neisseria gonorrhoeae (Unemo and
Nicholas, 2012), there are still some pathogens that have not
acquired the corresponding resistance as yet. In this situation,
exerting additional selective pressure by the non-antimicrobial use
of ceftriaxone may complicate the management of a number of
infectious diseases.
DISCUSSION
Based on many promising results of the non-antimicrobial use of
antimicrobials, the use of antibiotics for this purpose is expected
to rise dramatically. Although being considered in the most
recent clinical trials, a possible side effect of this therapy, such as
the emergence and dissemination of antibiotic resistance among
commensals and pathogens, has not received any considerable
attention, and, in fact, the majority of clinical trials cited here have
not monitored the occurrence of antibiotic resistance. There are
some indications, however, that even low, non-selective concen-
trations of antibiotics used for a long timemay affect the antibiotic
resistance proﬁle of human microbiota. For example, in a recent
clinical trial of long-term, low-dose erythromycin on pulmonary
exacerbations among patients with non-CF bronchiectasis, the
proportion of macrolide-resistant oropharyngeal streptococci at
the end of therapy has been substantially higher in the treatment
group compared to the placebo group, 27.7 vs. 0.04%, respec-
tively (Serisier et al., 2013). The use of azithromycin for the same
purpose has resulted in the macrolide resistance rate of 88% com-
pared to 26% in the placebo group (Altenburg et al., 2013). In
this regard, the use of modiﬁed antibiotics with abolished antimi-
crobial activities may be helpful to circumvent such undesirable
side effects of this type of therapy (Golub et al., 1991). Efforts to
design newer antibiotic derivatives, which have no antimicrobial
properties must be continued, especially for β-lactams that are
used at the concentration range far exceeding those employed in
infection control. For example, the recommended dose of ceftri-
axone for treatment of gonorrhea has been increased from 125 to
250 mg due to the increasing resistance of N. gonorrhoeae, where
for the majority of other infections the range rarely exceeds 1–
2 g per day. But the most efﬁcient management of, for example,
ALS may require dosages up to 4 g/day (Berry et al., 2013). In
combination with a generally long-term treatment required for
this type of therapy (i.e., 20 weeks used in Berry et al., 2013),
the total quantity of ceftriaxone consumed during a single course
(560 g)might easily exceed the corresponding values used in a typ-
ical infection treatment by approximately 30–60 times. This may
contribute to a signiﬁcantly broader spread of resistance against
third-generation cephalosporins among human commensals and,
possibly, pathogens.
This clearly powerful selective pressure of ceftriaxone to be
used for non-antimicrobial purposes brings forward another con-
sideration for a more careful assessment of the biotic effects
of antibiotics: that is, whether the effects of antibiotics are
exerted solely via the human receptor-antibiotic ligand mecha-
nisms. While the in vitro models largely have no issues with the
inﬂuence of an indirect factor such as commensal microbiota, the
corresponding experiments with animal models or human volun-
teers may need more careful interpretation because of a possible
interfering effect of this often neglected variable. Our views on the
role of commensal microbiota in human health and disease have
undergone cardinal changes during the last decade from view-
ing it as a fairly passive bystander with a limited contribution to
the host nutrition to an active organ of our body involved in many
aspects of ourmetabolism, physiology, immunity, anddisease. The
ﬁeld of host–microbiota research is overloaded with many works
revealing the role of commensal microbiota in various pathologies
ranging from inﬂammatory disorders to metabolic syndrome and
to autism. It is, however, not possible to extend the frames of this
review to include this fascinating area as well.
It is interesting to note, though, that there is an overlap between
the range of diseases that can be treated by the biotic action of
antibiotics and the diseases that have a substantial commensal
microbial component. In Parkinson’s disease subjects, for exam-
ple, the integrity of the intestinal lining is compromised thus
allowing translocation of proinﬂammatory bacteria and bacterial
products leading to the formation of the pathological hallmark of
the disease, i.e., Lewy bodieswith alpha-synuclein protein (Forsyth
et al., 2011). As discussed above, the neuroprotective effects of
minocycline may include reduced mitochondrial calcium uptake,
stabilized mitochondrial membranes, reduced release of apop-
totic factors, up-regulation of the anti-apoptotic protein Bcl-2,
direct scavenging for reactive oxygen species, and inhibition of
MAPKs (Orsucci et al., 2009). On the other side, minocycline may
affect and modulate the microbiota, both commensal and translo-
cated, thus reducing the load of proinﬂammatory bacteria and
bacterial products. The effect on microbiota may be particularly
profound for ceftriaxone, the biotic use concentration of which
is much higher than typical antimicrobial concentrations used for
infectious diseases. At concentrations used for typical antibacterial
therapy, the ceftriaxone-induced dysbacteriosis may signiﬁcantly
change the fecal metabolome and affect the populations of T lym-
phocytes, their subpopulations in Peyer’s patches, and expression
of various cytokines (Gao et al., 2012; Zhao et al., 2013b). Thus
ceftriaxone considerably modiﬁes the gut microbiome with the
subsequent alteration of the host metabolome and immunity. It is
currently unknown towhat extent these secondary alterations con-
tribute to theobserved therapeutic effects of thenon-antimicrobial
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ceftriaxone use in various diseases and pathologies. Because of
the dual role of antibiotics, further research on biotic effects
of antibiotics should incorporate both of these aspects in study
designs.
Similarly, in the use of antibiotics as antimicrobial agents,
their biotic effects are rarely considered as signiﬁcant. Almost
all infectious diseases, however, have a substantial inﬂammatory
component, and, if left unchecked, the host’s proinﬂammatory
responses may cause more harm than a pathogen would. In
this regard, the anti-inﬂammatory activities of tetracyclines and
macrolides discussed abovemay help to alleviate the overly aggres-
sive inﬂammatory responses and prevent the resulting excessive
tissue damage. In general, the number of diseases with a sig-
niﬁcant proinﬂammatory component, as exempliﬁed above in
this review, is on the rise, and one of the possible explana-
tions for this phenomenon is offered by the hygiene hypothesis
(Strachan, 1989). There used to be substantial exposure of humans
to environmental bacteria before the advent of industrial food
production resulting in essentially sterile food protected by preser-
vatives, conservatives and freezing and generally higher hygienic
standards of living. This exposure seems to have been an essen-
tial component of the immune system education and the lack of
it results in an unbalanced immune system development, with a
prominent proinﬂammatory bias. Thus antibiotics like tetracy-
clines and macrolides not only help to clear infections but also
prevent generally excessive immune responses to infections char-
acteristic for modern humans. Other antibiotics, however, may
display the opposite biotic effects. For example, rifampin, a major
drug used in tuberculosis treatment, increases inducible nitric
oxide synthase expression and NF-κB activation and decreases
PPARgamma expression (Yuhas et al., 2009), thus displaying
strong proinﬂammatory properties.
The ligand and signaling activities of antibiotics that are beyond
their intended antimicrobial use may explain the phenomena out-
side the human disease domain. Many are probably familiar with
the growth-promoting effect of antibiotics on food animals. The
growth-promoting antibiotics were completely phased out in the
EU countries in 2006 because of their alleged contribution to
the spread of antibiotic resistance, but it is still a legal practice
in many countries. Despite the fact that the growth-promoting
phenomenon was discovered more than 60 years ago, its mecha-
nisms are still poorly understood. One of the possible explanations
proposed has been the suppression of subclinical infections. But
the concentrations of antibiotics used for growth promotion are
well below the minimal inhibitory concentration (MICs) for the
majority of pathogens. The irony of the situation is that it has
been clear from the beginning that the growth-promoting effects
of antibiotics are not due to antimicrobial activities. Since the
very early days of the ﬁeld it has been shown that even if the
antibiotic activity of aureomycin in the culture supernatant of
S. aureofaciens is destroyed by alkaline hydrolysis, it still retains
the complete growth-promoting potential (Stokstad and Jukes,
1950). Thus Robert Stokstad and Thomas Jukes were the ﬁrst to
witness the biotic activity of the modiﬁed antibiotic but without
realizing this. In the context of results discussed in this review,
it is probable that the growth-promoting effect of antibiotics is
largely due to the biotic signaling. This may affect the host and
microbial components and can be realized through the modula-
tion and pleiotropic regulation of the physiology and metabolic
state of an entire microbiota as well as the regulatory mechanisms
operating in the host animal. The regulatory effect of antibi-
otics on the microbial component has been discussed elsewhere
(Davies et al., 2006; Linares et al., 2006; Yim et al., 2006, 2007;
Martínez, 2008; Aminov, 2009; Romero et al., 2011). Other regu-
latory effects can be instigated through signaling to the host cells
as has been demonstrated in this review. This could bemodulation
of immunity by suppressing subclinical inﬂammatory processes,
which drain the host resources. It is probably not a coincidence
that the vast majority of growth-promoting antibiotics belong to
macrolides and tetracyclines that exert potent anti-inﬂammatory
activities.
And ﬁnally, moving from the applications to the fundamentals,
it remains to be discussed whether this multiplicity of antibiotic
targets in the human/animal body we have just seen is merely acci-
dental. Our perception of antibiotics as instruments of warfare
in microbial communities is mainly inﬂuenced by the extrapo-
lation of antibiotic use in clinical and veterinary microbiology,
where high concentrations of antibiotics are used to eradicate bac-
terial infections in humans and animals. Several lines of evidence
gathered in recent years suggest that antibiotic concentrations
occurring in natural ecosystems are too low to kill the neighbors
and, instead, theymayplay signaling and regulatory roles inmicro-
bial communities (Davies et al., 2006; Linares et al., 2006; Yim
et al., 2006, 2007; Martínez, 2008; Aminov, 2009; Romero et al.,
2011). The concept of antibiotics serving as signaling molecules in
microbial ecosystems has gained considerable attention also in the
context that it may explain the effect of low-dose antibiotics on
the expression of genes regulating virulence, colonization, motil-
ity, stress response, bioﬁlm formation, gene transfer, secondary
metabolite production, and many other functions. If the sole role
of antibiotics were limited to killing, then no effect of antibi-
otics would be seen below the MIC levels, and the effect would be
neutral. However, it is not the case.
Are eukaryotes involved in this microbial signaling network?
Before the advent of the multicellular organization about 0.5 bil-
lion years ago, the single-celled eukaryotes were probably well-
incorporated into the then-existing microbial ecosystems, with
the corresponding ancient signaling systems, and were also pro-
ducing signaling substances themselves. They probably retained
this capability even after the shift to multicellular organization,
as may be exempliﬁed by some of the ancient eukaryotic organ-
isms having survived until the present days such as sponges which
produce plethora of biologically active compounds, including
antibiotics (Burkholder and Ruetzler, 1969; Laport et al., 2009).
Further developments in multicellular organization in the eukary-
otic world have led to a certain degree of isolation from the
environment and the invention of intra-organismal signaling by
hormones, but interaction and cross-talk with microbiota has
remained an integral part of the lifestyle of eukaryotes. As dis-
cussed above, the microbiota is involved in many aspects of our
metabolism, physiology, immunity, and disease through signaling
to the host, but this is indeed a cross-talk with the microbiota also
listening to the host signals (Burton et al., 2002; Sperandio et al.,
2003; Clarke et al., 2006; Karavolos et al., 2008, 2013).
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The importance of this host–microbe communication has been
exempliﬁed above by the hygiene hypothesis that explains a dra-
matic increase in the number of allergies and asthma in more
developed countries due to limited exposure to environmen-
tal microbiota in the modern world. Another good example of
the malfunctioning host–microbiota communication is the peri-
odontal disease that affects 10–15% of adult population globally
(Petersen and Ogawa, 2012). Although many suspected pathogens
have been implicated in this disease, the underlying cause is more
fundamental and mainly owes to the disrupted host–microbe
interaction (Armitage, 2013; Bartold and Van Dyke, 2013). This
disruption is the result of drastic changes in the lifestyle and
diet imposed by the conversion to farming ca. 10,000 years ago
and especially by the industrial revolution beginning from the
18th century. These changes shifted the oral microbial commu-
nity to a disease-associated conﬁguration (Adler et al., 2013), thus
provoking the host to overly aggressive immune responses that
result in tissue damage and disease progression. As discussed
above, the situation can be somewhat corrected by the use of
low-dose tetracyclines and tetracycline derivatives that suppress
these responses, but this is a temporal solution which does not
tackle the fundamental issue of the disease. The way of solving
this is through reinstatement of oral microbiota from a less sta-
ble and diverse state, which would allow restituting the proper
host–microbiota communication that has been selected and ﬁne-
tuned during prior long-term co-evolution of the host and
microbiota.
Antibiotic signaling network is possibly one of themost ancient
forms of inter-domain communication. It is not a coincidence
that there are so many distinct molecular targets and recep-
tors in eukaryotic cells for which antibiotics serve as ligands.
Although therapeutic potential of this molecular cross-talk is
well-understood and proven in certain pathologies and diseases,
the effect on healthy individuals needs further elaboration. This
is particularly important because the current exposure of humans
to antibiotics, even in generally healthy populations, could be sub-
stantial but the consequences of this are poorly understood. For
example, the phenomenon of the accelerated physiological devel-
opment and tendency to be overweight in modern humans: is it
the same effect of antibiotics similar to the growth promotion in
food animals? The existing regulations require that the level of
antibiotics for instance in meat products entering the human food
chain should be below a certain tolerance level. But how the toler-
ance levels are deﬁned? For example, detection of antibiotics and
sulfonamides in bob veal calf carcasses are performed with the
calf antibiotic and sulfonamide test (CAST) where Bacillus mega-
terium ATCC 9885 is used as the indicator organism (Dey et al.,
2005). In order for a tissue sample to be considered safe, a zone of
inhibition around a swab should be less than 18 mm. Under the
identical incubation conditions antibiotic disks with 8.0 μg of sul-
famethazine produce slightly smaller zones of inhibition, 17 mm
in diameter (Dey et al., 2005). Moreover, the samples may contain
the metabolized antibiotic residues that lost their antimicrobial
activity but may still retain other biotic signaling properties as
discussed in this review.
The use of antibiotics has been predominantly studied from the
antimicrobial activity perspective and focused mostly on infection
control and prevention of antibiotic resistance among pathogens.
The advent and rapid expansion of non-antimicrobial application
of antibiotics may enhance the already existing selective pressure
of antibiotics and contribute to the present antibiotic resistance
problem. Better understanding of biotic functions of antibiotics
may help to design newer antibiotic derivatives with abolished
antimicrobial activities and improved biotic functions.
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Antibiotics represent our bulwark to combat bacterial infections, but the spread of
antibiotic resistance compromises their clinical efﬁcacy. Alternatives to conventional
antibiotics are urgently needed in order to complement the existing antibacterial arsenal.
The macrolide antibiotic azithromycin (AZM) provides a paradigmatic example of an
“unconventional” antibacterial drug. Besides its growth-inhibiting activity, AZM displays
potent anti-inﬂammatory properties, as well as antivirulence activity on some intrinsically
resistant bacteria, such as Pseudomonas aeruginosa. In this bacterium, the antivirulence
activity of AZM mainly relies on its ability to interact with the ribosome, resulting in direct
and/or indirect repression of speciﬁc subsets of genes involved in virulence, quorum
sensing, bioﬁlm formation, and intrinsic antibiotic resistance. Both clinical experience
and clinical trials have shown the efﬁcacy of AZM in the treatment of chronic pulmonary
infections caused by P. aeruginosa. The aim of this review is to combine results from
laboratory studies with evidence from clinical trials in order to unify the information on the
in vivo mode of action of AZM in P. aeruginosa infection.
Keywords: antibiotic, cystic fibrosis, inflammation, macrolide, regulation, virulence
INTRODUCTION
Antibiotics are used as ﬁrst line drugs for the treatment of bac-
terial infections, but the widespread resistance to these agents
combined with the shortage of novel antimicrobial compounds
developedby thepharmaceutical industry results in anurgent need
for new strategies to combat bacterial infections (Fernebro, 2011).
Virulence factors are essential for bacterial pathogens to cause
infection. Hence, suppression of virulence factor production,
i.e., antivirulence therapy, has become an attractive anti-infective
approach. In-depth understanding of the mechanisms by which
pathogens cause disease has been essential for the recognition of
suitable targets for antivirulence drugs (Cegelski et al., 2008; Rasko
and Sperandio, 2010). Target-based rational design and screen-
ing of chemical libraries allowed the identiﬁcation of a variety
of virulence inhibitors (Clatworthy et al., 2007; Law et al., 2013).
However, none of the antivirulence compounds developed so far
have entered into clinical practice.
The unpredicted antivirulence activity observed a posteriori
among macrolide antibiotics prompted revisiting of laboratory
and clinical data to assess the potential of these compounds
as antivirulence drugs. In this review, the clinical impact
of azithromycin (AZM) on patients suffering from Pseu-
domonas aeruginosa infection are discussed in the light of the
biological activities exerted by AZM on both the pathogen and
the host.
THE MULTIFARIOUS BIOLOGICAL ACTIVITIES OF
MACROLIDES
Macrolides are polyketide compounds characterized by the pres-
ence of a 14- (e.g., erythromycin), 15- (e.g., AZM, Figure 1), or
16- (e.g., josamycin) membered macrocyclic lactone to which one
or more amino and/or neutral sugars are attached.
Macrolides have many important biological characteristics
including antibacterial, antifungal and immunomodulatory prop-
erties. Erythromycin is the progenitor of this class of antibiotics
and has served as the scaffold for the generation of newer semisyn-
thetic macrolides (Washington andWilson, 1985; Pal, 2006). AZM
was launched in 1991 and rapidly became one of the most fre-
quently used antimicrobials for outpatients (Hicks et al., 2013). A
number of favorable pharmacological properties contributed to
the success of AZM as an antibiotic, including acid resistance, a
short time to achieve peak concentrations with an up to 800-fold
accumulation in phagocytes at the infection site, and long half-life
allowing a large single oral dose to maintain bacteriostatic activity
in the infected tissue for 4 days (Girard et al., 1987; Foulds et al.,
1990; Blumer, 2005).
Macrolide antibiotics inhibit bacterial growth by binding the
23S rRNA in the 50S subunit of the bacterial ribosome, thereby
preventing the transfer of tRNA from the A to the P site of the
ribosome. Binding to the A site prevents addition of an incom-
ing amino acid-charged tRNA to the nascent polypeptide chain,
ultimately aborting polypeptide growth (Retsema and Fu, 2001;
Poehlsgaard and Douthwaite, 2005).
Some macrolides (e.g., rapamycin) lack antibacterial activity
but possess potent immunosuppressive or immunomodulatory
properties, and are therefore used in the therapy of autoimmune
disorders and proliferative diseases. They act through different
mechanisms at the level of the immune system, ultimately interfer-
ing with lymphocyte activation and cytokine production (McAlis-
ter et al., 2002; Ferrer et al., 2011; Salmond and Zamoyska, 2011).
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FIGURE 1 | Chemical structure of azithromycin, a drug belonging to
the azalide subclass of macrolides.The 15-membered lactone ring is
derived from erythromycin, upon incorporation of a methyl-substituted
nitrogen atom (bold).
Starting from the late 1960s, evidence has been obtained show-
ing that also macrolide antibiotics have anti-inﬂammatory and
pro-kinetic effects which play a prominent role in some infec-
tions (Itkin and Menzel, 1970). These effects have extensively been
reviewed in the recent literature (Amsden, 2005; Giamarellos-
Bourboulis, 2008; Kanoh and Rubin, 2010; Steel et al., 2012;
Aminov, 2013).
Macrolide antibiotics are typically bacteriostatic at therapeu-
tic concentrations (Retsema et al., 1987). Different from cell-
disrupting agents (e.g., β-lactams), they are unlikely to cause
bacterial lysis and release of cell-associated pro-inﬂammatory
molecules, thereby avoiding the induction of a detrimental inﬂam-
matory response (Spreer et al., 2003; Anderson et al., 2007).
Sub-inhibitory concentrations of macrolides cause substantial
inhibition of the synthesis of virulence factors in both Gram-
positive and Gram-negative bacteria (Steel et al., 2012).
Pseudomonas aeruginosa is a paradigmatic example of a
microorganism with intrinsic resistance to multiple classes of
antibiotics, including macrolides. Nonetheless, a number of clin-
ical studies have demonstrated that patients suffering from both
intermittent and chronicP. aeruginosa infection, e.g., cystic ﬁbrosis
(CF), chronic obstructive pulmonary disease (COPD), and diffuse
panbronchiolitis (DPB), beneﬁt from AZM treatment (reviewed
by Steel et al., 2012 andAminov, 2013). Hereafter, the many effects
of AZM on P. aeruginosa virulence and their impact on infection
are discussed.
EFFECT OF AZITHROMYCIN ON P. aeruginosa CELLS
The pathogenic potential of P. aeruginosa relies on the production
of cell-surface components with pro-inﬂammatory and/or adhe-
sion activity, and a huge arsenal of virulence factors (Driscoll et al.,
2007). Moreover, its ability to adopt the bioﬁlm lifestyle is critical
in chronic infections. In P. aeruginosa, the extracellular polysac-
charides (EPSs) Psl, Pel and alginate play an important role in
maintaining the bioﬁlm structure and in resistance to antibiotics
and to the host immune system (Wei and Ma, 2013).
AZM is not approved for the treatment of infections caused
by P. aeruginosa and there are no published breakpoints for this
species. TheAZMminimum inhibitory concentrations (MICs) for
P. aeruginosa range from 8 to 512 μg/ml, depending on the strain
and the testing procedure (e.g., Kita et al., 1991; Tateda et al., 1996;
Nicolau et al., 1999; Morita et al., 2001). Early studies showed that
sub-inhibitory AZM concentrations (sub-MIC AZM) suppressed
motility and the production of several virulence factors, includ-
ing proteases, pyocyanin, exotoxin A, phospholipase C (PLC),
and EPSs in P. aeruginosa (Kita et al., 1991; Molinari et al., 1992;
Molinari et al., 1993; Ichimiya et al., 1996; Nagino and Kobayashi,
1997; Favre-Bonté et al., 2003; Gillis and Iglewski, 2004). Since in
P. aeruginosa the expression of many virulence factors is activated
at the transcriptional level by the 3-oxo-C12-homoserine lactone
(3OC12-HSL) and butyryl-homoserine lactone (C4-HSL) quo-
rum sensing (QS) signal molecules, some studies focused on the
effect of sub-MIC AZM on these two QS systems.
AZM (2 μg/ml) reduces the production of both 3OC12-HSL
and C4-HSL. Transcriptional repression of the corresponding
synthase/receptor genes lasI/lasR and rhlI/rhlR contributes to
this effect (Tateda et al., 2001). Accordingly, transcriptomic and
proteomic analyses conﬁrmed that AZM down-regulates the
expression of many QS-dependent genes, as those encoding the
pilus, ﬂagellum, and oxidative stress response proteins (Nalca
et al., 2006; Skindersoe et al., 2008; Kai et al., 2009). In P. aerug-
inosa, the AZM-affected transcriptome largely overlaps with the
Gac/Rsm regulon, which also includes both las and rhl QS genes
(Pérez-Martínez andHaas,2011). In theGac/Rsmregulatory path-
way, the trans-membrane histidine kinase GacS phosphorylates
the response regulator GacA in response to an unknown signal.
Phosphorylated GacA activates the transcription of the two small
regulatory RNAs (srRNAs) RsmY and RsmZ. At high concentra-
tions, these srRNAs sequester the mRNA-binding protein RsmA,
which acts as a translational repressor. RsmA directly or indi-
rectly affects the expression of many virulence genes, including
those implicated in QS regulation (Coggan and Wolfgang, 2012;
Frangipani et al., 2014). Sub-MIC AZM reduced the expression of
several genes in the Gac/Rsm regulon, and inhibited the transcrip-
tion of the still uncharacterized ORFs PA0588–PA0584, which are
required for full expression of rsmZ and rsmY (Kai et al., 2009;
Pérez-Martínez and Haas, 2011). Therefore, AZM-dependent
repression of 3OC12-HSL and C4-HSL synthesis could, at least in
part, be explainedby a cascademechanism inwhichAZMrepresses
expression of the PA0588–PA0584 geneswhich are required for full
transcription of rsmZ and rsmY, resulting in down-regulation of
QS gene expression. However, the effect of AZMon rsmZ and rsmY
transcription was not completely abrogated in a PA0588–PA0584
deletion mutant, suggesting that AZM affects the Gac/Rsm system
and QS also via alternative pathways (Pérez-Martínez and Haas,
2011; Figure 2). Allied to this, AZM also repressed transcription
of genes for the synthesis of 3OC12-HSL and C4-HSL precursors
(Kai et al., 2009).
Sub-MIC AZM has many pleiotropic effects on P. aeruginosa
that cannot be explained only by its interference with the Gac/Rsm
and QS systems. Examples are (i) the inhibitory effect on alginate
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FIGURE 2 | Proposed molecular mechanisms for AZM-mediated
inhibition of P. aeruginosa virulence. AZM, even at sub-inhibitory
concentrations, interacts with the 50S ribosomal subunit and selectively
affects the expression of a speciﬁc subset of genes, such as those for the
Gac/Rsm and quorum sensing (QS) systems, and other unidentiﬁed
transcriptional factors involved in regulation of virulence genes. Some
genes (e.g., the QS regulator gene rhlR) may be affected by AZM via
independent and overlapping regulatory pathways, both at the
transcriptional and post-transcriptional level. The ﬁnal outcome of this
cascade is the suppression of a number of virulence-related phenotypes
(see text for details). T-shaped lines represent negative controls.
production (Ichimiya et al., 1996; Favre-Bonté et al., 2003; Lutz
et al., 2012), (ii) increased susceptibility to serum bactericidal
activity, probably due to alterations of cell-surface structures
such as lipopolysaccharides and outer membrane proteins (Tateda
et al., 1993, 1994), (iii) increased susceptibility to some antimicro-
bials, due to down-regulation of the MexAB-OprM efﬂux pump
(Sugimura et al., 2008), and (iv) killing of stationary-phase and
bioﬁlm-forming cells (Tateda et al., 1996; Imamura et al., 2005).
Some effects of sub-MIC AZM are dependent on a direct inter-
action with the ribosome. Indeed, heterologous expression of a
Clostridium perfrigens 23S rRNA methylase gene in P. aeruginosa
increased AZM resistance, counteracted inhibition of virulence
factors production, and alleviated killing of stationary-phase cells
(Kohler et al., 2007).
Macrolides block elongation of the nascent peptide chain
and cause premature dissociation of the tRNA-charged growing
polypeptide. Increased release of these abortive peptidyl-tRNAs, a
phenomenon known as “drop-off”, impairs the normal turnover
of tRNAs, affecting the overall protein translation rate (Retsema
and Fu, 2001; Gödeke et al., 2013). Interestingly, overexpression
in P. aeruginosa of the Pth peptidyl-tRNA hydrolase, an enzyme
which releases uncharged tRNA from the peptidyl-tRNA, partially
restored tRNAs turn-over and reversed some phenotypes caused
by sub-MIC AZM, such as the stationary-phase killing and inhi-
bition of pyocyanin and rhamnolipid production (Gödeke et al.,
2013). Therefore, some phenotypes induced by sub-MIC AZM
are determined by the increased peptidyl-tRNAs drop-off and
defective turn-over of tRNAs. Since production of pyocyanin and
rhamnolipids is dependent on the Rhl QS system, Gödeke et al.
(2013) by analysing the rhlI and rhlR coding sequences found
that the second codon of rhlR (AGG, encoding Arg) is very rarely
used in P. aeruginosa, suggesting that translation of this gene
could be particularly susceptible to defects in tRNAs turn-over.
Accordingly, replacement of this codon with the preferentially
used codon CGC reverted AZM-mediated inhibition of rhamno-
lipids and pyocyanin production (Gödeke et al., 2013). This result
suggests that sub-MIC AZM may selectively affect the expres-
sion of distinct subset of genes, depending on their codon usage.
Thus, the pleiotropic effects of sub-MICAZM on P. aeruginosa are
mainly due toAZMinteractionwith the ribosome and interference
with protein synthesis. Differential codon usage in P. aeruginosa
might explain the selective activity of AZM in translation of spe-
ciﬁc proteins. Besides RhlR, translation of still unidentiﬁed global
regulators could also be affected by sub-MIC AZM concentra-
tions, explaining AZM effects on P. aeruginosa transcriptome and
physiology (Nalca et al., 2006; Skindersoe et al., 2008; Kai et al.,
2009).
EFFECT OF AZITHROMYCIN ON P. aeruginosa INFECTION
In Japan, macrolides have been used since the 1980s to treat DPB,
a rare inﬂammatory lung disease that mainly affects elderly Asian
people, in which chronic P. aeruginosa lung infection is associ-
ated with a poor outcome (Schultz, 2004). In the late 1990s, the
similarities between DBP and CF drove Jaffé et al. (1998) to use
AZM as a last resort agent for treatment of a teenager with CF
on the waiting list for heart–lung transplantation; AZM treatment
almost doubled the patient’s pulmonary function, leading to his
removal from the list. This promising ﬁnding was conﬁrmed by
an open-label study on seven CF children infected by P. aerugi-
nosa not responding to conventional therapy (Jaffé et al., 1998).
Thereafter, several clinical trials have been conducted to validate
AZM efﬁcacy in CF. A recent meta-analysis of ten studies, includ-
ing almost 1,000 patients, showed that AZM therapy is associated
with a small but consistent improvement in respiratory function
at 6 months, and has a good safety proﬁle (Southern et al., 2012).
Hereafter, results from laboratory studies will be combined
with evidence from clinical trials in order to summarize the
information on the mode of action of AZM in P. aeruginosa
infection. As described above, sub-MIC AZM exerts multiple
effects on P. aeruginosa, including virulence inhibition, killing
of stationary-phase and/or bioﬁlm-forming cells, and synergism
with other antimicrobials and with serum complement (Tateda
et al., 1996; Imamura et al., 2005; Hoffmann et al., 2007; Lutz
et al., 2012). In two chronic lung infection models of CF mice
challenged with mucoid (alginate-producing) P. aeruginosa iso-
lates, AZM suppressed QS-regulated virulence factors, drastically
reduced the bacterial load in the lung, and improved lung pathol-
ogy (Hoffmann et al., 2007; Tsai et al., 2009). However, in only
one study AZM reduced P. aeruginosa associated mortality (Tsai
et al., 2009). It was also found that AZM attenuated the inﬂam-
matory response and promoted macrophage phagocytic activity
(Tsai et al., 2009), as previously reported for AZM-treated COPD
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patients (Hodge et al., 2008). The strongly reduced bacterial load
in the lungs of AZM-treated mice could be explained by concomi-
tant factors, including killing of bioﬁlm-forming cells, improved
phagocytic activity of macrophages, and/or increased susceptibil-
ity of QS-attenuated P. aeruginosa to the inﬂammatory/immune
response (Hoffmann et al., 2007; Tsai et al., 2009). However,
a reduced bacterial load was not observed for other antiviru-
lence drugs capable of protecting mice from lethal P. aeruginosa
lung infections (Miyairi et al., 2006; Imperi et al., 2013), sug-
gesting that AZM suppresses the infection by targeting both P.
aeruginosa and the immune system. Accordingly, relevant anti-
inﬂammatory effects of AZM were also observed in CF mice
that were not infected with P. aeruginosa, where AZM treatment
resulted in attenuated cellular inﬁltration and reduced cytokine
release (Legssyer et al., 2006). Therefore, the anti-inﬂammatory
properties of AZM in the lung are also independent of its anti-
Pseudomonas activity. It should be noted that previous work using
non-CF murine models of lethal sepsis or pneumonia caused
by non-mucoid and mucoid P. aeruginosa isolates, respectively,
failed to show protective effects of AZM alone, although AZM
acted synergistically with ceftazidime in both infection mod-
els (Nicolau et al., 1997, 1999). This suggests that experimental
conditions have a considerable impact on the outcome of AZM
treatment in animal infection models and/or that special features
of CF lungs could contribute to improved AZM activity on P.
aeruginosa.
The therapeutic efﬁcacy of AZM in CF has been proven
in many clinical trials. Beneﬁcial effects were observed in
CF patients chronically-infected with P. aeruginosa and, to a
lesser extent, in uninfected CF patients (reviewed in South-
ern et al., 2012). The latter observation is consistent with the
ﬁnding that AZM signiﬁcantly reduced various serum inﬂam-
matory markers in CF patients not infected with P. aerug-
inosa (Ratjen et al., 2012), conﬁrming again that AZM has
anti-inﬂammatory effects independent of its antivirulence activ-
ity. However, some pulmonary function parameters, includ-
ing forced expiratory volume in 1s (FEV1), were slightly
less improved in patients without chronic P. aeruginosa infec-
tion compared to chronically-infected patients (Southern et al.,
2012). Whether different outcomes are related primarily to
the anti-Pseudomonas activity of AZM or to the early stage of
lung disease in young patients uninfected with P. aeruginosa
(Clement et al., 2006; Saiman et al., 2010) cannot be established
at present.
Regarding the antivirulence activity of AZM in humans, a ret-
rospective study observed a correlation between the inhibitory
effect of AZM on PLC production by P. aeruginosa strains iso-
lated from CF patients and the observed FEV1 improvement
after AZM therapy (Nguyen et al., 2007), suggesting that in vivo
PLC production is a main target of AZM. This ﬁnding ﬁts
well with the relevant role of P. aeruginosa PLC in the impair-
ment of lung function in a mouse infection model (Wargo
et al., 2011). A more recent study in intubated patients col-
onized with P. aeruginosa attempted to directly correlate the
clinical effect of AZM on the patient with its antivirulence
activity (van Delden et al., 2012). Although no relevant differ-
ences were observed between AZM-treated and untreated patients
with regard to the occurrence of ventilator-associated pneumo-
nia (VAP), a lower incidence of VAP was reported in a small
sub-group (n = 5) of AZM-treated patients infected by P. aerugi-
nosa strains producing high levels of rhamnolipids compared with
the corresponding untreated group. Although preliminary, this
observation suggests that AZM could be more effective in indi-
viduals infected by these highly virulent strains (van Delden et al.,
2012).
Only few studies measured AZM levels during administration
to CF patients. Data so far available suggest a wide range of AZM
concentrations in sputa (0.6−79.3 μg/ml), depending on the indi-
vidual patient and the dosing regimen (Baumann et al., 2004;
Wilms et al., 2006). As discussed above, the growth inhibitory
activity of AZM is strongly inﬂuenced by culture conditions. Since
AZM MICs for P. aeruginosa are low (2–16 μg/ml) when deter-
mined in eukaryotic cellmedia or inmouse bronchoalveolar lavage
ﬂuid (Buyck et al., 2012), it may be possible that AZM also exerts
some inhibition of P. aeruginosa growth in CF lungs. However,
the insigniﬁcant differences in the frequency and concentration of
P. aeruginosa in sputa from AZM-treated and untreated patients
(Equi et al., 2002; Saiman et al., 2003; Clement et al., 2006) argue
against this possibility.
CONCLUSION
From a microbiological perspective, the therapeutic efﬁcacy of
an antimicrobial compound results mainly from its ability to
impair bacterial growth, and this assumption has driven antibi-
otic research until now. AZM provides a clear example of
how the therapeutic efﬁcacy of an antimicrobial cannot exclu-
sively be attributed to growth impairment. Anti-inﬂammatory
and antivirulence properties likely predominate in the treat-
ment of infections involving AZM-resistant pathogens, as in
the case of P. aeruginosa pulmonary infections. Although there
is strong evidence of antivirulence activity in vitro, it is not
possible to assess the contribution of this activity to the efﬁ-
cacy of AZM in vivo because of concomitant anti-inﬂammatory
activity and bactericidal effects under certain conditions. Accord-
ing to the current model, both antibacterial and antivirulence
activities are based on the interaction of AZM with the ribo-
some, so that tightly interwoven effects on bacterial viability
and production of virulence factors are hardly distinguishable in
vivo.
Beneﬁcial effects have so far been documented in CF patients
treated with AZM for up to 6 months, while reduced efﬁcacy
was associated with longer treatment duration (Southern et al.,
2012; Fleet et al., 2013). Loss of efﬁcacy could be explained by the
emergence of P. aeruginosa subpopulations that become insensi-
tive to the antivirulence activity. This hypothesis could be veriﬁed
by testing the virulence properties and the response to AZM in
serial P. aeruginosa isolates collected during long-term AZM ther-
apy. Under this condition, the emergence of macrolide resistance
among both commensal bacteria and co-infecting pathogens is a
matter of concern and deserves further study (Aminov, 2013).
In conclusion, AZM offers a unique model to reconsider the
central dogma of antibiotic activity, but further research is needed
to gain more insight into the effects of AZM on both the pathogen
and the host.
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Infections caused by Pseudomonas aeruginosa often are hard to treat; inappropriate
chemotherapy readily selects multidrug-resistant P. aeruginosa. This organism can be
exposed to a wide range of concentrations of antimicrobials during treatment; learning
more about the responses of P. aeruginosa to antimicrobials is therefore important. We
review here responses of the bacterium P. aeruginosa upon exposure to antimicrobials at
levels below the inhibitory concentration. Carbapenems (e.g., imipenem) have been shown
to induce the formation of thicker and more robust bioﬁlms, while ﬂuoroquinolones (e.g.,
ciproﬂoxacin) and aminoglycosides (e.g., tobramycin) have been shown to induce bioﬁlm
formation. Ciproﬂoxacin also has been demonstrated to enhance the frequency ofmutation
to carbapenem resistance. Conversely, although macrolides (e.g., azithromycin) typically
are not effective against P. aeruginosa because of the pseudomonal outer-membrane
impermeability and efﬂux, macrolides do lead to a reduction in virulence factor production.
Similarly, tetracycline is not very effective against this organism, but is known to induce the
type-III secretion system and consequently enhance cytotoxicity of P. aeruginosa in vivo.
Of special note are the effects of antibacterials and disinfectants on pseudomonal efﬂux
systems. Sub-inhibitory concentrations of protein synthesis inhibitors (aminoglycosides,
tetracycline, chloramphenicol, etc.) induce the MexXY multidrug efﬂux system. This
response is known to bemediated by interferencewith the translation of the leader peptide
PA5471.1, with consequent effects on expression of the PA5471 gene product. Additionally,
induction of the MexCD-OprJ multidrug efﬂux system is observed upon exposure to sub-
inhibitory concentrations of disinfectants such as chlorhexidine and benzalkonium. This
response is known to be dependent upon the AlgU stress response factor. Altogether,
these biological responses of P. aeruginosa provide useful clues for the improvement and
optimization of chemotherapy in order to appropriately treat pseudomonal infections while
minimizing the emergence of resistance.
Keywords: pseudomonas aeruginosa, anti-bacterial agents, stress responses, multidrug efflux systems, biofilms
INTRODUCTION
Pseudomonas aeruginosa, a motile, non-fermenting Gram-
negative bacterium, is an opportunistic pathogen implicated in
respiratory infections, urinary tract infections, gastrointestinal
infections, keratitis, otitis media, and bacteremia in patients with
compromised host defenses [e.g., cancer, burn, HIV, and cystic
ﬁbrosis (CF)]. These infections often result in signiﬁcant morbid-
ity and mortality. In the 21st century, when the life expectancy
of highly susceptible immunocompromised groups has been
extended in most countries, P. aeruginosa plays an increasingly
prominent role in hospital infections.
This organism is a ubiquitous and metabolically versatile
microbe that ﬂourishes in many environments. The bacterium
grows under both aerobic and anaerobic conditions, and possesses
numerous virulence factors that contribute to its pathogenesis
(Schurek et al., 2012). Moreover P. aeruginosa possesses an intrin-
sic resistance to many antimicrobials because of the bacterium’s
outer-membrane barrier, the presence of multidrug efﬂux trans-
porters, and endogenous antimicrobial inactivation (Poole, 2011).
Although anti-pseudomonas agents (e.g., carbapenems) have been
discovered and developed, P. aeruginosa readily acquires resistance
to individual agents via chromosomal mutations and lateral gene
transfer (Poole, 2011).
Pseudomonas aeruginosa possesses multifactorial mechanisms
of responses and resistance to antimicrobials. While antimicro-
bials were originally developed and used to kill bacteria, recent
work reveals that the biological functions of antibiotics are not
limited to bactericidal (killing) or bacteriostatic (growth inhibi-
tion) effects (Linares et al., 2006; Aminov, 2013). The most likely
function of antibiotics in natural ecosystems is in intercellular
“signaling,” with speciﬁc consequences on the collective behavior
of the bacterial population (Linares et al., 2006; Aminov, 2013).
Improved genetic tools and cutting-edge technologies (e.g., DNA
microarrays) have revolutionized our understanding of microbial
physiology (Wecke and Mascher, 2011). Here, we summarize and
discuss how P. aeruginosa responds to various antimicrobials and
survives against its competitors.
RESPONSES TO β-LACTAMS
β-lactams bind to cell wall transpeptidases [penicillin binding pro-
teins (PBPs)], blocking an important step inpeptidoglycanbiosyn-
thesis (Poole, 2004). Penicillins (e.g., ticarcillin, piperacillin),
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cephalosporins (e.g., ceftazidime, cefepime), monobactams (e.g.,
aztreonam), and carbapenems (e.g., imipenem, meropenem, and
doripenem) are commonly used to treat pseudomonal infec-
tions. P. aeruginosa is intrinsically resistant to most β-lactams
due to the interplay of the inducible β-lactamase AmpC and the
resistance nodulation cell division (RND) multidrug efﬂux sys-
tems (e.g., MexAB-OprM; Masuda et al., 1999). Benzyl-penicillins
(e.g., amoxicillin) and narrow-spectrum cephalosporins are
labile to hydrolysis and are strong inducers of ampC, lead-
ing to antibiotic degradation, whereas ureidopenicillins (e.g.,
piperacillin) and extended-spectrum cephalosporins are labile
but are weak inducers of ampC (Livermore, 1995). The mexAB-
oprM operon is constitutively expressed in wild-type cells under
usual laboratory conditions, where the operon contributes to
P. aeruginosa’s intrinsic resistance to most β-lactams (except
for imipenem) and many other antimicrobial agents, includ-
ing quinolones, tetracycline, chloramphenicol, and macrolides
(Morita et al., 2001). Blocking of dacB-encoded non-essential
PBP4 determines a highly efﬁcient and complex β-lactam resis-
tance response, triggering the overproduction of AmpC and the
speciﬁc activation of theCreAB (BlrAB) two-component regulator
(Moya et al., 2009).
Carbapenems are an important class of anti-pseudomonal β-
lactams. Carbapenems are strong inducers that are marginally
labile (imipenem) or effectively stable (meropenem; Livermore,
1995). Imipenem also has been shown to strongly induce ampC
gene expression in bioﬁlms (Bagge et al., 2004). In addition,
P. aeruginosa bioﬁlms exposed to imipenem exhibit elevated
expression of genes coding for alginate biosynthesis, causing
thicker and more robust bioﬁlms (Bagge et al., 2004).
Ceftazidime, a PBP3 inhibitor, does not induce ampC gene
expression, but is rather a substrate of AmpC. Ceftazidime
impacts the transcription of a large number of genes in P. aerug-
inosa, including those encoding the SOS response repressor
LexA-like proteins, causing induced mutagenesis and decreas-
ing ciproﬂoxacin toxicity (Blazquez et al., 2006). In addition, this
antimicrobial shows quorum sensing (QS) inhibitory activity,
decreasing the production of a range of QS-regulated viru-
lence factors, in contrast to piperacillin, another PBP3 inhibitor
(Skindersoe et al., 2008) These results imply that the QS inhibitory
activity of ceftazidime likely is not PBP3-dependent (Skindersoe
et al., 2008).
RESPONSES TO FLUOROQUINOLONES
Fluoroquinolones, particularly ciproﬂoxacin, are commonly used
for the treatment of P. aeruginosa infections (Poole, 2011). This
class of agents interacts with complexes composed of DNA
and either of the two target enzymes, DNA gyrase and/or
topoisomerase IV. Primary intrinsic resistance of the wild-type
P. aeruginosa to ﬂuoroquinolones is due to MexAB-OprM as well
as to MexXY-OprM (Morita et al., 2001). The four RND-type
multidrug efﬂux pumps (MexAB-OprM, MexCD-OprJ, MexEF-
OprN, and MexXY-OprM) are well recognized as signiﬁcant
determinants of ﬂuoroquinolone resistance in lab and clinical
isolates (Poole, 2011), although there are several additional chro-
mosomally encoded efﬂux pumps that are able to recognize
ﬂuoroquinolones (e.g.,MexHI-OpmD,MexVW-OprM, theNorM
ortholog; Morita et al., 1998; Li et al., 2003; Sekiya et al., 2003; He
et al., 2004).
The formation of static bioﬁlms increases when P. aeruginosa
cells are incubated in the presence of sub-inhibitory concentra-
tions of ciproﬂoxacin, tobramycin, or tetracycline, while no such
sub-inhibitory effect is detected with members of other antibi-
otic classes, such as carbenicillin, chloramphenicol, or polymyxin
(Hoffman et al., 2005; Linares et al., 2006). However, in the pres-
ence of a sub-inhibitory concentration of ciproﬂoxacin (but not
of tetracycline or tobramycin), P. aeruginosa shows a reduction in
swimming and swarming, both of which are important systems of
bacterial motility and probably related to the pathogenic process
in CF patients (Linares et al., 2006).
Transcriptional responses of P. aeruginosa to sub-inhibitory
and inhibitory concentrations of ciproﬂoxacin demonstrate the
induction or repression of 100s of genes (Brazas and Han-
cock, 2005; Cirz et al., 2006; Brazas et al., 2007). Surprisingly,
genes for bacteriophage-like pyocins are up-regulated and medi-
ate ﬂuoroquinolone susceptibility (Brazas and Hancock, 2005).
At least one-third of up-regulated genes occur in regulons that
are likely controlled by LexA-like SOS response repressor proteins
in response to inhibitory concentrations of ciproﬂoxacin, while
down-regulated genes appear to involve virtually every facet of
cellular metabolism (Cirz et al., 2006; Brazas et al., 2007). The Lon
protease modulates SOS response and consequently ciproﬂoxacin
susceptibility (Breidenstein et al., 2012).
The overall pattern of expression of the DNA replication
enzymes suggests a shift from canonical DNA replication enzymes
to inducible polymerases in response to inhibitory ciproﬂoxacin
concentrations (Cirz et al., 2006). These inhibitory concentra-
tions of ciproﬂoxacin create selection pressure in favor of mutants
with increased ampC expression (Wolter et al., 2007), while
sub-inhibitory levels of ciproﬂoxacin or oﬂoxacin enhance the
frequency of mutation to carbapenem (especially meropenem)
resistance (Tanimoto et al., 2008).
RESPONSES TO AMINOGLYCOSIDES
Aminoglycosides bind to the 30S ribosomal subunit and inter-
fere with protein synthesis, causing mistranslation and ultimately
cell death without lysis (Davis, 1987). APH(3′)-IIb, a chromo-
somal aphA-encoded aminoglycoside phosphoryltransferase, is
likely responsible for the general non-susceptibility of P. aeruginosa
to kanamycin (Hachler et al., 1996), andAPH(3′)-II predominates
in clinical isolates resistant to kanamycin (Poole, 2005). Anti-
pseudomonas aminoglycosides (e.g., amikacin, gentamicin, and
tobramycin) therefore can be used in the treatment of P. aeruginosa
infections (Poole, 2005). Aminoglycoside uptake and subsequent
action within bacterial cells is a complex process that involves
Lipopolysaccharides (LPS) binding and outer-membrane per-
meation, cytoplasmic membrane traversal driven by membrane
potential, and ribosome disruption, leading to the production
of membrane-damaging mistranslated polypeptides (Davis, 1987;
Krahn et al., 2012). Primary intrinsic and adaptive resistance to
aminoglycosides is due to the MexXY multidrug efﬂux system in
laboratory and clinical isolates (Morita et al., 2012b). The antag-
onism of aminoglycosides by divalent cations Mg2+ and Ca2+
is well documented in P. aeruginosa, and occurs via a process
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that requires the MexXY multidrug efﬂux system (Mao et al.,
2001; Morita et al., 2012a). In wild-type P. aeruginosa cells, the
MexXYefﬂux system is inducible by sub-inhibitory concentrations
of aminoglycoside- and ribosome-targeting antimicrobials (e.g.,
chloramphenicol and tetracycline), a process shown to be involved
in expression of the PA5471 gene product [recently renamed
ArmZ, for anti-repressor MexZ (Morita et al., 2006; Hay et al.,
2013)] The PA5471 system also is inducible through interference
via translation of the gene’s leader peptide, PA5471.1 (Morita et al.,
2009). Very recently a clinical strain overproducing MexXY was
reported also to harbor a 7-bp deletion in the coding sequence of
the leader peptide involved in ribosome-dependent, translational
attenuation of PA5471 expression (Guénard et al., 2013).
Transcriptomic analyses conﬁrm that aminoglycosides impact
the expression of a myriad of genes (Kindrachuk et al., 2011).
While prolonged exposure to sub-inhibitory concentrations of
tobramycin causes increased levels of expression, predominantly
of the mexXY efﬂux pump genes, the greatest increases in
gene expression levels in response to lethal concentrations of
tobramycin involve a number of P. aeruginosa heat shock genes
(e.g., htpG, ibpA, groES, and asrA; Kindrachuk et al., 2011). Under
these conditions, the likely intracellular ATP-dependent AsrA pro-
tease is noteworthy because of its modest positive impact on
aminoglycoside resistance (Kindrachuk et al., 2011). The Lon
protease also is inducible by aminoglycosides (Marr et al., 2007).
Sub-inhibitory concentrations of aminoglycosides, especially
tobramycin, induce bioﬁlm formation in P. aeruginosa (Hoffman
et al., 2005). Notably, the aminoglycoside tobramycin also induces
both swimming and swarming of P. aeruginosa (Linares et al.,
2006). Also induced is the aminoglycoside response regulator (arr)
gene, which is predicted to encode an inner membrane phospho-
diesterase. The Arr substrate is cyclic di-guanosine monophos-
phate (c-di-GMP), a bacterial second messenger that regulates
cell surface adhesiveness; c-di-GMP is essential for this induc-
tion and contributes to bioﬁlm-speciﬁc aminoglycoside resistance
(Hoffman et al., 2005).
RESPONSES TO POLYMYXINS
Owing to the increased prevalence of multidrug-resistant P.
aeruginosa, polymyxin B and colistin (also called polymyxin E),
belonging to a family of antimicrobial cyclic oligopeptides, have
returned to favor as a last-resort treatment option, although these
agents have strong side effects (e.g., nephrotoxicity) with high
incidence (Poole, 2011). Very recently, the polymyxin mutant pre-
vention concentrations (MPCs) for P. aeruginosa were shown to
be very high (≥64 μg/ml), even for susceptible isolates (i.e., with
minimum inhibitory concentration (MIC) ranges of 1–2 μg/ml;
Choi and Ko, 2013). In the MPC studies, mutation to polymyxin
resistance apparently can result from a single mutation (Choi and
Ko, 2013).
The mechanism of action of polymyxins involves an initial
stage of interaction with the lipid A of the LPS, leading to self-
promoted uptake of polymyxins across the membrane, followed
by cell death (Zhang et al., 2000; Fernandez et al., 2013). The most
commonmechanismof resistance to polymyxinhas been shown to
arise from modiﬁcation of LPS lipid A with 4-amino-L-arabinose,
a process that has been seen both in in vitro-selected mutants
and in CF isolates; other unknown mechanisms remain under
investigation (Miller et al., 2011; Poole, 2011; Moskowitz et al.,
2012). This modiﬁcation is carried out by the products of the arn-
BCADTEF-ugd operon, otherwise known as pmrHFIJKLM-ugd
(McPhee et al., 2003; Yan et al., 2007). The two-component ParRS
regulator leads to the induction of the LPS modiﬁcation operon
in response to sub-inhibitory concentrations of polymyixin B and
colistin (Fernandez et al., 2010).
Approximately 0.5% of genes showed signiﬁcantly altered
expression upon exposure to sub-inhibitory concentration of col-
istin (Cummins et al., 2009), a frequency that is no less dramatic
than that seen with the other anti-pseudomonas agents (e.g., cef-
tazidime, ciproﬂoxacin, and tobramycin) described above. The
most striking alterations were up-regulation of the Pseudomonas
quinolone signal (PQS) biosynthetic genes such as the pqsABCDE
operon, the phenazine biosynthetic operon, and the arn operon
(Cummins et al., 2009).
RESPONSES TO THE MAJOR HUMAN CATIONIC HOST
DEFENSE PEPTIDE, LL-37
The major human cationic host defense peptide LL37 [a.k.a.
hCAP-18, FALL-39, or cathelicidin antimicrobial peptide
(CAMP)], a 37-amino-acid, 18-kDa peptide, is encoded by the
cathelicidin gene (CAMP) and was originally identiﬁed in humans
(Kosciuczuk et al., 2012). Sub-inhibitory concentration of LL-
37 (1/4–1/128 of the MIC of 64 μg/ml) were shown to prevent
bioﬁlm formation by decreasing the attachment of P. aeruginosa
cells, stimulating twitching motility, and inﬂuencing two major
QS systems (Las and Rhl), leading to the down-regulation of genes
essential for bioﬁlm development (Overhage et al., 2008). Similar
results were obtained using the bovine neutrophil peptide indoli-
cidin, but no inhibitory effects on bioﬁlm formation were detected
using sub-inhibitory concentrations of themousepeptideCRAMP
(67% identical with LL-37), polymyxin B,or the bovine bactenecin
homolog Bac2A (Overhage et al., 2008).
RESPONSES TO MACROLIDES
Macrolides such as erythromycin and azithromycin are widely
used antibiotics that block translation by binding to the 50S ribo-
somal subunit. P. aeruginosa cells are intrinsically resistant to
macrolides when tested in standard broth culture; for instance, the
MIC of erythromycin for P. aeruginosa PAO1 is about 512 μg/mL
in Mueller-Hinton broth (e.g., Morita et al., 2001; Buyck et al.,
2012). Nonetheless, low-dose macrolides such as azithromycin
are effective treatments in patients with chronic lung infections
(Jaffe et al., 1998; Kudoh et al., 1998). Even at concentrations
(e.g., 2 μg/ml of azithromycin) far below the MIC, macrolides
inhibit the QS circuitry of P. aeruginsoa strain PAO1, leading to
a reduction in virulence factor production (Tateda et al., 2001).
Low-dose azithromycin shows bactericidal activity for P. aerugi-
nosa bioﬁlms, but selects for nfxB mutants, which overproduce
the MexCD-OprJ efﬂux pump (Mulet et al., 2009). Notably, the
AmpC β-lactamase produced by nfxB mutants is protective in
bioﬁlm growth, although over expression of the MexCD-OprJ
pump is known to impairP. aeruginosa’s intrinsic resistance,which
is dependent on the MexXY/MexAB-OprM efﬂux pump and the
AmpC (Mulet et al., 2011).
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Genome-wide approaches have revealed the QS antagonis-
tic activities of azithromycin (e.g., inhibition of QS, reduction
of virulence factor production, and strong induction of type-
III secretion systems; Nalca et al., 2006; Skindersoe et al., 2008).
This modulation causes decreased expression of the genes encod-
ing the MexAB-OprM efﬂux pump in P. aeruginosa (Sugimura
et al., 2008). Azithromycin inhibits expression of the small RNAs
rsmY and rsmZ, a process that depends on the GacA/Rsm sig-
nal transduction pathway; this pathway is known to positively
control P. aeruginosa QS (Perez-Martinez and Haas, 2011). Both
effects of azithromycin on QS (quorum factor-dependent viru-
lence factor production and cell death) require azithromycin to
interact with ribosomes (Kohler et al., 2007). The stationary-phase
killing of azithromycin is further enhanced by the production of
rhamnolipids, which likely facilitate macrolide uptake (Kohler
et al., 2007). The mode of action of azithromycin in vivo also
is demonstrated through mutations in 23S rRNA that confer
azithromycin resistance in bacterial isolates of P. aeruginosa in
chronically infected CF patients (Marvig et al., 2012). The clini-
cal efﬁcacy of macrolides in treating pseudomonal infections can
be partially explained by the increased susceptibility of P. aerug-
inosa to these compounds in eukaryotic cell culture media and
biological ﬂuids, due to decreased oprM expression and increased
outer-membrane permeability (Buyck et al., 2012).
RESPONSES TO TETRACYCLINES AND CHLORAMPHENICOL
Tetracyclines are bacteriostatic antibiotics based on a hydroan-
thracene nucleus, which contains four fused rings. The class also
includes glycylcyclines (e.g., tigecycline), a group of semisynthetic
tetracycline derivatives containing a glycylamido substitution at
position 9 (Yao and Moellering, 2011). Tetracyclines enter bacte-
ria by an energy-dependent process and bind reversibly to the 30S
ribosomal subunit, preventing the attachment of aminoacyl-tRNA
to the ribosomal acceptor A-site in the RNA-ribosome complex
(Yao and Moellering, 2011). P. aeruginosa is intrinsically resistant
to tetracyclines and glycylcyclines due to theMexAB/MexXY efﬂux
systems (Morita et al., 2001; Dean et al., 2003). Sub-inhibitory
concentrations of tetracycline and tigecycline induce the MexXY
RND efﬂux system via a mechanism dependent on the riboso-
mal inhibitor-inducible PA5471 gene product (Dean et al., 2003;
Morita et al., 2006).
Tetracycline increases bioﬁlm formation aswell as ciproﬂoxacin
and tobramycin, as described above (Linares et al., 2006). Surpris-
ingly, incubation with tetracycline at concentrations (∼1 μg/ml)
that do not decrease the growth rate of P. aeruginosa increases
the expression of type-III secretion system (T3SS) genes exsA and
exoS, and the presence of tetracycline increases the cytotoxicity of
P. aeruginosa by nearly 4-fold (Linares et al., 2006). The T3SS is
a mechanism by which bacterial pathogens can deliver effectors
directly into the cytoplasm of the eukaryotic host cell (Hauser,
2009). Expression of genes forming the T3SS regulon is triggered
by ExaA (Hauser, 2009), a transcriptional activator that auto-
regulates its own expression by a feedback mechanism (Hauser,
2009). ExoS corresponds to a T3SS-secreted toxin (Hauser, 2009).
Chloramphenicol is a bacteriostatic agent that inhibits pro-
tein synthesis by binding reversibly to the peptidyltransferase
component of the 50S ribosomal subunit and preventing the
transpeptidation process of peptide chain elongation (Yao and
Moellering, 2011). P. aeruginosa is usually intrinsically resistant to
chloramphenicol, in part due to the MexAB-OprM efﬂux system
(Morita et al., 2001). In addition, sub-inhibitory concentrations
of chloramphenicol induce the MexXY efﬂux system via a mech-
anism dependent on the ribosomal inhibitor-inducible PA5471
gene product (Morita et al., 2006). This effect is reminiscent of the
induction of the MexEF-OprN efﬂux system (via the MexT activa-
tor) in response to chloramphenicol and nitrosative stress (Fetar
et al., 2011). Chloramphenicol is a nitro-aromatic antimicrobial
and resembles a nitrosative stress product (Fetar et al., 2011).
RESPONSE TO BIOCIDES
Pseudomonas aeruginosa also has been reported to contaminate
disinfectants (e.g., chlorhexidine, benzalkonium, and triclosan) in
hospital or other such environments, thereby compromising the
disinfectant’s ability to reduce or eliminate bacterial contamina-
tion. Chlorhexidine and benzalkonium are a cationic biguanide
and a nitrogen-based quaternary ammonium compound, respec-
tively. These biocides function by affecting the cell membrane,
resulting in lysis and the loss of cytoplasmic material (Poole,
2002). The RND-type MexCD-OprJ multidrug efﬂux pump is
induced by sub-inhibitory concentrations of disinfectants such as
benzalkonium chloride or chlorhexidine (Morita et al., 2003), a
process that is dependent upon the AlgU stress response factor
(Fraud et al., 2008). Global transcriptome response to chlorhexi-
dine includes up-regulation of the mexCD-oprJ and oprH-phoPQ
operons and down-regulation of genes encoding proteins involved
in membrane transport, oxidative phosphorylation, electron
transport, and DNA repair (Nde et al., 2009). A P. aeruginosa
variant highly adapted to benzalkonium showed increased resis-
tance to ﬂuoroquinolones, owing to mutations in the quinolone
resistance-determining region of gyrA and to mutations in genes
(mexR and nfxB) that encode repressors of mexAB-oprM and
mexCD-oprJ, respectively (Mc Cay et al., 2010). Development of
chlorhexidine-tolerant sub-populations in P. aeruginosa bioﬁlms
also is dependent on the mexCD-oprJ genes (Chiang et al., 2012).
Triclosan speciﬁcally inhibits fatty acid synthesis through inhi-
bition of bacterial enoyl–acyl carrier protein reductase, although
P. aeruginosa is intrinsically resistant to triclosan due to the
structure of the pseudomonal FabV protein (a triclosan-resistant
enoyl–acyl carrier protein reductase) and active efﬂux. This innate
resistance stems from at least ﬁve RND efﬂux pumps, including
MexAB-OprM (Mima et al., 2007; Zhu et al., 2010). In P. aerugi-
nosa mutant cells lacking the mexAB-oprM genes, sub-inhibitory
concentrations of triclosan lead to alterations in the expression
of almost half the genome, with 28% of genes being signiﬁ-
cantly up-regulated and 16% being signiﬁcantly down-regulated
(Chuanchuen and Schweizer, 2012). QS-regulating genes are
among the most strongly down-regulated, and surprisingly, iron
homeostasis is completely blocked in triclosan-exposed cells,
thus mimicking conditions with excess iron (Chuanchuen and
Schweizer, 2012).
SUMMING UP AND FURTHER PROSPECTS
The primary biological responses of P. aeruginosa to sub-
inhibitory concentrations of antimicrobials are summarized
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Table 1 | Biological responses of P. aeruginosa exposed to various antimicrobials at levels below the inhibitory concentrations.
Antimicrobials Biological responses References
β-lactams Induction of the AmpC β-lactamase(some β-lactams are inducers, but others are not) Livermore (1995)
Carbapenems Formation of thicker and more robust bioﬁlms(induction of alginate biosynthesis) Bagge et al. (2004)
Ceftazidime Induction of mutagenesis and decreasing ciproﬂoxacin toxicity Blazquez et al. (2006)
Inhibition of quorum sensing Skindersoe et al. (2008)
Fluoroquinolones Induction of bioﬁlm formation Linares et al. (2006)
Reduction in swimming and swarming Linares et al. (2006)
Induction of SOS response Brazas and Hancock (2005)
Up-regulation of the bacteriophage-like pyocins Brazas and Hancock (2005)
Shift from canonical DNA replication enzymes to inducible polymerases Cirz et al. (2006)
Enhancement of mutation frequency to β-lactam resistance. Wolter et al. (2007), Tanimoto
et al. (2008)
Protein synthesis inhibitors Induction of the MexXY efﬂux system Morita et al. (2012b)
Aminoglycosides Induction of heat shock genes Kindrachuk et al. (2011)
Induction of bioﬁlm formation Hoffman et al. (2005)
Induction of swimming and swarming Linares et al. (2006)
Induction of the Lon protease Marr et al. (2007)
Macrolides Quorum sensing antagonistic activity(reduction in virulence factor) Tateda et al. (2001)
Induction of theT3SS Nalca et al. (2006)
Down-regulation of the MexAB-OprM pump Sugimura et al. (2008)
Tetracycline Induction of bioﬁlm formation Linares et al. (2006)
Induction of theT3SS and cytotoxicity Linares et al. (2006)
Chloramphenicol Induction of the MexEF-OprN efﬂux pump Fetar et al. (2011)
Polymyxins Modiﬁcation of LPS lipid A with 4-amino-L-arabinose Fernandez et al. (2010)
Up-regulation of the PQS biosynthetic genes Cummins et al. (2009)
Chlorhexidine Induction of the MexCD-OprJ efﬂux pump Morita et al. (2003)
Induction of the oprH-phoPQ operon Nde et al. (2009)
in Table 1. Interestingly, clinically useful anti-pseudomonas
agents (carbapenems, ﬂuoroquinolones, and aminoglycosides) are
known to efﬁciently kill P. aeruginosa planktonic cells when used
properly, but lead to more severe bioﬁlm development upon expo-
sure at sub-inhibitory concentrations. This pattern means that
optimization of anti-pseudomonas chemotherapy is critical; in
the absence of such optimization, chemotherapy fails to treat the
infection and readily selects multidrug-resistant P. aeruginosa. By
contrast, macrolides (which are not effective against P. aeruginosa
planktonic cells because of the planktonic cells’ intrinsic resis-
tance) provide activity that is antagonistic to QS, thereby reducing
pseudomonal virulence. These ﬁndings regarding responses to
antimicrobial agents suggest a route toward conquering P. aerug-
inosa infections. For example, macrolides have been shown to
augment the in vitro activity of anti-pseudomonas agents against
bioﬁlms (Lutz et al., 2012).
We are aware of potential molecular targets for novel anti-
pseudomonas agents, including essential genes (Morita et al.,
2010). Novel class anti-pseudomonas agents should be expected
to minimize a severe situation in which few agents are effective
against these organisms. However, it is a much more difﬁcult task
to develop novel class antimicrobials for P. aeruginosa because
of the presence of low membrane permeability and the RND
multidrug efﬂux pumps. In addition this organism has the ability
to adapt to various stresses, including sub-inhibitory antimicro-
bial exposure, by recruiting antimicrobial resistance mechanisms,
notably that of RND efﬂux systems such as the MexXY system.
While many laboratories are currently screening, so far no efﬂux
pump inhibitors have been made available for clinical settings.
Screening for novel antibacterial agents, including efﬂux pump
inhibitors, is currently in progress in many laboratories, including
our own.
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Clostridium perfringens is an opportunistic pathogen that can cause food poisoning
in humans and various enterotoxemia in animal species. Very little is known on the
bioﬁlm of C. perfringens and its exposure to subminimal inhibitory concentrations of
antimicrobials. This study was undertaken to address these issues. Most of the C.
perfringens human and animal isolates tested in this study were able to form bioﬁlm
(230/277). Porcine clinical isolates formed signiﬁcantly more bioﬁlm than the porcine
commensal isolates. A subgroup of clinical and commensal C. perfringens isolates was
randomly selected for further characterization. Bioﬁlm was found to protect C. perfringens
bacterial cells from exposure to high concentrations of tested antimicrobials. Exposure
to low doses of some of these antimicrobials tended to lead to a diminution of the
bioﬁlm formed. However, a few isolates showed an increase in bioﬁlm formation when
exposed to low doses of tylosin, bacitracin, virginiamycin, and monensin. Six isolates
were randomly selected for bioﬁlm analysis using scanning laser confocal microscopy.
Of those, four produced more bioﬁlm in presence of low doses of bacitracin whereas
bioﬁlms formed without bacitracin were thinner and less elevated. An increase in the area
occupied by bacteria in the bioﬁlm following exposure to low doses of bacitracin was
also observed in the majority of isolates. Morphology examination revealed ﬂat bioﬁlms
with the exception of one isolate that demonstrated a mushroom-like bioﬁlm. Matrix
composition analysis showed the presence of proteins, beta-1,4 linked polysaccharides
and extracellular DNA, but no poly-beta-1,6-N -acetyl-D-glucosamine.This study brings new
information on the bioﬁlm produced by C. perfringens and its exposure to low doses of
antimicrobials.
Keywords: Clostridium perfringens, biofilm formation, antibiotic prophylaxis, anticoccidials, biofilms, anaerobes,
low dose antibiotics
INTRODUCTION
The predominant organizational state of bacteria in nature is
bioﬁlms. They have been deﬁned as a structured commu-
nity of bacterial cells enclosed in a self-produced extracellular
matrix composed primarily of exopolysaccharides (Costerton
et al., 1999). The process of bioﬁlm formation involves the fol-
lowing stages: attachment, maturation and dispersion (Davey and
O’Toole, 2000; Hall-Stoodley and Stoodley, 2009). Features of cells
in bioﬁlms include: aggregation in suspension or on solid sur-
faces, increased antibiotic resistance, protection fromphagocytosis
and immune cells, and resistance to physical and environmental
stresses (Davey andO’Toole,2000;Davies,2003;Hall-Stoodley and
Stoodley, 2009). In Pseudomonas aeruginosa, extracellular DNA
present in the matrix was shown to chelate cations and to induce
the expression of antibiotic resistance (Mulcahy et al., 2008). Also,
promotion of bioﬁlm formation was observed through the abil-
ity of extracellular DNA to chelate Mg2+ (Mulcahy and Lewenza,
2011). Recently, current knowledge of bacterial bioﬁlms in animal
pathogens was reviewed (Jacques et al., 2010) and surprisingly,
very little is known about the bioﬁlm formed by Clostridium
perfringens.
Clostridiumperfringens is aGram-positive anaerobic bacterium
that causes numerous human and animal diseases, primarily as a
result of its ability to produce many different toxins (Markey et al.,
2013). A classiﬁcation based on the production of four major tox-
ins (alpha, beta, epsilon, and iota) divides the C. perfringens into
ﬁve toxigenic biotypes (A to E; Petit et al., 1999). C. perfringens has
been ranked by the Center for Disease Control and Prevention as
one of the most common bacterial causes of food-borne illness in
the United States, causing nearly a million cases each year, and is
also classiﬁed as a class-B bioterrorism agent (Scallan et al., 2011).
Recently, an increasing number of reports have implicated the
organism in antibiotic–associated diarrhea and sporadic diarrhea
cases inhumans, aswell as diarrhea cases in animals (Smedley et al.,
2004; Uzal et al., 2012; Banaszkiewicz et al., 2013). In chickens and
swine,C. perfringens causes enteritis, a disease of economic impor-
tance to the worldwide animal-food producing industry in terms
of both animal loss and vaccination costs (Markey et al., 2013). Iso-
lates of animal origin constitute a risk for transmission to humans
through the food chain. Recent studies have shown early signs
of acquired antibiotic resistance in C. perfringens indicating that
antibiotic resistance is now emerging (Lyras et al., 2009; Soge et al.,
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2009; Slavic´ et al., 2011; Charlebois et al., 2012). C. perfringens has
been the subject of considerable investigations in the past several
years; however, an area of substantial uncertainty relates to bioﬁlm
formationwith, orwithout exposure to low-doses of anticoccidials
and antibiotics. Anticoccidials are ionophores such as monensin,
narasin, and salinomycin that are used to prevent/treat infections
caused by coccidia, an obligate intracellular parasite, and in some
cases for their effect against C. perfringens. These compounds are
also used as growth promoters in some countries (Callaway et al.,
2003; Lefebvre et al., 2006; Diarra et al., 2007).
Only a few studies have reported on C. perfringens bioﬁlm
formation (Varga et al., 2008; Donelli et al., 2012). Type IV pilus
(TFP)-dependent gliding motility and the catabolite control pro-
tein (CcpA), a key regulator of the response to carbohydrate
limitation, were both shown to be necessary for efﬁcient bioﬁlm
formation (Varga et al., 2008). In the same study, the authors also
observed that bioﬁlm cells demonstrated 5- to 15-fold-increased
survival rate over planktonic cells after exposure to penicillin G
and an increased survival to oxygen stresses. It is suspected that
bioﬁlms of C. perfringens may play an important role in resis-
tance to environmental stresses (Varga et al., 2008). In a study
by Ledder et al. (2008) on coaggregation among numerically and
ecologically important intestinal bacteria, and between intestinal
bacteria and oral isolates, C. perfringens scored the highest over-
all for coaggregation among the gut species tested (Ledder et al.,
2008). To our knowledge, no other data is available on bioﬁlms of
C. perfringens.
Studies demonstrating that low-doses of antibiotics induce bac-
terial bioﬁlm formation have recently been reviewed by Kaplan
(Kaplan, 2011). In contrast, low dose of a ﬂuoroquinolone caused
a signiﬁcant decrease in adhesion and bioﬁlm formation by
Stenotrophomonas maltophilia (Pompilio et al., 2010). Also, lower
cell densities within bioﬁlms have been reported with sub-MIC of
dicloxicillin, a β-lactam antibiotic, for Staphylococcus epidermidis
and Staphylococcus haemolyticus (Cerca et al., 2005). The effect of
sub-MIC of bacitracin, virginiamycin, lincomycin, tylosin, and
ionophores on bioﬁlm formation has not yet been described in
C. perfringens. These antibiotics and ionophores are largely used in
swine and poultry production for therapy, prophylaxis purposes,
or as feed additives (low-dose usage) in some countries.
The aims of this study were to evaluate the bioﬁlm formation
of ﬁeld isolates of C. perfringens of various sources, to determine
bioﬁlm tolerance to oxygen and antibiotics, and to investigate
the effect of low doses of antibiotics and ionophores on bioﬁlm
formation.
MATERIALS AND METHODS
BACTERIAL ISOLATES
Commensal isolates of C. perfringens from poultry and swine were
recovered from the normal intestinal microbiota of animals taken
at seven (ﬁve poultry and two swine) processing plants located
in the province of Québec, Canada. Isolates were identiﬁed and
typed by PCR as previously described (Charlebois et al., 2012).
Clinical isolates of animal origin were provided by the Clinical
Laboratory of MolecularDiagnostic of Université deMontréal (St-
Hyacinthe, QC, Canada) and human isolates were provided by the
Infectious Disease Research Center of Université Laval (Québec,
Canada). Thawed isolates were grown on Columbia agar with 5%
sheep blood (Oxoid, Nepean, ON, Canada) and then incubated in
anaerobic condition at 37◦C.
BIOFILM GROWTH AND QUANTIFICATION
Different temperatures, incubation times and growth media with
and without glucose, as well as three different isolates (ATCC
13124, c1261A, FMV-CP12) were used to standardize the bioﬁlm
formation assay. More speciﬁcally, overnight blood agar cultures
of C. perfringens were resuspended at a density of 0.5 MacFarland
in Trypticase-peptone-glucose (TPG), ﬂuid thioglycolate (FTG),
tryptic soy broth (TSB; BD, Mississauga, ON, Canada) supple-
mented or not with 10 mM of ﬁlter-sterilized glucose (Sigma,
Oakville, ON, Canada), or Brain Heart Infusion (BHI) supple-
mented or not with 10 mM of ﬁlter-sterilized glucose. 100 μL of
cultures were added in 96-well polystyrene tissue culture plates
(Costar® #3595, Corning Incorporated, Corning, NY, USA) which
were then incubated anaerobically at 30, 35, or 44◦C for 1, 3,
or 6 days in a sealed container. All isolates recovered in this
study were tested for bioﬁlm formation. These experiments were
done in triplicate and repeated three times. Optimized bioﬁlm
growth conditions were as follows: bacterial cells were inoculated
in TSB medium supplemented with 10 mM of ﬁlter-sterilized
glucose and plates were incubated for 6 days at 44◦C in an
anaerobic environment. To quantify the bioﬁlm formation, the
crystal violet assay was used as described elsewhere (Varga et al.,
2008). C. perfringens ATCC 13124 was used as positive con-
trol because this strain was previously shown to produce bioﬁlm
(Varga et al., 2008).
Isolates were categorized as described previously (Stepanovic
et al., 2007). Brieﬂy, isolates were divided into the following cat-
egories: no bioﬁlm producer, weak bioﬁlm producer, moderate
bioﬁlm producer and strong bioﬁlm producer, based upon the
previously calculated optical density (OD) values measured at
570 nm: OD ≤ ODc = no bioﬁlm producer; ODc < OD ≤ 2×
ODc=weak bioﬁlmproducer; 2×ODc<OD≤ 4×ODc=mod-
erate bioﬁlm producer; 4× ODc<OD = strong bioﬁlm producer.
ODc is deﬁned as three standard deviations (SD) above the mean
OD of the negative control. Isolates were also compared in regards
to a few parameters: clinical or commensal and animal sources. A
subgroup of C. perfringens isolates (n = 18) was randomly selected
for further characterization (Table 1). These were from the col-
lection of isolates recovered in this study from seven processing
plants. To those was added C. perfringens ATCC 13124 as a positive
control.
ANTIMICROBIAL SUSCEPTIBILITY TESTING
The subset of isolates was tested for MICs as previously described
in the CLSI M11-A8 document (CLSI, 2012). Brieﬂy, colonies
of C. perfringens, from a 24 h culture grown at 37◦C on blood
agar plates (Oxoid) under anaerobic conditions, were resuspended
into 5 mL of saline to achieve a 0.5 McFarland turbidity. This
adjusted inoculumwas then diluted 1:75 in supplemented Brucella
broth. 50 μL of this suspension was then transferred to individual
wells on microplates containing antibiotics. The microplates were
sealed and incubated in an anaerobic chamber for 48 h at 37◦C.
Antimicrobials tested were penicillin, lincomycin, virginiamycin,
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tylosin, salinomycin, narasin, and monensin (all from Sigma).
For bacitracin susceptibility testing, the Etest technique was used
as described earlier (Charlebois et al., 2012). Isolates with MIC
higher than 256 μg/mL by Etest were tested with the microdilu-
tions broth technique to determine the exact MIC. C. perfringens
ATCC 13124 was used as a control. Breakpoint for penicillin
(2 μg/mL) is available from CLSI M11-A8. There is a previously
published breakpoint for bacitracin (16μg/mL) that is widely used
in the literature (Chalmers et al., 2008; Charlebois et al., 2012). No
other breakpoints are available for the antimicrobials tested in this
study.
BIOFILM TOLERANCE TO OXYGEN, ANTIBIOTICS AND ANTICOCCIDIALS
A subgroup of C. perfringens isolates (n = 18) was randomly
selected from the collection of isolates recovered in this study
from seven processing plants. These isolates were tested for their
tolerance to oxygen and antibiotics when grown as bioﬁlms.
Bioﬁlms were cultured in triplicates as described above and
the initial ATP levels were measured with the BacTiter Glo kit
(Promega, Madison, WI, USA) in accordance with the manufac-
turer’s instructions. After 6 days of incubation, the supernatants
were removed and replaced with TSB-glucose in the bioﬁlm
cultures. The supernatants of the bioﬁlm containing the plank-
tonic cells were centrifuged and resuspended in fresh TSB-glucose
medium. Planktonic cells were then transferred to fresh tissue cul-
ture plates. For both the bioﬁlm cultures and planktonic cells, the
antibiotic and oxygen tolerance assays were performed. Brieﬂy,
plates were incubated anaerobically at 44◦C with 1.5 mg/mL of
bacitracin, 20 μg/mL of penicillin, 512 μg/mL of lincomycin,
4 μg/mL of virginiamycin, 256 μg/mL of tylosin, 1 μg/mL of
narasin, 2 μg/mL of salinomycin, or 4 μg/mL of monensin (all
antimicrobials from Sigma) for 6 or 24 h. These concentrations
of antimicrobials correspond to two times the highest MIC found
among the isolates of the random group. The effects of differ-
ent combinations of anticoccidials and antibiotics (monensin,
narasin, or salinomycin with bacitracin, tylosin, or virginiamycin)
on pre-formed bioﬁlms were also analysed. For the oxygen tol-
erance assay, plates were incubated aerobically at 44◦C for 6 or
24 h. After the oxygen and antimicrobial treatments, the ATP
levels were measured with the BacTiter Glo kit. Percentages of
survival were calculated by dividing the ﬁnal ATP level by the ini-
tial ATP level. Treatment with penicillin was used as a positive
control. The effect of low doses of antibiotics and anticoccidials
on bioﬁlm formation was assessed on the randomly selected C.
perfringens isolates (n = 18). Brieﬂy, bioﬁlms were cultured as
described above with the exception that antibiotics were added at
a concentration of 0.1× the MICs of each isolate before incuba-
tion. All plates were incubated anaerobically at 44◦C for 6 days
in a sealed container. All isolates were done in triplicates. To
quantify the bioﬁlm formation, the crystal violet assay was used
as described above. Control wells were incubated with medium
only.
EFFECTS OF ENZYMATIC TREATMENTS ON BIOFILM FORMATION
Bioﬁlms of the selected C. perfringens isolates (n = 18) were
grown for 6 days in TSB supplemented with 10 mM of glucose
as described above. Wells were washed 2x with distilled water and
then ﬁlled with 100 μL of PBS containing 20 μg/mL of dispersin B
(Kane Biotech Inc.,Winnipeg, MB, Canada) as described by Izano
et al. (2007), or 100 μg/mL of DNase I or proteinase K (Kaplan
et al., 2004; Grasteau et al., 2011). Plateswere incubated at 37◦C for
5 min for the dispersin B or 1 h for the DNase I and the proteinase
K. For the cellulase treatment, wells were ﬁlled with 120 U/mL of
cellulase and then incubated at 45◦C for 72 h (Jain and Bhosle,
2008). After incubation, wells were washed once with distilled
water and stained with crystal violet. Staphylococcus aureus ATCC
25923 was used as a positive control for all treatments.
SCANNING LASER CONFOCAL MICROSCOPY
Bioﬁlms of the selected C. perfringens isolates (n = 18) were grown
in 96-well plates as described above with or without low doses of
bacitracin. Plates were incubated for 6 days at 44◦C under anaer-
obic conditions. After incubation, wells were washed two times
with PBS to remove unattached cells. 100 μL of PBS contain-
ing the ﬂuorescent FM 1-43 stain (Invitrogen, Burlington, ON,
Canada), was added to each well to allow visualization of individ-
ual bacteria by laser confocal microscopy. In addition, 50 μg/mL
of calcoﬂuor white dye (Sigma), which is speciﬁc for beta-1,3 and
beta-1,4 linkages in polysaccharides, was added to each well. This
stain was selected because it was previously shown to bind to
C. perfringens bioﬁlm matrix (Varga et al., 2008). After incuba-
tion at room temperature for 30 and 15 min, respectively, wells
were washed with 200 μL of sterile distilled water. Before read-
ings, 100 μL of sterile distilled water was added to each well. An
Olympus FV1000 IX81 laser confocal microscope was used to col-
lect three-dimensional images of the bioﬁlms. An argon laser set
at 472 nm was used to excite the FM 1-43 dye (emission green)
and a UV laser at 364 nm to excite the calcoﬂuor white dye (emis-
sion blue). The images were processed using Fluoview software
(Olympus). For the matrix composition, the bioﬁlms were cul-
tured as described above. The ﬂuorophores assay was done as
described previously (Wu et al., 2013a). Brieﬂy, after the incuba-
tion, the wells were ﬁlled with 100 μL of Wheat Germ Agglutinin
(WGA) – Oregon Green 488, Sypro Ruby Red or BOBO-3 (all
from Invitrogen). WGA was diluted 1/100 in PBS whereas BOBO-
3 was diluted 1/1500 in water. Sypro Ruby Red was used as
described by the manufacturer. Plates were incubated for 30 min
at room temperature in the dark then washed once with water
and ﬁlled with 100 μL PBS. The plates were observed by con-
focal microscopy. The excitation/emission wavelengths for the
ﬂuorophores were as follow: 496/524 nm (WGA), 450/610 nm
(Sypro Ruby Red), and 570/602 nm (BOBO-3). The images
were processed using Fluoview software (Olympus). Staphylo-
coccus aureus ATCC 25923 was used as a positive control for all
ﬂuorophores.
STATISTICAL ANALYSIS
The statistical signiﬁcance (p value) of differences in bioﬁlm
between the animal origin or commensal and clinical isolates were
calculated with an unequal variance linear model. A Student t-
test was used for the bioﬁlm tolerance to oxygen and antibiotics
assays, the low-dose and the enzymatic treatments. A p < 0.05
was considered to be signiﬁcant. Statistics were done with the SAS
software v.9.1. (Cary, NC, USA).
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RESULTS
BACTERIAL ISOLATES
A total of 277 C. perfringens isolates of poultry (clinical, n = 14;
commensal, n= 136), swine (clinical, n= 34; commensal, n= 50),
human (clinical, n = 9), and other animal origins [clinical isolates
from cows (n = 12), sheep (n = 10), goats (n = 3), horses (n = 3),
deer (n = 1), duck (n = 1), alpaca (n = 1), cat (n = 1), dog
(n = 1), and hare (n = 1)] were isolated for this study. A total of
273 isolates were of type A and 4 of type D. Type D isolates were
found in clinical samples from bovine (n = 1) and ovine (n = 3).
BIOFILM GROWTH AND QUANTIFICATION
Most of the C. perfringens isolates tested were able to form bioﬁlm
(n = 230/277) in the conditions used in this study. The OD val-
ues at 570 nm (OD570) ranged from 0.009 to 0.489 (Figure 1)
indicating that bioﬁlm formation can vary among tested iso-
lates. Of those, strong (n = 7), moderate (n = 42), and weak
(n = 181) bioﬁlm producers were observed. Bioﬁlm forma-
tion was compared among clinical and commensal isolates of
C. perfringens of animal origin to test whether there is a dif-
ference between these two groups of isolates. The mean OD
value of bioﬁlm formed by clinical isolates originating from
swine was signiﬁcantly higher (p < 0.05) than the mean OD
value of their commensal counterparts (Figure 1). However, no
difference in bioﬁlm formation was observed between clinical
and commensal isolates of poultry origin (p > 0.05). The low
number of clinical poultry isolates was likely not sufﬁcient to
allow a statistical signiﬁcance to be seen. Also, bioﬁlm forma-
tion was compared among isolates of C. perfringens of different
animal origins. No signiﬁcant difference in bioﬁlm formation
was observed between isolates recovered from swine, poultry,
human, and other animal origins (p > 0.05). Again, the low
number of human and other animal species isolates was likely
not sufﬁcient to allow a statistical signiﬁcance to be seen. A
FIGURE 1 | Biofilm formation by C. perfringens isolates. Bioﬁlm
formation of C. perfringens strains in 96-well plates, measured after 6 days
as described in Section “Materials and Methods.” The p values were
calculated using a linear model for unequal variances. Each dot represents
the mean of the replicates for each strain. The bars represent the mean
values of each group.
subgroup of C. perfringens isolates (n = 18) were randomly
selected for further characterization (Table 1). These were from
the collection of isolates recovered in this study from seven pro-
cessing plants. To those, we included the C. perfringens ATCC
13124. The following categories were covered in this subgroup:
commensal, clinical, swine, poultry, human, and different lev-
els of bioﬁlm productions. However, C. perfringens isolates of
other animal species from this study are not represented in this
subgroup.
ANTIMICROBIAL SUSCEPTIBILITY TESTING
Isolates tested (n = 19) demonstrated low MICs to penicillin
(0.002–0.12 μg/mL), virginiamycin (0.12–2 μg/mL), narasin
(0.03–0.25 μg/mL), salinomycin (0.015–1 μg/mL), and monensin
(0.015–2 μg/mL; Table 1). For bacitracin, 13 isolates were sus-
ceptible (0.75–16 μg/mL) and 5 were resistant (256–512 μg/mL).
For lincomycin, MICs between 0.5 and 512 μg/mL were observed
whereas for tylosin, MICs between 0.5 and 128 μg/mL were
obtained.
BIOFILM TOLERANCE TO OXYGEN, ANTIBIOTICS AND ANTICOCCIDIALS
In the atmospheric oxygen tolerance assays, the mean viability
rates of planktonic cells after exposure to oxygen for 6 and 24 h
were 63 and 7.4%, respectively (Figure 2A). However, the viability
rates were higher (80.6% of viable cells after 6 h and 61% after
24 h) when C. perfringens cells were organized in bioﬁlm. Data
between planktonic cells and bioﬁlm, obtained after an incuba-
tion of 24 h, were signiﬁcantly different (p < 0.05) (Figure 2A).
For the antibiotic and anticoccidials tolerance assays, planktonic
cells had between 7.0 and 69.1% of viability after 6 h exposure and
between 1.2 and 20.7% of viability after 24 h exposure to antibi-
otics or anticoccidials. On the other hand, cells in bioﬁlm had
between 32.7 and 65.0% of viability, and between 14.3 and 47.1%
of viability for the same periods of time, corresponding to a 0.6-
to 9-fold-increased survival rate after 6 h and to a 0.8- to 36-fold-
increased survival rate after 24 h over planktonic cells. Viability
rates for cells in bioﬁlm were signiﬁcantly higher (p < 0.05) than
those observed for planktonic cells (Figures 2B–I). Antibiotics
and anticoccidials were also used in combination to determine
if there was a synergistic activity toward cells of C. perfringens
ATCC 13124 within a bioﬁlm (Table 2). A higher activity was
observed for six combinations but these resultswere not signiﬁcant
(p > 0.05).
BACTERIAL EXPOSURE TO LOW DOSES OF ANTIBIOTICS AND
ANTICOCCIDIALS
After exposure of isolates (n = 19) to low doses of antibiotics and
anticoccidials, no clear trend was observed for bacitracin, tylosin,
virginiamycin, and monensin (Figures 3A,B,D,H) but a few iso-
lates showed an increase in bioﬁlm formation when exposed to
those compounds. However, exposure to low doses of penicillin,
lincomycin, salinomycin, and narasin tended to lead to a diminu-
tion of the bioﬁlm formed (Figures 3C,E,F,G). This phenomenon
was particularly observed within the poultry clinical group of iso-
lates. No other trends could be observed. Statistically signiﬁcant
results are indicated in Figure 3 (p < 0.05).
www.frontiersin.org April 2014 | Volume 5 | Article 183 | 42
Charlebois et al. Bioﬁlm of Clostridium perfringens and its exposure to antimicrobials
FIGURE 2 |Viability of planktonic cells compared to cells in biofilm
following exposure to oxygen and antimicrobials. C. perfringens
6-days-old bioﬁlms and planktonic cultures were exposed to (A) atmospheric
oxygen, (B) 1.5 mg/mL of bacitracin, (C) 20 μg/mL of penicillin, (D) 512 μg/mL
of lincomycin, (E) 4 μg/mL of virginiamycin, (F) 256 μg/mL of tylosin, (G)
4 μg/mL of monensin, (H) 2 μg/mL of salinomycin, or (I) 1 μg/mL of narasin
for the times indicated. Differences in survival of planktonic cells [P] versus
bioﬁlm [B] at each time were compared using Student’s t -test. *p < 0.05.
The error bars represent standard deviations. Results presented are for strain
C. perfringens ATCC 13124. For all isolates, statistically signiﬁcant increases
in viabilities were observed for bacteria in bioﬁlms compared to planktonic
cells.
SCANNING LASER CONFOCAL MICROSCOPY
Using laser confocalmicroscopy, bioﬁlmsof tested isolates (n=19)
were stainedwith the ﬂuorescent dyes SYPRORubyRed,WGAand
BOBO-3 in order to visualize extracellular proteins, poly-beta-1,6-
N-acetyl-D-glucosamine (PNAG) exopolysaccharide and DNA,
respectively. Extracellular proteins and DNA were visible in
bioﬁlms of all tested isolates (Figure 4). However, PNAG was
absent from the bioﬁlm formed by C. perfringens isolates. Binding
of calcoﬂuor white to the bioﬁlm matrix was observed. Cal-
coﬂuor white binds to polysaccharides with beta-1,3 and beta-1,4
Table 2 |Viability (%) of C. perfringens strain ATCC 13124 in biofilm
after 24 h incubation with antibiotics and anticoccidials alone or in
combinations.
Alone Monensin Salinomycin Narasin
Alone 100 65.5 79.5 61.8
Bacitracin 74.2 74.4 67.4 59.0
Virginiamycin 70.5 62.9 58.4 72.1
Tylosin 69.1 77.8 55.9 59.8
Values underlined: values of the combination lower than the antimicrobials used
alone.
linkages. Six isolates (C. perfringens c1261_A, c3807_A, ATCC
13124, SHY07-383, FMV-CP23 and c3437_A) were randomly
selected to further analyse their bioﬁlms in the presence of low
dose of bacitracin (0.3 × MIC). The bioﬁlms of these iso-
lates grown in the presence of bacitracin were approximately
between 35 and 80 μm in height, whereas bioﬁlms formed
without bacitracin were thinner with elevations between 30 and
60 μm (Table 3). It was also found that ﬁve of them showed an
increase in the area occupied by bacteria in the bioﬁlm follow-
ing exposure to low doses of bacitracin (Table 3). Laser confocal
microscopy images showed that the bioﬁlm formed by the C. per-
fringens isolates (n = 6) were mainly ﬂat (Figure 5A) with the
exception of one isolate demonstrating a mushroom-like bioﬁlm
(Figure 5B).
ENZYMATIC TREATMENTS ON BIOFILM FORMATION
Dispersion of the bioﬁlm matrix of C. perfringens iso-
lates (n = 19) was not observed with dispersin B enzy-
matic treatment conﬁrming that PNAG is absent from
the matrix formed by the tested C. perfringens isolates.
However, proteinase K, cellulase, and DNase I enzy-
matic treatments signiﬁcantly dispersed the preformed bioﬁlm
(p < 0.05) indicating the presence of proteins, beta-1,4
linked polysaccharides and extracellular DNA in the matrix
(Figure 6).
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FIGURE 3 | Effect of low-dose antimicrobials on biofilm formation.
Bioﬁlm formation of C. perfringens strains in 96-well plates in presence of
0.1× MIC of bacitracin (A), tylosin (B), penicillin (C), virginiamycin (D),
lincomycin (E), salinomycin (F), narasin (G), or monensin (H), measured as
described in Section “Materials and Methods.” Strains are in the following
order: c1261_A, c2188_B, c3336_B, c3342_A, c3342_B, c3437_A, c3807_A,
ATCC 13124, CCRI-16276, FMV-CP4, FMV-CP23, FMV-CP71, 1285414,
1304504, SHY07-383, STF2003-1256, 2006-4758, CP4, and JGS 4143.
Results are expressed as percentages of the control not exposed to
antibiotics. Conditions were compared to the control bioﬁlm using Student’s
t -test.*p < 0.05. The error bars represent standard deviation. Black bands
represent poultry clinical isolates.
FIGURE 4 | Matrix composition of C. perfringens biofilm. Representative
results of the matrix composition of C. perfringens bioﬁlm observed with
ﬂuorescent probes. Staphylococcus aureus ATCC 25923 was used as a
positive control for all ﬂuorophores. FM1-43: bacterial cells; BOBO-3:
extracellular DNA,WGA: PNAG; Ruby Red: proteins; Calcoﬂuor white:
beta-1,3 and beta-1,4 linked polysaccharides.
DISCUSSION
Most of the tested isolates in this study which originated from
various animal species were able to form bioﬁlm at various
degrees in the conditions used. Optimized bioﬁlm growth con-
ditions were different than those previously described (Varga
et al., 2008; Donelli et al., 2012). However, results of this study
are in accordance with the ones obtained by Varga et al. (2008)
where all sequenced strains of C. perfringens (biotypes A of
ATCC 13124, 13, and SM101), as well as representatives of
type C, D, and E strains which cause infections in animals were
shown to form bioﬁlms with OD values between 0.07 and 0.5
(Varga et al., 2008). Donelli et al. (2012) were able to obtain
a higher bioﬁlm formation for C. perfringens strain CpeBs31
in their study, with a mean OD of 3.2, which classiﬁed this
isolate as strongly adherent under the following conditions:
BHI supplemented with 1% glucose and 48 h incubation at
37◦C (Donelli et al., 2012). This strain was not tested in our
study.
In the present study, clinical isolates recovered from swine
formed signiﬁcantly more bioﬁlm than their commensal coun-
terparts. In Salmonella typhymurium, it was found that clinical,
outbreak-associated and retail product isolates produced thicker
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Table 3 | Effect of subinhibitory concentrations of bacitracin on biofilm
formation as analyzed by scanning laser confocal microscopy.
Isolates Total height
(μm)
Matrix
(μm)
Cells
(μm)
Increased
bioﬁlm
c1261_A 35 18 17
c1261_A + bacitracin 60 40 20
c3807_A 45 35 10
c3807_A + bacitracin 75 40 35
c3437_A 30 22 8
c3437_A + bacitracin 80 50 30
SHY07-383 50 25 25
SHY07-383 + bacitracin 55 20 35
Decreased
bioﬁlm
ATCC 13124 45 33 12
ATCC 13124 + bacitracin 40 23 17
FMV-CP23 60 35 25
FMV-CP23 + bacitracin 35 20 15
bioﬁlms compared to isolates recovered from food (Castelijn et al.,
2012). Reisner et al. (2006) did not observe an increased bioﬁlm
formation in human clinical strains of intestinal Escherichia coli.
Skyberg et al. (2007) also found that isolates of Escherichia coli
recovered from healthy birds produced signiﬁcantly stronger
bioﬁlms than isolates from cases of avian colibacillosis. In Lis-
teria monocytogenes, it was found that isolates from food formed
more bioﬁlm than clinical isolates recovered from cases of liste-
riosis (Barbosa et al., 2013). For C. perfringens, bioﬁlm formation
could play a role in the development of the disease because bioﬁlm
can help bacteria adhere to surfaces, and this facilitates coloniza-
tion and infection. Moreover, the ability to grow as a bioﬁlm favors
survival of bacteria in the environment (Semenyuk et al., 2014). In
this study, it was observed that clinical isolates of swine C. perfrin-
gens formed more bioﬁlms suggesting these isolates might survive
longer in the environment.
C. perfringens is known to be an aerotolerant bacterium capa-
ble of surviving in soil or water (Rood and Cole, 1991). Results
obtained with the atmospheric oxygen tolerance assays showed
that the bioﬁlm could protect C. perfringens cells from oxy-
gen stress. Varga et al. (2008) obtained similar results in their
study. The involvement of bioﬁlm in oxygen tolerance has already
been described in Fusobacterium nucleatum, another anaerobic
bacterium (Gursoy et al., 2010). The present study also showed
that the bioﬁlm could protect C. perfringens from high concen-
trations of antibiotics and anticoccidials. Increased survival of
C. perfringens cells in bioﬁlm following penicillin G exposure
have been described elsewhere (Varga et al., 2008). Interestingly,
virginiamycin, tylosin, and the three anticoccidials (namely mon-
ensin, narasin, and salinomycin) had good activity against cells
in bioﬁlm, decreasing the viability below 50%. Virginiamycin has
already been found to be active against bioﬁlms formed by some
strains of Lactobacillus spp. (Rich et al., 2011) but to our knowl-
edge, the effects of tylosin and anticoccidials on bioﬁlm have never
been described. Results could not be subdivided between bac-
tericidal and bacteriostatic antimicrobials because bacteriostatic
antimicrobials used at high concentrations likely become bacte-
ricidal (Pankey and Sabath, 2004). The reverse is also reported,
bactericidal agents used at low doses likely become bacteriostatic
(Pankey and Sabath, 2004). In the bioﬁlm tolerance assay, antimi-
crobials were used at high concentrations indicating that tylosin
and lincomycin are both likely acting as bactericidal in this exper-
iment. In the bacterial exposure to low doses of antimicrobials
assay, all antimicrobials likely became bacteriostatic due to the low
doses used in this experiment. Moreover, in the present study, dif-
ferent combinations of antibiotics and anticoccidials were assessed
for their activity against cells in bioﬁlm. In general, the viability
in the bioﬁlm tended to be lower when exposed to a combination
FIGURE 5 | Biofilm morphologies observed by scanning laser confocal microscopy. Bioﬁlms formed by the C. perfringens c3437_A isolate (A) or by the
C. perfringens SHY07-383 isolate (B) after 6 days of incubation. Blue: exopolysaccharides (Calcoﬂuor white); Green: bacteria (FM 1–43).
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FIGURE 6 | Effect of enzymatic treatments on pre-formed
C. perfringens biofilm. DNase, proteinase K, cellulase, and dispersin B
effects on pre-formed bioﬁlm of C. perfringens. Data were measured as
described in Section “Materials and Methods.” Results are the average of
all strains tested and are expressed as a percentage of the control. The
error bars represent standard deviation.*p < 0.05.
compared to either component used alone. Different combina-
tions of antibiotics have already been described to be active against
bioﬁlm of Staphylococcus epidermidis, methicillin-resistant and
-susceptible Staphylococcus aureus (MRSA and MSSA), P. aerug-
inosa, and Enterococcus faecalis (Saginur et al., 2006; Tre-Hardy
et al., 2008; Holmberg et al., 2012;Wu et al., 2013b). This tolerance
to antimicrobial agents observed in bioﬁlm makes the treatment
of these infections generally ineffective. For C. perfringens, it has
been hypothesized that bioﬁlm formation by this organism in the
small intestine could contribute to antibiotic-associated diarrhea,
a form of non-food-borne enteritis associated with antibiotic use,
by facilitating in bacterial persistence through antibiotic treatment
(Varga et al., 2008).
Because it has been described that low doses of antibiotics can
either reduce or increase the bioﬁlm production in other bacte-
ria (Cerca et al., 2005; Hoffman et al., 2005; Majtan et al., 2008;
Kaplan, 2011), the effect of low concentrations of antibiotics and
anticoccidials on C. perfringens bioﬁlm formation was studied by
microplates assays. No clear trend was observed when exposed
to low doses of antibiotics with the exception of penicillin, lin-
comycin, salinomycin, and narasin. In these cases, less bioﬁlm
was detected in the majority of isolates. Also, the effect of the
antibiotics and anticoccidials on the bioﬁlm varied depending on
the strain tested indicating that this phenomenon is strain depen-
dent. These variations among strains have also been observed for
Staphylococcus epidermidis exposed to 0.5× the MIC of cefazolin,
vancomycin, and dicloxacillin, and for Streptococcus pyogenes
exposed to 0.015× to 0.5× the MIC of ﬂuoroquinolones (Hen-
riques et al., 2005; Balaji et al., 2013). To further analyse the effect
of low doses of bacitracin on C. perfringens bioﬁlms, laser confocal
microscopy was used. An increase in the area occupied by bacte-
ria was observed in bioﬁlms exposed to low doses of bacitracin.
This increased area occupied by bacteria has also been observed in
Staphylococcus epidermidis bioﬁlms exposed to 0.25× the MIC of
erythromycin, in P. aeruginosa bioﬁlms exposed to 0.25X the MIC
of imipenem and in Streptococcus intermedius bioﬁlms exposed
to sub-MICs of ampicillin, ciproﬂoxacin, and tetracycline (Bagge
et al., 2004; Ahmed et al., 2009; Wang et al., 2010).
To analyse the structure of C. perfringens bioﬁlms, laser con-
focal microscopy was used and results obtained were consistent
with the ones found in the study of Varga et al. (2008). In this
study, most of the bioﬁlms analysed in confocal microscopy were
ﬂat with one exception that showed a mushroom-like structure.
To our knowledge, this is the ﬁrst description of a mushroom-
like bioﬁlm in C. perfringens. For the matrix, it was found that
the bioﬁlm of C. perfringens contained polysaccharides, proteins,
and extracellular DNA. Proteins and carbohydrates have already
been described as components of C. perfringens bioﬁlms (Varga
et al., 2008). In addition to polysaccharides and proteins, extra-
cellular DNA was also found to be a part of the matrix. The
presence of extracellular DNA in the matrix of the bioﬁlm has
been described in other Grampositive bacteria (Barnes et al., 2012;
Domenech et al., 2012; Kaplan et al., 2012) but to our knowledge,
not in Clostridia. The mechanisms by which the DNA is released
in bioﬁlms are poorly understood but autolysis of cells has been
hypothesized to mediate DNA release (Bayles, 2007; Ma et al.,
2009). In Enterococcus faecalis, the release of extracellular DNA
by autolysis is regulated by the action of the two proteases GelE
and SprE (Thomas et al., 2008) whereas in Staphylococcus aureus, a
ﬁnely tuned holin/antiholin system is thought to mediate cell lysis
and programmed cell death (Bayles, 2007; Rice and Bayles, 2008).
A previous study has revealed no extracellular DNA in bioﬁlms
of both Bordetella bronchiseptica strain 276 and Escherichia coli
strain ECL 17602 using confocal laser scanning microscopy (Wu
et al., 2013a), indicating that extracellular DNA is not a compo-
nent of all bioﬁlms. The presence of PNAG in the bioﬁlm was
studied because it is one of the most common and extensively
studied matrix EPS (Jacques et al., 2010). In this study, PNAG was
absent from C. perfringens bioﬁlm matrix. This has been observed
in other bacteria (Wu et al., 2013a). Binding of calcoﬂuor white
to the bioﬁlm indicated that polysaccharides with beta-1,3 and
beta-1,4 linkages, such as cellulose, are part of the matrix. To con-
ﬁrm this hypothesis, bioﬁlms were treated with cellulase (Jain and
Bhosle, 2008). It was observed that this enzyme could disperse the
bioﬁlmof C. perfringens conﬁrming, for the ﬁrst time, the presence
of beta-1,4 linked polysaccharides in the matrix.
In conclusion, this study reports for the ﬁrst time the pres-
ence of extracellular DNA and beta-1,4 linked polysaccharides
in the matrix of C. perfringens bioﬁlms. This study also demon-
strated that virginiamycin, tylosin, and anticoccidials were active
against C. perfringens cells in bioﬁlm. Exposure to low doses of
penicillin, lincomycin, salinomycin, and narasin tended to lead
to a diminution of the bioﬁlm formation. Further studies are
needed to characterize the exopolysaccharides found in the matrix
and to identify the genes involved in the bioﬁlm formation in C.
perfringens.
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Fungi are increasingly recognized as major pathogens in immunocompromised individuals.
With the increase in the number of fungal infections each year and the development
of resistance to current therapy, new approaches to treatment including stimulation of
the immune response in addition to concurrent pharmacotherapy is ongoing. The most
common invasive fungal infections are caused by Candida spp., Aspergillus spp., and
Cryptococcus spp. Amphotericin B (AmB) has remained the cornerstone of therapy against
many fulminant fungal infections but its use is limited by its multitude of side effects.
Echinocandins are a newer class of antifungal drugs with activity against Candida spp. and
Aspergillus spp. and constitutes an alternative to AmB due to superior patient tolerability
and fewer side effects. Due to their oral delivery, azoles continue to be heavily used for
simple and complex diseases, such as ﬂuconazole for candidal vaginitis and voriconazole
for aspergillosis. The objective of this paper is to present current knowledge regarding
the multiple interactions between the broad spectrum antifungals and the innate immune
response, primarily focusing on the toll-like receptors.
Keywords: antifungals, amphotericin B, echinocandins, caspofungin, voriconazole, toll-like receptors
INTRODUCTION
Fungal species are ubiquitous in the environment an estimated
1.5 million are known to exist (Hube, 2009). Only a few species
are actually true pathogens in humans. Opportunistic fungi can
cause life threatening infections ranging from superﬁcial to deep
seated infections in immunocompromised patients. In develop-
ing countries fungal infections affect both immunocompromised
and immunocompetent individuals in areas that are endemic to
mycoses (Brown et al., 2012). Fungal infections have increased
over the last few decades and this can be correlated to increased
invasive medical management, immunosuppressed patients either
from acquired infections or from treatment induced deﬁciencies
(Pfaller and Diekema, 2007). Interestingly, fungi are the fourth
main cause of hospital acquired infections in populations “at-
risk” despite the availability of antifungal treatment. This point
illustrates the need for further study to identify more efﬁcient
ways to combat these interesting pathogens. It is often chal-
lenging to treat fungal infections because current methods to
identify particular species are not always reliable or accurate result-
ing in delayed or inappropriate treatment (Perlin, 2011; Pfaller,
2012).
Amphotericin B (AmB) is a polyene antifungal agent ﬁrst iso-
lated from Streptomyces nodosus in 1955, from Venezuelan soil
samples near the Orinoco River region (Dutcher, 1968). AmB
is selectively toxic toward fungal cells, displaying high afﬁn-
ity for ergosterol, subsequently destabilizing fungal membranes
(refer to Table 1 – “Commonly used systemic antifungal drugs”
for mechanism of action of common antifungals). It is primar-
ily used in systemic fungal infections caused by Histoplasma,
Coccidioides, Candida, Blastomyces, Rhodotorula, Cryptococcus,
Sporothrix, Mucor and Aspergillus spp. and the drug has remained
the cornerstone of the therapy against fulminant fungal infections
(Ellis, 2002). AmB also has activity against some protozoans, and
prions (Adjou et al., 1997; Kafetzis et al., 2005). AmB is ampho-
teric as well as amphipathic, has a low therapeutic index, and is
associated with signiﬁcant dose-related nephrotoxicity (Fanos and
Cataldi, 2000), as well as acute, infusion-related febrile reactions
(Khoo et al., 1994). Lipid-based formulations of AmBhave allowed
patients to receive higher doses while sparing toxicity (Hiemenz
and Walsh, 1996). AmB also stimulates the production of inﬂam-
matory cytokines (TNF-α, IL-1β, IL-6, IL-8), chemokines (MCP-1,
MIP-1β, IL-8), prostaglandins, and nitric oxide (Cleary et al., 1992;
Arning et al., 1995; Razonable et al., 2005). In addition to its direct
antifungal activity,AmB activates toll-like receptors (TLRs), which
contribute to the cytokine responses.
Echinocandins are a newer class of antifungal drugs that display
a uniquemechanism of action, inhibiting the synthesis of 1,3-β-D-
glucan in the cell wall, through the inhibition of the enzyme 1,3-β
glucan synthase (Morris and Villmann, 2006; Fera et al., 2009).
Besides having a structural role, β-D-glucan also demonstrates
potent immunostimulatory properties mediated by the innate
immune receptor Dectin-1, as well as TLRs and C-type lectin
receptors, which are expressed on host cells (Brown, 2006;Wheeler
et al., 2008). Following binding, echinocandins induce the acti-
vation of phagocytic and proinﬂammatory responses (Dennehy
and Brown, 2007). The echinocandins’ antimicrobial spectrum
includes most of the Candida spp. strains,Aspergillus spp., and has
some activity against Pneumocystis jiroveci (Denning, 2002). The
advantages of echinocandins include long half-life allowing daily
dosing, no dose adjustment in renal impairment or hemodialysis,
minimal adverse effects, and limited drug interactions (Denning,
2002).
Human TLRs are closely related to the toll receptors in
Drosophila melanogaster, and they are important for defense
www.frontiersin.org March 2014 | Volume 5 | Article 99 | 49
Mihu et al. The immunomodulatory effects of antifungals
Table 1 | Commonly used systemic antifungal drugs [as reviewed by Lewis (2011)].
Mechanism Class Drugs
Cell membrane
Ergosterol inhibitors/binders
Azoles (14-α demethylaseinhibitors) Triazoles
Fluconazole, itraconazole, voriconazole, posaconazole,
Polyenes (ergosterol binding) Amphotericin B
Allylamines (squalene monooxygenase) Terbinaﬁne
Cell wall
B-1,3 D-glucan synthesis
Echinocandins (β-1,3 D-glucan synthesis inhibitors) Anidulafungin, caspofungin, micafungin
Intracellular Pyrimidine analogs/thymidylate synthase inhibitor Flucytosine
Mitotic inhibitor Griseofulvin
against microbial infection (Medzhitov et al., 1997). TLRs are a
class of proteins that play a critical role in the immune systems
response to invading pathogens. They are found in tissues involved
in immune function, as well as in tissues exposed to the exter-
nal environment (the respiratory and the gastrointestinal tract).
Ten TLRs have been identiﬁed in humans (TLR1–TLR10). They
recognize structural repeating sequences known as pathogen-
associated microbial patterns which are expressed by microbial
pathogens, or danger-associated molecular patterns that are
endogenous molecules released from necrotic cells and stimu-
late the release of inﬂammatory cytokines (Newton and Dixit,
2012). Some of the most important TLRs are TLR1 which recog-
nize pathogen-associated molecular pattern with a speciﬁcity for
Gram-positive bacteria, TLR2s that recognizemany bacterial, fun-
gal, viral, and certain endogenous substances, TLR4 which detects
lipopolysaccharide fromGram-negative bacteria and TLR9, which
is expressed by numerous cells of the immune system such
as dendritic cells, B lymphocytes, monocytes, and natural
killer cells and recognizes unmethylated CpG sequences in DNA
molecules.
AMPHOTERICIN B AND TLRs
AmB stimulates multiple TLRs, namely TLR1, TLR2, TLR4. Sau
et al. (2003) demonstrated that TLR2 and CD14 receptors play
an important role in the release of the inﬂammatory cytokines
TNF-α and IL-8. Moreover, TLR2 has a key role in the release of
IL-1β. Peritoneal macrophages, isolated from murine cells lack-
ing TLR2, failed to release TNF-α, IL-1β, and IL-8 in response to
AmB stimulation, in comparison with peritoneal macrophages
isolated from TLR2 positive mice, which displayed increased
inﬂammatory cytokine production. Furthermore AmB induced
TNF-α productionwas suppressed in peritonealmacrophages that
expressed mutant, non-functional TLR4. However, this effect was
observed only at higher AmB concentrations. The authors of the
study also demonstrated that TLR response to AmB was CD14
dependent. Therefore, CD14 positive cells produced TNF-α when
stimulated by AmB, whereas those which were CD14 negative did
not. Interestingly, lipid formulations of AmB did not elicit sig-
niﬁcant cytokine production and release from murine peritoneal
macrophages, possibly due to the low concentration of unbound,
non-lipid associated AmB (Sau et al., 2003).
The essential role of TLR1 in AmB induced cell activation was
proven by Razonable et al. (2005) using THP1monocytic cell line.
The preincubation of THP1 cells with murine anti-human TLR1
monoclonal antibody (anti-TLR1 MAb) reduced the production
of IL-6, IL-8, and TNF-α in response to AmB. Anti-TLR1 MAb
also inhibited IL-8 secretion in response to the TLR2–TLR1 ligand
Pam-3-Cys. Additionally, IL-8 inhibitionwith anti-TLR1MAbwas
superior than with anti-TLR2MAb and the addition of anti-TLR1
MAb augmented the degree of IL-8 inhibition by anti-TLR2 MAb
(Razonable et al., 2005).
To further characterize the inﬂuence of AmB on TLRs,
Bellocchio et al. (2005) showed that the expression of TLR2 and
TLR4 was activated upon exposure of neutrophils (human and
mice) to Aspergillus conidia. However, TLR4 was only stimulated
upon exposure to the fungal hyphae. AmB increased the expression
of TLR2, while liposomal AmB increased the expression of TLR4
in neutrophils. Using puriﬁed murine neutrophils, the authors
were able to demonstrate that both TLR4 activation and liposomal
AmB deter production of pro-inﬂammatory cytokines and stim-
ulate anti-inﬂammatory cytokines. Additionally, in the absence of
TLR4, liposomal AmB acts like deoxycholate AmB, stimulating the
release of inﬂammatory cytokines (Bellocchio et al., 2005).
In another study published by Matsuo et al. (2006) using
monocyte-like cell lines, the authors demonstrated that AmB
phosphorylates p65 of nuclear factor-kappaB. Further evidence in
the study suggested that this leads to stimulation of proinﬂamma-
tory cytokine production, mediated by receptors including TLR2
and NF-kappaB (Matsuo et al., 2006).
ECHINOCANDINS AND TLRs
The inﬂuence of echinocandins on the innate immune recep-
tors is achieved through the inﬂuence of these antifungals on
β-D-glucan. A report published by Moretti et al. (2012) demon-
strated that caspofungin inﬂuenced TLR2/Dectin-1 interactions,
as wells as Dectin-1 engagement with TLR4 and TLR9. Using
an invasive aspergillosis model in which two different strains
of Dectin-1/TLR2 deﬁcient murines were treated with caspo-
fungin, the authors found that at lower concentration of the
drug (0.1 mg/kg) the restricting activity on fungal growth was
preserved, as well as the inﬂammatory cell recruitment. How-
ever, this was dependent on the genetic background of the
host (C57BL/6 responded to treatment with caspofungin but
BALB/c did not). At higher doses (5 mg/kg) both types of
mutant mice had signiﬁcant restriction of fungal growth and
reduction of inﬂammatory cell recruitment. Both the protective
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(at 0.1 mg/kg) and the exacerbating (at 5 mg/kg) effects of
caspofungin were lost in TLR2 deﬁcient mice, indicating that
TLR2 is required for the antifungal activity of echinocan-
dins against aspergillosis. Furthermore, using TLR4 and TLR9
deﬁcient mice with invasive aspergillosis, the authors showed
that TLR4 contributes to the protective effect and TLR9 con-
tributes to the exacerbating effect of caspofungin (Moretti et al.,
2012).
Similarly, using a murine model of infective aspergillosis,
Moretti et al. (2013) studied the immunomodulatory activity of
echinocandins. Micafungin controlled cytokine response to A.
fumigatus by decreasing the expression of TNF-α and increas-
ing IL-10 release. The anti-inﬂammatory activity of micafun-
gin required IL-10 and occurred through signaling via the
TLR2/dectin-1 and TLR3/TRIF pathways (Moretti et al., 2013).
In another article published by Salvenmoser et al. (2010),
caspofungin treatment resulted in the highest upregulation of
TLR2 by A. fumigatus whereas exposure of C. albicans to caspo-
fungin let to the signiﬁcant upregulation of TLR4 and TLR9.
AZOLES AND TLRs
There seems to be a similar interaction of azoles on TLR and
subsequent immunomodulation, however, the data is limited.
In previously mentioned article published by Salvenmoser et al.
(2010), voriconazole treatment upregulated TLR2, TLR4, and
TLR9 by A. fumigatus. In another study by Simitsopoulou et al.
(2008) an additive antifungal effect was demonstrated when
voriconazole was combined with monocytes and A. fumigatus
hyphae. Both A. fumigatus hyphae and voriconazole induced
increased expression of TLR2 as well as TNF-α in monocytic cells
compared to untreated cells. The effects were seen when both were
used independently but more signiﬁcantly when used in combi-
nation. In contrast, TLR4 expression was not increased by either
voriconazole or fungal hyphae. In addition, signiﬁcantly more
NF-kappaB was translocated to monocyte cell nuclei treated with
voriconazole than untreated cells. The study suggests that TLR2
signaling, TNF-α, and NF-kappaB activation in the presence of
voriconazole proposes an immunomodulation effect leading to
a more efﬁcient response to A. fumigatus (Simitsopoulou et al.,
2008).
DISCUSSION
Fungi are increasingly recognized asmajor pathogens in immuno-
compromised individuals. Risk factors for invasive fungal infec-
tions include prolonged neutropenia, hematological malignancy,
transplantation (particularly bone marrow transplant), cytotoxic
drugs, and steroid therapy (Enoch et al., 2006).
The most common invasive fungal infections are candidiasis,
followed by aspergillosis and cryptococcosis (Shoham and Marr,
2012). Disseminated candidiasis is associated with a mortality in
excess of 25% (Kibbler et al., 2003), and represents the fourth
most common cause of nosocomial blood stream infection in
United States (Wenzel and Edmond, 2001). Invasive aspergillo-
sis is also associated with signiﬁcant morbidity and mortality,
lung, and heart–lung transplant recipients being at greatest risk of
infection, affecting 14–18%of patients (Hagerty et al., 2003). AmB
remains themost effective drug against fulminant fungal infections
but its use is limited by the multitude of side effects including
nephrotoxicity, infusion related toxicity, electrolyte abnormali-
ties, and others. Echinocandins are a newer class of antifungal
drugs with activity against Candida spp. and Aspergillus spp. and
constitutes an alternative to AmB due to a superior toleration
proﬁle and less side effects. The azoles used for systemic fun-
gal infections are triazoles and include ﬂuconazole, itraconazole,
voriconazole, and posaconazole. They inhibit the cytochrome
P450 dependent enzyme lanosterol 14-alpha-demethylase, thus
inhibiting the synthesis of ergosterol, which represents a vital com-
ponent of the cellular membrane of fungi (Zonios and Bennett,
2008). As outlined in this review, AmB, echinocandins, and some
of the studied azoles have long been used and their mechanisms
of action against fungi are well established. However, these drugs
also act on components of the innate immune system aiding in
the body’s natural defense against the infecting pathogens. As out-
lined in this review, TLRs seem to be signiﬁcant components in
this setting. The innate immune response has physical barriers
that provide protection from the environment which include the
skin and mucus membranes of the respiratory, gastrointestinal,
and genito-urinary tracts. Once fungi have invaded these barri-
ers they encounter a multitude of innate defenses that include
phagocytes, natural killer cells, T cells, B cells, and endothe-
lial cells (Blanco and Garcia, 2008). Generally the interaction
between antifungal therapy and the immune system is syner-
gistic. Chemotactic factors are produced at the site of fungal
infections, leading to activation of the complement pathway. The
synthesis of these chemotactic factors is stimulated by pathogen
associated molecular patterns, (PAMPs) that are recognized by
pattern recognition receptors (PRRs). PRRs include TLRs. PRRs
and TLRs activate PAMPs which signal the synthesis and release
of pro-inﬂammatory cytokines that activate the adaptive immu-
nity. A fungal pathogen activates multiple PRRs, which alerts
the immune system to respond with a broad range of possibili-
ties (Janeway and Medzhitov, 2002; Roeder et al., 2004; Romani,
2004). Antimicrobial peptides are other components of the innate
immune system that have an antimicrobial effect against fungi.
There exact mechanism is not known but they are likely to activate
andmediate the innate and adaptive immune response in infection
and inﬂammation. They also inactivate fungi by directly affecting
theirmembrane (Ganz, 2003;Aerts et al., 2008, Steinstraesser et al.,
2008).
Polymorphisms in TLR genes have been associated with a sus-
ceptibility to fungal infections. The type of infection depends
on which TLR has mutated. Recognition of Candida normally
occurs through PRRs such as TLRs. Plantinga et al. (2012) ana-
lyzed that TLR single nucleotide polymorphisms (SNPs) [R80T,
S248N, 1602S] on TLR1 were associated with candidemia in white
populations. This was not present in African American popula-
tions but this was attributed to the lower power in the smaller
study population. These polymorphisms also impaired cytokine
release by monocytes (Plantinga et al., 2012).
Invasive aspergillosis is a particular concern in patients that
have had hematopoietic-cell transplants, with its incidence rate
increasing. Despite the availability of new medications (azoles
and echinocandins) their outcome remains poor (Marr et al.,
2002). Aspergillosis activates the immune system through TLR4.
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Bochud et al. (2008) analyzed that donor TLR4 haplotypes (S3,
S4) increased the risk of invasive aspergillosis among recipients of
allogenic hematopoietic-cell transplants.
The ability of antifungals to simultaneously elicit an efﬁcient
immune response should be researched further for the potential
development of new drugs to induce effective activation of the
innate immune system via TLRs and subsequent pathways that
may synergistically help clear fungal infections.
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INTRODUCTION
Combined serendipitous and rational
drug-design and -retasking approaches
continue to identify many natural and syn-
thetic substances with multipurpose ther-
apeutic properties (Clark, 2013a). Among
these substances are Ca2+ modulators
capable of attenuating the transmission
and severity of viral, bacterial, fungal,
and protozoal infections (Clark and
Eisenstein, 2013; Clark et al., 2013). The
majority of purported Ca2+-modulating
antiinfective compounds belong to the
functional drug class termed Ca2+-
channel blockers, including traditional
synthetic 1,4-dihydropyridines, pheny-
lalkylamines, and benzodiazepines long
approved andmarketed for various human
and animal cardiovascular and neurolog-
ical indications (Clark and Eisenstein,
2013; Clark et al., 2013). Additional
Ca2+-modulating (putative) antiinfec-
tive substances, such as artemisinin,
caloxin, dantrolene, cyclosporin A, and
FK506, can be further categorized within
a broader set of natural and synthetic
compounds that affect operation of Ca2+
channels, transporters, exchangers, and/or
protein sensors of both hosts and infec-
tious agents (Clark and Eisenstein, 2013;
Clark et al., 2013). Notably, depending
on chemical structure, site, and mecha-
nism of chemical action, and delivered
chemical concentrations, these and other
non-traditional antimicrobial and -viral
compounds, many of which are expressed
by pathogens themselves, may instead
exert helpful trophic effects on hosts,
their symbiotic microbiota, and harbored
mutualistic copathogens. The reasons
for such biphasic drug-response profiles
partly derive from how pathogens evolved
to parasitize host Ca2+-dependent func-
tions and resources, yielding insights
into devising better antiinfective treat-
ment regimens and new valued probiotic
medicines.
PATHOGEN USURPATION OF HOST
Ca2+ SYSTEMS
Viruses, bacteria, fungi, and protozoa
evolved the strong obligate parasitic strat-
egy of hijacking host systems to augment
their comparatively primitive genomic,
epigenomic, and somatic capabilities,
thereby facilitating infectious disease
adaptation and propagation. Though
infectious agents coopt many different
host systems, few are more significant
than host intracellular Ca2+ signaling
pathways. Free intracellular Ca2+ serves
as an intermediate between sensory input
and response output for all known cel-
lular life. Its ubiquitous presence within
cells of diverse phylogeny and function
makes Ca2+ an essential messenger for
controlling host-cell stress responses, fate
and death, synaptic plasticity, home-
ostasis, motility, bioenergetics, growth,
morphogenesis, immunodefenses, protein
modification and transport, cytoskele-
tal polymerization, endosome formation,
and various other host processes (Clark
and Eisenstein, 2013; Clark et al., 2013).
Therefore, the ability of microbes to pref-
erentially control host intracellular Ca2+
pathways enables them to optimize the
timing and effectiveness of infection stages
against barriers to invasion, pathogen-
esis, proliferation, and release (Moreno
and Docampo, 2003; TranVan et al., 2004;
Kozubowski et al., 2009; Zhou et al., 2009;
Clark and Eisenstein, 2013; Clark et al.,
2013).
Pathogens, mainly via toxic proteins
and lipopolysaccharides, manipulate host
intracellular Ca2+ systems by modulating
(1) ligand- [e.g., N-methyl-D-aspartate
receptors (NMDAr)] and voltage-gated
(e.g., L-, N-, P/Q-, R-, and T-type recep-
tors and Bsc1, Cch1, and NaChBac recep-
tors) channels that permit Ca2+ entry
from extracellular spaces, (2) upstream
first or second messengers (e.g., inositol
1,4,5-trisphosphate (IP3), AMP-activated
protein kinase, and mitogen-activated
protein kinase pathways), (3) ion- (e.g.,
Ca2+/H+ and Na+/Ca2+ exchangers)
and ATP-dependent (e.g., sarcoplasmic-
endoplasmic-reticulum (SERCA) and
plasma-membrane (PMCA) ATPases)
Ca2+ pumps that sequester or extrude
free cytosolic Ca2+, (4) ligand-gated chan-
nels (e.g., IP3 and ryanodine receptors)
and peptidergic porins (e.g., amoebapor-
ins, aquaporins, and PorB) responsible
for store-operated Ca2+ mobilization
and leakage, and (5) downstream host
Ca2+ binding proteins and sensors (e.g.,
calmodulin, calrectulin, calcineurin, cal-
nexin, and annexin) (Clark and Eisenstein,
2013; Clark et al., 2013). The wide
range of host intracellular Ca2+ systems
influenced by pathogen factors gives
microbes remarkable control over the
behavior and well-being of humans and
animals, including, but not limited to,
mental function and psychological state,
voluntary and involuntary motor perfor-
mance, and gastrointestinal absorption
and metabolism. Yet, for microbes, the
advantages of pathogen-mediated regu-
lation of host intracellular Ca2+ systems
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extend beyond the impact on host health.
In the case of viruses, increased host free
cytosolic Ca2+ levels may promote viral
adsorption, structural stability, capsid
uncoating, enzymatic activity, replication,
assembly, transport, and fusion (cf. Zhou
et al., 2009; Clark and Eisenstein, 2013).
Whereas, in cases of bacteria, fungi, and
protozoa, alterations of host intracellular
Ca2+ homeostasis is critical for pathogen
sensory transduction, cell energetics,
infection sequences, stress adaptation,
gene expression, toxin biosynthesis and
secretion, molecular biomimicry, conju-
gation and true sexual reproduction, cell
motility and tropisms, growth, biofilm
formation and cell aggregation, antigenic
variation, and morphogenesis and lifecy-
cle transitions (cf. Cyert, 2003; Moreno
and Docampo, 2003; TranVan et al., 2004;
Kozubowski et al., 2009; Clark et al., 2013).
PATHOGEN SELECTIVE MANIPULATION
OF HOST Ca2+ SYSTEMS
To coordinate pathogen needs with oper-
ation of host cells, infectious agents
must precisely change their host envi-
ronment to maximize survival, prolifer-
ation, and spread with a repertoire of
social-like (e.g., cell-cell communication,
biofilm formation, cooperative, and com-
petitive coinfection, etc.) and non-social
(e.g., phenotypic variation, biomimicry,
etc.) phenomena sometimes interpreted
as pathogen intelligence (cf. Crespi, 2001;
Casadesus and D’Ari, 2002; Ben-Jacob
et al., 2004; Hellingwerf, 2005; Marijuán
et al., 2010; Clark, 2013b). In regard
to host intracellular Ca2+ homeostasis,
pathogens rely on certain toxins that may
either increase or decrease intracellular
Ca2+ levels depending on stages of infec-
tion and host status. Such fine-tuned
aptitude for altering host Ca2+ systems
confers both advantages and disadvantages
on hosts in relation to proper cell func-
tion and fate. Although most pathogens
have evolved suites of toxins to manipulate
host processes, including Ca2+-mediated
ones, the selective fitness of surprisingly
numerous single toxin molecules achieves
multiplexed pathogen attacks on their
host niche. This kind of pathogen intel-
ligence conserves viral, bacterial, fungal,
and protozoal resources for highly effi-
cient and integrated host invasion and
exploitation.
For example, overexpression of the
multifunctional Hepatitus B Virus (HBV)
protein HBx activates caspase-dependent
cleavage of host Ca2+ PMCA, elevat-
ing free intracellular Ca2+ concentrations
(Chami et al., 2003) as well as IP3 pro-
duction and mitochondrial Ca2+ uptake
during virus replication (Gearhart and
Bouchard, 2010a,b; Yang and Bouchard,
2012). Unless competitively antagonized
by IP3-receptor-inhibitors dantrolene and
FK506 or other drug types, temporary
stimulation of the endoplasmic reticu-
lum/mitochondrial interface by IP3 boosts
ATP synthesis and transport for energy-
dependent cell processes required dur-
ing early viral infection stages. However,
when mitochondrial Ca2+ uptake subse-
quently exceeds buffering capacity, HBx
advances mitochondrial swelling and frag-
mentation (Chami et al., 2003), making
host cells more vulnerable to free radical
generation, metabolic stress, and apopto-
sis prior to viral release. While sequalae
are treatable with non-traditional com-
pounds, including dual-active Beta Cell
Lymphoma (Bcl)-related proteins (Clark
and Eisenstein, 2013), HBV obviously
evolved to carefully manage host-cell oper-
ation through well-timed, titrated levels
of a single toxin, with lower concentra-
tions of HBx causing long-term/short-
term positive outcomes for virus/host
and higher concentrations of HBx largely
causing positive/negative outcomes for
virus/host. This sort of versatility for single
viral toxins to exploit host Ca2+ systems
is observed for other viruses, including
Human Immunodeficiency Virus type 1
(HIV-1). HIV-1, via the transcription fac-
tor Tat, for instance, potentiates Ca2+
influx through dihydropyridine-sensitive
voltage-gated L-type Ca2+ (Lannuzel et al.,
1995) and NMDAr channels (Prendergast
et al., 2002; Self et al., 2004), lead-
ing to host-cell cytotoxicity. By means
of the same Ca2+ channels, Tat also
evokes production of the tumor necrosis
factor (TNF)-alpha cytokine, an impor-
tant compound for HIV-1 replication and
pathogennesis (Contreras et al., 2005).
Each harmful effect on host cells may be
mitigated by voltage-gated L-type Ca2+
(e.g., nifedipine) and NMDAr channel
antagonists (e.g., memantine). In contrast,
Tat, similar to verapamil, inhibits cytotoxic
release of serine esterases by blocking the
phenylalkylamine-binding site of voltage-
gated Ca2+ channels (Zocchi et al., 1998).
As with protein HBx of HBV, Tat therefore
affords HIV-1 with the ability to either
facilitate or guard against host-cell death
depending on infection stage and location
(e.g., molecule-binding site, cell type, and
organ). Moreover, besides direct influence
over host condition, both HBx and Tat
may act synergistically on HBV and HIV-1
infections (Li et al., 2012) as well as pro-
vide opportunistic copathogens, such as
mycobacteria (Pathak et al., 2010; Toossi
et al., 2012), herpesviruses (Huang et al.,
2001; Guo et al., 2004; Caselli et al., 2005),
and commensal host fungi (Cassone
and Cauda, 2012) and coliform bacte-
ria (cf. Diniello et al., 1998; Mani et al.,
2007), an (probiotic) enriched or (anti-
infective) hostile host habitat affecting
communicable disease progression.
Only two among many instances of
viral proteins were discussed above to
illustrate the powerful biphasic regula-
tion of pathogen toxins in modifying host
and infectious agent physiology (cf. Clark
and Eisenstein, 2013). A large number
of pathogen-associated Ca2+-modulating
factors exist for bacteria, fungi, and pro-
tozoa as well (cf. Clark et al., 2013).
These endo- and exotoxins, of which
just a few exemplars will be described
here for protists, often allow microbes to
evade host defenses by usurping mem-
brane repair systems, down-regulating
redox immunological responses, mim-
icking proinflammatory chemokine and
cytokine mobilization, and initiating ire-
versible host programmed cell death. In
addition to purely selfish pathogen infec-
tive, survival, and reproductive strategies,
such compounds may render trophic sup-
port and protective immunity for hosts
and their microbiota. Prime examples,
similar to those also reported for obli-
gate parasitic Chlamydia, Rickettsia, and
Toxoplasma species (cf. Romano et al.,
2013), come from intracellular protozoan
trypanosomes, etiogenic agents of Chagas’
disease, sleeping sickness, and other
human and animal illnesses. Several sub-
stances, a serine endopeptidase, also called
a proteolytically generated trypomastig-
ote factor, Tc-Tox, an acidic pore-forming
protein, and acidic sphingomyelinase, syn-
thesized and secreted by Trypanosoma
cruzi induce host plasma-membrane
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damage, extracellular Ca2+ entry, IP3 for-
mation, transient store-operated cytosolic
Ca2+ liberation, and/or cytoskeletal
reorganization to assist in parasite inter-
nalization and trafficking (Tardieux
et al., 1994; Burleigh and Andrews, 1995;
Rodríguez et al., 1995; Burleigh et al.,
1997; Fernandes et al., 2011). These com-
pounds are only produced during the
infective stage of trypanosome lifecycles,
when Ca2+-dependent, energy-expensive
lysosome and endosome recruitment
works to restore integrity of pathogen-
injured host plasma membranes. To a
limited extent, toxin activation of store-
operated Ca2+ release can be decreased
by IP3-receptor blockers. But by directly
commandeering host membrane-repair
systems and subverting intracellular
innate immune-surveillance and potent
inflammatory signaling pathways, trypo-
mastigotes ensure successful host invasion
and maintenance of host structural and
biotic reliability for persistent cryptic
and latent trypanosome and copathogen
disease states, such as those involving
multiple trypanosome strains, symbiotic
enterobacteria and other Gram-negative
bacteria, and entomopathic double-
stranded DNA viruses (Peacock et al.,
2007; Alam et al., 2012; Lowry et al.,
2013). In turn, these processes, directed
by identical toxin concentrations used
for trypanosome benefit, can present
formidable obstacles to other infectious
agents, including convergent trypanosome
strains (Ulrich and Schmid-Hempel,
2012) and possible Encephalitozoon (cf.
Leitch et al., 2001) and Toxoplasma
parasites (cf. Meirelles and De Souza,
1983), which compete for limited shared
host resources and/or must overcome
toxin-modified host immunoresponses.
PROSPECTIVE Ca2+-MODULATING
PROBIOTIC AND OTHER TREATMENT
STRATEGIES
Repurposed medications which tar-
get pathogen capacities to alter host
Ca2+ homeostasis and vital cell func-
tions, such as traditional Ca2+-channel
blockers, SERCA-inhibitor artemisinins,
PMCA-inhibitor caloxins, and the IP3-
receptor-inhibitors dantrolene, FK506,
and Bcl antiapoptotic compounds (Clark
and Eisenstein, 2013; Clark et al., 2013),
show efficacious antiinfective effects
against both treatable and previous drug-
resistant pathogens. Given examples of
HBV, HIV-1, and trypanosome infec-
tions readily demonstrate how these
drugs exert their chemotherapeutic prop-
erties through disruption of pathogen
attack, reinforcement of compromised
host immunity, and trophic support for
host operation. Perhapsmore significantly,
toxins encoded by pathogens also show
non-traditional antiinfective and probiotic
traits, oftentimes in a concentration-
dependent manner. Such highly adaptive
cooperative and competitive traits evolved
so pathogens can invade, inhabit, and
abandon host niches. Many of these mul-
tipurpose pathogen toxins modulate Ca2+
systems of host cells and host microbiota,
including aforementioned viral and pro-
tozoan toxins, HBx, Tat, and Tc-Tox, and
different pathogen virulence factors, such
as mycobacterial (macolide) mycolactone
and lipoarabinomannan (Rojas et al.,
2000; Snyder and Small, 2003; Vergne
et al., 2003; Boulkroun et al., 2010),
staphylococcal leukotoxins (Jover et al.,
2013), coliform heat-stable enterotoxin B
(Dreyfus et al., 1993), and saccharomycete
and ascomycete gliotoxins (Niide et al.,
2006), to name a few. In some cases,
predictable antiinfective properties of
pathogen toxins result from mechanisms
known for antibiotic drugs, including the
streptomycin-analogous (Diniello et al.,
1998) polyamine-starving characteris-
tics of Tat (Mani et al., 2007), or from
entirely novel mechanisms. Regardless,
pathogen toxins with combined anti-
infective and biotic qualities provide
exciting substrate to begin developing new
medicines of broad therapeutic potential
and lifespan.
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Since the introduction of penicillin in
the 1940s, antimicrobial resistance (AMR)
has become an ever-increasing threat to
human and animal health (Carlet et al.,
2012; ITFAR, 2012). The low-dose antimi-
crobial use in food-producing animals for
production purposes, i.e., disease preven-
tion and growth promotion, has been
documented to drive AMR, though the
risk to human health from such uses
has been a source of a heated debate
among stakeholders including industry
members, citizen advocacy groups, aca-
demics, and public health workers (Davis
and Rutkow, 2012). In the United States
(US), it remains common practice to use
medically-important antibiotics1 for pro-
duction purposes. Since the 2000s, the
European Union (EU) has banned many
low-dose antimicrobial uses. The crucial
element to the debate has been whether
scientific evidence supports similar action
in the US. Industrial food animal pro-
duction advocates, henceforth “industry,”
claims that scientific evidence is currently
lacking, while other stakeholders argue
that a convincing and substantial body of
evidence exists to support policy change.
The US and the EU have taken vastly
different approaches to AMR surveillance
and research, and these choices have led
to a wide variance in the current policy
climate regarding antimicrobial use and
AMR.We argue that the EU has prioritized
1Based on definitions for critically-important
antimicrobials used by the Food and Agriculture
Organization of the United Nations, World Health
Organization, and World Organization for Animal
Health (OIE), and definitions of medically-important
antibiotics in the Preservation of Antibiotics for
Medical Treatment Act, first introduced to the U.S.
Congress in 1999.
scientific research and surveillance efforts
that target uses of antimicrobials in ani-
mals. The US has not invested deeply
in either research funding or surveillance
programs that include such uses. If pol-
icy shifts will occur in the US, changes in
AMR surveillance and allocation of scien-
tific research funding are required.
CURRENT US PRACTICES
The US National Antimicrobial Resistance
Monitoring System (NARMS) is a
joint effort of the US Department of
Agriculture (USDA), the Food and Drug
Administration (FDA), and the Centers for
Disease Control and Prevention (CDC)
for AMR surveillance. The three arms
of NARMS—VetNet (USDA), PulseNet
(CDC), and retail (FDA)—collect sam-
ples from animal carcasses at the time
of slaughter, human food-borne infec-
tions, and retail meat samples, respectively.
Techniques in each arm vary in regards
to both isolates collected and laboratory
definitions for resistance, making data
comparison across branches challenging
(US GAO, 2011). Collection of data on
antimicrobial use and sales in food animals
in the US is limited, though the FDA has
made recent efforts to obtain more data.
The Government Accountability Office, in
a report published in 2011, commented on
the limited scope of sampling techniques
in the US:
This non-random sampling method
means the NARMS data obtained . . . are
not representative of food animals across
the country and cannot be used for
trend analysis because bacteria tested
by NARMS are now collected at greater
rates from slaughter plants that are not
in compliance with food safety stan-
dards. According to FDA officials, due to
this sampling method, the resulting data
are skewed for NARMS purposes (US
GAO, 2011).
The lack of harmonization within NARMS
limits the interpretation of these data, with
resulting impacts on evidence available to
support science-driven policy.
Current NARMS funding is approx-
imately $7.8 million, bringing the per-
capita investment in this surveillance tool
to $0.025 (US GAO, 2011). Lack of fund-
ing is routinely cited as the primary cause
of limited government-led research and
lack of advancement in surveillance tech-
niques, though the lack of coordination
within the current approach suggests that
changes could be made to use existing
budget funds more effectively (Pew Trust,
2008; US GAO, 2011; IDSA, 2012).
CURRENT EUROPEAN PRACTICES
The European approach to AMR surveil-
lance, research, and policy development
began with individual country efforts,
with Denmark and Sweden as leaders. In
recent years, the EU has begun to compile
data from numerous countries through
the functions of the European Centers for
Disease Control, European Antimicrobial
Susceptibility Surveillance in Animals
Center, and the European Animal Health
Study. In general, European efforts have
been more systematic than US efforts,
including sampling of healthy and dis-
eased animals and people, monitoring
antimicrobial usage patterns through
novel techniques such as geomapping,
and using veterinarians to obtain samples
from awide variety of regions and animals,
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including pets (DANMAP, 2011; Davis
and Rutkow, 2012; IDSA, 2012; ITFAR,
2012; de Jong et al., 2013).
Selective bans on antimicrobials for
growth promotion were instituted in
the 1990s, and a complete ban of drugs
for non-therapeutic uses was established
in Denmark and the EU in 2000 and
2006, respectively (DANMAP, 2011;
US GAO, 2011). Research is priori-
tized and is typically led by industry
rather than government; this approach
may reflect differences in cultural or
social norms between the EU and US.
Indeed, industry participation in such
programs has been largely voluntary,
and the additional cost is thus often
internalized to industry rather than exter-
nalized to the public through government
expenditures.
COMPARISON OF APPROACHES
According to the 2011 GAO audit of
NARMS, policy in the EU, “. . . has been
built around the precautionary principle,
which states that where there are threats
of serious or irreversible damage, lack of
scientific certainty should not postpone
cost-effective measures to reduce risks to
humans” (US GAO, 2011). In contrast to
the US approach of risk assessment, the
EU method is buoyed by consumer con-
cern and voluntary industry measures. At
a recent meeting, the Infectious Disease
Society of America (IDSA) released a
statement comparing current US and EU
efforts:
Even given the value [National Health
Safety Network], [Emerging Infections
Program], Prevention Epi-centers,
NARMS, and [Multidrug Resistant
Repository and Surveillance Network]
provide, IDSA remains deeply con-
cerned about the lack of detailed,
publicly available data on both resis-
tance trends and human antimicrobial
use in humans, food animals and other
areas of agriculture and food produc-
tion in the United States. The U.S. is
far behind other countries in collecting
and benefiting from data on antibi-
otic consumption and resistance (IDSA,
2012).
In the same vein, the 2011 GAO report
noted that CDC did not routinely pub-
lish data on AMR patterns in pathogens
associated with outbreaks of foodborne ill-
ness (US GAO, 2011). Such statements
indicate the low political priority assigned
to AMR surveillance and program evalu-
ation in the US. Evaluation is a vital part
of any system, and as the 2011 GAO report
indicated, NARMS, FDA, USDA, and CDC
have conducted few evaluations. Without
regular evaluation, programs and policies
that are neither cost-effective nor impact-
ful can waste money and prevent new and
more efficacious systems from being put in
place.
DANMAP was established in 1995
with 2.4 million kroner ($0.3 million)
and in 2000 further supported with 2.6
million kroner resulting in a total of
5 million kroner ($0.7 million) of ini-
tial investment across that time period2.
This program was one of the pioneers
in European surveillance efforts, predat-
ing EU-wide efforts (Davis and Rutkow,
2012). Currently, DANMAP is not funded
by earmarked money but is a part of the
general tasks of Statens Serum Institut and
Danish Technological University (DTU-
Food) financed by Danish Ministry of
Health and the Danish Ministry of Food,
Agriculture, and Fisheries. Although the
budget for DANMAP changes relative to
general fund availability and is subject
to annual decreases, the budget from
the Ministry of Food, Agriculture and
Fisheries alone for all food research (not
just application to AMR) was 246 million
kroner ($44.8 million), or a per-capita
investment of $8 for 20143. Funding across
multiple federal agencies places US food
research investment at an estimated $1863
million, or a per-capita investment of less
than $6 for 20134. Given similar per-capita
budgets, the food safety and DANMAP
programs have more effectively influenced
AMR policy in Denmark than parallel
2Based on a year 2000 exchange rate of 7.3855kr/US
dollar. With a year 2000 Danish population of 4.8 mil-
lion, the per-capita investment was roughly $0.14. We
thank Robert Skov for his assistance in obtaining this
DANMAP funding information.
3Based on a December 1, 2013 exchange rate of
5.489810kr/US dollar. With a year 2013 Danish pop-
ulation of 5.6 million, the per-capita investment was
$8.
4Based on the sum of food safety budget estimates
of $42 million (NIFA), $108 million (ARS), $1 mil-
lion (ERS), $1425 (FDA), and $287 (NIH), for a total
of $1863 million (Ohlhorst et al., 2013). With a year
2013 US population of 320.6 million, the per-capita
investment was $5.8.
programs have in the US. This example
suggests that the choice of where and how
to apply funding may be more important
than total expenditure in the generation of
scientific evidence to support policy deci-
sions.
The role of industry in the US is com-
plex, and the 2008 report of the Pew
Commission on Industrial Farm Animal
Production noted, “We found significant
influence by the industry at every turn:
in academic research, agriculture policy
development, government regulation, and
enforcement” (Pew Trust, 2008). Industry
itself is not held accountable for ensuring
public health, nor is it charged with con-
tributing peer-reviewed research to sup-
port or refute its current or preferred
practices, yet it remains able to exercise
tremendous influence in government and
academia, especially among land grant
universities where industry funding has
largely replaced public research funding
(Pew Trust, 2008).
Hence, policy success, defined as both
action by agencies and reductions in AMR
rates, in the EU has been driven in part
by strategic allocation of funding sup-
port, adherence to the precautionary prin-
ciple, involvement of industry, and peri-
odic mandatory participation of EUmem-
bers in region-wide data collection efforts
(DANMAP, 2011; IDSA, 2012; Silley et al.,
2012). In contrast the US has not seen the
same returns relative to funding efforts,
has not applied the precautionary princi-
ple in formulating policy, has not required
participation of producers or benefited
from voluntary support by industry, and
has conducted limited and flawed surveil-
lance for antimicrobial use in livestock
and AMR.
RECOMMENDATIONS
In an era of resource constraints for gov-
ernment agencies, we do not expect AMR
surveillance efforts in the US to experi-
ence significant budget increases. The EU
approach, including the specific example
of Denmark, offers lessons for change in
the US. We propose that efforts be made
to provide minimal increases in funding
to obtain more representative and compa-
rable data, and to analyze data currently
being collected in a more effective way. For
example, NARMS data in the US are avail-
able online, but manipulation of the data
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is not feasible (Silley et al., 2012). Allowing
independent researchers and their stu-
dents to use the NARMS data for analysis
may lead to more rapid reports that can
be used for comparison with data from
other countries, while supplying a no-cost
source of analysis and enhancing educa-
tional opportunities. In particular, provi-
sion of data at the sample level, allowing
for analysis of cross-resistance patterns,
would inform both scientific and policy
efforts to understand and combat the rise
of AMR pathogens.
Additionally, a shift in industry’s role
toward a more harmonized partnership
with government and other stakeholders
would assist national efforts to address
the problem of AMR. Voluntary FDA
guidance to phase-in veterinary over-
sight and phase-out growth promotion
uses of antimicrobials in livestock is
a first step toward this goal (FDA,
2013). Following the EU example for
industry involvement in research efforts
would ultimately offer a solution to
meet the needs for representative sam-
pling within a country as large and
diverse as the US. While industry may
be faced with higher costs, all stake-
holders would benefit from improve-
ments in data collection—and hence data
interpretation—in driving evidence-based
policy change.
Ultimately, changes need to occur
within the US to encourage industry
accountability, research efforts, and gov-
ernment investment in adequate surveil-
lance systems. Some improvements within
the US surveillance system, such as report-
ing of data already collected, would require
minimal funding adjustments. AMR is a
pressing problem that threatens the health
and well-being of humans and animals,
with impacts through the food system.
Fundamental shifts in the governmental
and industry approaches, including struc-
tural changes to enhance data collection
and dissemination, are urgently needed to
generate science-based policies and then
understand the impact of the policies on
AMR.
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The rapid increase in obesity prevalence in the United States in the last 20 years is unprece-
dented and not well explained. Here, we explore a hypothesis that the obesity epidemic
may be driven by population-wide chronic exposures to low-residue antibiotics that have
increasingly entered the American food chain over the same time period. We propose
this hypothesis based on two recent bodies of published reports – (1) those that provide
evidence for the spread of antibiotics into the American food chain, and (2) those that
examine the relationship between the gut microbiota and body physiology. The livestock
use of antimicrobial agents has sharply increased in the US over the same 20-year period
of the obesity epidemic, especially with the expansion of intensified livestock production,
such as the concentrated animal feeding operations. Observational and experimental stud-
ies support the idea that changes in the intestinal microbiota exert a profound effect on
body physiology. We propose that chronic exposures to low-residue antimicrobial drugs in
food could disrupt the equilibrium state of intestinal microbiota and cause dysbiosis that
can contribute to changes in body physiology. The obesity epidemic in the United States
may be partly driven by the mass exposure of Americans to food containing low-residue
antimicrobial agents. While this hypothesis cannot discount the impact of diet and other
factors associated with obesity, we believe studies are warranted to consider this possible
driver of the epidemic.
Keywords: obesity, antibiotic residues, intestinal microbiota, food chain, CAFOs, animal husbandry, polysaccharide
diet
INTRODUCTION
Obesity in non-elderly adults is defined as a body mass index
(BMI=weight in kilograms divided by height in meters squared)
of 30 or higher (1). Obesity has emerged as an epidemic, espe-
cially in the United States, accompanied by a variety of chronic
medical problems, including diabetes, hypertension, and dyslipi-
demia. In the United States, the increase in overweight and obesity
prevalence has particularly accelerated in the last 20 years. The
overweight prevalence doubled from a mean of 15.1% in 1976–
80 to 31.2% in 2001–2004 (2). In 2000, none of the states had
an obesity prevalence exceeding 30%; by 2010, 12 states reported
an obesity prevalence of >30% (3). Although the prevalence
appears to be leveling off, it had increased to 35.7% among adults
by 2009–10 (4). A Centers for Disease Control and Prevention
(CDC) survey of 3141 counties in the US in 2007 revealed dis-
tinct geographic clustering of obesity prevalence, with the highest
prevalence (>30.9%) occurring in the Southeastern states and in
the Appalachian counties of Tennessee and Kentucky (5).
Many putative causes of obesity and its epidemic in the US have
been suggested (6). Most reports attribute the obesity epidemic to
factors such as excess food energy intake, changes in diet and eating
behavior, and increasing sedentary life style. Undoubtedly, these
factors contribute, but can they all account for the rapid increase
in this problem that occurred over the last two decades? Recently,
a series of experimental and observational studies have described
the role and impact of intestinal microbial population structure
(microbiota) on body metabolism and energy balance, and how its
disruption (dysbiosis) could adversely affect body physiology and
health (7–9). If such a mechanism – disruption of the intestinal
microbiota – occurred at the population level, it could potentially
explain the obesity epidemic.
As with infectious disease epidemics, the obesity epidemic
affecting large segments of a population within a short time frame
suggests common population-wide exposures. What such com-
mon exposures could alter the gut microbiota at the population
level? Here, we review a body of literature to support a hypothesis
that the American human intestinal microbiota may have been dis-
rupted by chronic, widespread exposures to antimicrobial residues
that have increasingly entered our food chain and the environment
over the last 20 years. These exposures may be contributing to the
obesity epidemic.
Our hypothesis is based on review of relevant literature, per-
formed as follows. We first searched PubMed by cross-referencing
the word “obesity” with the following terms: epidemic, prevalence,
diet, calorie intake, nutrients, physical activity, lifestyle, host fac-
tors, genetics, antibiotics/antimicrobial agents, antibiotic residues
in food, antibiotics in plants, antibiotic growth promoters, envi-
ronmental release of antibiotics, animal husbandry, animal feed,
gut microbiome/microbiota, and metagenome. We then found
additional references by reviewing the cited references from the
primary articles. We excluded abstract reports or conference pro-
ceedings. Articles not available electronically were sought at the
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University of California library collections. The search was limited
to publications in English up to August 2013.
ANTIBIOTICS IN THE ENVIRONMENT AND FOOD
What is the evidence that American food contains antimicrobial
agents or that food can become contaminated with them? One
major potential source of antibiotics that enter the food chain in
the US is the food animal reservoir. The intensification in live-
stock production and animal feeding operations (AFOs) greatly
expanded in the 1990s, which also greatly expanded the therapeu-
tic and prophylactic use of antibiotics (10). In the US, at least 17
classes of antimicrobial agents are approved for use in animal hus-
bandry (11). The estimates of antibiotic use in food animals prior
to 2008 are not readily obtainable, but various sources report the
use in the US to range from 20.5 million pounds for all purposes
in 1999 (12) to 24.6 million pounds a year for non-therapeutic
purposes alone (13). An Institute of Medicine report in 1989 esti-
mated that more than 50% of all antimicrobial agents produced in
the US are used for livestock (14). The Food and Drug Adminis-
tration (FDA) reported that in 2011, the sales and distribution of
antimicrobial agents approved for use in food-producing animals
were 13,542,030 kg (15), which is about four times the total sold
and distributed for use to treat human infections (15). Chlortetra-
cycline alone had the highest annual estimated use at 533,973 kg
just for swine production in the US (16).
About 75% of antibiotics given to feedlot animals are not
absorbed by the body and hence excreted in waste (manure and
urine) (17, 18). In 2002, 185 million swine sold in the US generated
about 280 million tons of fresh manure; in 2006, chicken produced
even more (460 million tons), while, in 2007, beef cattle produced
3.6 million tons of manure (19–21). Environmental pollution
from animal waste results from direct discharges, open feedlots,
pastures, storage lagoons, stockpiles, and land application fields.
Manure is converted into fertilizers and spread over crops. From
these sources, contamination can occur on surface water, ground-
water, and soil. Based on the amount of antibiotics estimated to be
used for growth promotion in animal husbandry, 7.5–18 million
pounds of these antimicrobial drugs could be released into the
environment annually (12, 13).
In the last 20 years, the above practices as well as the shift
from integrated farming operations to concentrated animal feed-
ing operations (CAFOs) have led waste-related pollution to be
concentrated in certain geographic regions of the US (18). The
largest increase in broiler chicken CAFOs occurred in the South-
eastern states in the last 20 years (22) – practically overlapping with
the counties with the highest obesity prevalence in the US (5).
Antibiotics released into the environment have varied
biodegradability, depending on their chemical property, soil com-
position, climactic conditions, and other environmental factors
(10). Some antibiotics released into soil by manure may be detected
up to 5 months (23). Yang and Carlson analyzed tetracyclines and
sulfonamides along the Cache la Poudre River in Colorado, and
found that while no drugs were found in the pristine, mountain
stretch of the river, sulfonamides were found along the remain-
ing stretch and tetracycline concentrations progressively increased
downstream from urban areas (24). The tetracycline concentra-
tions correlated with agricultural activity (24). In another study
of 139 streams sampled in the US between 1999 and 2000,
trimethoprim, erythromycin, lincomycin, and sulfamethoxazole
were detected in more than 15% of the samples (25).
Antibiotics can also accumulate in plant tissue. Dolliver et al.
showed experimentally that sulfamethazine in manure-amended
soil accumulated in corn, lettuce, and potato at concentrations of
0.1–1.2 mg/kg dry weight (26). Others have shown accumulation
of low concentrations of antibiotics in carrot roots, green onion,
and cabbage (23, 27).
In addition to livestock sources, antimicrobial agents are
released into the environment from aquaculture (e.g., shrimp and
fish farms) (28–30), spraying fruit orchards and vegetables (31,32),
and from discarded expired drugs, hospital effluents, and other
human activities (33). Thus, there is ample evidence that antibi-
otics can enter our food chain from a variety of sources, and that
humans are chronically exposed to these drugs (Table 1). These
exposures have greatly increased in the US in the last 20 years,
overlapping closely both in time and place with the increasing
prevalence of obesity.
Of course, we acknowledge that exposure does not necessar-
ily indicate cause and effect, and the evidence to date showing
the association is largely ecologic. Furthermore, the impact of
changes in dietary intake that also took place in the US in the
last 20 years cannot be completely discounted. The average per
capita per day energy levels available in the US food supply was
3,400 kcal in 1909–1919, 3,600 kcal in 1990–1999, and 3,900 kcal
in 2004 (59). National Center for Health Statistics through series
of surveys (National Health Examination Surveys from 1959 to
1970 and the National Health and Nutrition Examination Surveys
from 1971 to 2004) shows that the prevalence of overweight and
obese Americans increased slowly through the middle of 1970s
and then sharply began to rise thereafter (2). Thus, the period of
accelerated increase in weight gain overlaps with both increased
dietary caloric intake and antibiotic exposures in food. Here, we
argue that the effect of diet and exposure to low-residue antibi-
otics in food on weight gain may be related and that they cannot
be easily disassociated. We provide below the biological plausibil-
ity evidence for how antibiotics may influence body physiology
and how diet contributes to this effect in ways that had not been
previously considered.
ANTIBIOTICS AS GROWTH PROMOTERS
In 1946, Moore et al. reported that the administration of low-dose
streptomycin and sulfasuxidine in chicken feed caused increased
weight gain in chicks (60). Stokstad et al. reported in 1949 that
chlortetracycline-containing mash had a growth-promoting effect
on poultry (61). In 1950, Luecke et al. reported that strepto-
mycin in combination with vitamin B12 included in a basal diet
caused 40% weight gain in pigs (62). These and other similar
observations led the food animal industry to gradually adopt the
practice of administering subtherapeutic doses of antibiotics as
growth promoters and to enhance feed efficiency (63, 64). Debate
concerning the economic benefits versus health hazards of this
practice began in the 1960s and continues to this day (64–72).
Much of the debate has focused on whether or not this practice
contributes significantly to the selection of pathogens that cause
human drug-resistant infectious diseases. Here, we propose a new
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Table 1 | Food, water, and environmental sources found to contain residues of antimicrobial agents.
Source Antimicrobial agents found Concentrations Country Reference
FOOD
Shrimp Fluoroquinolones 0.1–1 ng/g USA (28)
Salmon, trout, shrimp tissues Fluoroquinolones 0.28–16 ng/g Canada (29)
Swine, chicken, shrimp tissues Fluoroquinolones 1–100 ng/g China (34)
Bob veal, heavy calves, heifers, market hogs,
non-formula-fed veal, roaster pig, sows
Sulfonamides 0.1–1 ppm USA (35)
Bull meat Moxidectin (milbemycin) 89.13 ppb USA (35)
Goat meat Oxytetracycline 4.66 ppm USA (35)
Market hog, roaster pig meat Carbadox 47–110 ppb USA (35)
Catfish, basa Fluoroquinolones 1.9–6.5 ppb China (36)
Honey Erythromycin 50–1776 ng/g Turkey (37)
Corn, green onion, cabbage Chlortetracycline 2–17 ng/g USA (27)
Pig farm waste water Sulfonamides 20µg/mL Vietnam (38)
Sewage samples Cefalexin, cefotaxime >1µg/mL Hong Kong, Shenzhen (39)
Swine farm lagoon Chlortetracycline 68–1000µg/L USA (40)
Wastewater treatment plant effluent Minocycline, epitetracycline,
tetracycline, doxycycline
95.8–915.3µg/L Portugal (41)
Wastewater treatment plant final effluents Erythromycin, ciprofloxacin,
sulfamethoxazole, tetracycline
0.08, 0.118, 0.243,
0.151µg/L
Canada (42)
Wastewater Chlortetracycline, ciprofloxacin,
erythromycin, sulfamethoxazole,
tetracycline, trimethoprim
0.69, 0.03–0.14, 0.9–1.7,
0.05–1.9, 0.05–0.85,
0.05–0.71µg/L
USA (25, 43)
Cache la Poudre River Macrolides 0.06–0.17µg/L USA (44)
Wastewater Sulfamethoxazole 232–9000 ng/L Austria, Switzerland,
USA, Spain, Germany
(45)
Elbe and Saal rivers Erythromycin, sulfamethoxazole,
trimethoprim
30–70, 30–70,
<30–40 ng/L
Germany (46)
Po river Macrolides 0.7–68.3 ng/L Italy (47)
Wastewater treatment plant effluents Quinolones 40–580 ng/L France, Italy, Sweden,
Greece, Switzerland
(48, 49)
Wastewater treatment plant effluent Sulfamethoxazole, trimethoprim,
ofloxacin, erythromycin
310–400, 180–320,
110 ng/L, 2.5µg/L
USA, Germany (50, 51)
Rio Grande river Sulfamethoxazole 300 ng/L USA (51)
Surface water Erythromycin, sulfamethoxazole 150, 30 ng/L Germany (50)
Cattle manure Chlortetracycline 7.73 mg/L USA (52)
Cattle, turkey manure Monensin 1–4.4, 1.2–1.5 mg/L USA (53)
Swine manure Chlortetracycline 27 mg/L USA (54)
Swine slurry Tetracycline 5–24 mg/L Germany (55)
(Continued)
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Table 1 | Continued
Source Antimicrobial agents found Concentrations Country Reference
OTHERS
Hospital effluent sludge Oxofloxacin, ciprofloxacin 0.7–2.0 mg/kg Sweden (56)
Hospital effluent Ciprofloxacin, ampicillin 0.7–124.5, 20–80µg/L Germany (57)
Hospital effluent Minocycline, epitetracycline,
tetracycline, doxycycline
8.1–531.7µg/L Portugal (41)
Hospital effluent Ciprofloxacin, metronidazole,
sulfamethoxazole, trimethoprim,
doxycycline
3.6–101, 0.1–90.2,
0.4–12.8, 0.6–7.6,
0.6–7.6µg/L
Sweden (58)
Hospital effluent Sulfamethoxazole, trimethoprim,
ofloxacin, ciprofloxacin,
lincomycin, penicillin G
400–2100,
2900–5000 ng/L,
25.5–35.5µg/L,
850–2000, 300–2000,
850–5200 ng/L
USA (51)
Dairy plant effluent Lincomycin 700–6600 ng/L USA (51)
hypothesis that this practice may also contribute to the human
obesity epidemic.
Several hypotheses to explain the mechanism of weight gain
in antibiotic-fed animals have been proposed: (1) suppression of
subclinical infections and overt diseases which promotes general
health of the animal and hence better nutrition, (2) stimulation of
growth of bacteria in the gut that synthesize essential nutrients, (3)
suppression of microbes that compete with the host for nutrients,
and (4) improvement in intestinal absorption of nutrients (73, 74).
The possibility that humans are exposed to subtherapeutic
doses of antibiotics led Ternak to first propose in 2004 that human
exposure to low-dose antibiotics may be contributing to weight
gain in humans (75). Raoult in 2008 proposed that the gut micro-
biota modifiers, such as antibiotics and probiotics used in animal
husbandry as growth promoters, may contribute to human body
weight gain (76). Thus, if humans are indeed chronically exposed
to low-dose antibiotics from the environment, there is a good
reason to believe that they too can gain weight.
CHANGE IN INTESTINAL MICROBIAL POPULATION
STRUCTURE AND ITS EFFECT ON BODY PHYSIOLOGY
A recent series of reports has shown that the structure of the total
human intestinal microbial population (microbiota) has a pro-
found influence on body physiology (8, 77–89). The total number
of bacterial cells in the human intestine (~100 trillion) is estimated
to exceed the total number of somatic and germ cells of the human
body by 10-fold (90). Thus, the gut microbiota requires an external
supply of energy and nutrients for its own long-term residence in
the intestine. It also has to share these nutrients with the human
body. In fact, this homeostatic competition, if not disrupted, ben-
efits the host in many different ways. The gut microbiota may even
be considered as another vital human organ.
Anaerobic bacterial species that ferment dietary polysaccha-
rides produce short-chain fatty acids (SCFAs) that are taken up by
the host as an energy source (91). It is estimated that ~4–10% of
the food energy intake of the human body, or 80–200 kcal/day, is
derived from these SCFA produced by colonic bacterial fermenta-
tion (92, 93). Other bacterial populations produce vitamins (e.g., B
and K) and amino acids essential for the host (94). The microbiota
also protects the host against pathogens by competitive exclusion
(95). Finally, it is needed for the proper development of the intesti-
nal immune system (96, 97). Over a course of tens of thousands
of years, the intestinal bacterial population evolved with the Homo
sapiens body to share and compete for energy and nutrient supply
and, in the process, has come to establish a stable equilibrium state.
This intestinal microbial equilibrium state contributes to home-
ostatic maintenance of body weight. A disruption of this steady
state (dysbiosis) could affect nutrient and energy utilization by
the human body and therefore its physiology.
The human gut microbiota is predominantly composed of four
bacterial phyla – Firmicutes, Bacteroidetes, Actinobacteria, and
Proteobacteria, with the first two accounting for about 90% of the
gut phylotypes (98). Cultivation-independent methods (e.g., 16S
rDNA sequence analysis) have revealed that the total number of
bacterial species in the gut could be in the range 15,000–36,000
(99). The largest number of bacteria is found in the colon with
up to 1011 microorganisms/gram of feces (100). A study of 22
samples of intestinal microbiomes from four countries identified
three predominant clusters (enterotypes) that differ in species and
functional composition, independent of nation or continent (101).
Studies of mammalian host gut microbiota have shown that its
alteration can affect body weight (7, 77–79, 81–83, 85). The impact
of dysbiosis on obesity and metabolic disorders has been recently
reviewed in detail by Harris et al. (9). Backhed et al. first reported
that conventionally reared (CONV-R) mice fed polysaccharide-
rich diet weighed about 40% more than its germ-free (GF) coun-
terpart fed the same diet (77). When the gut microflora from the
CONV-R mice was transferred to the GF mice, the latter under-
went a 60% weight gain in 2 weeks (77). The increase in weight
of the lean mice was attributed to the gut microflora that allowed
energy to be salvaged from otherwise indigestible polysaccharide
diet. Ley et al. have shown that obese mice, due to a homozygous
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mutation in the leptin gene (ob/ob), have a 50% reduction in
the Bacteroidetes population with a proportional increase in Fir-
micutes (102). Turnbaugh et al. reported that a transfer of the
microbiota from obese mice to GF mice resulted in greater increase
in total body fat in the latter (7).
Differences in gut microbiota have also been documented in
obese versus lean human subjects (8, 80, 86, 87). One study char-
acterized the fecal microbial communities of obese and lean pairs
of adult female monozygotic and dizygotic twins and their mothers
and found that obesity was associated with phylum-level changes
in the microbiota and reduced bacterial diversity (8). A study
by Schwiertz et al. showed that rather than Firmicutes, increased
Bacteroidetes to Firmicutes population ratio was associated with
obesity (88). Ley et al. followed obese subjects on weight-reducing
diet for 1 year and found Bacteroidetes proportion to increase rel-
ative to Firmicutes (80). Other authors have observed that weight-
reducing diets in obese subjects can alter the gut microbiota species
composition, but no major changes in the ratio of Bacteroidetes to
Firmicutes between lean and obese subjects were found (84). The
study that examined the three enterotypes of human gut micro-
biota did not find any correlation between Bacteroidetes/Firmicute
ratio and BMI (101). Jumpertz et al. prospectively measured
ingested and stool calories of lean volunteers, and found that a
20% increase in Firmicutes with a corresponding decrease in Bac-
teroidetes correlated with an increased energy harvest of ~150 kcal
(103). The above studies that compared intestinal microbiomes
at the phylum-level show mixed and conflicting results. However,
when the intestinal microbiota is examined at the functional group
level, correlations with host characteristics begin to be revealed.
Several studies have found that obese mice and human subjects
have a larger amount of SCFA in their stool than do lean indi-
viduals (7, 82, 88). Arumugam et al. reported that while the three
human gut enterotypes did not show any correlation with BMI,
there was strong correlation between F-type ATPase abundance
and increasing BMI (101). Cani et al. showed that lipopolysac-
charide purified from E. coli injected subcutaneously into mice
induced obesity as well as insulin resistance (82).
Another report showed that endotoxin-producing Enterobac-
ter given to GF mice on high-fat diet became obese, while control
GF mice fed the same diet did not gain weight (104). Mice given
Enterobacter and normal mouse chow did not gain weight. The
Enterobacter was obtained from a morbidly obese volunteer sub-
ject, whose intestinal microbiota was largely (35%) comprised
of this bacterial genus (104). With shift to a diet comprised of
whole grain and traditional Chinese medicinal food, the volun-
teer’s weight decreased>57 kg after 23 weeks, and the Enterobacter
population decreased to 1.8% of the intestinal microbiota (104).
Indeed, Zhang et al. recently reported that in mice, diet changes
explained 57% of the population variation in the intestinal micro-
biota, whereas genetic mutation accounted for no more than
12% (105).
More recently, Ridaura et al. transplanted fecal microbiota from
human monozygotic twins discordant for obesity into GF mice and
showed that mice given the microbiota from the obese member of
the twin increased in adiposity (89). Then, mice transplanted with
fecal microbiota from the co-twins were cohoused. Mice given
obese co-twins’ microbiota were prevented from gaining adiposity
when cohoused with mice given lean co-twins’ microbiota (89).
This transformation was associated with invasion of Bacteroidales
from lean into obese microbiota. Mass spectrometry analysis of
sera revealed significant increases in branched chain amino acids
in mice that received fecal microbiota from obese co-twins, while
the microbiota transplanted from lean co-twins exhibited a sig-
nificantly higher expression of genes involved in plant-derived
polysaccharides and a higher concentration of SCFAs (butyrate
and propionate)(89). These observations demonstrate that the
interactions between diet and gut microbiota can influence body
physiology. Such interactions can certainly be profoundly affected
by antibiotics.
The next relevant question would be, how does exposure
to antibiotics contribute to alteration in intestinal microbial
population?
EVIDENCE OF ANTIBIOTIC-INDUCED CHANGES IN THE
HUMAN GUT MICROBIOTA AND BODY PHYSIOLOGY
The intestinal microbiota serves as an interface between the human
body and its environment. Its perturbation is bound to affect body
physiology. We argue that low-dose antibiotics in food are a major
contributor to this perturbation. The analysis of the intestinal
microbiota or body physiology in humans exposed to antibiotics
has been largely confined to those studies of subjects receiving
therapeutic drug doses. Blaser and Falkow have suggested that the
accelerated disappearance of the normal human microbial com-
munity, such as Helicobacter pylori in the stomach, due in part to
the human use of antibiotics to treat peptic ulcer disease, may be
contributing to post-modern conditions, including obesity (106).
In a 10-month prospective experimental study of three human
subjects given two courses of ciprofloxacin, Dethlefsin and Rel-
man showed that the gut microbiota was rapidly altered with the
antimicrobial drug exposure (107). The composition of the micro-
biota stabilized after 10 months, but in an altered state (107). A
study in France of patients with infective endocarditis showed that
a 6-week treatment course with vancomycin and gentamicin, but
not other antibiotics, was associated with a significant increase in
BMI among males >65 years of age (108). Trasande et al. exam-
ined the long-term effect of antibiotic exposures in the first 2 years
of life of children born in Avon, United Kingdom between 1991
and 1992 (109). They found that exposure to antibiotics during
the first 6 months of life, but not during 6–14 or 15–23 months
was consistently associated with a later increase in BMI (109).
Thus, even short-term exposures to antibiotics appear to have
an effect on BMI in humans. If indeed, a large proportion of
Americans are exposed to low-residue antibiotics in the food they
eat, chronic exposures to such sources could certainly disrupt the
normal steady state gut microbiota, which should be reflected by
changes in body physiology that occur at the community and pop-
ulation level. It is interesting to note that adult obesity prevalence
increased only slightly from the 1950s through the mid-1970s
(involving cohort of people born in the 1930–50s, who would
have had no or low-dose exposure to antibiotics in food) (2).
The sharp rise began after the 1970s, with the greatest increase
occurring after 2000, when obesity among children and teenagers
also had the greatest increase (4) (involving cohort of people born
during the period of sharpest increase in CAFOs and other forms
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of intensified livestock production and AFOs). These population-
based data do not show a causal effect, but the fact that low-dose
antibiotics do cause weight gain in food animals provides a strong
rationale to examine the effect of this type of exposure at the
human population level.
FUTURE RESEARCH
This new hypothesis raises several research questions. To date,
the demonstration of the link between intestinal microbiota with
changes in body physiology has been experimental, involving mice
or selected human subjects. The impact of antibiotic exposures
on the gut microbiota ecology and body physiology needs to be
examined at the population level. The comparison of gut micro-
biota of populations residing near CAFOs versus those living away
from such places may reveal microbiota population structures
associated with differences in body physiology. Antibiotic con-
centrations in the water and food these populations ingest could
be measured for some class of drugs. Serial analysis of the gut
microbiome of children at risk for weight gain followed prospec-
tively may reveal changes associated with weight gain. Clearly,
obesity has multifactorial causes. Prospective, population-based
studies can be conducted to determine the relative proportion
of the obesity prevalence that may be contributed by antibiotic
exposure in food, if any. Obesity prevalence is also increasing in
other countries, especially in the emerging economy nations. The
practice and trend of use of antibiotics as growth promoters in
animal husbandry can be assessed to examine the relevance of this
hypothesis to the obesity epidemic in these other regions of the
world. Finally, a more systematic and comprehensive analysis of
antimicrobial residues in food and the environment is needed.
CONCLUSION
There is accumulating evidence that changes in gut microbiota
can affect body physiology. While the exact mechanism remains
unsolved, animal experimental and human observation studies
provide tantalizing evidence that these changes in the intestine
can be triggered by exposures to antimicrobial agents, especially
in the context of certain dietary nutrients introduced into the gut,
and that these changes can contribute to weight gain. What has
been lacking is the epidemiologic evidence in support of this idea.
Today, the core gut microbiota of many Americans may be sub-
stantially different from that of most Americans living before the
1950s. We propose this idea to be considered to explain part of the
obesity epidemic in the US. Clearly more observational as well as
experimental studies are necessary to support the hypothesis.
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It is a common practice for decades to use of sub-therapeutic dose of antibiotics in food-
animal feeds to prevent animals from diseases and to improve production performance in
modern animal husbandry. In the meantime, concerns over the increasing emergence of
antibiotic-resistant bacteria due to the unreasonable use of antibiotics and an appearance
of less novelty antibiotics have prompted efforts to develop so-called alternatives to
antibiotics. Whether or not the alternatives could really replace antibiotics remains a
controversial issue. This review summarizes recent development and perspectives of
alternatives to antibiotics. The mechanism of actions, applications, and prospectives of
the alternatives such as immunity modulating agents, bacteriophages and their lysins,
antimicrobial peptides, pro-, pre-, and synbiotics, plant extracts, inhibitors targeting
pathogenicity (bacterial quorum sensing, bioﬁlm, and virulence), and feeding enzymes
are thoroughly discussed. Lastly, the feasibility of alternatives to antibiotics is deeply
analyzed. It is hard to conclude that the alternativesmight substitute antibiotics in veterinary
medicine in the foreseeable future. At the present time, prudent use of antibiotics and the
establishment of scientiﬁc monitoring systems are the best and fastest way to limit the
adverse effects of the abuse of antibiotics and to ensure the safety of animal-derived food
and environment.
Keywords: antibiotics, antibiotic alternatives, application, limitation
INTRODUCTION
Since the discovery and application of penicillin in 1940s, antibi-
otics have played unparalleled roles in the prevention, control, and
treatment of infectious diseases for humans and animals. It is also
proved that the use of antibiotics in animal feeds is an impor-
tant way to enhance feed efﬁciency, to promote animal growth,
and to improve the quality of the animal products. Recent stud-
ies showed that the growth-promoting effect of antibiotics was
correlated with the decreased activity of bile salt hydrolase, an
intestinal bacteria-produced enzyme that exerts negative impact
on host fat digestion and utilization (Lin, 2014). Therefore, antibi-
otics are effective tools for ensuring the development of intensive
and large-scale farming industry. However, the unreasonable use
of antibiotics has given rise to a fear of the development of
resistant bacteria (Aarestrup et al., 1998) that may lead to the
transfer of resistant bacteria and its resistant factors from ani-
mals to humans (Stanton, 2013). Non-therapeutic antimicrobial
uses are also linked to the propagation of multidrug resistance
(MDR), including resistance against drugs that were never used
on the farm (Marshall and Levy, 2011). Due to this concern,
Sweden ﬁrstly prohibited the use of some of the antibiotics in
animal feeds in 1986 (Castanon, 2007), and European Union (EU)
member nations banned all antibiotic growth promoters in 2006
according to European Parliament andCouncil Regulation ECNo.
1831/2003.
However, the ban of in-feed use of antibiotics has brought
unintended impacts on animal production industries in EU, such
as the increase of infections in animals and the decrease of animal
production. Meanwhile, the total usage amount of antibiotics in
animals increased because the use of therapeutic antibiotics and
disinfectants was signiﬁcantly increased due to the fact that the
high incidence of diseases occurred resulted from the ban. Unlike
its golden age when a lots of antibiotics were discovered and com-
mercialized, the discovery and development of new antibiotics
dramatically decreased for decades (Stanton, 2013). The antimi-
crobial shortages increased by 283% in 2006∼2010 (Borchardt
and Rolston, 2013). The lack of novel core moiety of antibiotics
potentially compensate for the resistance to existing antibiotics
and owes to the high cost and risk associated with the devel-
opment and application of such products (Cooper and Shlaes,
2011).
To overcome the increased rate of mortality and morbidity
due to the ban of in-feed antibiotics, a number of alterna-
tives/replacements have been proposed (Seal et al., 2013). They
are antibacterial vaccines, immunomodulatory agents, bacterio-
phages and their lysins, antimicrobial peptides (AMPs), pro-,
pre-, and synbiotics, plant extracts, inhibitors for bacterial quo-
rum sensing (QS), bioﬁlm and virulence, and feed enzymes,
etc. (Millet and Maertens, 2011). Are these antibiotic alternatives
really as effective as antibiotics to control the diseases in animals?
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The development and application of the alternatives to antibiotic
was reviewed, and the possibility of the alternatives to antibiotics
was discussed in this paper.
IMMUNITY MODULATING AGENTS
The development of an infection is the interaction between the
pathogen and the immune system of the host. The immune sys-
tem protects the body against the disease by recognizing and
neutralizing the pathogen. The innate immune response includes
both humoral and cellular defense such as the complement sys-
tem and the processes played by granulocytes and macrophages.
Immunity modulating agents (immunomodulators) are used for
immunotherapy,which is deﬁned as treatment of disease by induc-
ing, enhancing, or suppressing an immune response. Vaccine
is one of the most important immunomodulators, and some
pharmaceutical agents could also be used as immunomodulators.
ANTIBACTERIAL VACCINES
Traditional vaccines are generally classiﬁed into live-attenuated
and inactivated/killed vaccines. Bacterin is a suspension of killed
or weakened bacteria used as a vaccine. Live-attenuated bacteria,
replicating transiently in the host, are capable of expressing a full
repertoire of antigens. Take Salmonella vaccine for an example.
Many live Salmonella vaccine strains have been tested with vary-
ing degrees of efﬁcacies (Desin et al., 2013). However, the major
drawbacks of the live strains is that they persist in the animal
body for a longer time (Tan et al., 1997) and have a high risk of
reverting to full virulence (Barrow, 2007; Gast, 2007). Although
various Salmonella live-attenuated vaccines have been reported,
not all of them have been tested under ﬁeld conditions. In addi-
tion, they do not induce sufﬁcient cross protection against other
non-host-adapted serotypes (Desin et al., 2013).
Killed vaccines are safer than the live vaccines. It is made
by killing in vitro-grown bacterial cultures and packing with
oil-based adjuvants to enhance immune responses (Potter et al.,
2008). They are quite inexpensive in production and stable
in storage. The inactivated autogenous poultry vaccines cur-
rently include Pasteurella multocida, Salmonella, Mycoplasma,
Ornithobacterium, Haemophilus, Staphylococcus, Escherichia coli,
and Bordatella Bacterins. However, killed vaccines have numer-
ous disadvantages such as the lack of relevant protective antigens
(PAs) due to in vitro growth conditions and killing processes
(Barrow, 2007; Gast, 2007), antigenic competition between non-
protective and protective components, a lack of safety due to
potentially harmful components such as lipopolysaccharide, and a
lack of broad-spectrum protection. In addition, killed vaccines
require the use of adjuvants which limits the delivery options
for the vaccines. Moreover, most of the killed vaccines are
injectable products and are not routinely used in intensive broiler
operations.
With the increasing use of bacterins, there are concerns that this
may lead to the increasing virulence of bacteria. As an alternative,
subunit vaccine is composed of either a single antigen or multiple
deﬁned antigens (predominantly proteins). This kind of vaccines
lack the regulatory and biological complications associated with
the living organisms. On the other hand, subunit vaccines are usu-
ally poorly immunogenic, requiring formulation with appropriate
adjuvant(s) (Mutwiri et al., 2011). Although Salmonella subunit
vaccines are under development, it is hard to conclude that one
class of vaccines is more efﬁcacious than another (Desin et al.,
2013). Besides, the use of oral subunit vaccines in large animals
remains problematic due to the degradation of the antigens and
poor absorption in guts (Potter et al., 2008).
DNA vaccines offer another promising improvement to con-
ventional vaccines (Haygreen et al., 2005). DNAvaccine ismadeup
of a small, circular piece of bacterial DNA (called a plasmid) that
has been genetically engineered to include the DNA sequence(s)
encoding the antigen(s) from a pathogen. When the vaccine DNA
is injected into the cells of the body, the host cells “reads” the DNA
and converts it into pathogenic proteins which would trigger a
range of immune responses. Nevertheless, DNA vaccine is limited
in its protective capacity to the encoded proteins on the vector
and may pose a risk of integrating the genetic elements of the
vector into the host genome. Most of the literatures dealing with
DNA vaccines have described the use of viral antigens delivered in
mouse models. However, when they are used in large animals,
results are often disappointing (Potter et al., 2008). Therefore,
DNA vaccines are unlikely to reach the market until the plasmid
dose can be controlled and the problems of effective delivery are
solved.
Unlike the anti-viral vaccine market which is quite mature, the
available antibacterial vaccines are still rare in market. For exam-
ple, no vaccines are commercially available for either C. jejuni
or E. coli O157 although immunization against both of these
strains has been respectively demonstrated in chicken and cat-
tle (Potter et al., 2008). In the case of E. coli O157, immunization
with bacterins has not shown any protection effect. Although vac-
cines against E. coli and Brachyspira hyodysenteriae for treating
swine dysentery have been reported (Francis and Willgohs, 1991;
Song et al., 2009), safety and efﬁcacy data are still lacking, hin-
dering the commercialization process of these biological products
(Ruan et al., 2011). S. aureus vaccines are developed for bovine
mastitis, but a systematic review evaluating 24 in vivo studies sug-
gests that the methodological differences and a lack of more rigid
scientiﬁc criteria (such as double blind protocols) in some cases
hinder the assessment of the efﬁcacy of these vaccines (Pereira
et al., 2011). Moreover, the protection rates of animals by antibac-
terial vaccine in the market are low (Buckley et al., 2010; Crouch
et al., 2010).
Last but not least, the development of a vaccine that is
both practical and inexpensive so that it can be affordable for
use in poor countries is still a key problem (Zhang and Sack,
2012). As for poultry vaccines, the most important challenge for
mass immunization is the cost of vaccine as well as the abil-
ity in most cases. While vaccines may lessen our reliance on
the use of antibiotics, they are complementary rather than a
replacement.
OTHER IMMUNOMODULATORS
Immunomodulators, mainly immunostimulants, are able to non-
speciﬁcally enhance the innate immune function and to improve
the host’s resistance to diseases. The use of immunotherapy
in infectious diseases may resulting in modulating the immune
response to a microbe (e.g., by using cytokines and cytokine
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inhibitors), modifying a speciﬁc antigen-based response (e.g.,
using interferons) and minimizing end-organ damage using non-
speciﬁc anti-inﬂammatory agents (e.g., steroids; Masihi, 2000).
β-Glucans, bacterial products, and plant constituents could
directly initiate activation of innate defense mechanisms acting
on receptors and triggering intracellular gene(s) that may result in
the production of antimicrobial molecules.
There is a variety of immunostimulants, no less than a dozen
categories with hundreds of varieties (Table 1). Since 1990s,
nucleotides, thymosin, and oregano oil have mainly been used
as immunostimulants. Later, probiotics, herbs and their extracts
have also become subjects to immunostimulant studies (Thacker,
2010). Studies in animals exhibit signiﬁcant health beneﬁts by
using β-1,3/1,6-glucan (from yeast cell walls) as a feed ingredi-
ent to protect animals against microorganisms (Williams et al.,
1996). It is suggested that the use of immunostimulants as feed
additives can improve the innate defense of animals, providing
resistance against pathogens during periods of high stress, such
as grading, reproduction, transfer, and vaccination (Bricknell and
Dalmo, 2005).
Many factors affect the efﬁcacy of immunostimulants.
Immunostimulants exhibit different effects in different animal
species. They do not reveal a linear relationship between dose
and effect, usually more efﬁcient during or prior to infec-
tion. Besides the beneﬁcial effects, immunostimulants have so
broad effects among which they inhibit the protective aspects
of the host immune system (Thacker, 2010). When immuno-
genic stimulation persists or autoregulatory immune mechanisms
cease, adaptive immunologic events can result in immune-
mediated processes detrimental to systemic or organ-speciﬁc
homeostasis (Moore, 2004). It has been proposed in larval ﬁsh
aquaculture that the delivery of immunostimulants as a feed
additive could be of considerable beneﬁt in boosting the ani-
mals’ innate defense with little detriment to the developing
of ﬁshes. Conversely, immunomodulating a neotenous ani-
mal before its immune system is fully formed may adversely
affect the development of a normal immune response (Bricknell
and Dalmo, 2005). Importantly, most immunomodulators just
enhance the immune systemof animals, rather thandirectly kill the
bacteria.
Presently, there are no uniform standards for evaluating
the efﬁcacy and safety of immunostimulants. It was reported
that a reputed immunostimulant composed of Propionibacterium
acnes extract,Ochrobactrum intermedium lipopolysaccharides and
Proclin® did not affect the immune system of goats (Morales-
delaNuez et al., 2009). The widespread notion of immunostimu-
latory plant natural products and their potential therapeutic use is
rather obscure, suggesting that the product is some sort of “tonic”
for the immune system without actually specifying the mecha-
nisms (Gertsch et al., 2011). It is argued that the paradigm of oral
plant immunostimulants lacks clinical evidence, originating from
primary in vitro studies. No conclusive data on orally administered
immunostimulants can be found in the scientiﬁc literatures up to
now. Overall, immunotherapy to modulate the immune response
just can be used as an adjunct to the antimicrobial therapy (Kak
et al., 2012).
Table 1 | Classification of immunostimulants.
Category Variety
Mineral substances Selenium, zinc, etc.
Vitamins Vitamin A, vitamin E, vitamin C, etc.
Amino acids Arginine, leucine, ubenimex, etc.
Chinese herbal medicines Astragalus, Echinacea, etc.
Plant polysaccharides Astragalus polysaccharide, lentinan, algal polysaccharides, ganoderan, Polyporus polysaccharide, chitosan,
etc.
Oligosaccharides Mannan-oligosaccharides, fructooligosaccharide, etc.
Microbial preparations BCG vaccine, corynebacterium seedlings, Lactobacillus, cholera toxin B subunit, Mycobacterium phlei,
muroetasin, prodigiosin, etc.
Immunologic adjuvants Aluminum adjuvant, propolis, liposome, Freund’s adjuvant, etc.
Hormones and hormone-like substances Growth hormone, thymosin, metallothionein, thymopentin, etc.
Nucleic acid preparations Polynucleotide, immune ribonucleic acid, etc.
Anthelmintics Levomisole, metronidazole, etc.
Chemical synthetics Levomisole, cimetidine, sodium houttuyfonate, imiquimod, pidotimod, ubenimex, tilorone, polyinosinic acid,
etc.
Bacterial extracts β-Glucan, peptidoglycan, lipopolysaccharide, etc.
Biological (cytokines) Interferon, transfer factor, interleukin, immune globulin, etc.
Others Bee pollen, bursa extracts, gamma globulin, heat shock protein, poly IC, glycyrrhizin, etc.
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BACTERIOPHAGES AND THEIR LYSINS
BACTERIOPHAGES
Bacteriophages are viruses that are parasitic on bacteria, and they
have been considered as one of the types of agents to treat bacte-
rial infections for a long time (Wittebole et al., 2014). They were
ﬁrst discovered by Frederick Twort in UK in 1915 and by Félix
d’Herell in France in 1917. The ﬁrst study on the clinical use
of phage was published in Belgium in 1921 by Bruynoghe and
Maisin who injected staphylococcus-speciﬁc phage near the base
of the cutaneous boils to treat cutaneous furuncles and carbuncles.
The commercial phages was introduced by two companies in the
United States and France in 1940s. Recent animal studies show that
phage therapy is worth of recognition (O’Flaherty et al., 2009). It
is reported that phages has certain preventive effects on pathogens
as E. coli O157:H7, Salmonella and Campylobacter (Huff et al.,
2005; Johnson et al., 2008). In 2006, a phage cocktail desig-
nated LMP-102TM containing six types of pure bacteriophages was
approved by US-FDA as a food additives for prevention of meat
contaminationwith Listeria. In 2007,United States Department of
Agriculture (USDA) approved another phage product to be used
for disinfection of E. coli in hidden parts of cattle. Nonetheless,
most of the bacteriophage products to date are still in the research
stage.
Bacteriophages can replicate in host cells and are able to pro-
duce new lytic phages to keeppacewith themutation of pathogens.
However, the replacement of antibiotics by phages in treatment of
bacterial diseases encounters controversy because of the following
characteristics (Pirnay et al., 2011):
(1) Since phages have strict host strain speciﬁcity, the precise
etiologicalmicroorganismcausing infectionneeds to be deter-
mined with accuracy before the use of phage therapy (Allen
et al., 2013). Also, the narrow host range impedes the abil-
ity of a single kind of phages to be used as replacement of
antibiotics, which are typically broader in their antibacterial
spectrum;
(2) Since they are viruses, phages can be seen by the immune
system of the host as a potential invader and may there-
fore rapidly be eliminated from the systemic circulation by
reticulo-endothelial system clearance before they are accu-
mulated in the target sites, or, they may be inactivated by
the adaptive immune defense mechanisms (Dabrowska et al.,
2005), which may lead to the treatment failure (Merril et al.,
1996);
(3) Another concern of phage therapy is the potential ability of
bacteriophages to transfer their DNA from a bacterial cell
to another. This could be responsible for the transfer of
pathogenicity determinants and virulence factors, leading to
the development of a new microbe or even more resistant
bacteria (Brabban et al., 2005; Maiques et al., 2007). There-
fore, the use of phages that are unable to package extra
host DNA or of phages that use the host DNA to synthe-
size its own DNA would be preferred (Gorski et al., 2009).
In addition, under certain conditions, lytic phages would
be transformed into lysogenic phages, making it possible
to transfer their own virulence factors to the host bacteria
(Brussow, 2007);
(4) Pharmacokinetic characteristics of phages are barely
known. Optimal dose, route of administration, fre-
quency, and duration of treatment still need to be
deﬁned before widespread clinical trials are contem-
plated;
(5) Phage therapy is time-sensitive. Use phages early in a dis-
ease setting could obtain a better therapeutic effect. For
example, when the phages were given immediately after
the infection of E. coli O18ac:K1:H7 ColV+, the efﬁcacy
was 100%; whereas when phage treatment was carried out
16 h after infection, the therapy failed (Smith and Huggins,
1982);
(6) Phages can cause the release of toxins, e.g., endo-
toxin (LPS), in large quantities from bacteria, especially
Gram-negative bacteria. This may account for several
side effects on the host such as the development of an
inﬂammatory cascade leading to a multiple organ fail-
ure;
(7) Bacteria can obtain resistance to phages by mutation.
The mutation rates for antibiotics and phages are 10−7
and 10−6, respectively (Carlton, 1999). There are at
least four mechanisms that may be involved in bacterial
resistance to a speciﬁc phage. Loss or lack of recep-
tor (Liu et al., 2002), structural modiﬁcation (Riede and
Eschbach, 1986) and/or masking of the receptor (Drulis-
Kawa et al., 2012) may prevent phage adsorption to the
bacteria and prevent further an ability to generate new
phages. The other mechanisms include the prevention of
phage DNA integration by superinfection exclusion sys-
tem (Sie), the degradation of phage DNA by restriction–
modiﬁcation defense system or by clustered regularly inter-
spaced short palindromic repeats (CRISPR), and the blockage
of phage replication, transcription, translation, or virion
assembly by abortive infection system (Drulis-Kawa et al.,
2012);
(8) Some phages can only survive in the intestines when
bacteria counts reach certain numbers. Phages can only
reduce but not completely eliminate S. typhimurium in
the animal intestines (Berchieri et al., 1991; Callaway et al.,
2011);
(9) Preparation of phages should be at a low temperature (Bur-
rowes et al., 2011), and this kind of biological products are not
stable.
Currently, the main challenge for the promotion of phage
preparations is the lack of data obtained from large-scale clinical
trials, thus hindering the universal application of them. Regu-
latory loopholes remain another major hurdle. In addition to
the inherent safety concern, neither the US-FDA nor the Euro-
pean Medicines Agency has an approval process in place that can
easily accommodate the ever-changing combinations of phages
that accompanies the need to continuously develop the prod-
uct in order to stay one step ahead of evolving MDR bacteria
(Miedzybrodzki et al., 2012).
ENDOLYSINS
Endolysins, including glucosidase, amidase, endopeptidase, and
transglycosylase, are generated at the late phage lytic cycle,
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degrading bacterial peptidoglycan to facilitate the release of new
phages from the infected bacteria. Endolysins were ﬁrst discov-
ered in the 1950s (Ralston et al., 1955), and revealed antibacterial
activity against Staphylococcus, Bacillus anthracis, L. monocy-
togenes, and Clostridium butyricum in the 1990s (Low et al.,
2005). Endolysins can treat sepsis and a few Gram-positive
bacteria infections, such as Enterococcus faecalis, C. perfrin-
gens, and Group B Streptococcus (Fenton et al., 2010). Endolysin
PAL is able to kill Group A Streptococcus which cause tonsilli-
tis and other infections. Amidase PAL and endopeptidase Cpl-1
from phage Cpl-1 is capable of synergistically reducing the inci-
dence of local and systemic pneumococcal disease (Loefﬂer et al.,
2003; Fischetti, 2005). Endolysins LysK from phage K could
kill nine Staphylococcus, including methicillin-resistant S. aureus
(MRSA; O’Flaherty et al., 2005). Endolysins PlyV12 shows a good
lytic activity against Enterococci, vancomycin-resistant E. faecalis
and E. faecium (Yoong et al., 2004). Endolysins isolated from
phage phi3626 can treat Clostridium infections (Courchesne et al.,
2009).
Endolysins can quickly kill susceptible strains with wider
antibacterial spectrum than phages and the activities are easier
to be detected. Long-term evolution of endolysins makes them
target only for some of the key elements on bacterial cell walls
(Loefﬂer et al., 2003) thus cause bacteria lysed fast. Therefore,
there is not enough time for bacteria to develop a resistance (Fis-
chetti, 2005). However, the conventional methods for endolysin
production are complicated, making the cost higher than that of
the phage production. The use of recombinant DNA technology
can reduce the costs (Loefﬂer et al., 2001), but it cannot guarantee
the correct structure and full activity of the enzymes. Meanwhile,
endolysins are easily degraded and lose activities during use and
storage; hence they should be usedwith a full dose. In addition, the
efﬁcacy of endolysins is poor against Gram-negative bacteria; thus
the use of single type of endolysin limits the scope of application.
Future studies will focus on the chimeric endolysin (O’Flaherty
et al., 2009), which could widen the antibacterial spectrum of this
kind of enzymes. Presently, there are no published clinical studies
concerning the endolysins.
VIRION-ASSOCIATED PEPTIDOGLYCAN HYDROLASES
Bacteriophage virion-associated peptidoglycan hydrolases
(VAPGHs) are a kind of phage lyases that hydrolyze bacterial pep-
tidoglycan to assist the entry of phages into the bacterial cells
(Rodriguez-Rubio et al., 2013). Many VAPGHs have been discov-
ered and proved exhibiting antibacterial activities. Protein HydH5
from phage phiIPLA88 shows higher activity against S. aureus in
the early logarithmic growth phase (Rodriguez et al., 2011). Pro-
tein 17 from phage P68 and protein gp61 from phage phiMR11
exhibit lytic activity against S. aureus including MRSA (Takac
and Blasi, 2005; Rashel et al., 2008). Protein P5 from phage 6
possess the antibacterial activity against Pseudomonas, E. coli, S.
typhimurium, Proteus vulgaris, and other Gram-negative bacteria
whose outer membrane structures are unstable (Caldentey and
Bamford, 1992). Protein Gp181 from phage KZ demonstrates a
lytic activity against the above mentioned Gram-negative bacte-
ria as well as Ralstonia solanacearum and Yersinia. Protein gp36
of phage KMV is effective against P. aeruginosa and E. coli,
and exhibits a high thermal stability as the enzyme retained
26% of activity after incubation at 100◦C for 2 h (Lavigne et al.,
2004).
Currently, the researches onpuriﬁedVAPGHs are limited. Since
bacterial resistance caused by endolysin has not been reported to
date, this may also be the case for VAPGHs (Rodriguez-Rubio
et al., 2013). VAPGHs from Gram-negative bacterial phages have
broad antimicrobial spectrum while the antibacterial spectrum
of VAPGHs from Gram-positive bacterial phages only conﬁne
to speciﬁc host bacteria. VAPGHs are also effective against
some antibiotic-resistant pathogens, increasing their application
prospects (Paul et al., 2001; Rodriguez-Rubio et al., 2012). Many
VAPGHs exhibit thermal stability, retaining activity at high tem-
peratures generally associated with food technology. Taking into
account that extracellular action can reduce the intracellular action
which may trigger widespread bacterial resistance mechanisms,
such as efﬂux pumps, VAPGHs provides an alternative source
for bacterial lyases except for endolysins (Rodriguez-Rubio et al.,
2013).
ANTIMICROBIAL PEPTIDES
Antimicrobial peptides are classiﬁed into two categories, non-
ribosomally synthesizedAMPs and ribosomally synthesizedAMPs,
according to thepeptide synthesismechanism. Thenon-ribosomal
AMPs, mainly produced by bacteria, are synthesized by peptide
synthetases and structural modiﬁcations. They include grami-
cidin, polymyxin, bacitracin, and sugar-peptide. Polymyxin is
fromB. polymyxa, playing bactericidal effect by destroying the bac-
terial cell membranes. It is effective against many Gram-negative
bacteria, such as P. aeruginosa, E. coli, Klebsiella pneumoniae,
Haemophilus, and Salmonella. Bacitracin is a cyclic peptide pro-
duced by B. subtilis and B. licheniformis, and it functions by
inhibiting the synthesis of cell wall peptidoglycans and glycopro-
tein core oligosaccharides in Gram-positive bacteria. Bacitracin
shows bactericidal effects against Gram-positive bacteria, Gram-
negative cocci and spirochetes. The USA and China have approved
the use of bacitracin zinc and bacitracin methylene salicylic acid as
feed additives in 1960 and 1990, respectively. These two bacitracins
have a wide compatibility with other medicines.
Ribosomally synthesizedAMPs can be further classiﬁed accord-
ing to the sources of the peptides, such as mammals, amphibians,
insects, plants, bacteria, viruses, etc. These AMPs are not only
anti-bacterial or anti-mycotic, but also anti-protozoal, anti-
viral, or anti-neoplastic, with broad application prospects. The
positive charges of AMPs could form electrostatic adsorption
with negatively charged phospholipid molecules on the bac-
terial cell membranes, resulting in structural damage of the
membranes.
There are many reports on the protective effect of AMPs on
humans (Guani-Guerra et al., 2010) and animals (Leonard et al.,
2012). Here, bacteriocins which are produced by bacteria are taken
as an example. Bacteriocins are deﬁned into four classes as lantibi-
otics, the small heat-stable peptides (SHSPs), the large heat-labile
proteins (LHLPs), and undeﬁned mixture proteins with lipids and
carbohydrates (Bierbaum and Sahl, 2009). Bacteriocins can also be
subdivided on the basis of their modiﬁcations into class I (modi-
ﬁed) and class II (unmodiﬁedor circular; Cotter et al.,2013). There
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have been lots of identiﬁed bacteriocins such as nisin, lactacin,
lactocin, helveticin, fermenticin, sakacin, lacticin, plantacin, sub-
ticin, etc. In vitro tests show that bacteriocins have strong killing
and suppressive effects on a variety of pathogens, including resis-
tant pathogens (Field et al., 2011). In 1988, nisin received the
US-FDA approval as food additive for the ﬁrst time. Pediocin
PA-1 from Pediococcus is on the market now. However, pure
bacteriocins have so far only few and limited authorized uses in
foods.
Bacteriocins have been found to have many distinct mecha-
nisms of action. In addition to punch holes in the cell membrane
like other AMPs do (Cotter et al., 2005), nisin, several lantibi-
otics and some class II bacteriocins, target lipid II (Bierbaum and
Sahl, 2009), a key intermediate in the peptidoglycan biosynthesis
machinery. Besides, bacteriocins can kill bacterial cells by interfer-
ing with DNA, RNA, and protein metabolism. MccB17 functions
by inhibiting DNA gyrase-mediated DNA supercoiling, thereby
interfering with DNA replication (Parks et al., 2007). MccC7-C51
inhibits aspartyl-tRNA synthetase, thus blocking mRNA synthesis
(Metlitskaya et al., 2006). Nocathiacins and several other thiopep-
tides target the bacterial ribosome, binding the 23S rRNA of the
50S ribosomal subunit (Bagley et al., 2005).
Although AMPs are with good bactericidal effects and eas-
ily digested by bodies without adverse effect to the taste of feed
or polluting the environment, a number of constraints have
accompanied with the deepening research concerning AMPs.
(1) The high production cost limits the use of AMPs as effective
antibiotic alternatives to livestock. Nowadays, bacteriocins are
produced traditionally by culturing the wild strains, but the
yield is low and the puriﬁcation process is complex;
(2) Scientists begin to use genetic engineering techniques to syn-
thesize bacteriocins owing to their peptidenature because they
are directly encoded by genes (Cotter et al., 2013). AMPs can
be modiﬁed by protein engineering to improve their efﬁcacy.
Site-saturation mutagenesis approach is used to create a bank
of nisin A derivatives to screen the ones exhibiting enhanced
bioactivity (Molloy et al., 2013). However, it cannot guarantee
that the spatial structures of AMPs obtained by genetic engi-
neering are consistent with the those of natural AMPs, which
often causes differences in activities (Field et al., 2011);
(3) Many natural AMPs, such as melittin (a peptide which is
the principal active component of bee venom), buthotoxin
(a scorpion venom polypeptide) and plant AMPs, are poten-
tially toxic to eukaryotic cells due to their hemolytic effects.
Recently, a potent E. coli displaying multimeric AMPs on the
cell surface was constructed (Shin et al., 2013). The multi-
meric AMPs can be converted into active AMP monomers by
the pepsin in the stomach of livestock;
(4) Antibacterial spectrum of most bacteriocins is narrow, only
effective to the related bacterial species (Lee and Kim, 2011);
(5) Bacteria can still develop resistance to AMPs by reducing
the corresponding receptors (Piper et al., 2009), changing the
composition of cell wall (Kramer et al., 2006), or changing the
primary target of bacteriocin (del Castillo et al., 2001). Some
bacteria can also utilize immune genes (Draper et al., 2009)
or bacteriocin-hydrolase (Sun et al., 2009; Nocek et al., 2012)
to obtain resistance. In fact, the widely used polymyxin AMPs
has caused serious resistance in clinically important bacterial
species, in both human and veterinary medicine;
(6) In vivo studies about pharmacodynamics, pharmacokinetics,
and stability of AMPs are few. It is unclear whether AMPs or
their metabolites are harmful to the body, and the immune
response and other issues still need to be veriﬁed;
(7) AMPs are unstable during transportation, and are easily
hydrolyzed by proteases in the alimentary canal during use.
PRO-, PRE-, AND SYNBIOTICS
PROBIOTICS
Probiotics have been deﬁned by the World Health Organization
as “microorganisms which, administered live and in adequate
amounts, confer a beneﬁt to the health of the host.” Probiotics
are considered to be able to destroy pathogenic microorganisms
by producing antimicrobial compounds such as bacteriocins and
organic acids, improve gastrointestinal microbial environment by
adherence to intestinal mucosa thereby preventing attachment of
pathogens and competing with pathogens for nutrients, stimu-
late the intestinal immune responses and improve the digestion
and absorption of nutrients. The commonly used probiotics
include Bacillus, Lactobacillus, Lactococcus, Streptococcus, Ente-
rococcus, Pediococcus, Biﬁdobacterium, Bacteroides, Pseudomonas,
yeast,Aspergillus, andTrichoderma, etc. Microbiological feed addi-
tives used in EU mainly include Bacillus (B. cereus var. toyoi,
B. licheniformis, B. subtilis), Enterococcus (E. faecium), Lacto-
bacillus (L. acidophilus, L. casei, L. farciminis, L. plantarum, L.
rhamnosus), Pediococcus (P. acidilactici), Streptococcus (S. infan-
tarius), and some fungi such as Saccharomyces cerevisiae and
kluyveromyces (Anadon et al., 2006). Japan started using probi-
otics in 1960s, and China began the application of probiotics in
1980s. US-FDA approved 42 probiotics till 1989 (Gaggia et al.,
2010). In 2000, the total sale of feed probiotics worldwidewas $186
million.
However, the probiotic market is very less organized and the
supervision and management of probiotic production are defec-
tive. For instance, China Ministry of Agriculture has approved 12
probiotics, but there are more than 50 probiotics being used in
China. Due to lack of standards, animal poisoning, allergies, and
diarrhea after using probiotics are reported from time to time.
Despite years of experiences in the use of lactobacilli and biﬁ-
dobacteria which are proved to be safe, the safety of other species
still need to be examined (Borriello et al., 2003). Meanwhile, probi-
otics are potentially harmful to the congenitally immunodeﬁcient
animals (Balish and Wagner, 1998). Besides, previous studies have
failed to consistently prove the beneﬁcial effects of probiotics in
animals. For example, microcin-producing E. coli could inhibit
the growth of Salmonella in vitro, but the results in vivo were
not satisfactory (Frana et al., 2004). Contradictory results with
very heterogeneous studies are reported on the treatment and the
prophylaxis of upper respiratory tract infections (Alexandre et al.,
2014). Furthermore, probiotics have adverse effect on the nor-
mal gut ﬂora. Lactobacillus and Bacillus can destroy the ecological
balance of normal ﬂora in the body, which may be related to the
occurrence of urinary tract infections and other diseases. Dietary
cider yeast can potentially alter the gut microbiota. However, such
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changes depend on their endogenous microbiota that causes a
divergence in relative response to that given diet (Upadrasta et al.,
2013).
For putting probiotics into practice as feed additives, the fol-
lowings are challenged: (1) the number of safe bacterial species is
limited; (2) microbial preparations are easily inactivated in feed
processing, transport, and storage processes; (3) they cannot with-
stand low pH in gastrointestinal tract and bile acids during use;
(4) it is difﬁcult to reach high enoughnumber of viable cells to col-
onize in the intestine. In addition, because there are no adequate
corresponding regulations and standards, probiotic products can-
not be labeled with proper dose, indicated in suitable animal target
as well as other factors that may affect the efﬁcacy.
PREBIOTICS
Prebiotics are non-digestible (by the host) food ingredients
that have a beneﬁcial effect through their selective metabolism
in the intestinal tract (Gibson et al., 2004). Prebiotics include
oligosaccharides [such as fructooligosaccharide (FOS), mannan-
oligosaccharide (MOS)], polysaccharides, natural plant extracts,
protein hydrolysates, polyols, etc. Prebiotics can selectively prolif-
erate intestinal bacteria, promote immune functions and show
anti-viral activity. Some of them are able to promote mineral
absorption and regulate metabolism. The applications of prebi-
otics as feed additives began in the late 1980s. China began to use
them in the late 1990s. Currently, the most promising prebiotics
are multifunctional oligosaccharides and acidiﬁers.
Prebiotics are stable compounds with no residue, no induced
resistance, and wide variety of sources. However, nowadays in EU
manyprebiotic products are not authorized as feed additives under
the commission regulation (EC) 1831/2003 (European Commis-
sion,2003). This is due to somedrawbacks of this kind of products.
First, prebiotics themselves cannot inhibit and kill pathogens, thus
they cannot prevent or treat bacterial infections as antibiotics
do. Second, feeding with large quantity of prebiotics may cause
bloating, diarrhea, and other adverse reactions due to the fermen-
tation in the gastrointestinal tract (de Vrese and Schrezenmeir,
2008). Third, a study suggests that the prebiotic role of mannose
is related to its oligosaccharide structure (Badia et al., 2013). Both
β-galactomannan and MOS from yeast Saccharomyces cerevisiae
attenuates Salmonella-induced secretion of IL6 and CXCL8, but
cells treated with monosaccharide D-mannose show similar levels
of these proinﬂammatory factors compared with the control of
infection. Since the relationship between structure and physiolog-
ical function of prebiotics is not clear, the efﬁcacy of prebiotics
is always variable with different animal species, ages, and physical
conditions. Sometimes, mutual antagonism occurs. In addition,
the high cost of prebiotic production limits their application in
the animal husbandry industry.
SYNBIOTICS
Synbiotics are the joint preparations of probiotics and prebi-
otics, and thus have the dual role of them (Andersson et al.,
2001). There are some reports on the effect of synbiotics on the
physiological and biochemical indexes of piglets including the
enhancement of immune function in piglets, the improvement
of average daily gain and digestibility, the reduction of diarrhea
morbidity and mortality, the ease of weaning stress response, and
the signiﬁcant promotion of piglet performance (Gaggia et al.,
2010). However, the reports of the beneﬁcial effects of synbi-
otics on swine production are still limited (Modesto et al., 2009).
The mixing proportions of probiotics/prebiotics for the major-
ity of synbiotics are inadequate (Kolida and Gibson, 2011), thus
resulting in a non-synergistic effect. So far, synergy mechanism of
probiotics and prebiotics has not been thoroughly understood;
hence, the extensive application of synbiotics has a long way
to go.
PLANT EXTRACTS
Plant materials are used widely in traditional systems of medicine
(Savoia, 2012). Plant extracts, also known as phytobiotics, have
been exploited in animal nutrition, particularly for their antimi-
crobial, anti-inﬂammatory, anti-oxidative, and anti-parasitic
activities (Vondruskova et al., 2010; Hashemi and Davoodi, 2011).
Many plants have beneﬁcial multifunctional properties derived
from their speciﬁc bioactive components. Biologically active con-
stituents of plants are mostly secondary metabolites, such as
terpenoids (mono- and sesquiterpenes, steroids, etc.), phenolics
(tannins), glycosides, and alkaloids (present as alcohols, alde-
hydes, ketones, esters, ethers, lactones, etc.; Huyghebaert et al.,
2011). Among 109 new antibacterial drugs, approved in the period
of 1981∼2006, 69% originated from natural products, and 21%
of the antifungal drugs were natural derivatives or compounds
mimicking natural products (Newman, 2008).
Plant extracts are generally considered safe and effective against
certain bacteria. They are extensively used in feed as growth
promoters and health protectants (Hashemi and Davoodi, 2011;
Abreu et al., 2012), particularly inAsian,African, and SouthAmer-
ican countries, and are gradually used in developed countries in
recent years. In pig production, it is thought that oregano, cinna-
mon, Mexican pepper, thyme, oregano, and Camellia sinensis can
decrease pathogenic microbial mass in the intestines (Manzanilla
et al., 2004; Namkung et al., 2004; Zanchi et al., 2008); sangrovit,
aged garlic extract, and allicin are able to increase body weight
gain (Borovan, 2004; Tatara et al., 2008); thyme, clove, oregano,
eugenol, and carvacrol are capable of improving pig performance
(Oetting et al., 2006; Costa et al., 2007). Effects of phytogenic
feed additives on the production performance of poultry are also
reported (Hashemi and Davoodi, 2010).
It is considered that plant extracts at minimum inhibitory
concentrations (MICs) of 100∼1000 μg/ml in the in vitro bac-
terial susceptibility tests possess antibacterial activities (Simoes
et al., 2009). Useful antimicrobial phytochemicals can be divided
into several categories, such as phenolics/polyphenols, ter-
penoids/essential oils, alkaloids, lectins/polypeptides (Windisch
et al., 2008). Phytochemicals exert their antimicrobial activity
through different mechanisms. For example, (1) tannins act by
iron deprivation and interactions with vital proteins such as
enzymes (Scalbert, 1991); (2) the main indoloquinoline alkaloid,
cryptolepine, is a DNA intercalator and an inhibitor of topoi-
somerase (Karou et al., 2006); and (3) saponins form complexes
with sterols presenting in the membrane of microorganisms,
causing membrane damages and consequent collapse of cells
(Morrissey and Osbourn, 1999). Essential oils have long been
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recognized for their antimicrobial properties (Lee et al., 2004),
but the exact antimicrobial mechanism is poorly understood.
In fact, the antimicrobial activities of many plant extracts have
not been elucidated clearly yet (Stavri et al., 2007). Some in vivo
observations support the assumption that the general antimicro-
bial potential of phytogenic feed additives is contributed to a
ﬁnal reduction of intestinal pathogen pressure (Windisch et al.,
2008). To the year of 2008, only two kinds of human-used
antibacterial plant extracts have completed the clinical trials, and
additional 13 plant extracts are under clinical trials (Harvey,
2008).
A common feature of phytobiotics is that they are a very com-
plex blend of bioactive components. There is a lot of variations
in the composition of phytobiotics due to the biological factors
(plant species, growing location, and harvest conditions), manu-
facturing (extraction/distillation and stabilization) and the storage
conditions (light, temperature, oxygen tension, and time; Huyghe-
baert et al., 2011). Only under certain circumstances, plant extracts
could improve animal performance and control diseases. Bird
growth responses to herbal plants are still controversial, since
the exact quality as well as the quantity of the active chemi-
cals in plant extract are required to determine the response for
bird performance (Cross et al., 2007), which are often lacking.
Some parameters that affect the efﬁcacy of the phytobioticsmainly
include the plant parts and their physical properties, the genetic
variation of the plant, age of the plant, different dosage used,
extraction method, harvest time, and compatibility with other
ingredients (Yang et al., 2009). In addition, the beneﬁcial effect of
dietary phytobiotics can be inﬂuenced by the nutritional status of
animals, the infection, the diet composition and the environment
condition (Giannenas et al., 2003).
It is difﬁcult to perform systematic and comprehensive toxi-
cology studies and safety assessment on herbs and their extracts,
due to their complex composition. The challenge is to identify and
quantify the multitude of actions in order to claim improving feed
utilization, animal physiology and health status. Currently, herbal
feed additives on the market do not meet the “trace and efﬁcient”
principle for feed additives. They are commonly used at very large
dose, generally at feed ratio of 1–2%, some up to 5%, and this
may affect the nutrition of a feed. Another consideration when
using phytogenic feed additives is the possible interactions with
other feed additives. There are reports on the adverse interactions
of phytogenics with enzyme preparations (Sarica et al., 2005) and
with protein throughpartial denaturation (Anadon et al., 2005). In
summary, although phytobiotics are a group of natural additives,
researches on their mechanisms of action, compatibility with diet,
toxicity and safety assessment need to be done before they can be
applied more extensively in animal feeds.
INHIBITORS TARGETING PATHOGENICITY
QUORUM SENSING INHIBITORS
Bacterial pathogenicity is, in part, under the regulation and control
of QS system (Swift et al., 2001). QS system consists of self-induced
signaling molecules (autoinducers, AIs), receptors, and down-
stream regulatory proteins. AIs are N-acyl homoserine lactones
(AHLs) secreted by Gram-negative bacteria, autoinducing peptide
(AIPs) secreted by Gram-positive bacteria, autoinducer-2 (AI-2),
and other signaling molecules such as quinolones, esters, and fatty
acids.
Inhibitors targeting QS can block the functions of QS system
and therefore prevent bacterial virulence regulated by QS system.
QS inhibitors (QSIs) are classiﬁed into three groups including
non-peptide small molecule, peptide (mainly AIPs homologs),
andproteinQSIs. Non-peptideQSIsmainly includeAHLs analogs,
such asACP homologs, L/D-S-adenosylhomocysteine and butyryl-
S-adenosyl-L-methionine (Parsek et al., 1999), which can interfere
with the synthesis of QS signal molecules or the binding to the
receptors. Mice treated with synthetic AIP-II had resistance to
S. aureus infection (Mayville et al., 1999) and treated with fura-
none observed the decrease of virulence of P. aeruginosa (Hentzer
et al., 2003). QS quenching enzymes and QS quenching anti-
bodies are proteinaceous QSIs (Amara et al., 2011). The former,
such as AHL-acylase, lactonase, oxidoreductases from Rhodococ-
cus and paraoxonase frommammals, degrade signalingmolecules.
Human and murine paraoxonases 1 show the host modulators
of P. aeruginosa QS (Ozer et al., 2005). In addition, competi-
tive organisms are able to clear the signal molecule to quench
QS (Kalia and Purohit, 2011). For instance, E. coli ingest AI-
2s to inﬂuence the QS of Vibrio harveyi (Xavier and Bassler,
2005). Bacteria with AHL-degrading activity protect Artemia spp.,
rotifers and larvae of turbot or prawn from infection (Nhan et al.,
2010). In animal serum, apolipoprotein B (ApoB) bind with AIP1
molecules of S. aureus, effectively reducing its QS (Peterson et al.,
2008).
Importance of QSIs is inferred from a growing number of
patents related to this ﬁeld in the last few years and extensive
researches in this ﬁeld (Kalia and Purohit, 2011; Romero et al.,
2012). QSI appears to be effective in vitro and in various ani-
mal models; however, all the structural classes of compounds that
have been studied and patented have limitations when used in vivo
(Bhardwaj et al., 2013):
(1) Except for LED209 that has entered pre-clinical trial, the vast
majority of QSIs cannot be widely applied because of their
toxicity to eukaryotic cells. Penicillic acid and patulin are toxic
to human cells, and halogenated furanone has carcinogenic
toxicity (Bjarnsholt and Givskov, 2007);
(2) Although QSI itself does not interfere with the growth of bac-
teria and thus dose not cause selective pressure on bacteria, it
is still possible for bacteria to develop new resistance (Kalia
and Purohit, 2011). For example, mutations of bacterial AHL
synthases and QS signal receptors (e.g., LuxR) remain (Kalia
and Purohit, 2011);
(3) Drugs based on AHL analogs could suffer from hydrolysis of
lactone ring and drugs based on proteins could have stability
problems. For example, lactonases produced in the human
airway epithelia show to quench QS signals from P. aerugi-
nosa (Chun et al., 2004). Therefore, special caution needs to
be exercised in the development of synthetic anti-QS analogs
based on the lactone core (Sintim et al., 2010). Unraveling the
structures of molecules like AI-3 and deciphering the struc-
tural nuances of AI-2 receptors, LuxS and the myriad signal
transduction cascades involved in QS processes are of utmost
importance;
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(4) Bacterium only use its speciﬁc signal molecules; therefore,
it is difﬁcult to ﬁnd a broad-spectrum QSIs (Bjarnsholt and
Givskov, 2008). Broad-spectrum QS quenching enzymes have
goodprospects, but the possibility that proteinQSIsmay cause
host immune response should be considered;
(5) The degradation of QS signaling molecules will affect the
normal activities of the host intestinal ﬂora (Amara et al.,
2011);
(6) Expression of virulence factors in bioﬁlm-forming bacteria is
much lower than that in the planktonic bacteria (Resch et al.,
2005); hence, one has to consider the actual value to use QSIs
for treating pathogens which have generated bioﬁlms.
It is reported that bacteria are more sensitive to the antibiotics
when the antibiotics are used in combination with QSIs. There-
fore, combination usage serves a better strategy to enhance the
antimicrobial effects and prevent the bacterial resistance.
BIOFILM INHIBITORS
Bioﬁlms are structured consortium of bacteria embedded in a self-
produced polymer matrix consisting of polysaccharide, protein
and DNA. Bioﬁlm-forming bacteria may cause chronic infec-
tions because they show increased tolerance to antibiotics and
disinfectant chemicals as well as resisting phagocytosis and other
components of the body’s defense system (Hoiby et al., 2010). As
for treating staphylococcal bioﬁlm, protein synthesis inhibitors
(e.g., oxazolidinones and tetracyclines), cell membrane and
wall-active antibiotics (e.g., lipopeptides and glycopeptides) and
inhibitors for DNA and RNA synthesis (e.g., rifampin) are often
used (Kiedrowski andHorswill, 2011). Methane-thiosulfonate and
mercurial p-hydroxymercuribenzoic acid could target sortases,
a membrane enzyme catalyzing the covalent anchoring of sur-
face proteins to peptidoglycans, which are involved in bacteria
adhesion (Chen and Wen, 2011).
Bioﬁlm formation involves bacterial cell adhesion, QS reg-
ulation, bioﬁlm maturation, and bacteria spread; therefore, a
single drug is difﬁcult to completely remove pathogens in bioﬁlms.
Combination therapy is a wise choice, which generally uses antibi-
otics with antibiotics or antibiotics with bioﬁlm inhibitor as
the combination. Combination of both ﬂuoroquinolones and
macrolides or fosfomycin seems to be most effective regimen
against bioﬁlm infections in urinary tract (Kumon,2000). Another
promising strategy is the use of enzymes that can dissolve the
bioﬁlm matrix [e.g., polysaccharide hydrolases (Kaplan et al.,
2004), DNases (Izano et al., 2008), proteases (Marti et al., 2010),
and alginate lyases] as well as quorum-sensing inhibitors that
increase bioﬁlm susceptibility to antibiotics. It is shown that
administration of DNase and alginate lyase enhances the activ-
ity of tobramycin against bioﬁlms by dissolving the bioﬁlm
matrix of Pseudomonas aeruginosa (Alipour et al., 2009). In
addition, monoclonal antibody of alginate shows certain dam-
aging effects against P. aeruginosa bioﬁlms (Mai et al., 1993),
and enhances the ability of antibiotic to penetrate bioﬁlms
(Hatch and Schiller, 1998). Urokinase or lumbrokinase combin-
ing with ﬂeroxacin signiﬁcantly enhances the inhibition of P.
aeruginosa bioﬁlms (Selan et al., 1993). This combination not
only degrades the polysaccharide protein complex in the bac-
terial bioﬁlms, but also affects the bacterial DNA synthesis.
Efﬂux pump inhibitor in combination with miconazole can effec-
tively remove Candida albicans from the bioﬁlm (Qi and Wang,
2009).
The way from molecular mechanisms of bioﬁlm formation
to anti-bioﬁlm products is promising, but still a long one.
Although bioﬁlm inhibitors can inhibit bioﬁlm formation, they
do not inhibit bacterial growth or kill bacteria. Hence, when
bioﬁlm inhibitor use is discontinued, bacteria will produce bioﬁlm
again to protect themselves against the adverse environmental
conditions.
BACTERIAL VIRULENCE INHIBITORS
An important emerging strategy to combat bacteria seeks to block
the ability of bacteria to harm the host by inhibiting bacterial viru-
lence factors. Development of compounds inhibiting the function
and transmission of bacterial toxins is a novel anti-infective strat-
egy. The protein complex of anthrax toxin contains lethal factor
(LF),edema factor (EF),PA,andother components. Single compo-
nent is non-toxic, but the combinationof LForEFwithPAwill lead
to a pathological effect (Young and Collier, 2007). A small molecu-
lar, hydroxamate (LFI), can bind to the active site of LF, inhibiting
the activation of LF and preventing anthrax infection (Shoop et al.,
2005). Cisplatin shows inhibitory effect to PA heptamer assembly,
thus blocks the toxicity of LF and EF. However, only simultane-
ous feeding of cisplatin and a lethal amount of anthrax toxin has
a protective effect on rodents, while delayed feeding of cisplatin
would have resulted in a failure (Moayeri et al., 2006). Cholestyra-
mine can bind with clostridial toxin to prevent its adsorption to
intestinal epithelial cells, thus weakening the toxicity cause by the
toxin.
The type three secretion system (T3SS) is found in over two
dozens of Gram-negative bacteria and functions by injecting effec-
tor proteins directly into the cytosol of the host cells. One acyl
salicylaldehyde compound targeting the T3SS of Yersinia pseudo-
tuberculosis prevents the translocation of effector molecules, and
thus attenuates the pathogens (Nordfelth et al., 2005). Different
acyl salicylaldehydes inhibit two T3SS effector molecules to pre-
vent Salmonella invasion of the intestinal epithelial cells (Hudson
et al., 2007). Currently, studies on the acyl salicylaldehyde under
bovine intestinal model are still limited.
Prevention of bacterial adhesion is equally important. Pili-
cides inhibit bacterial pili formation. Pyridone and its N-terminal
amino acid derivatives competitively inhibit the chaperone pro-
tein binding to pilus protein. Pyridone is also able to inhibit blood
clotting and bioﬁlm formation, thus inhibiting bacterial adhesion
(Pinkner et al., 2006). Regulating the expression of bacterial viru-
lence factor is meaningful as well. For instance, virstatin inhibits
the expression of Vibrio cholerae toxin and pilus, thereby prohibit-
ing the colonization of V. cholerae in the gut (Hung et al., 2005).
Virulence regulation can be achieved through different aspects,
such as interfering bacterial QS (Clatworthy et al., 2007). Inhibi-
tion of the downstream effects of toxin is feasible. For example,
Cl− secretion inhibitors can moderate diarrhea.
Toxin inhibitors carry out the function by disrupting the bac-
terial toxins, or modulate the host responses to the toxins. They
do not directly inhibit bacteria, thus causing no bacteria resis-
tance selection pressure. However, like the bioﬁlm inhibitors, even
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in the presence of toxin inhibitors, bacteria can still grow and
reproduce. Therefore, in the absence of these substances, bacteria
may produce toxins and exhibit virulence again.
FEED ENZYMES
The nutrients for the multiplication and growth of bacteria in
the intestinal tract are derived largely from dietary components,
which are either not digested by digestive enzymes or absorbed
so slowly that bacteria in host guts compete for them. Exoge-
nous enzymes not only inﬂuence the absorption of nutrients
but also produce nutrients for speciﬁc populations of bacteria
through their action (Bedford and Cowieson, 2012). Therefore,
their use has a direct impact on the microﬂoral populations
(Apajalahti et al., 2004).
The most widely used feed enzymes are mixture of a variety
of glycanases, and the single-using degrading enzyme is phytase
(Ravindran and Son, 2011). Recombinant synthesized enzymes
such as phytases and carbohydrases are commercially produced
and sold as feed additives in monogastric food-animal production
(Adeola and Cowieson, 2011). Phytase has signiﬁcant effects on
the digestibility of calcium, phosphorus, and minerals as well as
the intestinal mucin production and the endogenous losses, all of
which inﬂuence the nutrient supply and the intestinal environ-
ment which will alter the selection pressures on bacterial species
(Bedford and Cowieson, 2012). Xylanase added to a wheat-based
diet alleviates the pathological effects of C. perfringens in broiler
chickens (Liu et al., 2012a). Dietary use of encapsulated lysozyme,
as a feed additive in the diet of chickens signiﬁcantly reduced the
concentration of C. perfringens and gastrointestinal lesions due to
the organism in the ilium (Liu et al., 2012b).
Despite themature phytasemarket, other kinds of feed enzymes
have different defects. Generally, the activity of the enzyme is low;
the cost is high; and the production and quality control lack stan-
dards. The stability and activity of feed enzymes depend mainly
on the production process (Slominski, 2011). It is well recognized
that animal responses to feed enzyme additives are not entirely
predictable, and these inconsistencies could be attributed inter
alia to the enzyme type, the amount of enzyme applied, the pres-
ence of enzyme side activities, the diet composition and the animal
variation (Ravindran and Son, 2011). The mechanisms by which
feed enzymes inﬂuence the intestinal microbiota have been known
for some time, e.g., through enhancing nutrient delivery to the
host and by provision of fermentable oligosaccharides. It is still
unknown, however, to which extent this effect contributes to the
net beneﬁt of the enzyme use, nor is it clear which are the major
microbial species involved (Bedford and Cowieson, 2012). Recent
work shows that if the use of enzymes is to replace prophylactic
antibiotics, then the target must be to enrich the ileum and cecum
with Clostridium cluster XIVa species and E. coli while depressing
the numbers of Lactobacillus spp. (Smulikowska et al., 2010). Until
an accurate description of a desirable ﬂora can be documented, the
feed enzymes can be appropriately used.
Since enzymes do not directly attack bacteria, but only reduce
the substrates for the growth of bacteria, the antibacterial effect
is not obvious. Glucose oxidase (GOD), mainly from Aspergillus
niger and Penicillium, can speciﬁcally oxidize D-glucose to pro-
duce gluconic acid and hydrogen peroxide (Geisen, 1999). When
hydrogen peroxide accumulates to a certain level, it can be harmful
to intestinal bacteria and inhibits their propagation while con-
suming oxygen in the intestine, which may help the growth of
Biﬁdobacterium and Lactobacillus and other beneﬁcial anaerobic
bacteria. An enzyme alginogel composed of GOD, lactoperoxi-
dase, and guaiacol was able to prevent the formation of bioﬁlms
and inhibit the established bioﬁlms (Cooper, 2013). Given that the
mechanism of action of this enzyme is different from other feed
enzymes, the related feeding effects of GOD are worthy of further
study.
PERSPECTIVES
Ideal alternatives to antibiotics should: (i) have non-toxic or no
side effects on animals, (ii) be easy to eliminate from the body
or consist of short term of residues, (iii) not induce bacterial
resistance, (iv) be stable in the feed and animal gastrointestinal
tract, (v) be easily decomposed and not affect the environment,
(vi) not affect palatability, (vii) not destroy the normal intestinal
ﬂora of animals, (viii) kill or inhibit the growth of pathogenic bac-
teria, (ix) enhance the body resistance to the disease, (x) improve
feed efﬁciency and promote animal growth, and (xi) have good
compatibility. In fact, there are no alternatives to antibiotic that
currently meet all the above mentioned requirements.
There is still a considerable gap between antibiotic alter-
natives and antibiotics concerning the effectiveness of disease
prevention and growth promotion. Antibacterial vaccines are
generally used for the prevention of bacterial infections, and cur-
rently only a small number of bacterial infective diseases can be
controlled by vaccines. Immunomodulators and feed enzymes
mainly preserve the health of animals, but do not directly kill
or inhibit bacteria. Bacteriophages are currently only used in
food, and the safety is still questionable. The composition of
plant extracts and probiotics is complex and the quality in terms
of stability is poor, resulting in varying effects and safety risks.
Inhibitors targeting QS and virulence of bacteria are still in
research with no approved products, and most QSIs are toxic
to eukaryotic cells. Bioﬁlm inhibitors show good results only
when used in combination with antibiotics. Although AMPs can
treat bacterial infections, the high cost and narrow antibacte-
rial spectrum restrict their wide use, and they can still induce
bacterial resistance. Meanwhile, proteinaceous compounds, for
example, feed enzymes and AMPs that have been put into
market as well as bacteriophage lysins, QS quenching enzymes
and enzymatic bioﬁlm inhibitors under development, are nat-
urally unstable and easily degraded in the digestive tract. On
the other hand, antibiotics can directly inhibit or kill bacteria
with better antibacterial effect than all antibiotic alternatives.
Moreover, antibiotics are made by single and relatively pure
active ingredient with high stability, consistency, and quality
ensured by good manufacturing practice. Considering clinical
efﬁcacy, humans have not yet found a more effective way than
selecting appropriate antibiotics for the treatment of indicated
bacteria.
Antimicrobial resistance is the major reason for EU to ban low
dose of antibiotics as feed additive. In fact, the penicillin’s pro-
ducer, Penicillium, has coexisted with other bacteria for tens of
thousands of years. Only after the extensive use of penicillin was
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the emergence penicillin-resistance discovered. Drug pressure is
proportional to the chance of development and dissemination of
drug resistance; therefore, although antibiotic alternatives have
not been associated with bacterial resistance yet, with a large num-
ber of these alternatives in use, bacteria might mutate eventually
to develop resistance. Like the precedent use of antibiotics, the
irregular and illegal use of antibiotic alternatives may also bring
negative issues.
Meanwhile, we must not forget that “it’s better to prevent than
cure” (Bourlioux, 2013). For many developing countries, because
of the poor farming environment and the high incidence of dis-
ease, antibiotics are still an effective tool in the prevention and
control of animal diseases. It is shown that the ban of growth
promoters in EU demands the improvement of the farm hygiene
(Castanon, 2007). When the amount of “old” antibiotics used in
feed reduces due to the ban, prevalence of bacterial infections
in the target animals would likely increase without fundamen-
tal improvement of production environment. This may lead to
the increase of therapeutic uses of advanced antibiotics and result
in some unintended consequence that may cause new challenges
for public health concern. Additionally, there are no scientiﬁc
evidences to clearly separate the causal relationship between treat-
ment use and prevention use of the antibiotics with respect to
resistance development. The ultimate beneﬁt and risk should be
assessed before implementing such a policy as a result of politi-
cal/social pressure, as bacteria may not necessarily “listen” to the
policy-makers. Thus, the decision concerning the use of in-feed
antibiotics should be made based on scientiﬁc approaches. The
ban of antibiotics as growth promoters cannot be copied in every
country of the world.
The efﬁcacy of traditional antibiotics can still be improved.
Some “old” antibiotics can ﬁnd new bacterial targets and rein-
force the anti-infectious therapy toward someMDRbacteria. It has
been demonstrated that in many cases, there are non-carbapenem
alternatives for the treatment of extended-spectrum-β-lactamase-
producing E. coli (ESBL-Ec) infections (Fournier et al., 2013).
Besides, new formulations can allow targeted drug delivery via
nanoparticles and the association of molecules can reinforce the
antimicrobial effect of antibiotics (Bourlioux,2013). Furthermore,
in empirical therapy, use of broad-spectrum bactericidal agents
that will eradicate the presumed infective microorganism(s),
which potentially could be MDR, should be preferred. Once
an infection is under control and the culture and susceptibility
results are reported, it is important to switch to the most suitable
narrow-spectrum agent thus decreasing the potential of adverse
drug effects and the risk of development of antibiotic-induced
resistance (Lynch, 2012).
In summary, reasonable use of antibiotics and continuous
development of alternatives to antibiotics are needed to ensure
the long-term sustainable development of animal husbandry. We
must strictly deﬁne the target animals, duration of the treatment
and the withdrawal period, for prudent use of antibiotics as well as
regulation/policymaking regarding their use. At the same time, we
must strengthen the supervision and enforcement of laws in order
to control antibiotic resistance and residues from the food chain
within established safe levels. Furthermore, we must improve the
management of animal nutrition and production hygiene, since
recent European developments showed a distinctly more positive
outcome of the ban of antibiotic growth promoters thanwas antic-
ipated during the ﬁrst years after the ban due to the improvement
of animal welfare (Cogliani et al., 2011). The research of antibi-
otics alternatives will be a long process. In addition to research
and development of new efﬁcient and safe alternatives, we should
strengthen the study concerning the effects of combined use of
antibiotics and their alternatives aimed at maintaining a healthy
agricultural economy and preservation of potent antibiotics for
efﬁcacious therapy in humans.
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INTRODUCTION
Antibiotics are chemotherapeutic agents
used for the clinical management of infec-
tious diseases in humans, plants and
animals. However a sizeable fraction of
antibiotics produced every year all over
the world is used for non-therapeutic pur-
poses. In US alone, about 24.6 million
pounds of antibiotics are used in animal
agriculture annually and a substantial por-
tion of this is used as growth promoters
and not for the treatment of infections
(Oliver et al., 2011). According to a recent
report, out of 13 million kg of antibi-
otics administered to animals in 2010, the
major portion was meant for promoting
the growth of the livestock (Spellberg et al.,
2013). The ability of low doses antibi-
otics to promote growth of animals and
birds was discovered serendipitously in
the 1940s (Gustafson and Bowen, 1997).
Subsequently, it was widely exploited and
by this time, addition of antibiotics to the
animal feed to stimulate growth has turned
into a global practice.
The basis of growth-promoting effect of
antibiotics is not clearly known. It is pos-
tulated that microorganisms present in the
animal feed consume a considerable por-
tion of nutrients in the feed. They also
inhibit absorption from the intestine and
produce toxins having adverse effect on
the health of the animals. The growth-
promoting effect of antibiotics might stem
from their ability to suppress these harm-
ful organisms. It is also suggested that
animals reared in the unhygienic environ-
ments always bear some latent infections,
which trigger a cascade of events in their
immune system. Cytokines produced in
the process lead to the release of some
catabolic hormones which cause wastage
of muscles. Antibiotics relieve the animals
of the need to produce cytokines by sup-
pressing the causative agents of infections.
BENEFITS ASSOCIATED WITH THE USE
OF ANTIBIOTICS
Evidences available in the literature speak
volumes on the beneficial effects obtained
from antibiotics used as a feed addi-
tive. Pigs supplemented with antibiotics
in their feed require 10–15% less feed
to achieve a desired level of growth.
Cost of feed constitutes a major portion
of the expenses involved in rearing ani-
mals. Hence addition of antibiotics sub-
stantially cuts down the expenditure.
Antibiotics added to the feed also ensure
more efficient conversion of feed to ani-
mal product and improvement. The daily
growth rate of animals subsisting on
antibiotic-supplemented food is known
to be improved by 1–10% compared to
that of the animals provided feed with-
out antibiotic. The meat obtained from
antibiotic-fed animals is also of better
quality with higher amount of protein
and less amount of fat compared to that
obtained from animals not supplemented
with antibiotics (Hughes and Heritage,
2002). Use of tetracycline and penicillin in
chicken feed led to a significant improve-
ment in the production of eggs and hatch-
ability besides feed efficiency (Gustafson
and Bowen, 1997). Health of the live-
stock fed with antibiotic-mixed food is also
markedly improved. Following addition
of chlortetracycline and sulfamethazine
to the feed, the rate of bovine respira-
tory disease morbidity, the rate of relapses
and mortality and also the rate of ani-
mals diagnosed with chronic respiratory
disease were found to be significantly
decreased (Gallo and Berg, 1995). Benefits
in terms of the rate and efficiency in
the gain of body weight, decrease in
mortality and morbidity and reduction
in the occurrence of subclinical diseases,
were observed using of antibiotics during
all phases of growth of pigs (Cromwell,
2002). The adverse effects of inflamma-
tion and pro-inflammatory mediators in
animals (e.g., reduction in growth, feed
intake, reproduction, milk production,
and metabolic health) are well-known.
The anti-inflammatory potential of antibi-
otics (particularly macrolides) provides a
rational basis of their beneficial effects
which is independent of their antimicro-
bial effect (Buret, 2010). Hence there is no
doubt about the important role of antibi-
otics in profitable and efficient production
of livestock.
RISKS ASSOCIATED WITH THE USE OF
ANTIBIOTICS
On the other hand, use of antibiotics in
animal feed as growth-promoters appears
to promote emergence of antibiotic-
resistant strains. The problem of bacterial
resistance to antibiotics is a burning ques-
tion throughout the world. According
to an estimate of the World Health
Organization, during the past decade
number of deaths caused by some resistant
strains exceeded the combined number
of deaths caused by influenza, Human
Immunodeficiency Virus and traffic acci-
dent (Yap, 2013). While emergence of
antibiotic-resistant strains is most often
correlated with the use of antibiotics, resis-
tance is detected even in bacteria obtained
from places which are uninhabited, thinly
populated (Chattopadhyay and Grossart,
2010) and totally detached from human
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intervention (Bhullar et al., 2012). In this
backdrop, quite understandably the pos-
sibility that presence of antibiotics in the
animal feed might contribute to the cri-
sis, has triggered a vigorous controversy.
It is widely believed that use of antibiotics
as growth promoters promotes evolution
and/or selection of antibiotic-resistant
strains in animal farms. Reports pub-
lished from time to time on the isolation
of bacterial strains from animals, resis-
tant to the antibiotics that are added to
their feed, have fueled the debate further.
It is also evident that the possibility of
emergence of bacterial strains resistant to
the therapeutically useful antibiotics for
humans cannot be bypassed by substitut-
ing the antibiotics with their analogs in
the animal feed. For example avoparcin
is a glycopeptide antibiotic not used in
humans. Use of this antibiotic as feed addi-
tive has been known to be associated with
emergence of avoparcin- resistant strains,
which are cross-tolerant to vancomycin,
a glycopeptide antibiotic used in humans
(Marshall and Levy, 2011) Transfer of
resistance-conferring genes from the bac-
teria of animal origin to the bacteria of
human origin has also been demonstrated
in animal model (Moubareck et al., 2003).
Dissemination of resistance is promoted
even by sepiolite, a non-antibiotic feed
additive, which facilitates horizontal gene
transfer in the digestive tract of the animals
(Rodríguez-Beltrán et al., 2013).
THE CONTROVERSY
The proponents for the use of antibi-
otics in animal feed as growth- promoters
however remain unconvinced about the
potential of the practice to aggravate the
problem of antibiotic resistance (Wallinga
and Burch, 2013). They argue that the
doses of antibiotics used for this purpose
are small compared to their therapeu-
tic doses and it is not definitely known
whether such low doses really select for
resistance or not. Even those, who accept
that agricultural use of antibiotics pro-
motes emergence of antibiotic-resistant
strains, believe that evidence of this pos-
sibility having a major impact on human
health is either non-existent or mini-
mal (Turnidge, 2004). Notwithstanding
the fact that bacterial isolates resistant to
various antibiotics used in animals are
found in humans, it is contended that
such people might contract the infection
from some other source and it is also
possible that both the animals and the
humans are infected with the same organ-
ism from a common source. Isolates from
humans and animals in many cases are
claimed to be genetically different (Phillips
et al., 2004). The hypothesis on trans-
mission of resistance through food chains
is also not universally accepted. Those,
who accept it, recommend good hygienic
practices in the kitchen and use of vac-
cines in the birds and animals to reduce
the incidence of transmission. Following
a ban on the prophylactic use of antibi-
otics, an overall deterioration of animal
health (in terms of diarrhea, weight loss
andmortality) was observed in some cases.
Hence a ban on the use of antibiotics in
animals is believed to be associated with
an increased incidence of food-borne dis-
eases in humans as well as more frequent
use of antibiotics for therapeutic purposes
in animals (Casewell et al., 2003; Spellberg
et al., 2013). Therefore restriction on the
use of antibiotics as feed additive is consid-
ered unwarranted by the proponents. They
firmly believe that advantages associated
with use of antibiotics in animals outweigh
the risks.
On the contrary, it has been demon-
strated that exposure to sub-inhibitory
concentration of some antibiotics can not
only enrich resistant bacteria (Gullberg
et al., 2011) but in some cases also
stimulate the production of reactive
oxygen species which might contribute
to an increase in the rate of mutation
and emergence of multidrug-resistant
mutants (Kohanski et al., 2010). It was
also shown that antibiotics in animal
feed might facilitate phage-mediated
gene transfer thus promoting dissemi-
nation of antibiotic resistance (Allen et al.,
2011). Horizontal gene transfer, the major
mechanism involved in dissemination of
antibiotic resistance, is also fostered by
sub-inhibitory concentration of some
antibiotics (Couce and Blázquez, 2009).
The number of food animals exceeds the
number of humans by far. Hence use of
antibiotics in animal farms poses a risk
of creating a large reservoir of resistance
genes, the far reaching consequence of
which needs hardly to be over-emphasized
(Turnidge, 2004). Adverse effects on
the health and productivity of animals,
observed following a ban on the use of
antibiotics in animal feed by the European
Union (EU), appeared to be diminished in
course of time. Furthermore, the beneficial
effects associated with the use of antibi-
otics were found to be waned in some
particular cases (reviewed by Marshall and
Levy, 2011). A systematic survey in Danish
swine farms indicated improvement in the
long-term productivity following decrease
in the use of antibiotics in animal feed
(Aarestrup et al., 2010). Besides being
used as growth-promoters, antibiotics
are also widely used for prevention and
treatment of the infections of the live-
stock. Normal microbiota of the organism
may be adversely affected by the antibi-
otics added to the feed. This phenomenon
called dysbiosis may foster overgrowth of
some already existing harmful microor-
ganisms in the flora (e.g., Clostridium
difficile), decreased production of short
chain fatty acids and other beneficial com-
pounds by the normal flora and increased
susceptibility of the livestock to infec-
tions (Hawrelak and Myers, 2004). Thus
the practice of addition of antibiotics to
animal feed might be self-defeating.
DILEMMA FACED BY THE POLICY
MAKERS
Policy makers all over the world are in
a quandary to formulate a guideline for
the addition of antibiotics to the animal
feed. The Guidelines for Industry issued
by the Center for Veterinary Medicines of
the Food and Drug Administration (FDA,
2012), USA recommend use of antibiotics
only for the prevention, control and treat-
ment of infections in animals but not for
the promotion of growth, increased per-
formance, and improved feed efficiency.
Additionally, use of some antibiotics of
critical importance (e.g., the third gener-
ation of cephalosporins) is restricted in
animal agriculture and they are reserved
only for use in humans. Development
of suitable alternatives of antibiotics for
the clinical management of the infections
of the livestock appears to be the need
of the hour (Allen et al., 2013). Search
for prophylactic measures (e.g., vaccines)
for the prevention of diseases is also of
crucial importance. Unregulated sale and
easy availability of antibiotics have signifi-
cantly contributed to the problem in many
developing countries, where antibiotics
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are continued to be added to the ani-
mal feed as growth promoters. Moreover,
unhygienic environment prevailing in the
poultries and farm houses in these coun-
tries makes the animals more suscepti-
ble to infections and necessitates frequent
use of antibiotics. Hence it is strongly
advocated to do away with or minimize
the use of antibiotics by improving the
hygiene (Gulland, 2013). It might not be
possible to impose a blanket ban (the
approach based on precautionary princi-
ple adopted by the EU) on the use of
antibiotics in animal farms in a global
scale. But close monitoring of the situa-
tion is imperative everywhere to avert or
restrain emergence of resistant strains. The
“principle of proof” (gathering evidence
before banning a particular compound),
adopted by FDA seems to be a practica-
ble approach to contain the conundrum.
Recently, FDA has asked the antibiotic-
manufacturers to relabel their products
voluntarily in order to make people aware
of its disapproval for the use of antibi-
otics as growth-promoters in animals. The
label should also indicate that the use of
antibiotics in animals must be supervised
by a veterinarian. The proposal seeks to
put an end to the use of medically useful
antibiotics as growth-promoters and also
to restrict the scope of prophylactic use of
antibiotics in animals against pathogens.
However it does not propose for any stric-
ture on the use of non-human antibiotics
(e.g., ionophores) in animals as growth-
promoters. The initiative is highly appreci-
ated by various organizations and eminent
scientists though its success calls for the
cooperation of the business lobby (Kuehn,
2014). Use of antibiotics in animal feed
remains a highly-debated issue which calls
for awareness among common people in
the society.
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Beneﬁts and risks of antimicrobial drugs, used in food-producing animals, continue to
be complex and controversial issues. This review comprehensively presents the beneﬁts
of antimicrobials drugs regarding control of animal diseases, protection of public health,
enhancement of animal production, improvement of environment, and effects of the
drugs on biogas production and public health associated with antimicrobial resistance.
The positive and negative impacts, due to ban issue of antimicrobial agents used in food-
producing animals, are also included in the discussion. As a double-edged sword, use of
these drugs in food-animals persists as a great challenge.
Keywords: antimicrobial drug, benefit, risk, animal food production, public health
INTRODUCTION
Over the decades, world population tremendously increased to 7
billion (Food and Agriculture Organization [FAO], 2012) and 870
million (12.5%) of them were estimated to be undernourished
during 2010–2012 (Food and Agriculture Organization [FAO],
2012; Krehbiel, 2013). Demand for animal source food tends to
be soaring day by day, especially in developing countries (Food
and Agriculture Organization [FAO], 2009; Krehbiel, 2013). It
is acknowledged that the antimicrobial use is one of the most
successful chemotherapies. Various antimicrobials have made sig-
niﬁcant contribution for the prevention, control, and treatment
of infectious diseases in animals since 1940s (Forman and Burch,
1947). Low and sub-therapeutic dose of antimicrobials plays very
important role for the improvement of feed efﬁciency, promo-
tion of animal growth, and prevention and control of the diseases
(Dibner and Richards, 2005; Niewold, 2007). Internationalmarket
value of veterinary drugs (including antimicrobials) tremendously
increased from $8.65 billion in 1992 to $20.1 billion in 2010 and in
2018, it is expected to increase to $42.9 billion (GIA, 2012; Reports,
2012).
It is undeniable that rational use of antimicrobials plays
a vital role in the production of food animals and protect-
ing public health, while irrational and irresponsible use may
cause antimicrobial resistance. On the basis of “Swan Reports”
in 1969, Great British took ﬁrst action for the restriction of
antibiotics, being used in animals or capable of cross-resisting
with antibiotics used in human medicine. In 1973, the Euro-
pean Community (EC) commenced the withdrawal of some
important antibiotic use as growth promoters in animal feed.
After that, Sweden banned the use of all growth-promoting
antibiotics in 1986. Avoparcin, bacitracin, spiramycin, tylosin,
and virginiamycin were withdrawn as growth promoters in the
European Union (EU) from 1995 to 1999, on the basis of pre-
cautionary principle. In 2006, all the uses of low-dose antibiotics
(5∼40 ppm) in food animals, including ﬂavomycin, avilamycin,
salinomycin, monensin, and other animal-speciﬁc antibiotics,
were banned in the EU with the intention to avoid their nega-
tive impact of resistant development (EPC, 2005; Marshall and
Levy, 2011).
The beneﬁts and risks of antimicrobials continue to be com-
plex and controversial issues. The risks of antimicrobial drugs
to public health associated with antimicrobial resistance raised
great concern recently, while the beneﬁts of antimicrobial drugs,
such as prevention and treatment of animal diseases, protection of
public health, enhancement of animal production, and improve-
ment of environment, were disregarded most of the time. Many
beneﬁt-related claims have not yet been fully demonstrated in
large-scale trials, and other trials revealed that the overall impact of
the short-term beneﬁts was poorly described. This article presents
the beneﬁts and risks of antimicrobials drugs used in food ani-
mals and discusses the positive and negative effects of the ban on
antimicrobial growth promoters.
BENEFITS OF ANTIMICROBIAL DRUGS
PREVENTION AND TREATMENT OF ANIMAL DISEASES
With intensive animal production, bacterial and parasitic dis-
eases became more and more frequent. According to an estimate,
80 types of bacteria, such as Escherichia coli, Salmonella, and
Clostridium welchii, posed a serious threat to poultry industry.
Mastitis, caused by Staphylococcus aureus in dairy animals, led to
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a loss of $2 billion/year in the United States of America (USA)
and an average cost of €485/dairy cow in the EU during 2012
(Heikkila et al., 2012). Due to infection caused by Streptococcus
pneumonia, morbidity and mortality rates in calves increased to
40 and 20%, respectively (Akkermans andVecht, 1994; Vogel et al.,
2001). More than 50%of aquatic animals were infected by bacteria
each year (Scarfe et al., 2011). Vibrio vulniﬁcus became a potential
health hazard for aquatic animals and human beings (Yano et al.,
2004).
Approximately, 2169 parasites including 203 protozoa, 373
trematodes, 150 tapeworms, 404 nematodes, and 1030 arthropods
have been found in livestock and poultry in China. About 4–20
billion dollars/year (8.3% annual output of animal husbandry)
were lost due to parasitic diseases caused by coccidia, nema-
todes, ticks, and others in USA (Krausse and Schubert, 2010).
Acute outbreaks of chicken coccidiosis paid a loss of 42 million
pounds annually in the United Kingdom (Franklyn et al., 2010).
In China, poultry industry had to face billions of dollars annual
loss due to almost 100% chicken morbidity by coccidiosis (Zhang
et al., 2013). Sheep helminthiasis led to a loss of 2.22 million
dollars annually in Australia (Hosking et al., 2009; Larsen et al.,
2009).
Over one hundred of antimicrobials, including β-lactams,
aminoglycosides, tetracyclines, amphenicols, macrolides, sul-
fonamides, ﬂuoroquinolones, lincosamides, polypeptides, and
polyene, have been used in food-producing animals around the
world. These antimicrobials have played an essential role in the
prevention, treatment, and control of food animal diseases caused
by pathogens, such as pathogenic E. coli, S. aureus, S. pneumonia,
Actinobacillus pleuropneumoniae, mycoplasma, Vibrio, and others
(Hoﬂack et al., 2001; Krausse and Schubert, 2010). It was reported
that in USA, 52.1% of total antimicrobials were used for the treat-
ment of infectious diseases in animals, where 90% of starter pigs,
75% of grower pigs, 50% of ﬁnisher pigs, and 25∼70% of cat-
tle received the drugs through feed (Van Lunen, 2003; USFDA,
2009; GRACE, 2013). With a dose of 40 mg/kg, avilamycin in
feed could remarkably decrease the incidence of diarrhea in post-
weaning pigs (Partanen et al., 2007). When salinomycin was used
in sows and pigs simultaneously, incidence of diarrhea in piglets
was signiﬁcantly reduced and the survival rate was increased by
13.95% (Nagaraja and Taylor, 1987). Sulfonamide and folic acid
supplementation in diet increased live birth rate of piglets by 1%
(Lindemann and Kornegay, 1989). Hence, it is concluded that
the use of antimicrobials is a primary strategy for prevention and
treatment of bacterial infections in food-producing animals.
Many antimicrobials have strong activity against parasites in
animals. Use of sulfonamides in animals opened a new era of
anti-parasitic drugs and made lots of parasitic diseases under
control. Up till now, anti-parasitic drugs have shared about one-
third sale of the global veterinary drug markets. Macrolides and
benzimidazoles effectively controlled nematodes. Doramectin and
ivermectin helped to prevent infection of Argulus siamensis in carp
and Labeo rohita (Hemaprasanth et al., 2012). In rabbit, subcuta-
neous injection of ivermectin, at dose of 400 mg per kg, not only
helped to clinical cure ear mite infection but also prevented loss
of fur and thus, played a vital role for the improvement of fur
production (McKellar et al., 1992).
Conclusively, due to unique advantages, such as exact target-
ing of pathogens, well-known mechanisms of activity and desired
stability, antimicrobials justiﬁed their usage in livestock and
poultry, and played important part for prevention and treatment
of bacterial and parasite diseases.
PROTECTION OF HUMANS AGAINST ZOONOSIS
Among animal infectious and parasitic diseases, more than 200
can affect human life. Campylobacter spp., Salmonella spp., E.
coli O157, Vibrio parahaemolyticus, and Aeromonas hydrophila
from animals pose great health threat to both humans and ani-
mals (Altwegg and Geiss, 1989; Mellata, 2013). The United
States Centers for Disease Control and Prevention (US-CDC)
estimated that there were about 76 million annual cases of food-
borne illness in USA, including 325,000 hospitalizations and 5000
deaths (Mead et al., 1999a). Annual cases of Campylobacter spp.,
Salmonella spp., E. coli O157, and V. parahaemolyticus were
1,963,000, 1,332,000, 62,500, and 5000, respectively (Mead et al.,
1999a,b).
To some extent, antimicrobial agents guaranteed human food
security and public health by controlling animal diseases and
preventing transmission of zoonotic pathogens from animals to
humans. When added to animal feed or drinking water, these
drugs could signiﬁcantly decrease the bacterial contamination
in animal products. For examples, virginiamycin decreased the
contamination of Clostridium perfringens, Campylobacter spp.,
and other food-borne pathogens in animal carcasses (Tice, 2001;
Russell, 2003; Hurd et al., 2005). Salinomycin reduced infec-
tion of type C Clostridium in sows and weaning piglets by 43%
(Nagaraja and Taylor, 1987). Neomycin in animal feed signif-
icantly reduced the number of E. coli O157: H7 in animal
feces, and gentamycin reduced bacterial count in poultry eggs
and meat (Elder et al., 2002; Doyle and Erickson, 2006). When
cattle was fed with neomycin sulfate for 48 h and held for
24-h drug withdrawal period before slaughtering, it shed con-
siderably less E. coli O157:H7 cells than those pen mates who
did not receive the treatment (Elder et al., 2002). A farm-level
study in 2008 by Ohio State University demonstrated that only
39% of hogs, raised on conventional antimicrobial operations,
were infected with Salmonella, while those were 54% in case of
antimicrobial-free operations (Nunes, 2008; AMI, 2010). Flor-
fenicol (10 mg/kg) presented 100% efﬁciency for the treatment
of A. hydrophila of Piaractus mesopotamicus (Carraschi et al.,
2012). Oxytetracycline hydrochloride or norﬂoxacin in bait feed
reduced the number of A. hydrophila in water by 46.86∼66.24%,
indicating that the risk of the bacterial infection to humans be
decreased.
ENHANCEMENT OF ANIMAL PRODUCTION
In 1943, a few farmers in USA found that pigs fed with penicillin-
fermented mixture grew faster (Wahlstrom et al., 1950; Hewes,
1955; Taylor and Gordon, 1955). In 1946, Moore found that
low dose of streptomycin stimulated chick’s growth (Moore
and Evenson, 1946; Dibner and Richards, 2005). Subsequently,
chlortetracycline, doxycycline, and sulfonamides helped growth
promotion in calves, pigs, and chicken. Cunha from Univer-
sity of Florida and Stokstad from University of Washington
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reported that penicillin in fermentation mixture functioned as
a growth promoter for food-animals (Cunha et al., 1951). Legal
use of the antimicrobials in feed has a history of over 60 years.
Food and Drug Administration in USA (US FDA) approved
these drugs as growth promoters for animals in 1951. Till 1978,
47.9% of the antimicrobials were used to be added in animal
feed in USA. About 60% of poultry, 93% of chicken, 97% of
growing pigs, and 80% of fattening pigs received antimicro-
bials through diet during the early 1990s. More than 40% of
the drugs were added in animal feed at subtherapeutic level for
improving animal production in USA during 1990s (Van Lunen,
2003). With a substantial contribution to the development of
food-animal production at global level, veterinary antimicrobials
tend to be necessities to cope with increasing food demand for
humans.
Role of antimicrobials for the improvement of feed con-
version ratio (FCR), animal growth, and reproductive perfor-
mance has been well proven as given in Table 1, and discussed
under following points (Cromwell, 2002). (1) Orally admin-
istered antimicrobials in pigs increased diet digestibility and
improved feed utilization efﬁciency by 1.7∼5.1% and 6.9∼7%,
respectively (Cromwell, 1999; Hardy, 1999; JETACAR, 1999;
Van Lunen, 2003). (2) Addition of the drugs (e.g., chlortetra-
cycline, sulfonamide, folic acid, carbadox, tilmicosin, tylosin,
or sulfamethazine) in feed could remarkably improve the con-
ception rate, farrowing rate, milk secretion, productive efﬁ-
ciency of sow, and live birth rate of piglet (Soma and Speer,
1975; Lindemann and Kornegay, 1989; Alexopoulos et al., 1998;
Kantas et al., 1998; Weber et al., 2001; Partanen et al., 2007).
(3) Feeding antimicrobials to pigs increased their weight gain
by 1.9∼16.4% (Nagaraja and Taylor, 1987; Cromwell, 1999;
JETACAR, 1999; Van Lunen, 2003; IFAH-EuroP, 2005). (4)
Administration of antibiotics (bacitracin zinc, colistin sulfate,
ﬂavomycin, and ﬂorfenicol) in ﬁsh diet signiﬁcantly improved
the feed conversion and promoted their growth (He et al., 2011;
Zhou et al., 2011). (5) Antimicrobial (tiamulin, nosiheptide,
Table 1 | Part of evidences for the role of antimicrobials on feed utilization, growth promotion, reproductive performance, and carcass quality.
Example no Reference Drugs and animals Parameters of animal
production
Increase or
decrease rate
1 Hardy (1999), Van Lunen (2003) Antimicrobials to growing and
fattening pigs
Digestion of energy 5.10%↑
Digestion of nitrogen 1.80%↑
Digestion of phosphorus 3.40%↑
2 Van Lunen (2003) Antimicrobials to swine Feed utilization 7%↑
Average weight gain 3.3–8.8%↑
3 JETACAR (1999), Van Lunen (2003) Antimicrobials to young pigs Feed utilization 4.60%↑
Average weight gain 6.80%↑
Antimicrobials to grower pigs Feed utilization 1.70%↑
Average weight gain 1.90%↓
4 Cromwell (1999), Van Lunen (2003) Antimicrobials to piglet Feed utilization 6.90%↑
5 IFAH-EuroP (2005) Antimicrobials to food animal Average weight gain 4–5%↑
6 Cromwell (1999), Van Lunen (2003) Antimicrobials to piglet Average weight gain 16.40%↑
7 Nagaraja andTaylor (1987) Salinomycin to weanling piglets Average weight gain 15.82%↑
8 He et al. (2011), Zhou et al. (2011) (Bacitracin zinc, colistin sulfate,
Flavomycin and ﬂorfenicol) to
(Carassius, Carp or hybrid tilapia)
Average weight gain 24.5∼40.87%↑
9 Soma and Speer (1975) Chlortetracycline to sow Conception rate 4.10%↑
Farrowing rate 5.80%↑
10 Lindemann and Kornegay (1989) Folic acid to sow Gestation gain 18%↑
11 Cromwell and Stahly (1985),
Cromwell et al. (1984a,b),
Lindemann et al. (1985)
Tiamulin, nosiheptide, and
salinomycin to pig
Thickness of backfat 9.7%↓
Thickness of total fat 8%↓
Eye muscle area 9.80%↑
Lean meat 4.40%↑
↑ Denotes increase, while ↓ denotes decrease.
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salinomycin, and tylosin) supplementation could also improve the
carcass quality by decreasing the fat thickness and increasing the
lean meat of food-producing animals (Cromwell et al., 1984a,b;
Cromwell and Stahly, 1985; Lindemann et al., 1985; Van Lunen,
2003).
A lot of studies were carried out to ﬁnd themechanism involved
inbeneﬁcial aspects of antimicrobials in animals. Jukes, Franti, and
other scientists proved that the drugs attenuated intestinal wall and
improved the digestibility of nutrients (Manson, 1968; Falkow,
1970; Jukes, 1970; Franti et al., 1971, 1972; Dibner and Richards,
2005). Midtvedt (1986) and Norin (1997) conﬁrmed that oral
doses of antimicrobials improved the structure of intestinal ﬂora
(Midtvedt,1986;Norin,1997). Salinomycin and avilamycin in feed
improved the bioavailability of α-tocopheryl acetate in broilers by
altering lipid absorption (Knarreborg et al., 2004). According to a
previous review by Allen et al. (2013), antimicrobials have multi-
functional role in animals, elaborated under following points:
(1) these could reduce the colonization of intestinal bacteria and
inhibit the growth of pathogenic microorganisms; (2) by decreas-
ing the thickness of mucous membrane, led to more absorption of
nutrients and reduced fermentation; (3) they directly neutralized
the host immune response. In short, antimicrobials could affect
the host intestinal ﬂora, intestinal physiology, and immune sys-
tem, and consequently, prevent disease, improve feed conversion,
and enhance the growth of animals (Niewold, 2007). Till now,
there are no appropriate alternatives which can replace antimicro-
bial growth promoters, in case those remain banned. Although
numerous feed additives, mainly pre- and pro-biotic products,
are commercially available now and seem to have potential to
replace these growth promoters, but their true efﬁcacy and mech-
anism of action in domestic animals remain unclear because of
some inconsistent experimental results (Gaggia et al., 2010; Allen
et al., 2013). Additionally, lack of safety evaluation and poor sta-
bility also limited the practical use of pre- and pro-biotic as feed
additives.
IMPROVEMENT OF ENVIRONMENT
According to a report of Center for Food Safety (CFS, 2013) and
Food and Agriculture Organization (FAO, 2006), housing stress,
due to over-crowding of animals, creates sweeping and devastat-
ing impacts on the natural and human environment leading to
global warming, land degradation, air and water pollution, and
loss of biodiversity. Livestock waste is one of the major sources
of greenhouse gases, as the abnormal fermentation of gastroin-
testinal tract contents can produce lots of methane, ammonia,
carbon dioxide, as well as stench gases (e.g., nitrate, ethylene acid,
methyl mercaptan, hydrogen sulﬁde, methylamine, and trimethy-
lamine). Fecal waste of animals generally contains 24% protein
and 6.1∼17.96% amino acids. Nitrogen and phosphorus in the
waste lead to environmental pollution, water eutrophication and
ecological imbalance.
Some antimicrobials in feed could inhibit the abnormal fer-
mentation and consequently, reduce the emission of greenhouse
gases (mainly CH4). For example, ionophores (monensin, lasa-
locid, and salinomycin), amoxicillin, ovoparcin, nigericin, or
laidlomycin inhibited rumen microbial fermentation at different
levels and thus, reduced the proportion of volatile fatty acids
(VFA) and methane (Van Nevel and Demeyer, 1995; Fellner
et al., 1997; Domescik and Martin, 1999). Since the mid-1970s,
ionophorous antibiotics have been widely used as feed additives in
ruminants due to their favorable effects on rumen fermentation
and methane reduction (Kobayashi, 2010). Due to the efﬁcacy
and affordable price, ionophores have widely been used to reduce
methane emission from livestock (Hook et al., 2010; Kobayashi,
2010). When ionophores (monensin and lasalocid) were mixed
with rumen microorganisms in vitro, these inhibited methane
by 50 and 44%, respectively and decreased NH3 by more than
50% (Russell and Jeraci, 1984). In rumen models, ionophores
(monensin, lasalocid, and salinomycin) inhibited 10∼20% lipol-
ysis and biological hydrogenation (Van Nevel and Demeyer, 1977,
1995). The effects of the antibiotics on the abatement of methane
production may be attributed to a selective antimicrobial action
on rumen microbes (protozoa, ruminococci, streptococci, and
lactobacilli). Addition of monensin and lasalocid in cow forage
killed 82.5 and 76.8%, respectively, of the intestinal ciliated pro-
tozoa in rumen and hence, reduced the production of methane
and VFAs (acetic acid and propionic acid) by ciliates (Guan et al.,
2006). Generally, the gas production was reduced from 4 to 31%
by monensin (Schelling, 1984; Rumpler et al., 1986; Kobayashi,
2010). A recent report has indicated that long-term administra-
tion of monensin in dairy cattle steadily reduced methane by 7%
and this reduction persisted for 6 months with no adverse effect
on milk yield (Odongo et al., 2007). However, previous studies
also found that both, the methane level and protozoal number,
returned to baseline after long-term administration of high con-
centration of the antibiotic (Guan et al., 2006; Odongo et al., 2007;
Hook et al., 2010). The efﬁciency of monensin supplementation,
for reducing methane output in ruminants, appeared to be differ-
ent in the degree of abatement depending on the diet and animal
used (Guan et al., 2006; Odongo et al., 2007; Hook et al., 2010).
Effect of the drug on the methane levels in rumen was closely
related to the ciliated, protozoal population. Microbial consor-
tia, like protozoal population, in the ruminant gut may adapt
to the antibiotics leading to the recovery of methane production
yield, in case of a long-term usage. Therefore, the ciliates in the
rumen may impact the outcome of antimicrobial supplementa-
tion, with adaptation being a possibility (Guan et al., 2006; Hook
et al., 2010).
Through manure application, antibiotics got released into soil
and could be absorbed by plants in arable land. Certain species
of plants have the ability to bio-accumulate sulfamethoxine in
their roots and stems, and this bioaccumulation was often higher
in roots than in stems (Sarmah et al., 2006). Low concentrations
of chlortetracycline and oxytetracycline in the soil media could
markedly affect plant growth and development (Sarmah et al.,
2006). However, there was a large variation in sensitivity among
plant species to the soil used as the growth media (Sarmah et al.,
2006).
When residues seeped into water, certain antimicrobials also
played signiﬁcant role in the prevention of water eutrophication
for aquatic animals. For example, chlortetracycline, lomeﬂoxacin
hydrochloride, and sulfamethoxazole strengthened the absorp-
tion of nitrogen and phosphorus in water by aquatic plants, and
chlortetracycline effectively removed 25% of water nitrate and
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nitrogen (Dodds et al., 1991; Jones, 2010). On the other hand,
the presence of antibiotic residues in environment may cause
some adverse impacts, like acute and chronic toxicity, during early
life stages of different aquatic organisms (Halling-Sorensen et al.,
2003; Sarmah et al., 2006).
NEGATIVE IMPACT OF ANTIMICROBIAL BAN
Ban on addition of sub-therapeutic antimicrobials in feed
appeared to result in a certain extent of recovery of some bac-
teria and some unintended impacts on animal health and welfare
(Drouin, 1999; Rose et al., 1999; Lovland and Kaldhusdal, 2001;
Jensen et al., 2003). Emergence of E. coli and Lawsonia intracel-
lularis infection in post-weaning pigs was signiﬁcantly increased
and consequently, the morbidity and mortality due to diar-
rhea were considerably increased (Casewell et al., 2003; Dibner
and Richards, 2005). In Denmark, the mortality rate in wean-
ing piglets increased from 2.7% (before the ban) to 3.5% (after
the ban) and the morbidity rate of enteric infections in post-
weaning pigs increased by 600% (Casewell et al., 2003; Dibner
and Richards, 2005). In Sweden, chronic infections due to E. coli
and L. intracellularis became more common and the mortality in
weaning pigs increased by 1.5% (Wierup, 2001; Casewell et al.,
2003).
To control animal diseases and to keep animals healthy, more
therapeutic antimicrobials had to be used after the ban. It was
reported that the usage amount of therapeutic antimicrobials
in Denmark increased by 33.6%, from 48 tons/year in 2001
to 125.5 tons/year in 2010 (DANMAP, 2010). The increased
amount of therapeutic antimicrobials was equal to or even more
than the total quantity of antimicrobials being used before the
ban (Phillips, 1999; Casewell et al., 2003; Phillips et al., 2004a,b;
Turnidge, 2004; DANMAP, 2010). As shown in Figure 1, ther-
apeutic use of tetracycline, penicillins, and macrolides markedly
increased from 28.5, 16.4, and 13.4 tons in 2001 to 35.55, 27.1,
and 16.8 tons in 2010, respectively (Phillips, 2007; DANMAP,
2010).
FIGURE 1 | Estimated total consumption (kg) of prescribed
antimicrobial agents for production animals in Denmark (data
obtained from DANMAP, 2010).
Withdrawal of low-dose antimicrobial use as feed additives
may increase the level of pathogens such as Salmonella spp.,
Campylobacter spp., Clostridium and E. coli O157 in animal gut,
boost the contamination of food and environment, and hence,
enhance the opportunities for humans to be infected by these
pathogens. Population of Campylobacter in broilers fed without
antimicrobials was threefold higher than that in the broilers fed
with any antimicrobials (Heuer et al., 2001). Incidence of food-
borne Campylobacter in EU has been increased after the ban
issue. Recovery of Clostridium from animal meat was also signif-
icantly increased in EU after its ban policy (Jones, 2000; Poduval
et al., 2000). As a consequence, clostridial infections resulted in
an outbreak affecting large human population in Demark and
pointed out the high level of threat to public health (DAN-
MAP, 2010). It is known that clostridial necrotic enteritis in
animals is suppressed by some of the banned antimicrobials (e.g.,
virginiamycin). In the absence of these antibiotics, the bacte-
rial population may increase in animal guts and colonization
may lead to poor weight uniformity and fragile intestines in
pigs and chicks. During food processing, infected animal car-
casses could be the sources of contamination for food-borne
pathogens and thereby, jeopardize food hygiene (Tice, 2001;
Russell, 2003). Bacterial contamination of meat may, therefore,
increase the risk of human infections. Contrary to EU, inci-
dence of food-borne diseases in USA was declined by 23% in
1996 and among those, the infections due to Campylobacter and
Salmonella were decreased by 30 and 17%, respectively. It was
believed that ban of virginiamycin in USA might annually con-
tribute to the death of 40,000 people, infected by Campylobacter
(Cox, 2005).
The ban may lead to increased food-borne infections and ele-
vated usage of therapeutic antimicrobials in both animals and
humans. It is noteworthy that therapeutic use of antimicrobial
agents in animals has a close relationship with the drugs used in
humans with respect to the types of drugs used (Cook, 1999).
The increased therapeutic use in animals may contribute to a
worse, drug-resistance scenario both in animals and humans. It
was noted that clinical isolates of vancomycin- or teicoplanin-
resistant Enterococci from humans were very uncommon and the
cases of quinupristin/dalfopristin-resistant Enterococcus faecium
were very rare before the ban. Similarly, resistant E. faecium bur-
den markedly increased and became a big challenge after the ban
(Phillips, 2007).
After the European ban on growth-promoting antibiotics, it
was found that FCR (total kg of feed used per grow out/total
kg of live weight per grow out) in broiler was decreased by
0.016 kg/kg from November 1995 to May 1999 (1.78–1.796) in
Denmark. Feed efﬁciency raised to a higher value of 1.83 imme-
diately after the restrictions and more than 1.84 in late 1999
(Emborg et al., 2002; Dibner and Richards, 2005). Average daily
gain of weaning piglets in Denmark was decreased from 422 g
in 1995 to 415 g in 2001 (Casewell et al., 2003; Dibner and
Richards, 2005). Production of broilers, cattle, and dairy cows
was signiﬁcantly decreased in 2006, as shown in Figure 2. In
Sweden, weight gain of post-weaning piglets was reduced and
feed costs were signiﬁcantly increased after the abolishment of
growth-promoting antimicrobial agents (Wierup, 2001; Casewell
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FIGURE 2 | Production of food animals in Denmark from 1998 to 2010
(data obtained from DANMAP, 2010).
et al., 2003). Even after 10 years, aquaculture production in
Sweden was unable to return to the past level (Casewell et al.,
2003).
If the use of antimicrobials is banned in USA, FCR may decline
by 5% and more than 1100 km2 area is required to plant corn
and soybeans to meet the demand of feedstuff production. Con-
sequently, required facilities for livestock and poultry production
will be correspondingly increased by 100 million m2, and farming
area will also be increased by 500 million m2 to obtain the current
level of animal production (Casewell et al., 2003). It was esti-
mated that withdrawal of antimicrobial growth promoters might
lead to a loss of 5∼10 or even 40 dollars/pig in USA (Matthews,
2001). It does not seem to be a high cost for the developed coun-
tries but what will be the consequences if these antimicrobials
are banned worldwide? It was also investigated that 25% of the
current poultry industry and $3 billions would be additionally
required to attain the current annual animal production (Rode-
hutscord et al., 2002; IFAH-EuroP, 2005). In conclusion, keeping
in view the ever-increasing world population and its demands,
more food animals should be raised to meet the food supply
demand in the case of growth-promoting antibiotics remain pro-
hibited and this increased number of animals will again lead to
the increase in greenhouse gas emission and deeper environmental
pollution.
RISKS OF ANTIMICROBIALS
INHIBITION OF BIOGAS PRODUCTION
Following the wide use of antimicrobial drugs in intensive animal
production for growth promotion and prevention or treatment
of disease, a large proportion of ingested drugs are excreted in
manure and end up with livestock wastewater. Excreted antibi-
otics in the environment may partially inhibit methanogenesis in
anaerobicwaste-storage facilities, commonlyused atConcentrated
Animal Feeding Operation (CAFOs), and thus, decrease the rate
at which bacteria metabolize animal waste products (Loftin et al.,
2005; Sarmah et al., 2006).
During the anaerobic digestion of livestock waste, certain
antimicrobials, including amoxicillin, aureomycin, oxytetracy-
cline, thiamphenicol, ﬂorfenicol, sulfadimethoxine, and tylosin,
had inhibitory effects on methane production (Lallai et al., 2002;
Sun et al., 2009; Shi et al., 2011; Amin et al., 2012). However,
no inhibitory effect but a stimulus for methane production was
observed during anaerobic digestion of piggery wastewater in the
presence of 10 mg/L ﬂorfenicol, amoxicillin, aureomycin, and sul-
fadimethoxine, while only the combination of high concentration
of certain antimicrobials (130 mg/L ﬂorfenicol, 210mg/L amoxi-
cillin, 10mg/L doxycycline, and 210mg/L sulfadimethoxine) could
decrease the methane production rate (Sun et al., 2009). Biogas
volume, produced from per unit weight of biomass, was decreased
with increasing concentrations of antibiotics, such as oxytetracy-
cline, amoxicillin, and tylosin, and the inhibitory concentrations
of oxytetracycline, amoxicillin, and tylosin were 8000, 9000, and
9000 mg/L, respectively (Amin et al., 2012). Only high concen-
tration of thiamphenicol (160 mg/L), amoxicillin (120 mg/L),
tetracycline (50 mg/L), and sulfamethoxydiazine (50 mg/L) had
inhibitory effect on biogas production in the anaerobic digestion
of pig waste slurry (Lallai et al., 2002; Shi et al., 2011). Actually, it
is too difﬁcult to attain those high concentrations of antibiotics in
the excreta.
ANTIMICROBIAL RESISTANCE CONCERNS
Misuse and overuse of antimicrobial may culminate in the devel-
opment of drug-resistant pathogens resulting in poor response
to treatment. Long-term and low-level exposure to antimicro-
bials may have greater selective potential than short-term and
full-dose therapeutic use. A study observed that the percentage
of tetracycline resistance genes in the fecal ﬂora of convention-
ally raised feedlot steers was signiﬁcantly higher than that in fecal
samples from antimicrobial-free cattle (Harvey et al., 2009). Addi-
tionally, use of single antimicrobial may induce cross-resistance
to antimicrobials used for animal and human medical therapy.
For example, chlortetracycline use in growth rations was associ-
ated with ampicillin and tetracycline resistance in generic fecal E.
coli, isolated from swine farms (Varga et al., 2009). Addition of
chlortetracycline and sulfamethazine in cattle feed may be asso-
ciated with higher prevalence (three to four fold greater than the
control) of ampicillin- and tetracycline-resistant E. coli, isolated
from the feces of treated animals (Alexander et al., 2010). There-
fore, how to use antimicrobials, for effective treatment of bacterial
and parasitic infections in food-producing animals, became the
most important question for their use by avoiding the resistance
development.
Regarding public health risk, more concern has been raised
for the use of antibiotics in animals that may represent a poten-
tial threat to human health because the resistant pathogens in
animals may transmit to humans and cause treatment failure
of human medicines. A longitudinal study of the relationship
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between antimicrobial-resistant E. coli from human wastewa-
ter and swine fecal samples reported that the use of injectable
(e.g., ceftiofur sodium) or oral (e.g., chlortetracycline) antibi-
otics may contribute to the high levels of E. coli resistance in
swine and human isolates. Thus, slaughter plant workers may
be at higher risk of carrying multidrug-resistant E. coli as com-
pared to workers dealing with other animals (Alali et al., 2008).
A study analyzed the correlation between E. coli isolates from
human blood stream and food-producing animals (poultry, pigs,
and cattle) for the prevalence of antimicrobial resistance in 11
countries during 2005–2008. Results revealed that there were
strong and signiﬁcant correlations between the strains from ani-
mals (especially poultry and pigs) and humans for resistance to
multiple drugs (especially ampicillin, aminoglycoside, and ﬂuoro-
quinolone; Vieira et al., 2011). However, there is not enough and
direct evidence to support the hypothesis that a large proportion of
resistant isolates in humans be derived from animal source foods.
Some recent studies suggested that some resistant isolates from
humans were more easily transmitted from companion animals
(having close contact) or birds (by bird droppings especially dur-
ing their migration; Haenni et al., 2012; Loncaric et al., 2013). The
resistant bacteria may also be released into the environment by
humans and then transferred into new hosts in the environment
(Hower et al., 2013; Verkade and Kluytmans, 2013). Based on the
results of some current studies, Dr. Hurt pointed out that pub-
lic health risk due to infected animals need more attention than
antibiotic resistance concern (Hurd et al., 2008, 2012). Therefore,
further efforts are required for the risk assessment of antimicro-
bial use in food animals to check their potential impact on public
health.
POSITIVE EFFECTS OF ANTIMICROBIAL BAN
Aim for thewithdrawal of antimicrobial agents usedwas to prevent
humans and animals from drug resistance. The ban on antimi-
crobial growth promoters led to decreased drug resistance in
some bacteria. For example, according to report from the DAN-
MAP, substantial reductions (from 80 to 2%) in the prevalence
of vancomycin-resistant enterococci (VRE) were observed after
ban of avoparcin as the growth promoter during 1995 and 2010
(DANMAP, 2010). E. faecium and Enterococcus faecalis are two
of the most common Enterococci species and in Europe, only
vancomycin-resistant E. faecium (VREF) is highly prevalent in
poultry (Werner et al., 2008). VREF was still present as a threat
in the food chain even after 15 years of the EU ban on avoparcin
and could be detected in 47% of the broiler feces with a selec-
tive enrichment method (Garcia-Migura et al., 2007; DANMAP,
2010).
The ban on tylosin as the growth promoter had a remark-
able effect on the level of macrolide (erythromycin) resistance
in Campylobacter coli (most common Campylobacter species in
pigs) from pigs as it decreased from 66 to 20% in Denmark
between 1998 and 2005 (Hammerumet al., 2007). However,DAN-
MAP data showed that during 2006–2010, macrolide resistance
in C. coli varied within the range of 10–20% without signiﬁcant
reduction (DANMAP, 2010). In contrast to EU, macrolides (e.g.,
tylosin) in USA had been approved for usage in food-producing
animals as growth promoter for decades. Macrolide resistance
in C. coli isolated from poultry, although higher than that in
C. jejuni, has no signiﬁcant change (5–20%) between 2002 and
2010.
Use of enroﬂoxacin in poultry was withdrawn by US-FDA in
2005 because it was supposed to induce ﬂuoroquinolone resistance
in Campylobacter and Salmonella from poultry and contribute
to the antibiotic treatment failure in humans [Food and Drug
Administration (FDA),1998, 2002; Nelson et al., 2007]. Afterwith-
drawal of enroﬂoxacin from poultry, the rate of ﬂuoroquinolone
resistance in Campylobacter and Salmonella had been reduced in
chicken during 2005–2007 (NARMS, 2010). Human clinicians
also observed a reduction in domestically acquired Campylobacter
and Salmonella infections with decreased susceptibility to ﬂu-
oroquinolones, and it was thought to be a great achievement
regarding public health (Nelson et al., 2007). However, the inci-
dence rate of ﬂuoroquinolone-resistant C. jejuni, from chicken
breast, again increased (15.2∼22.5%) in 2008–2010. Similarly,
ﬂuoroquinolone-resistant Campylobacter from broilers was also
raised from 5.3 to 8.6% and from 0.8 to 7.7% in Denmark and
Japan, respectively (CIPARS,2008; JVARM,2008;DANMAP,2010;
NARMS, 2010).
CONCLUSION AND PERSPECTIVES
Deﬁnite targeting of pathogens, well-known mechanisms of activ-
ity, and preferable stability for administration are the unique
advantages of antimicrobial use in food-animals for the prevention
and treatment of bacterial and parasitic diseases, improvement
of animal production performance, and protection of environ-
ment and public health. Withdrawal of antimicrobial use from
food-producing animals may bring adverse effects on the produc-
tion of food derived from animals and thus, on public health.
EU banned only low-dose antibiotics (5∼40 ppm) for their use
as growth promoters in food animals. Until now, without help-
ing for the cause, it led to some negative effects on food animal
production and public health. What will happen if the antimicro-
bial agents are banned worldwide, especially in some developing
countries with rapid increase in human population and food
demand?
As a double-edged sword, non-rational uses of veterinary
antimicrobials may result in pressure selection of antimicro-
bial resistant pathogens which may endanger both the ani-
mal and public health. Additionally, the presence of antibiotic
residues in the environment, associated with overuse of antimi-
crobial drugs, may adversely inﬂuence the manure treatment
systems by inhibition of biogas production. An economic analysis
about use and withdrawal of antimicrobial growth promot-
ers in USA revealed that the withdrawal may cause increased
cost ($10/person) for food consumption and antibiotic-resistant
infections cost the US healthcare system an excess of $20
billion ($60/person) annually (APUA, 2010). However, it is
unknown that how much of these $20 billion is due to antimi-
crobial resistance associated with their use in food-producing
animals.
Recently, the US FDA has also proposed restrictions on the
antimicrobial growth promoters because some available infor-
mation and evidences suggested that the sub-therapeutic use
may increase the risk of antimicrobial resistance. To make wise
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strategies for controlling antimicrobial resistance and effectively
respond to the public health concerns associated with drug resis-
tance, FDA believes that it is very important and imperative
to consider how antimicrobial drugs are being used and how
to address their injudicious uses in nature. Only rational use
and effective regulation can ensure a beneﬁt–risk balance of the
antimicrobial application in animal production. However, long-
term policies will be required for the international regulation of
antibiotic use in food-producing animals.
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Antibiotics are used in livestock and poultry production to treat and prevent disease as well
as to promote animal growth. Carbadox is an in-feed antibiotic that is widely used in swine
production to prevent dysentery and to improve feed efficiency. The goal of this study was
to characterize the effects of carbadox and its withdrawal on the swine gut microbiota. Six
pigs (initially 3-weeks old) received feed containing carbadox and six received unamended
feed. After 3-weeks of continuous carbadox administration, all pigs were switched to
a maintenance diet without carbadox. DNA was extracted from feces (n = 142) taken
before, during, and following (6-week withdrawal) carbadox treatment. Phylotype analysis
using 16S rRNA sequences showed the gradual development of the non-medicated swine
gut microbiota over the 8-week study, and that the carbadox-treated pigs had significant
differences in bacterial membership relative to non-medicated pigs. Enumeration of fecal
Escherichia coli showed that a diet change concurrent with carbadox withdrawal was
associated with an increase in the E. coli in the non-medicated pigs, suggesting that
carbadox pre-treatment prevented an increase of E. coli populations. In-feed carbadox
caused striking effects within 4 days of administration, with significant alterations in
both community structure and bacterial membership, notably a large relative increase in
Prevotella populations in medicated pigs. Digital PCR was used to show that the absolute
abundance of Prevotella was unchanged between the medicated and non-medicated pigs
despite the relative increase shown in the phylotype analysis. Carbadox therefore caused a
decrease in the abundance of other gut bacteria but did not affect the absolute abundance
of Prevotella. The pending regulation on antibiotics used in animal production underscores
the importance of understanding how they modulate the microbiota and impact animal
health, which will inform the search for antibiotic alternatives.
Keywords: carbadox, antibiotics, microbiome, phylotype, 16S rRNA, digital PCR
INTRODUCTION
Antibiotics are used in animal agriculture for both therapeu-
tic and non-therapeutic applications (Animal Health Institute,
2012). Appropriately high doses of antibiotics are adminis-
tered to treat or prevent disease (therapeutic use), and rela-
tively low doses are typically used to improve feed efficiency
(non-therapeutic use). These differing doses of antibiotics are
important because they are at the core of regulatory efforts,
with many countries banning or regulating non-therapeutic
veterinary antibiotics that have human medical importance
(European Union, 2003; FDA, 2012). This is because low-
dose antibiotics can result in bodily concentrations of antibi-
otics that are subinhibitory to bacteria. Indeed, it is likely
that both therapeutic and non-therapeutic doses of antibiotics
can lead to subinhibitory antibiotic concentrations for some
host-associated bacteria. Subinhibitory antibiotic concentrations
are undesired because they can have adverse effects, in par-
ticular enhancing the selection for antibiotic resistance genes
and their horizontal transfer (Barbosa and Levy, 2000; Smith
et al., 2002; Barlow, 2009; Brewer et al., 2013), thus promoting
the antibiotic resistance problem in animal and human
pathogens.
Carbadox is a quinoxaline-di-N-oxide antibiotic compound
that is fed to almost a third of nursery-age pigs in the US to con-
trol enteric diseases and improve feed efficiency (USDA, 2007).
Medicated early weaning, including carbadox, is credited with
nearly eradicating the enteric pathogen Brachyspira hyodysente-
riae in domestic swine [cause of swine dysentery (Stanton et al.,
1999)]. Carbadox inhibits bacteria by intercalating DNA and
causing mutations, and this mutagenic property has led to its ban
in many countries (Beutin et al., 1981; Chen et al., 2009). The
current US regulation includes a 42-day withdrawal period prior
to slaughter to prevent carbadox residues in the carcass (Joint
FAO/WHO Expert Committee on Food Additives, 2003). It is
unclear if it will be further regulated in the US because carbadox
is not an antibiotic of human clinical importance (FDA, 2003).
We are interested in carbadox because of its importance to the
US swine industry and its unknown effects on swine gut bac-
teria. One specific collateral effect of carbadox is the induction
of prophages or prophage-like gene transfer agents, as has been
shown in vitro in Shiga toxin-producing Escherichia coli (Kohler
et al., 2000), Salmonella enterica serovar Typhimurium (Bearson
et al., 2014), and B. hyodysenteriae (Stanton et al., 2008). In addi-
tion to these results, research in our lab on total swine fecal
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phages suggested that prophages were induced in pigs that were
fed either carbadox or ASP250 (penicillin, chlortetracycline, sul-
famethazine) (Allen et al., 2011). Further identification of the
effects of carbadox on the swine gut microbiome could lead to
a greater understanding of its mechanism of growth promotion.
Here we analyzed the bacterial component of the swine fecal
microbiota in samples taken prior to and during carbadox treat-
ment, as well as periodically during the 6-week withdrawal
period. We found that carbadox altered bacterial membership
and community structure relative to non-medicated pigs, includ-
ing a reduction in total bacteria. This study is an important step
toward defining the effects of carbadox on the swine gut micro-
biome, which in turn will lead to informed alternatives to this
antibiotic.
MATERIALS AND METHODS
SWINE
Piglets were acquired and managed in accordance with the
National Animal Disease Center Animal Care and Use Committee
guidelines, as previously described (Allen et al., 2011). At 3 weeks
of age, 12 piglets from 2 litters were divided into two rooms of
six pigs each, with equal representation of littermates and gen-
der. All pigs were fed a standard starter diet (TechStart® 17-25,
Kent Feeds, Muscatine, IA) ad libitum for 3 weeks, after which six
control pigs continued to receive non-medicated feed while the
other group received feed containing carbadox (50 g/ton). After
21 days of continuous feed with or without carbadox, all pigs (60
days old) were switched to a non-medicated maintenance diet
(Pork Finisher diet, Kent Feeds). The age of pigs receiving car-
badox and transitioning to maintenance diet are consistent with
standard industry practices.
Feces were collected from each pig at multiple times before,
during, and after antibiotic withdrawal (Figure 1), and DNAs
were extracted with the PowerBiome DNA Isolation Kit using the
manufacturer’s protocol (Mo Bio Laboratories, Solana Beach, CA,
USA).
16S rRNA GENE SEQUENCING
Amplification of the V1-V3 region of bacterial 16S rRNA genes
from individual samples was carried out as previously described
(Allen et al., 2011). Primers 8F (5′-AGAGTTTGATCCTGGC
TCAG) (Weisburg et al., 1991) and 518R (5′-ATTACCGCGGCT
GCTGG) (Muyzer et al., 1993) were designed with an eight-
nucleotide unique sequence barcodes (Hamady et al., 2008; Allen
et al., 2011). PCRs were performed for 22 cycles, and the prod-
ucts were separated by gel electrophoresis and purified using
the MinElute kit (Qiagen Inc., Valencia, CA). Amplicons were
sequenced on a 454 Genome Sequencer (GS) FLX using the man-
ufacturer’s protocol for Titanium chemistry (Roche Diagnostics,
Branford, CT).
SEQUENCE ANALYSIS
Sequence data that passed Roche’s quality thresholds were pro-
cessed by AmpliconNoise (Quince et al., 2011), mothur (Schloss
et al., 2009, 2011), and Uchime (Edgar et al., 2011) to denoise
sequencing data, remove barcodes, and reduce sequence artifacts
produced during PCR. The Schloss analysis pipeline SOP was fol-
lowed (Schloss et al., 2011). Briefly, mothur’s implementation of
the AmpliconNoise program reduced sequencing and PCR arti-
facts, then sequences were aligned to the Silva bacterial database
(Quast et al., 2013). Screen.seqs, filter.seqs, and pre.cluster com-
mands were performed in mothur to improve the quality of the
dataset, and Uchime was used to remove chimeras (using the
sequences of each sample as their own reference). OTU-based
phylogenetic analysis (97% similarity cutoff) and hypothesis test-
ing were performed with normalized data in mothur (Schloss
et al., 2009). Data were normalized by subsampling each sam-
ple to 3454 reads and unless otherwise stated, and samples were
analyzed by time and treatment (Figure 1). To visualize changes
in community structure, the Bray-Curtis dissimilarity statistic
(OTU data) and Pearson’s correlations (vectors of environmental
variables) were calculated and plotted by nonmetric multidi-
mensional scaling (NMDS) in PAST (Hammer et al., 2001).
FIGURE 1 | Timeline of carbadox feed-trial. Sample days are noted above the thick line, and dates are noted below. Dashed region not to scale. Timepoints
that were grouped for some statistical analyses are labeled along the top. CARB, carbadox; WD, withdrawal.
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Community metrics such as diversity (Shannon index, inverse
Simpson index), evenness (Heips index), and richness [best para-
metric model in CatchAll (Bunge, 2011; Bunge et al., 2012)] were
calculated in mothur based on the OTU data. Multiple t-tests
were performed on community metrics in GraphPad Prism v.
6.02 (La Jolla, CA). Statistical significance was determined using
the Holm-Sidak correction for multiple comparisons when com-
paring medicated vs. non-medicated at a timepoint, or using the
Kruskal-Wallis test with Dunn’s multiple comparison correction
when comparing the all days of the carbadox group to pre-
treatment (alpha = 5%). The resilience index was calculated from
Shannon, Heips evenness, and inverse Simpson diversity indices
using the formula described by Shade et al. (2012) based on the
diversity index of the microbiota of the carbadox-treated animals
at pre-treatment, at the most significantly changed time (day 7),
and at the first time that was not significant from pre-treatment
(day 14). Samples were analyzed by treatment per timepoint, or
by treatment per range of time (pre-treatment, early carbadox
exposure [days 1–4], late carbadox exposure [days 7–21], early
withdrawal [days 2 and 4], and late withdrawal [days 21 and 42];
Figure 1). For most statistics, samples were compared between
pigs in the medicated and non-medicated groups at each time.
Taxonomic assignments of the 16S rRNA gene sequences were
made using the Ribosomal Database project (RDP) web tools,
with training set version 9.0 (Cole et al., 2009). The Metastats
statistical software was used in mothur for making comparisons
between samples and identifying trends (White et al., 2009).
Analysis of similarities (ANOSIM) was also performed in mothur
to test whether difference between groups were significant.
Linear discriminant analysis effect size (LEfSe) was per-
formed using the LEfSe web tool on taxonomic assignments from
RDP’s sequence classifier (Cole et al., 2009; Segata et al., 2011).
The LEfSe program was used to identify indicator organisms
most likely to explain the differences between treatment groups
with a logarithmic cutoff value of linear discriminant analysis
(LDA)> 4.0.
QUANTIFICATION OF PREVOTELLA (BY digPCR AND qPCR)
Digital PCR (digPCR) counts the number of target molecules
in each DNA sample, enabling reliable estimates of the abso-
lute number of target molecules in the original sample (feces),
without the need for an internal standard. Digital PCR was
performed to estimate the number of copies of Prevotella 16S
rRNA genes in fecal DNA from carbadox-fed and non-medicated
animals at day 4 of carbadox treatment (early exposure). The
Quantstudio 3D digPCR system (Life Technologies) was used
according to the manufacturer’s recommendations and each sam-
ple was run in triplicate. Prevotella-specific digPCR primers were
adapted from Mieszkin et al. (2009): Bac32 Fm, 5′AACGCTAG
CTACAGGCTTAAC; Bac108R, 5′ CGGGCTATTCCTGACTATG
GG; Bac82Probe, 5′ 6-FAM-ACGGGTGAG/ZEN/TAACGCGT
ATCCAAC-IBFQ (fluorophore and quenchers in bold). All reac-
tions were performed using QuantStudio 3D Digital PCR Master
Mix (Life Technologies, Carlsbad, California) following manu-
facturer’s recommended cycling conditions. Each 15μL reaction
consisted of 1.0μMof each primer, 0.2μMprobe, 1.0 ng or 0.1 ng
DNA. Prevotella cells per gram of feces were calculated using the
DNA quantity extracted from 0.5 grams of feces, and assuming a
Prevotella spp. average of two 16S rRNA gene copies per cell [aver-
age of 58 Prevotella genomes available on the IntegratedMicrobial
Genomes (IMG) website (Markowitz et al., 2012)].
Quantitative PCR (qPCR) was performed on the same samples
as digPCR to evaluate the relative amount of Prevotella to total
16S rRNA gene copies (all bacteria). Prevotella-specific primers
were used (F, 5′CGGGTTGTAAACTGCTTTTATGAAG; and
R, 5′CGCTCCCTTTAAACCCAATAAA) as previously described
(Okabe et al., 2007). Universal bacterial primers targeting the
16S rRNA gene (341F, 5′ CCTACGGGRSGCAGCAG; and 529R,
5′ ACCGCGGCKGCTGGC) (Baker et al., 2003) were used to
amplify all bacterial 16S rRNA genes. All reactions were done
using iTaq Universal SYBR Green Supermix following manufac-
turer’s recommended conditions (Bio-Rad, Hercules, California).
Each 20μL reaction consisted of 0.01 ng fecal DNA and the
Prevotella or universal primers at 0.2μM or 0.5μM, respectively.
Relative quantification was calculated using the Pfaffl method
(Pfaffl, 2001) and t-tests were performed in PAST (Hammer et al.,
2001).
E. COLI VIABLE CELL POPULATIONS
One gram of fresh feces was suspended in 10ml LB broth.
Samples were vortexed vigorously to make a slurry for 10-fold
serial dilutions in phosphate buffered saline. Duplicate dilutions
were plated on MacConkey agar medium (March and Ratnam,
1986) and incubated at 37◦C. Lactose positive colonies (fecal col-
iforms, predominantly E. coli) were enumerated on the countable
dilution the following day.
DATA PRESENTATION
A P-value less than 0.05 with a q-value (false discovery rate)
less than 0.05 was considered significant, and R between 0
and 0.3 was considered a slight correlation while R greater
than 0.3 was considered a correlation. Data are deposited
in NCBI’s Short Read Archive (SRA) under accession num-
bers SAMN02645017-SAMN02645066 and are associated with
BioProject PRJNA237795.
RESULTS
CARBADOX ALTERS BACTERIAL MEMBERSHIP EARLY IN THE
TREATMENT
We first examined differences in bacterial membership at the
phylum and genus taxonomic levels during the first week of
carbadox treatment. The results showed that the Firmicutes,
Proteobacteria, Elusimicrobia, Planctomycetes, and Lentisphaerae
phyla were of lower relative abundance, while the Bacteroidetes
phylum was of higher abundance in the medicated animals
(q < 0.03) (Figure 2). Interestingly, Bacteroidetes populations
increased in the medicated animals proportionately to the
decrease in Firmicutes populations (∼17% change). This early
carbadox-mediated transition to a Bacteroidetes-dominantmicro-
biota was also seen when comparing early medicated animals to
pre-treatment (∼25%). Genus-level taxonomic assignments were
also analyzed, revealing significant differences between the med-
icated and non-medicated animal microbiotas during the early
carbadox time points. Many genera showed a relative decrease
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FIGURE 2 | Bacterial phyla representation in the microbiota, based on
taxonomic inference of bacteria (16S rRNA sequences). Data are pooled
by treatment and period of time. Carb, carbadox; wd, withdrawal; non,
non-medicated.
with antibiotic treatment (Figure S1), most of which belonged
to the Firmicutes phylum (q < 0.05). The relative increase in
Prevotella spp. was reflected in the increase in Bacteroidetes in the
carbadox-treated animals (q < 0.05).
The LEfSe analysis was used to resolve bacterial taxa associ-
ated with antibiotic treatment, which could define biomarkers
for carbadox effects. This analysis explains why biological sam-
ples differ using tests of consistency and effect size estimation
(Segata et al., 2011), with the results suggesting members of the
community that benefit from or contribute to the community-
wide effects described above. The results showed four genera to be
enriched in early samples from carbadox-fed animals: Prevotella,
Roseburia, Faecalibacterium, and Asteroleplasma (Figure 3 and
Figure S2). Lactobacillus was enriched in samples from the early
non-medicated animals (Figure 3 and Figure S2). This indicates
that a few key members of the community could be the drivers of
community dynamics.
CARBADOX CAUSES RAPID CHANGES IN BACTERIAL COMMUNITY
STRUCTURE
Comparisons of community structures apply broad measures
of similarities among bacterial communities in their entirety,
allowing inferences to be made about populations as a whole.
The effects of dietary changes on bacterial community struc-
ture were first analyzed via OTUs binned at the 97% similarity
level. Estimates of the total number of OTUs (bacterial rich-
ness) during the early treatment period were significantly lower
for the communities in medicated animals (661 ± 55 vs. 962 ±
96, respectively; Figure 4). Additional measures of alpha diver-
sity (Shannon diversity, Heips evenness, and inverse Simpson
indices) of samples from medicated animals compared to non-
medicated animals were significantly different at 2, 3, and 4 days
after continuous carbadox, but not different in either late car-
badox or at any time during the withdrawal period (Figure S3).
Analysis of the community structure yielded further support,
showing significant differences at days 3 and 4 of early carba-
dox treatment ([R = 0.32, p = 0.015] and [R = 0.54, p = 0.003],
respectively), but not before starting antibiotic treatment (p =
0.82; Figure 5). Communities from medicated animals at the
remaining time points did not clearly separate from those of the
non-medicated animals. The alpha diversity indices of the micro-
biota from the carbadox-treated animals at each sample time were
compared to their pre-treatment values to determine when the
microbiota recovered. Significant differences were revealed from
the pre-treatment diversity at days 2, 3, 4, and 7 but at no other
times, including the withdrawal period (p < 0.01). The swine
gut microbiota showed similar resilience in response to carbadox
disturbance regardless of the diversity index used to calculate it
(0.16, 0.17, 0.19 from the Heips evenness, inverse Simpson, and
Shannon diversity indices, respectively). Together these data show
that carbadox caused an initial decrease in both bacterial rich-
ness and evenness, and that the swine gut bacterial community
structure recovered after 1 week of carbadox initiation despite the
continued presence of carbadox.
COMPARISON OF ABSOLUTE AND RELATIVE DIFFERENCES IN
MICROBIOTA MEMBERSHIP
Because of the altered microbial diversity and reduction of rich-
ness early in the antibiotic treatment, digital PCR was used to
evaluate whether statistically significant changes in the bacterial
community of medicated animals was due to absolute changes in
bacterial membership or due to reductions of carbadox-sensitive
organisms. The relative abundance of Prevotella was most signif-
icantly impacted by carbadox and so was chosen for analysis by
digPCR to determine if this was an absolute or relative change in
the Prevotella population. Analysis of early carbadox samples (day
4) showed no significant differences in Prevotella counts (LOG10)
per gram of feces between medicated (10.0, SE = 0.11) and non-
medicated animals (9.8, SE = 0.26). This suggests that observed
differences in Prevotella sequence data are due to decreases
of other bacterial species rather than to increases in absolute
numbers of Prevotella. To verify the results of the phylotype
analysis and to compare with the digPCR results, qPCR was
performed on the same day 4 samples. Quantitative PCR of
Prevotella abundances, relative to total 16S rRNA genes, con-
firmed a 1.8-fold increase in the relative abundance of Prevotella
in the carbadox-fed animals (p < 0.05). These data demonstrate
the value of using digPCR to resolve the absolute abundance of
taxa that show relative changes in high-throughput phylotype
analyses.
CARBADOX ABROGATES E. COLI POPULATION SHIFTS DURING A
DIETARY CHANGE
Culturing bacteria directly from feces also yields absolute counts,
but selecting individual groups requires a priori knowledge and
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FIGURE 3 | Taxonomic tree showing biomarkers that were significantly
enriched with either antibiotic exposure or lack of exposure over time.
The LEfSe-generated tree shows bacterial nodes (diameter is relative to
abundance in community) with a taxonomic hierarchy. Samples were grouped
together as either carbadox-treated (Carb) or non-medicated (Non-med) over
the period of the study as pre-treatment, early exposure, late exposure, early
withdrawal, late withdrawal. No biomarkers were identified for the late
carbadox samples. The cutoff value of linear discriminant analysis (LDA) > 4.0.
available selective media. Because carbadox is often used to pre-
vent enteric diseases in young swine, we cultured E. coli from
fecal samples at different experimental time points to monitor
this species for potential enteric pathogens. No significant dif-
ferences in E. coli colony forming units (CFUs) were observed
during the carbadox-treatment portion of the study or late in the
withdrawal period (Figure S4). Interestingly, E. coli CFUs were
significantly different between the medicated and non-medicated
groups on day 2 after the withdrawal of carbadox, with the dif-
ference being driven by increased E. coli CFUs in samples from
non-medicated animals at that time (Figure S4). The diet for all
animals was switched (consistent with industry practice) con-
comitant with the withdrawal of carbadox (seeMethods), and this
result suggests that the change in diet caused a brief increase in
E. coli populations that was prevented in the pigs previously fed
carbadox.
CARBADOX MODIFIES THE DEVELOPMENT OF THE SWINE GUT
MICROBIOTA
This study involved a time series that encompassed 21 days
of antibiotic treatment and 42 days following its withdrawal,
enabling the examination of the development of the swine gut
microbiota. Members of the Firmicutes phylum were relatively
more abundant at the beginning of the study (54% of total com-
munity) than at the end of the withdrawal period (34%) (q <
0.01; Figure 2). An increase in the relative abundance of other
phyla [Proteobacteria, Spirochaetes, Planctomycetes, Fibrobacteres,
Synergistetes (q < 0.01)] was observed over the 9-week study.
Much of this maturation happened late in the experiment regard-
less of antibiotic treatment. However, carbadox treatment did
exert some significant changes on the microbiota even after its
withdrawal. Analysis of community structure revealed significant
differences between the medicated and non-medicated groups
late in the withdrawal period (21 days [R = 0.49, p = 0.001] and
42 days [R = 0.54, p = 0.001]), but not in the early withdrawal
period (days 1, 2, 3, or 4) (Figure 5). This suggests significant
changes in bacterial membership over time because there were
no significant differences in comparisons of community met-
rics, such as richness and diversity, during the withdrawal period
(Figure 4 and Figure S3). The LEfSe analysis suggested bacterial
members were relatively increased with these late-withdrawal dif-
ferences, including Succinivibrio, Hallella, and Treponema in the
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late-withdrawal medicated animals and Spirochaetaceae in the late
non-medicated animals (Figure 4). Taken together, these results
show that the swine gut bacterial community changes over time,
and that carbadox influences thesemicrobiotas even several weeks
after its removal.
FIGURE 4 | Operational Taxonomic Unit (OTU) estimates, averaged by
treatment and time. Bars indicate the standard error around the mean.
Multiple comparisons star indicates significant difference at timepoint.
DISCUSSION
Here we define short- and long-term effects of in-feed car-
badox and its withdrawal on the swine intestinal microbiota.
Carbadox is one of the most common antibiotics used in the
US swine industry, with indications for both disease prevention
and feed-efficiency improvement. We are interested in defining
the effects of carbadox to inform both its mechanism-of-action
and non-antibiotic alternatives (with similar effects on produc-
tion performance). Carbadox was administered continuously for
3 weeks, constituting an ecological press rather than pulse dis-
turbance to the microbiota (Shade et al., 2012). The results show
that carbadox immediately and significantly altered the bacte-
rial community, but it did not show the same effects from 1 to
3 weeks of continual administration. This demonstrates that the
swine gut microbiota was initially disturbed by carbadox, but the
microbial community structure recovered despite the continued
presence of carbadox. Interestingly, the discontinuation of carba-
dox resulted in enduring effects at the species level but not on
community metrics such as diversity, suggesting that carbadox
altered the membership but not the structure of the commu-
nity. Similar dynamics were observed in a study of a human
undergoing press β-lactam therapy, which showed an immediate
reduction in Firmicutes populations after 6 days, a reduction
in overall species richness, and subsequent reestablishment of
Firmicutes populations after 2 weeks (Perez-Cobas et al., 2013).
Furthermore, analysis of physiochemical and microbial variables
in a batch reactor has shown that microbial communities can
FIGURE 5 | Non-metric multidimensional scaling analysis of
OTU-based bacterial 16S rRNA gene sequence abundances in
individual pig samples. Environmental variables are plotted as
vectors. The length of each vector is arbitrarily scaled, so only
their directions and relative lengths should be considered. Stress
proportion = 0.1656.
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enter alternative stable states that have consequences on ecosys-
tem processes (Burgmann et al., 2011). Further work is needed
to determine how the carbadox-altered microbiota interacts with
the host and how this relates to feed efficiency.
The most dramatic bacterial change was the relative increase
in the Prevotella population during the first 4 days of carba-
dox exposure. However, based on the digPCR results, this was
not due to an absolute increase in the Prevotella population,
which was unchanged compared with samples from non-treated
pigs, but rather to a reduction in other members of the micro-
biota. Prevotella is a well-studied swine commensal bacterium
and has been identified as one of the most abundant genera
in the pig intestine (Leser et al., 2002; Lamendella et al., 2011;
Looft et al., 2012). The relative number of intestinal Prevotella
has been shown to decrease after amoxicillin exposure (Mozes
et al., 2013), suggesting that the antimicrobial effect on this genus
is specific to the antibiotic being administered. Prevotella spp.
metabolize recalcitrant food, such as hemicelluloses and pectin
in the swine intestinal tract, which is important to animal health
because fermentation end products, from these substrates, sup-
ply the host with a large portion of its energy supply. Prevotella
was identified with Roseburia and Faecalibacterium as biomarkers
that increase in relative abundance soon after carbadox admin-
istration. These bacteria are metabolically complementary since
Prevotella produces acetate, and Roseburia and Faecalibacterium
consume acetate to produce butyrate (Duncan et al., 2004a,b).
Butyrate is a short chain fatty acid (SCFA) that has been shown
to benefit host health (Flint et al., 2012; Furusawa et al., 2013).
Additionally, links between bacterial fermentation products and
host energy regulation suggest bacterial roles for improved feed
efficiency. A recent study of fructo-oligosaccharides and other
soluble fibers showed an intestinal microbiota shift in mice
(increased Bacteroidetes populations and decreased Firmicutes)
that resulted in increased SCFA production, specifically acetate,
propionate, and butyrate (De Vadder et al., 2014). This led
to increased concentrations of propionate in the blood, which
induced intestinal gluconeogenesis to benefit glucose and energy
homeostasis (De Vadder et al., 2014). Although the relative
Prevotella increase in response to carbadox was relatively short-
lived, and not an absolute change, studies of food-producing
animals suggest that small health advantages at key production
stages (e.g., weaning, transport, etc.) can convey significant per-
formance improvements over time and at slaughter (Alexopoulos
et al., 2004).
The health benefits of microbial SCFA production has been
well documented, and certain diets and antibiotic alterna-
tives have been shown to be particularly good modulators of
SCFAs. Interestingly, studies on the host health- and microbiota-
modulating effects of some prebiotics, such as dietary fiber, have
shown microbiota shifts similar to what was shown in the present
study with carbadox. The prebiotics arabinoxylan and inulin
similarly caused a relative increase in Prevotella, Roseburia, and
Faecalibacterium populations, thereby increasing propionate and
butyrate production (Ramirez-Farias et al., 2009; Scott et al.,
2014). Prevotella spp. also had relative increases after soluble
fiber and non-starch polysaccharides were added to pig feed,
and this diet was also associated with increased abundance of
butyryl-coenzyme A (CoA) CoA transferase gene copies in feces
(Metzler-Zebeli et al., 2010). It is as yet unclear if these micro-
biota shifts are related to the improved feed efficiency observed
with agricultural antibiotics such as carbadox, but further studies
are warranted.
One unexpected discovery was that carbadox abrogates a
potential bloom in E. coli populations as a result of a diet change.
Previous results from our lab and others have suggested that
increased E. coli populations are a collateral effect of some ecosys-
tem disturbances, including antibiotics (Janczyk et al., 2007; Looft
and Allen, 2012). An abrupt change in diet has been shown to
increase E. coli O157:H7 shedding in sheep (Kudva et al., 1997)
and in pigs, diet change and weaning is associated with increase
susceptibility to enterotoxigenic E. coli infection, a leading cause
of post-weaning diarrhea (Wu et al., 2007). In the present study,
we found that the initial carbadox disturbance caused no such
E. coli increase. However, due to the pigs advancing age over the
course of our extended experiment, the diet was changed from
a standard nursery diet to a grower/maintenance diet (consis-
tent with industry practice) at the same time that carbadox was
withdrawn. This dietary change caused an increase in E. coli pop-
ulations in the non-medicated animals, but not in the pigs that
had previously been fed carbadox, demonstrating a protective
effect of prior carbadox administration.
In contrast to the potential modulation of SCFA production
described above, other commonly accepted mechanisms of how
in-feed antibiotics improve feed efficiency are related to bacterial
disease suppression, the reduction of the host’s microbial load,
or both (Dibner and Richards, 2005; Mathew et al., 2007). Our
study showed a significant reduction of bacterial species richness
after 4 days of continuous carbadox administration, confirming
that the bacterial load is reduced albeit temporarily. Reduced
bacterial richness has also been observed with the use of other
in-feed antibiotics such as ASP250 (chlortetracycline, sulfamet-
hazine, and penicillin) in swine (Allen et al., 2011). Regarding
the potential mechanism of disease suppression, an intriguing
result from our study is that the family Spirochaetaceae was
lower in the carbadox-treated animals than the matched non-
medicated animals 42 days after the withdrawal of carbadox. The
Spirochaetaceae family includes Brachyspira hyodysenteriae, which
is the causative agent of swine dysentery and one of the primary
reasons carbadox is used in pig production in the US (Stanton
et al., 1999). As efficacious alternatives to in-feed antibiotics con-
tinue to be explored, these data are a reminder of the need to
diversify the antibiotic alternative armament with specific tools of
targeting pathogens, such as vaccines, in addition to feed additives
that are general modulators of bacterial community structure
(Allen et al., 2013).
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The use of antibiotics in food-producing animals has significantly increased animal
health by lowering mortality and the incidence of diseases. Antibiotics also have largely
contributed to increase productivity of farms. However, antibiotic usage in general and
relevance of non-therapeutic antibiotics (growth promoters) in feed need to be reevaluated
especially because bacterial pathogens of humans and animals have developed and shared
a variety of antibiotic resistance mechanisms that can easily be spread within microbial
communities. In Canada, poultry production involves more than 2600 regulated chicken
producers who have access to several antibiotics approved as feed additives for poultry.
Feed recipes and mixtures vary greatly geographically and from one farm to another,
making links between use of a specific antibiotic feed additive and production yields
or selection of specific antibiotic-resistant bacteria difficult to establish. Many on-farm
studies have revealed the widespread presence of antibiotic-resistant bacteria in broiler
chickens. While some reports linked the presence of antibiotic-resistant organisms to the
use of feed supplemented with antibiotics, no recent studies could clearly demonstrate
the benefit of antimicrobial growth promoters on performance and production yields. With
modern biosecurity and hygienic practices, there is a genuine concern that intensive
utilization of antibiotics or use of antimicrobial growth promoters in feed might no
longer be useful. Public pressure and concerns about food and environmental safety
(antibiotic residues, antibiotic-resistant pathogens) have driven researchers to actively look
for alternatives to antibiotics. Some of the alternatives include pre- and probiotics, organic
acids and essential oils. We will describe here the properties of some bioactive molecules,
like those found in cranberry, which have shown interesting polyvalent antibacterial and
immuno-stimulatory activities.
Keywords: growth promoters, non-therapeutic antibiotics, alternatives to antibiotics, cranberry, c-di-GMP, poultry
production, broilers
INTRODUCTION
Since the discovery of penicillin by Fleming in 1928, several
antibiotics which can be classified based on their molecular tar-
gets in bacteria (cell wall, protein synthesis, nucleic acids, folic
acid metabolism) have been marketed for the treatment of infec-
tious diseases both in animals and humans. The agents used in the
treatment of animals and humans often belong to the same classes
of antibiotics having similar modes of action and bacterial cell
targets. This interface brings a variety of problems and worries.
Bacteria developing resistance to these drugs in animals may be
transmitted to humans or spread their mechanisms of resistance,
which may eventually be found in human pathogens. Such a situ-
ationmay lead to the loss of therapeutic efficacy in both veterinary
and human medicine.
It is evident that antibiotics substantially improved pub-
lic health. For example, since their discovery about 70 years
ago, antibiotics have greatly reduced mortality and morbid-
ity associated with infectious diseases and have increased life
expectancy around the world. In addition to their therapeutic
use, antibiotics also are deployed in animals for prophylaxis and
growth promotion (improvement of animal zootechnical param-
eters). For example, antibiotics such as ceftiofur (a third genera-
tion cephalosporin), bacitracin (polypeptide) and virginiamycin
(streptogramin) are used in poultry production to respectively
prevent and control infections (respiratory diseases and necrotic
enteritis) and to improve food conversion and body-weight gain.
The use of antibiotics as growth promoters was adopted in the
1940s when animals fed dried mycelia of Streptomyces aureo-
faciens containing chlortetracycline residues showed improved
performances (Castanon, 2007). It has been estimated that antibi-
otic growth promoters in animals, through unspecific and not
well defined mechanisms, improve bodyweight by 5–6% and feed
efficiency by 3–4%, with the most pronounced effects observed
in young animals (Butaye et al., 2003). However, the deploy-
ment of antimicrobial agents can change the bacterial envi-
ronment by eliminating susceptible strains, and only allowing
antibiotic resistant bacteria (i.e., those with higher fitness) to
survive (O’Brien, 2002). Antimicrobial agents may thus modify
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the intestinal microflora and create a favorable environment for
establishment of resistant and pathogenic bacteria. Accordingly,
positive associations were found between the presence of certain
virulence genes and antibiotic resistance determinants (Aslam
et al., 2012; Johnson et al., 2012). The impact of antimicrobial
growth promoters on the development of antimicrobial resistant
bacteria has been the subject of several reports and led to their
ban in the European Union in 2006.
The poultry industry has grown and improved in recent years
due to the continuous integration of various disciplines for pro-
duction such as poultry health, nutrition, breeding, husbandry,
and knowledge of poultry products (Anonymous, 2007). For
example, in 1928, the average broiler required 112 days and 22 kg
of feed to reach 1.7 kg. Since 1990, broilers required about 35–42
days and 4 kg of feed to reach 2 kg (National Research Council,
1999). Even though this improvement could be attributable in
part to antibiotics, relevance of their use as growth promoters
in feed needs to be re-evaluated. With modern broiler produc-
tion practices, a broiler body weight of 1.8 kg can be reached by
using 3.2 kg of feed in 35 days without addition of any antibi-
otic in feed (Diarra et al., 2007). In this chapter, we will review
the use of antimicrobial agents in the Canadian poultry industry
and discuss public health issues and concerns related to antibiotic
resistant bacteria. We also will explore possible alternatives that
could be developed in respect to food and environmental safety
as well as to public and animal health and welfare.
ANTIBIOTIC SELECTIVE PRESSURE
The use of antibiotics as growth promoters is negatively per-
ceived because pathogenic bacteria of humans and animals have
developed and shared a variety of antibiotic resistance mecha-
nisms that can be easily spread within microbial communities.
Nowadays, worldwide spread of antibiotic resistance mechanisms
resulting from selective pressures (use of antibiotics) has undeni-
ably reduced treatment options and therapeutic efficacy in human
medicine. However, the relative responsibility of selective pres-
sures occasioned by human medicine, veterinary or agricultural
practices is still unclear. Furthermore, metagenomic studies have
established some links between resistance mechanisms found in
microorganisms from the environment and the clinic (Perry and
Wright, 2013), making even more difficult the identification of
the primary cause of selective pressure and support arguments for
multiple sources of antibiotic resistance genes (Lupo et al., 2012).
Transformation and conjugation are mechanisms accommo-
dating gene transfer among bacteria and are believed to play
important roles in the rapid spread of antibiotic resistance (Chen
et al., 2005). In addition, the horizontal transfer of mobile genetic
elements also contributes to the evolution of emerging pathogens
through dissemination of virulence genes. A variety of genetic
materials, such as plasmids, can participate to this evolution
(Carattoli, 2013). Moreover, integrative and conjugative elements
(ICEs) can be disseminated through transferable elements like
conjugative plasmids but can also integrate into the genome of
new bacterial hosts (Burrus and Waldor, 2004). Transposons are
also other mobile genetic elements that can contain antibiotic
resistance gene cassettes such as resistance integrons (Hall, 2012).
class 1 integrons, which can be disseminated through a wide
variety of taxonomically divergent bacteria, are often found in
bacteria associated with livestock and poultry (Mathew et al.,
2007). Another mean for gene transfer across bacterial species of
different taxa includes transduction (gene transfer mediated by
bacteriophages) as evidenced by using a metagenomic approach
for antibiotic resistance genes (Muniesa et al., 2013). Noteworthy,
antibiotic resistance gene transfer can be insidious as phenotypic
detection of inducible antibiotic resistance may be difficult and
may account for the “silent” spread of such genes in bacterial
communities (Chancey et al., 2012).
Hence, some bacterial isolates of animal origin might not be
pathogenic to humans but theymay carry and disseminate impor-
tant antibiotic resistance genes. For example, the same vanA gene
cluster involved in vancomycin resistance could be detected in
enterococci of both human and animal origins, indicating hori-
zontal transfer of gene clusters between enterococci of different
origins (Conly, 2002; Hammerum, 2012). Similarly, multidrug-
resistant commensal E. coli of animal origin represent an impor-
tant reservoir of antibiotic resistance genes that can be transferred
to other strains and bacterial species through contact with other
animals or humans and through contaminated food (Szmolka
and Nagy, 2013). Many food animals are now broadly recog-
nized as carriers of livestock-associated pathogens that can in
many occurrences cause diseases in the human host. For example,
Livestock-Associated Methicillin-Resistant Staphylococcus aureus
(LA-MRSA) have been transmitted from cows or pigs to humans
and could cause diseases (Witte et al., 2007; Garcia-Alvarez et al.,
2011; Laurent et al., 2012). Also recently, it was suggested that
multiple cases of community-acquired urinary tract infections
(UTI) caused by antibiotic-resistant bacteria could be consid-
ered outbreaks of foodborne origins (Nordstrom et al., 2013). In
Canada, studies suggested that poultry meats could play a role in
human infections (Manges et al., 2007) and that chicken repre-
sented the most probable reservoir of extraintestinal pathogenic
E. coli causingUTI (Bergeron et al., 2012). Certainly, in view of the
complexity of the antibiotic resistance spread allowed by various
means (genes, resistant commensals, or resistant pathogens) from
various reservoirs (food and environment), global coordinated
actions are required (Marshall and Levy, 2011; Laxminarayan
et al., 2013). Toward a global action in the Canadian poul-
try industry, at least two reasonable questions should arise. Are
antibiotics acting as growth promoters still needed nowadays?
What are possible alternatives to antibiotics that could be used
in preserving poultry health while maintaining farm profitability,
food safety and environmental health?
POULTRY INDUSTRY IN CANADA
According to the Food and Agriculture Organization (FAO) of
the United Nations, the world chicken production was esti-
mated at 71,851,372 tons in 2005, up 3% from the previous year
(Lacobucci et al., 2006). It is interesting to note that chicken pro-
duction has been grown steadily worldwide since the early 1990s.
From 1985 to 2005, 158% growth was recorded. The leading
chicken-producing countries include the United States, China,
the European Union and Brazil. In 2005, those four countries
or group of countries accounted for about 61% of world chicken
production. Canada was the thirteenth-largest chicken-producing
country in 2005 with 981.2 million kilograms representing 1.4%
of the world’s production (Lacobucci et al., 2006).
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Poultry production is an important industry in Canada. In
2012, the value of Canadian chicken products was estimated
at $2.4 billion, involving 2645 regulated chicken producers and
a large number of businesses associated with chicken farming
http://www.agr.gc.ca/poultry/index_eng.htm). In the same year,
Canada produced 1.02 billion kilograms of chicken (eviscer-
ated weight), 60% of which was produced in the provinces of
Quebec and Ontario. Canadian domestic consumption was 30
kilograms per person and retail purchases accounted for approxi-
mately 634 million kilograms representing 62% of Canada’s total
consumption. Canada exported over 5.9 million chicks to 13
countries; a commercial value estimated at over $14.5 million
in 2012. The United States was the largest market (91%). Other
countries included Mexico, Japan, the Philippines, and China
(http://www.agr.gc.ca/poultry/index_eng.htm).
In Canada, several medical ingredients are approved as feed
additives for poultry farmers. Among them, several classes
of antimicrobial agents, such as glycolipids (bambermycin),
polypeptides (bacitracin), ionophores (salinomycin), β-lactams
(penicillin), streptogramins (virginiamycin), and tetracyclines
(chlortetracycline) are used in broiler production for growth
promotion and prevention of infectious diseases (Table 1). For
broilers, salinomycin and bacitracin are widely used in starter,
grower or finisher feeds while virginiamycin is used in the finisher.
Many of the above antimicrobials are effective against Gram-
positive bacteria such as Clostridium perfringens, the etiological
cause of necrotic enteritis which is one of the main disease con-
cerns for poultry producers worldwide (Stutz et al., 1983; Heredia
and Labbé, 2001; Shojadoost et al., 2013). Since C. perfringens
also is one of the foodborne pathogens associated with poultry, it
is believed that antimicrobial agents targeting this pathogen also
help to prevent any potential food safety problems.
The preventive use of antibiotics in poultry production may
impact therapeutic efficacy in human medicine. Ceftiofur is a
third-generation cephalosporin, marketed for use in turkey, cat-
tle, swine, lambs, dogs, and horses. This antibiotic is often sub-
cutaneously injected in day old chicks (0.17mg/chick) or into
eggs (0.08–0.20mg) as a prophylactic measure in Canada to pre-
vent the yolk-sac infection (omphalitis), a costly disease caused
by Escherichia coli (Canadian Medical Association, 2009). This
use is under Canadian provincial regulations which differ from
province to province (Government of Canada, 2002). Overall
data on antibiotic use in Canadian hatcheries are not avail-
able; however, it seems that about 30% of the chicks hatched
in the province of Ontario would be treated mostly with ceftio-
fur followed by gentamicin (Rosengren et al., 2009). Ceftiofur
is not used in humans, however, its analog ceftriaxone, another
third-generation cephalosporin, is an important medical antibi-
otic used in humans. Resistance to these related antibiotics
can be mediated by similar mechanisms involving genes such
as blaCMY−2, an AmpC-type β-lactamase that hydrolyzes third-
generation cephalosporins.
In Canada as well as in several countries, various combina-
tions of antimicrobial agents are used in feed depending on birds’
ages, formulation and mixtures and such recipes greatly vary
geographically and from one farm to another. Hence, despite
the intuitive link between antibiotic usage in poultry and the
Table 1 | Agents approved as medicating ingredients in Canadian
poultry feed.
Agents Chicken Turkey
Arsanilic acid GP GP
Bacitracin (zinc or methylene disalicylate) GP, NE, EM GP
Zinc bacitracin and procaine penicillin EM
Bambermycin GP GP
Chlortetracycline hydrochloride GP, OT, ST CRD, GP, HE, NE,
OT, spE, ST
Oxytetracycline hydrochloride OT, ST CRD, OT, spE, ST,
SI, SY
Virginiamycin GP, NE
3-nitro-4-hydroxyphenylarsonic acid GP GP
Penicillin procaine GP
Amprolium CO CO
Clopidol CO
Decoquinate CO
Diclazuril CO CO
Halofuginone hydrobromide CO
Lasalocid sodium CO CO
Maduramicin ammonium CO CO
Monensin sodium CO CO
Narasin CO, NE
Narasin and nicarbazin CO
Nicarbazin CO
Robenidine hydrochloride CO CO
Salinomycin sodium CO
Semduramicin sodium CO
Zoalene CO CO
Hygromycin B WO
Piperazine WO WO
Tylosin phosphate NE
Nitarsone (4-Nitrophenylarsonic acid) BH
Novobiocin SY
Abbreviations: BH, blackhead; CO, coccidiosis; CRD, chronic respiratory disease;
EM, early mortality; GP, growth promotion and/or feed efficiency; HE, hexamitia-
sis; NE, necrotic enteritis; OT, other nutritional uses; spE, non-specific enteritis,
ST, stress; SY, synovitis; SI, sinusitis; WO, worms (Government of Canada,
2013a).
emergence of antibiotic resistant bacteria, variations in antimi-
crobial usage make links between the use of specific feed additives
and the selection of specific antibiotic resistant bacteria difficult
to establish (Diarrassouba et al., 2007). Furthermore, the origins
of antibiotic resistant bacteria remain uncertain and the sources
are certainly numerous (Marshall and Levy, 2011). Consequently,
antibiotic resistance in commensal enterococci can be found as
early as in 1-day old chicks (Table 2).
GROWTH PROMOTERS AND PERFORMANCE
Few studies have been performed to demonstrate the economic
benefits of antimicrobial growth promoters in the Canadian
poultry production system (Table 3). In controlled studies, the
effects of diet supplementation with bambermycin, penicillin,
salinomycin, bacitracin, salinomycin-bacitracin, virginiamycin,
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Table 2 | Antibiotic susceptibility phenotypes of some enterococci isolates from day-old chicks before placement and of some enterococci
isolates found in freshly manufactured feed (starter, grower, and finisher).
Antibiotic susceptibility phenotypeb
Categorya Antibiotic Day-old chick isolates Feed isolates
1 2 3 4 5 6 7 Starter Grower Finisher
I Ciprofloxacin R I S S S S S I S I
Daptomycin S S S S S S S S S S
Linezolid S S S S S S S S S S
Vancomycin S I S S I S I S S S
II Erythromycin R S R R I R S S S I
Gentamicin S S S S S S S S S S
Kanamycin R S R R S R S S S S
Lincomycin R R R R R R R R R R
Penicillin S S S S S S S S S S
Q/Dc R S R R S S S R S S
Streptomycin R S R R S R S S S S
Tylosin R S R R S R S S S S
III Chloramphenicol S S S S S S S S S S
Nitrofurantoin S S S S S S S I S S
Tetracycline R R R R R R R S S R
Bacitrcin R R R R R R R R R R
IV Flavomycin R S R R R R S R R R
aCategory indicates antibiotic ranking based on importance in human medicine.
bThe antibiotic susceptibility phenotypes are presented as S, sensitive; R, resistant; I, intermediary, using CIPARS susceptibility breakpoints (Government of Canada,
2013b).
cQuinupristin/Dalfopristin.
chlortetracycline, monensin, and narasin on body weight, feed
intake, feed efficiency, and mortality were evaluated (Diarra
et al., 2007; Bonnet et al., 2009). No significant difference was
noted between the treatment groups for the overall performance
although virginiamycin and penicillin improved feed efficiency.
The experiment conducted by Dumonceaux et al. (2006) found
that dietary inclusion of virginiamycin increased body weight and
improved feed efficiency from days 0 to 15 but that no difference
was noted for bird’s performance parameters for the remainder
of the study. The used of chlortetracycline as a feed supple-
ment at a rate permitted in Canada has been reported to induce
no significant improvement in 21- and 42-day old live body
weights or feed conversion efficiencies (Proudfoot et al., 1988).
Avoparcin an analog of vancomycin, has not been approved in
Canada, however, the growth promotion effect of this agent was
reported in experimental turkeys by a Canadian study (Leeson
and Summers, 1981). The economic effect of removing antibi-
otics used for growth promotion in commercial broiler chickens
was evaluated in a non-randomized study in the USA (Graham
et al., 2007). Positive production changes were associated with
the use of antibiotic agents, but these benefits were insufficient
to offset their cost (Graham et al., 2007). Well-designed on-farm
studies should be encouraged in the Canadian poultry production
system to support or not the use of growth promoting antimicro-
bial agents. With the improved hygienic and biosecurity practices
currently observed in modern poultry production, there is a gen-
uine concern that utilization of antibiotics as growth promoters
in feed might no longer be useful.
GROWTH PROMOTERS AND GUT MICROFLORA
The lives of human beings, livestock and poultry are closely asso-
ciated with microorganisms and the microbiota of their gut plays
an important role in their overall health, productivity and well-
being (Callaway et al., 2008; Ley et al., 2008). The growth of
normal intestinal bacteria varies with the gut environment, and
there is an increasing interest in the commensal components of
the gut microflora associated with food-producing animals (Yost
et al., 2011). Due to public and possible food safety and envi-
ronmental health concerns, the monitoring of the changes in
the microbiome (microbial genomes) as a function of chicken
production practices is imperative. Knowledge of the impacts
of antimicrobial agents on the gut microbiome might lead to
production practices that improve broiler intestinal health and
growth performances.
The use of virginiamycin as a growth promoter was associ-
ated with an increased abundance of bacteria in the duodenal
loop to proximal ileum, with fewer bacteria affected in the dis-
tal regions (ileocecal junction and cecum) indicating that vir-
giniamycin modifies the composition of the chicken intestinal
microbiota (Dumonceaux et al., 2006). Using the 16S rRNA
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Table 3 | Canadian studies evaluating growth promotion gains and health parameters of in-feed antibiotic supplementations.
References Promoter Route Study objectives Conclusions/Observations
Leeson and Summers,
1981
Avoparcin (10 ppm) and robenz
(33 ppm) alone or in combination
In-feed: Turkeys Performance and carcass
grades
Avoparcin improved weight gain
irrespective of coccidiostat robenz
inclusion. Feed utilization and carcass
grades were not influenced by diet
Proudfoot et al., 1988 Chlortetracycline (5.5mg/kg) In-feed: Broiler Growth promotion No further gain
Proudfoot et al., 1990 Lincomycin (2.2 ppm) In-feed or in
water: Broiler
Growth promotion No effect on mortality, efficiency of food
utilization, final body weights or monetary
indices
Dumonceaux et al., 2006 Virginiamycin (20 ppm) In-feed: Broiler Performance; intestinal
microbiota
Improved body weight and feed efficiency
from 0 to 15 days. Increased abundance
Lactobacillus spp. in the proximal
digestive tract with fewer targets affected
in the distal regions
Guban et al., 2006 Bacitracin and monensin alone or in
combination (0.5 g/kg)
In-feed: Broiler Growth performance;
population levels of
Lactobacillus salivarius;
bile salts deconjugation
Bacitracin increased feed intake and
decreased conversion ratio while
improving weight gain and concentrations
of conjugated bile salts. Monensin
increased fat digestibility. Antimicrobials
reduced populations of Lactobacillus
salivarius
Diarra et al., 2007 Bambermycin (2 ppm), penicillin
(2.2 ppm), salinomycin (60 ppm), and
bacitracin (55 ppm) or a combination
of salinomycin (60 ppm) + bacitracin
(ppm)
In-feed: Broiler Growth performances;
pathogen counts;
resistance phenotypes;
resistance determinants
Except for penicillin (improvement of feed
efficiency), no significant effect on
performance; no effect on bacterial count
in the intestine, ceca or litter. Significant
effect on antimicrobial resistance
phenotypes and genotypes
Brisbin et al., 2008 Virginiamycin (11 or 22 ppm) In-feed: Broiler Antibody response Enhancing systemic antibody responses
to some antigens
Gong et al., 2008 Bacitracin (50 ppm) In-feed: Broiler Ileum and caeca
microbiota
Alteration of the microbiota composition in
3-day-old chicks but no effect on the
microbial richness
Bonnet et al., 2009 Bambermycin (2 ppm); penicillin
(2.2 ppm); salinomycin (60 ppm); and
bacitracin (55 ppm); a combination of
salinomycin (60 ppm) + bacitracin
(ppm); chlortetracycline (110 ppm),
virginiamycin (11 or 22 ppm);
monensin (99 ppm); narasin (70 ppm)
In-feed: Broiler E. coli pathotypes and
phylogenetic group
Affect the phylogenetic group and
pathotypes distribution in the gut
Baurhoo et al., 2009 Mannanoligosaccharide (0.2 or 0.5%);
Virginiamycin (16.5 ppm); Bacitracin
(55 ppm)
In-feed: Broiler Performance; intestinal
development; cecal and
litter microbial
populations; carcass
parameters
No effect of antimicrobial on performance
and carcass. Some effect on cecal and
litter microbial population on day 34
Salim et al., 2013 Direct-fed microbial (DFM) such as
Lactobacillus reuteri (0.1%) or a
mixture of L. reuteri, Bacillus subtilis,
and Saccharomyces cerevisiae (0.1%);
Virginiamycin (0.1%)
In-feed: Broiler Performance; immune
response; cecal microbial
population; ileal
morphology
Increase performance from 0 to 21 days.
DFM increases white blood cells,
monocytes and the plasma
immunoglobulin concentrations while
decreases cecal E. coli population
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gene-based polymerase chain reaction followed by denaturing
gradient gel electrophoresis profiling, dietary treatment with bac-
itracin (50mg/kg) has been shown to alter the composition of
the microbiota but did not change its richness (Gong et al.,
2008). The authors demonstrated that the impact of bacitracin
was particularly obvious in 3-day-old chicks. Lactobacilli were
abundant in the cecal microbiota of 3-day-old chicks regard-
less of the dietary treatment with bacitracin (Gong et al., 2008).
Recently, metagenomic sequencing approaches demonstrated
that salinomycin-feeding (60 ppm) has a profound impact on the
dynamics of the chicken ceca microbiome (Fung et al., 2013).
These authors showed that the salinomycin fed group had an
increased abundance of the Elusimicrobia, and a decreased abun-
dance of Chloroflexi, Cyanobacteria, and Synergistetes. For exam-
ple, the abundance of Bifidiobacterium spp. and Lactobacillus spp.
increased significantly in the salinomycin-fed birds compared to
the untreated control group. A functional analysis of environmen-
tal gene tags (EGTs) revealed that in the salinomycin-treated birds
there was an increased abundance of the cell wall and capsule,
iron acquisition, motility and β-lactamase gene categories while
a decrease of multidrug efflux pump EGTs was detected (Fung
et al., 2013). In addition to such Canadian studies, other authors
demonstrated the impact of antimicrobial growth promoters on
the chicken gut microflora (Knarreborg et al., 2002; Torok et al.,
2011; Singh et al., 2013). For example, pyrosequencing followed
by phylogenetic analyses indicated that diet supplementation with
penicillin resulted in an elevated proportion of bacteria of the
phylum Firmicutes from 58.1 to 91.5% and a decreased propor-
tion of members of the phylum Bacteroidetes from 31.1 to 2.9%
in the gut microflora of broilers compared to that observed in
broilers fed with the control non-supplemented diet (Singh et al.,
2013). Besides, the decrease of broiler ileal sucrase and maltase
activities and increase of ileal mucosal immunoglobulin A (IgA)
as well as the increase of Lactobacillus counts were suggested to
be among the effects of bacitracin (55 ppm) and oxytetracycline
(2.5 ppm) that could explain the improvement of feed efficiency
in broilers from days 0 to 21 (Lee et al., 2011).
GROWTH PROMOTERS AND RESISTANCE
The use of antibiotics in poultry production and the attendant
selection of resistant bacteria has been the subject of numer-
ous studies (Aarestrup, 2000; Angulo et al., 2000; O’Brien, 2002;
Butaye et al., 2003; Asai et al., 2005; Anonymous, 2007; Castanon,
2007; Diarra et al., 2007; Diarrassouba et al., 2007). However,
besides the simple principle that exposure to an antimicrobial
agent can select for a resistant bacterium, the selection and dis-
semination of antimicrobial resistance is a complex phenomenon,
which should be examined with ecological and population per-
spectives. Several studies have shown the presence of antibiotic
resistant bacteria (E. coli, Salmonella serovars; Enterococcus spp.,
C. perfringens) in Canadian poultry (Diarrassouba et al., 2007;
Diarra et al., 2010; Slavic et al., 2011; Agunos et al., 2012; St.
Amand et al., 2013).Many antibiotic resistance genes in these bac-
teria have been identified onmobile genetic elements such as plas-
mids, transposons and integrons, allowing their dissemination
among bacteria in the chicken gut or in extra-intestinal environ-
ments. However little is known about the selection, distribution
and dissemination of antibiotic resistance genes in Canadian
broiler chicken productions in relation to the use of specific
therapeutic agents or antimicrobial growth promoters.
Recently, the Canadian Integrated Program for Antimicrobial
Resistance Surveillance (CIPARS) reported a possible association
between ceftiofur-resistant Salmonella enterica serovar Heidelberg
isolated from retail chicken meats and the incidence of ceftiofur-
resistant Salmonella Heidelberg infections in humans across
Canada (Dutil et al., 2010). In the province of Quebec, the
prophylactic use of ceftiofur in broiler chickens coincided with
the rise of the prevalence of ceftiofur resistance in Salmonella
that significantly decreased following voluntary withdrawal of
this antibiotic (Rosengren et al., 2009). In relation to this,
it is noteworthy to mention that the presence of β-lactam
resistant Salmonella enterica serovars Kentucky, Typhimurium,
Enteritidis, and Heidelberg that harbored a variety of important
β-lactamase genes (CMY, TEM, SHV) either alone or in combina-
tion with other resistance genes were reported in chickens (Diarra
et al., 2014). This observation is of concern because the use of
cephalosporins at therapeutic levels can decrease the susceptibil-
ity to other antibiotics such as tetracycline and amikacin which
resistance genes can be co-located on CMY-2 plasmids (Hamilton
et al., 2012).
Using antimicrobial agents in feed, it was demonstrated that
multi-antibiotic-resistant E. coli can colonize and persist in the
broiler gut. Of 256 E. coli isolates analyzed usingDNA-microarray,
88% possessed at least one antimicrobial resistance gene with
42% showing multiple resistance genes (Diarra et al., 2007). The
bacterial phenotypes and distribution of resistance determinants
in E. coli were found to be modulated by feed supplementation
with some of the antimicrobial agents used in broiler chicken
production (Diarra et al., 2007; Thibodaux et al., 2008; Bonnet
et al., 2009). In E. coli, class 1 intregron and the aminogly-
cosides resistance aadA gene were predominantly found in the
isolates from bacitracin and salinomycin treatments (Diarra et al.,
2007), while the streptogramin resistance vatD gene was more
prevalent in enterococci isolated from virginiamycin-treated birds
compared to that found in the control birds (Thibodaux et al.,
2008). Detailed antibiotic resistance genotypes of a variety of
enterococci isolated from the feces and ceca of Canadian com-
mercial broiler chickens were reported (Diarra et al., 2010). Genes
conferring resistance to aminoglycosides (aac, aacA-aphD, aadB,
aphA, sat4), macrolides (ermA, ermB, ermAM, msrC), tetracy-
cline (tetL, tetM, tetO), streptogramins (satG_vatE8), bacitracin
(bcrR), and lincosamide (linB) were detected in corresponding
resistant E. faecium and E. faecalis strains (Diarra et al., 2010).
Although food-producing animals are not considered as a source
of Enterococcus infection in humans, antibiotic-resistant ente-
rococci from these animals may transfer their resistance genes
to bacterial strains infecting humans. Thus, the prevalence of
antibiotic-resistant enterococci, in poultry can constitute a seri-
ous public health problem.
Accurate estimates of the volume of antimicrobials specifi-
cally used as growth promoters in Canadian animal productions
including poultry is lacking. According to the Canadian Institute
of Animal Health estimates reported par CIPARS (Government
of Canada, 2013b), a total of 1,766,126, 1,617,747, 1,615,571, and
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy June 2014 | Volume 5 | Article 282 | 112
Diarra and Malouin Antibiotics in Canadian poultry productions
1,632,364 kg of antimicrobials were distributed in Canada for use
in animals in 2006, 2007, 2008, and 2009, respectively. During
these years, tetracyclines which are broad spectrum agents, ranked
first with 48.0, 46.6, 42.1, and 42.1% of all antimicrobials being
used in 2006, 2007, 2008, and 2009, respectively. The total
amount of tetracyclines used specifically in poultry production is
unknown. However, a high prevalence of tetracycline resistance in
both Gram negative and Gram positive bacteria has been reported
in Canadian poultry farms and poultry meats which could be
related to the extensive used of this antibiotic.
In Gram negative bacteria such as E. coli, tetracycline resis-
tance is frequently mediated by several efflux genes. The tetB,
one of such genes, seems to be the most prevalent in E. coli iso-
lated from Canadian broilers (Diarrassouba et al., 2007; Bonnet
et al., 2009). The tetracycline resistance genes can be associated
with large plasmids, which often carry other antibiotic resistance
genes, heavy metal resistance genes, and/or other pathogenic fac-
tors such as toxins (Forgetta et al., 2012). Hence, selection for any
of these factors selects for these plasmids. Associations between
the β-lactamase (tem), tetracycline (tet), sulfonamide (sulI or
sulII), aminoglycoside [ant(3′′)-Ia (aadA)] and phenicol resis-
tance (floR) genes and class 1 integrons were reported in E. coli
isolated from broilers (Diarra et al., 2007). These associations
increase the risk of selection and dissemination of resistance.
In Gram positive bacteria, the tetL gene encodes a large pro-
tein which confers resistance to tetracycline by active efflux while
tetM encodes a cytoplasmic ribosome protecting protein also
leading to resistance. The tetL and tetM genes were the most
frequently found in association with the ermB gene (encod-
ing resistance to macrolide, lincosamide and streptogramin B
quinupristin-dalfopristin) and the bacitracin resistance gene bcrA
in enterococci isolated from broiler chickens (Diarra et al.,
2010). As mentioned above, bacitracin is one of the antimicro-
bial agents used as a growth promoter and to prevent necrotic
enteritis (Table 1). The use of this antibiotic can co-select for
resistance to other unrelated antibiotics as well, which demon-
strates that the spread of antimicrobial resistance is a complex
phenomenon.
The origin of the antimicrobial resistant bacteria colonizing
the broiler gut needs to be established. In our laboratory, exami-
nation of the gut contents of day-old chicks revealed the presence
of about 1.6 Log CFU of enterococci spp. per gram (Diarra,
unpublished data). Some of these isolates were multi-resistant
to bacitracin, ciprofloxacin, erythromycin, tylosin, flavomycin,
streptomycin, kanamycin, lincomycin, quinupristin-dalfopristin,
and tetracycline (Table 2). In Canada and other countries where
poultry production is intensive, high numbers of broilers are
raised in confined and non-sterile environments. Broilers can
be exposed to such environmental bacteria among which some
could be resistant. For example, chicken feed has been shown
to contain E. coli, Klebsiella and Pseudomonas spp. isolates resis-
tant to four to nine antibiotics (Saleha et al., 2009). In another
study, examination of 23 commercial broiler feed samples and
of 66 samples of raw feeding materials revealed that feedstuffs
and poultry feed are extensively contaminated with resistant ente-
rococci in agreement with our observations (Table 2) and, to a
lesser extent, by E. coli (da Costa et al., 2007). Note that other
factors also contribute to bacterial gut colonization such as the
age of the animals and the microflora may thus vary over time.
This should be taken into account when assessing antimicrobial
resistance prevalence.
ENVIRONMENTAL PERSPECTIVES
Poultry litter, a mixture of materials including bedding, feces and
feathers, is a valuable soil amendment that is rich in nutrients and
can improve soil physical, chemical, and biological properties for
agricultural crops (Brye et al., 2004). Most of the antimicrobial
agents administrated through feed or water are not fully absorbed
in the chicken gut and up to 90% of the administered dose of
some of the antimicrobials can be excreted in the feces. Residues
of chicken feed additives such as bacitracin, chlortetracycline,
monensin, narasin, nicarbazin, penicillin, salinomycin, and vir-
giniamycin can be detected in the litter at concentrations ranging
from 0.07 to 66mg/L depending on the compounds (Furtula
et al., 2010). Such a litter, if not treated to remove these com-
pounds, may be an important source of antimicrobial residues
when used as fertilizer. These residues also could contribute in
the selection of antibiotic resistant bacteria as demonstrated for
ceftiofur residues by Call et al. (2013).
Litter can be a source of antimicrobial resistant bacteria as well.
Various antibiotic resistant E. coli strains harboring genes con-
ferring resistance to β-lactams (blaCMY−2, blaTEM), tetracycline
(tetAB) and streptomycin (strAB) have been reported to survive
for several months in soil following late summer litter applica-
tion (Merchant et al., 2012). Estimating survival of antibiotic
resistant and potential pathogenic bacteria in soil amended with
raw untreated litter from broiler fed antimicrobial supplemented
diets is essential for developing intervention strategies against
resistant pathogens and toward pathogen control in agricultural
soils.
Drinking water should be very low in bacterial counts and no
pathogenic microorganism should be detected in it. From 2005
to 2006, a bacteriologic study on 353,388 drinking water sam-
ples from private wells in Alberta and Ontario found that 4.6% of
these samples were contaminated with E. coli. Antibiotic suscepti-
bility tests done on 7063 of these E. coli isolates showed that 10.5%
were resistant mainly to tetracycline, sulfonamides, β-lactams or
aminoglycosides (Coleman et al., 2013). These authors reported
that such antibiotic resistant E. coli were more commonly isolated
from farms housing chickens or turkeys than from properties
without poultry.
Primary biological aerosols (airborne biological particles
derived from, or which are composed of living microorganisms)
are of special concern in poultry barns and slaughterhouses,
where the high number of chickens handled in these facilities
leads to the presence of substantial concentrations of bacteria and
other microorganisms in air (Donham et al., 2000). Antibiotic-
resistant bacteria have been reported in broiler chicken air
(Brooks et al., 2010; Vela et al., 2012). Biofilm forming staphylo-
cocci harboring genes conferring resistance to tetracycline (tetK),
lincomycin (linA), erythromycin (ermB), and β-lactams (blaZ)
were isolated from air inside and outside broiler production facil-
ities (Vela et al., 2012). The airborne dispersion of antimicrobial
resistant bacteria should not be underestimated since the presence
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of pathogenic bacteria in air represents a potential risk to poultry
farm workers and to people working or living near these facilities.
CONCERNS ABOUT FOOD SAFETY AND SPREAD OF
ANTIBIOTIC RESISTANCE
Antibiotic-resistant bacteria constitute a major food safety issue.
Antibiotic-resistant bacterial pathogens such as Salmonella or
E. coli can infect humans through contact or consumption of
contaminated food while non-pathogenic resistant isolates can
transfer their resistant genes to human pathogens. Although mul-
tifactorial, practices contributing to the selection of antibiotic
resistant bacteria include antibiotic use in livestock feed, and
concerns about food safety and reduced efficacy of antibiotic
treatment in human medicine have stimulated expert groups to
action (Mathew et al., 2007; Laxminarayan et al., 2013).
Antibiotic resistance has become a worldwide threat to pub-
lic health. For example in the United States of America (USA),
according to a recent report from the Centers for Disease Control
and Prevention (CDC), at least 2 million people become infected
with “antibiotic resistant bacteria” among which at least 23,000
people die each year as a direct result of these infections (CDC,
2013). The USA National Antimicrobial Resistance Monitoring
System (NARMS) assisted by the Food and Drug Administration
(FDA) and the Department of Agriculture (USDA), monitor
antimicrobial susceptibility of enteric bacteria from humans,
retail meats and food-producing animals, in order to make deci-
sions related to the approval of safe and effective antimicrobial
drugs for animals (NARMS, 2012). In Canada, the Public Health
Agency of Canada and the CIPARS track antimicrobial resistance
to generate data helping to limit the spread of antibiotic resistant
bacteria. More so, initiatives that collect data on commensal and
environmental strains as reservoirs of antibiotic resistance genes
are invaluable (Marshall and Levy, 2011). It is thought that the
frequency of resistance genes in commensals may act as a marker
of the emergence of resistance in pathogens (www.roarproject.
org).
Concerns for safe food and effective medical antibiotics have
pressured authorities for elimination of antibiotics as growth
promoters as well as those of medical importance in animal pro-
duction. Despite incomplete data, there were sufficient genuine
and reasonable arguments for implementing such regulations in
the European Union and similar policies and recommendations
in North America were made based on the precautionary prin-
ciple. For example, the CDC supports the strategy of the FDA
to promote the judicious use of antibiotics that are important
in treating humans. In Canada, there is a variety of efforts that
follow this trend (Agunos et al., 2012). The Canadian Veterinary
Medical Association is developing prudent and judicious antimi-
crobial use guidelines for veterinarians working with swine,
beef or dairy herds and poultry flocks. The Veterinary Drugs
Directorate (VDD) of Health Canada, which is responsible for
the approval and registration of all antimicrobials for use in agri-
culture, is developing a risk management strategy to reduce the
human health impact of antimicrobial resistance due to use of
antimicrobials in animals.
Still, efficient control of foodborne pathogens remains a con-
cern (Smadi and Sargeant, 2013) and removal of non-therapeutic
antimicrobials from animal production may possibly increase the
prevalence of pathogens in the animal gut and the frequency
of foodborne illnesses. Alternatives to antibiotics are therefore
required.
ALTERNATIVES TO ANTIBIOTICS
Public pressure and concerns about food and environmen-
tal safety (antibiotic residues, spread of antibiotic genes and
antibiotic-resistant pathogens) have driven researchers to actively
look for alternative approaches that could eliminate or decrease
the use of antibiotics while maintaining production yields and
low mortality in poultry production. As discussed in previ-
ous sections, the biological basis for antibiotic effects on ani-
mal growth efficiency is most likely derived from effects on
the intestinal microbiota, which in turn may reduce oppor-
tunistic subclinical infections, reduce the host response to the
gut microflora, decrease competition for nutrients, and improve
nutrient digestibility consequent to a reduction in some micro-
bial fermentation by-products (Dibner and Richards, 2005). With
such pleiotropic effects, it will be difficult to find alternatives to
antimicrobials administered for prevention or provided as growth
promoters in feed.
Several alternative strategies to antibiotics in poultry and live-
stock production are under investigation (Dahiya et al., 2006;
Zakeri and Kashefi, 2011; Seal et al., 2013). Individual strate-
gies examined included direct-fed microbial (probiotics) and live
microbial feed supplements which beneficially affect the host ani-
mal by improving its intestinal balance (Rajput et al., 2013; Salim
et al., 2013); prebiotics, indigestible feed ingredients that ben-
eficially affect the host by selectively stimulating the activity of
beneficial bacteria resident in the animal tract (Patterson and
Burkholder, 2003; Baurhoo et al., 2009; Samanta et al., 2013); vac-
cination (Desin et al., 2013) and immune-stimulation through
cationic peptides and cytokines (Asif et al., 2004; Kogut et al.,
2013); bacteriocins and antimicrobial peptides (Joerger, 2003;
Svetoch and Stern, 2010); bacteriophages (Huff et al., 2005, 2013;
Zhang et al., 2013); organic acids with antimicrobial activities;
herbs, spices and other plant extracts (González-Lamothe et al.,
2009); and controlled organic productions with emphasis on diet
formulation and ingredient selection, cereal type and dietary pro-
tein source and level (Drew et al., 2004; O’Bryan et al., 2008).
To date, none of these strategies have been systematically imple-
mented. Consequently, exploration for new approaches to pre-
vent poultry diseases and colonization of poultry by foodborne
pathogens is continuing worldwide.
BERRIES AS A GENERIC SOURCE OF BIOACTIVE MOLECULES
Natural products as tools for disease prevention and health main-
tenance have reached public acceptance leading to an accelerated
research in this area. There are now abundant reports of plant
products with bioactivities against a wide variety of pathogenic
bacteria. Multiple classes of antibacterial products, including
phenolic acids and polyphenols, phenanthrenes, flavonoids, and
terpenoids have been described and reviewed (González-Lamothe
et al., 2009).
Some products may have antibacterial activities of their own
by significantly altering growth or bacterial cell structures. Others
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which may be defined as “antibiotic potentiators or adjuvants”
could allow reduction of antibiotic usage. Some may have anti-
virulence effects or alter quorum-sensing necessary for efficient
pathogenesis. Besides, others, defined as “immuno-stimulants”
could assist the host immune system to adequately respond to
the pathogen invasion, while others may positively affect the
intestinal microbiota. Knowing that subclinical diseases caused
by pathogens can impact productivity, this review presents
some results on the potential of cranberry extracts to control
pathogenic bacteria.
Cranberries, Vaccinium macrocarpon Aiton (Ericales:
Ericaceae), are indigenous to wetlands of central and eastern
North America (Eck, 1990). Canadian cranberry productions
increased from 95,655 tons in 2009 to 134,575 tons in 2013. Most
of the productions come from British Columbia, Quebec, New
Brunswick, Nova Scotia and Prince Edward Island (Statistics
Canada, 2013). Polyphenolic compounds are widely distributed
in higher plants and are integral parts of the human diet. An
important and often overlooked group of polyphenols is the
proanthocyanidins (condensed tannins).
Particular interest is being shown in the proanthocyanidins
from cranberry (Foo et al., 2000). Flavonoids in cranberry may
reduce or prevent atherosclerosis by preventing oxidation of low
density lipids (Reed, 2002). Cranberry proanthocyanidins at a
concentration of 75μg/mL were found to inhibit the adher-
ence of E. coli to urinary epithelial cells, preventing or miti-
gating thus UTI (Foo et al., 2000; Howell and Foxman, 2002).
Cranberry extracts were also reported to inhibit the sialyllactose-
specific adhesion of Helicobacter pylori to immobilized human
mucus, erythrocytes, and cultured gastric epithelial cells (Burger
et al., 2002). Because the inhibitors of adhesion are not neces-
sarily bactericidal, the selection of resistant strains is unlikely to
occur and anti-adhesion agents represent an interesting thera-
peutic strategy (Sharon and Ofek, 2002). The potential of plant
tannins, including proanthocyanidins, as alternatives to growth
promoters in poultry has recently been reviewed by Redondo
et al. (2014). It is expected that the value of cranberry-based
food and nutraceutical products will remain high as health
benefits of cranberry become more firmly established. Recent
studies suggest that the potential health effects of cranberry
are associated with its phytochemical constituents (Blumberg
et al., 2013). Furthermore, studies have revealed that extracts
from these sources can affect various bacterial functions includ-
ing disruption of their cell envelope, which parallels that of
some antibiotics widely used as growth promoters in the poultry
industry.
It has however been difficult to isolate specific active compo-
nents from plant extracts which often consist of a mixture of a
large number of structurally related compounds (Puupponen-
Pimiä et al., 2005). These compounds have varying degrees of
bioactivity or even opposing effects (growth inhibitors vs. growth
stimulants) and even some with cytotoxicity (Jaki et al., 2008).
Also, the spectrum of activity or the mode of action of purified
components is often very narrow or non-specific and the use of
berry extracts or pomace containing mixtures of bioactive com-
pounds has become an attractive alternative to create an added
value to berry by-products.
The antimicrobial activities of cranberry extracts were evalu-
ated against important pathogenic Gram negative bacteria such
as E. coli and Salmonella enterica serovar Typhimurium, which
is often associated with poultry (Wu et al., 2008; Harmidy
et al., 2011). It has been reported that treatment with cranberry
proanthocyanidins (CPACs) inhibited Salmonella invasion and
enteropathogenic E. coli pedestal formation, likely by perturb-
ing the host cell cytoskeleton by CPACs rather than by an effect
on bacterial virulence itself (Harmidy et al., 2011). Dehydrated,
crushed cranberries or purified CPACs were also shown to inhibit
the expression of the flagellin gene (fliC) in uropathogenic E. coli
(Hidalgo et al., 2011).
In order to study the pleiotropic effects of cranberry extracts
on E. coli, we (Gattuso et al., 2008) and others (Lin et al., 2011)
have used a DNA array-based approach in an attempt to corre-
late specific transcriptional signatures with modes of action. The
effects observed on the transcriptome of E. coli exposed to cran-
berry extracts correlated with known characteristics of cranberry
constituents such as condensed tannins (flavonoids) and pheno-
lic acids that could possibly act as iron chelators. In view of these
results, cranberry extracts could be used to perturb bacterial iron
homeostasis and improve nutritional immunity in the gut (Hood
and Skaar, 2012).
Based on our own experience, commercially available cran-
berry products like Nutricran®90 (NC90) and some of our
own cranberry extracts yielded stronger growth inhibition effects
against Gram positive pathogens such as Staphylococcus aureus
(Diarra et al., 2013), Listeria monocytogenes (Block et al., 2012),
and Clostridium perfringens (Delaquis et al., 2010), although the
minimal inhibitory concentrations of the cranberry products
were several times higher than that of conventional antibiotics
such as penicillin. Similarly to work done with E. coli, transcrip-
tional analyses by microarrays allowed determining the modes of
action of the cranberry product NC90 against S. aureus (Diarra
et al., 2013). The effect of cranberry on the S. aureus transcrip-
tome yielded the identification of several bacterial genes known
to be up-regulated by the presence of cell-wall acting antibi-
otics, such as oxacillin, vancomycin, and daptomycin (Singh et al.,
2001; Utaida et al., 2003; Muthaiyan et al., 2008), as represented
in Figure 1. More specifically, a group of genes known as the
cell wall stress regulon was strongly up-regulated and clearly
demonstrated an effect of cranberry on S. aureus cell wall biosyn-
thesis. Ethanol extraction of pomaces (pressed cakes) from fresh
fruits also produced a cranberry fraction (FC111) modulating
the same marker genes as demonstrated by qPCR. S. aureus cell
surface disruption by cranberry is also supported by work from
Wu et al. (2008) and by cell wall biosynthesis assays (Diarra
et al., 2013). Besides, it was noted that NC90 and FC111 also
modulated the expression of some S. aureus genes (like lytM,
Figure 1) that respond to membrane depolarization, as provoked
by carbonyl cyanidem-chlorophenylhydrazone (CCCP) and dap-
tomycin (Muthaiyan et al., 2008). Interestingly, cranberry extracts
also strongly down-regulated capsular biosynthesis genes, an
effect that was corroborated by electron microscopy (Figure 1).
Listeria spp. are important foodborne pathogens that can be
associated with various foods including fresh and frozen meat
and poultry. Cranberry fraction FC111 also showed bactericidal
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FIGURE 1 | Venn diagrams showing some of the S. aureus genes up-
and down-regulated following exposure to cranberry (left). The
transcriptional signature resembles to that of the cell wall stress stimulon
provoked by peptidoglycan biosynthesis inhibitors such as vancomycin,
oxacillin, and to some extent daptomycin. Compounds causing membrane
depolarization like daptomycin and CCCP also share a common
transcriptional signature with cranberry. Genes up- and down-regulated are
represented by up and down arrows, respectively. Genes affected by
cranberry also include those involved in capsular polysaccharide
biosynthesis (Diarra et al., 2013), which correlates with the presence of a
thinner capsule at the surface of S. aureus (lower right panel compared to
the untreated control, top right panel). The capsule material (indicated by
arrows) was labeled using polycationic ferritin as described before (Diarra
et al., 2002).
effects as well as antibiofilm formation activities against Listeria
monocytogenes (Block et al., 2012). Apostolidis et al. (2008)
reported a proline dependent inhibition of L. monocytogenes by
combinations of phenolic extracts of oregano and cranberry in
both broth and cooked meat studies. These data indicate that
further examination of the antimicrobial potential of cranberry
extract is warranted (Wu et al., 2008).
The multiple biological effects of cranberry observed against
E. coli, Salmonella, S. aureus, C. perfringens, and Listeria, certainly
reflect the complexity of its composition and physical properties.
The cranberry tannins include polyphenols and more specifi-
cally anthocyanins, flavonols and flavan-3-ols (Puupponen-Pimiä
et al., 2005). Flavonoids, including anthocyanins and proantho-
cyanidins, are believed to be the major antimicrobial components
(Puupponen-Pimiä et al., 2001). At this time, our mass spectrom-
etry analysis of cranberry fraction FC111 could not determine if
the observed antibacterial activity originates from iridoids, phe-
nolics, or flavonoid components. Besides, we showed that the
cranberry fraction FC111 obtained from pomace is an excel-
lent natural polyphenolic product with potent antioxidant and
vasorelaxant properties (Harrison et al., 2013), which combined
with its antibacterial activities might represent an interesting
alternative in poultry production. In this regard, a poultry feed-
ing trial using a commercial whole cranberry fruit extract showed
that a concentration of 40mg of cranberry extracts per kg of
feed induced low early mortality rates (improvement by 40%
compared to the control) in birds. The mechanism of action
leading to this improvement remains to be determined. However,
diet supplementation with such extracts caused a shift of the
intestinal tract bacterial population while not altering any broiler
meat properties (Leusink et al., 2010).
CYCLIC DIGUANOSINE MONOPHOSPHATE (C-DI-GMP)
c-di-GMP is a bacterial intracellular second messenger control-
ling diverse bacterial processes. This molecule is important for a
wide range of pathogenic agents as it is involved in the modula-
tion of the infection process through modulation of motility, cell
adhesion and biofilm formation (Tamayo et al., 2007; Bordeleau
et al., 2011). However, c-di-GMP is also a potent immuno-
stimulatory agent that can modulate the host immune response
and several reports demonstrated its adjuvant and therapeutic
properties (Brouillette et al., 2005; Karaolis et al., 2007; Ogunniyi
et al., 2008; Hu et al., 2009). Moreover, the ability of c-di-GMP
as a mucosal adjuvant was also documented (Ebensen et al.,
2007; Zhao et al., 2011). c-di-GMPmight thus represent an inter-
esting alternative to non-therapeutic antibiotics used in poultry
production.
The infectious bursal disease virus (IBDV, Gumboro dis-
ease) is one of the major immuno-suppressive viruses affecting
broilers. This virus is highly contagious and represents a major
economic threat in poultry production worldwide (Bumstead
et al., 1993). Since the effects of c-di-GMP on chicken immune
responses had not yet been investigated, we evaluated the humoral
immune response following oral administration or intramuscular
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injection of c-di-GMP in conjunction with the IBDV vac-
cine S-706 in broiler chickens (Fatima et al., 2011). Results
indicated that c-di-GMP stimulated IgA production in serum
and confirmed the potential of this molecule as a mucosal
adjuvant.
Asmentioned above, an enteric pathogen of particular concern
in poultry is C. perfringens Type A, the causative agent of necrotic
enteritis (Timbermont et al., 2011). Hence, in an effort to explore
strategies to controlC. perfringens, we investigated the potential of
c-di-GMP in a broiler challenge model (Fatima et al., 2013). We
found that c-di-GMP can modulate C. perfringens colonization
in the host ceca with no noticeable effect on the microbiota and
the commensal bacterial community of the intestine. It will be
interesting to investigate in more details the value of c-di-GMP as
an in-feed additive in poultry production.
CONCLUSION
Antibiotics are important tools for the treatment of old and
emerging infectious diseases. Their efficacy for this purpose
should be preserved as it is now well documented that their
abusive and inappropriate use in humans, livestock and poul-
try selects for antibiotic resistant bacteria, compromising thus
their therapeutic efficacy. One of questionable practices in ani-
mal agriculture is the use of non-therapeutic antimicrobials for
growth promotion. Even if this practice was determinant in the
past, its advantage in current modern agriculture including poul-
try production needs to be re-evaluated because of the actual
prevalence of antibiotic resistant bacteria in livestock and poultry
and their products worldwide. The presence of multi-drug resis-
tant commensal bacteria (Escherichia spp., Enterococcus spp.) and
foodborne pathogens such as non-typhoid Salmonella associated
with poultry are some of the examples among others. It is imper-
ative to determine the exact sources and ecology of these resistant
bacteria in order to develop strategies to stop their spread. It is
also urgent to develop alternatives to antimicrobial growth pro-
moters that will not compromise livestock and poultry health
as well as the actual industry productivity. Canadian studies in
this area identified some promising sources of alternatives to
antibiotics which have been discussed here.
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Antibiotics have been included in the formulation of feed for livestock production for more
than 40 years as a strategy to improve feed conversion rates and to reduce costs.The use of
antimicrobials as growth-promoting factors (AGP) in sub-therapeutic doses for long periods
is particularly favorable for the selection of antimicrobial resistant microorganisms. In the
last years, global concern about development of antimicrobial resistance and transference
of resistance genes from animal to human strains has been rising. Removal of AGP from
animal diets involves tremendous pressure on the livestock and poultry farmers, one of the
main consequences being a substantial increase in the incidence of infectious diseases
with the associated increase in the use of antibiotics for therapy, and concomitantly,
economic cost. Therefore, alternatives to AGP are urgently needed. The challenge is to
implement new alternatives without affecting the production performances of livestock
and avoiding the increase of antimicrobial resistant microorganisms. Plant extracts and
puriﬁed derived substances are showing promising results for animal nutrition, either
from their efﬁcacy as well as from an economical point of view. Tannins are plant derived
compounds that are being successfully used as additives in poultry feed to control diseases
and to improve animal performance. Successful use of any of these extracts as feed
additives must ensure a product of consistent quality in enough quantity to fulﬁll the actual
requirements of the poultry industry. Chestnut (hydrolysable) and Quebracho (condensed)
tannins are probably the most readily available commercial products that are covering those
needs. The present report intends to analyze the available data supporting their use.
Keywords: tannins, antibiotics, poultry, growth promoting factors, necrotic enteritis, plant extracts, animal health
INTRODUCTION
Antimicrobial compounds were initially added to feed at thera-
peutic doses for treatment and prevention of infectious diseases
but soon the growth promoting effect of antibiotics was observed.
Therefore, since the beginning of the 1950s antibiotics have been
added to feeds to improve feed utilization and growth of farm ani-
mals, reducing the cost of production (Moore and Evenson, 1946;
Jukes et al., 1950). The use of antimicrobials as growth-promoting
factors (AGP) should be distinguished from therapeutic and pro-
phylactic use of antibiotics that are administrated at higher doses
and for short periods of time.
The mode of action of AGPs is not yet fully understood.
Different potential mechanisms have been proposed to explain
AGP-mediated growth enhancement (Gaskins et al., 2002; Dibner
and Richards, 2005; Page, 2006). The most accepted mechanism
would be through modulation of the gut microbiota, which plays
a critical role in maintaining the host health (Tuohy et al., 2005).
Microbiota composition inﬂuences the intestinal environment
and the development and responses of the host immune system
against pathogenic and non-pathogenic antigens (Cebra, 1999;
Kelly and Conway, 2005).
The poultry industry has massively adopted the use of AGPs,
but comparatively, little research has been conducted in order to
systematically evaluate the potential effects that antibiotics may
have on the dynamics of the overall gut microbiota of chicken.
Thus, studies are indispensable to elucidate the impact on bacte-
rial community, including selection and distribution of antibiotic
resistance genes among commensal bacteria in chickens fed with
AGP (Diarra et al., 2007; da Costa et al., 2013).
The use of AGP in livestock and their role in selecting antibi-
otic resistant bacteria have been extensively reviewed (Butaye et al.,
2003; Wegener, 2003; Kazimierczak et al., 2006; Landers et al.,
2012). It is important to remark that AGP are used in sub-
therapeutic doses for long periods, a situation that is particularly
favorable to select antimicrobial-resistant microorganisms. Dur-
ing the last several years, global concern about development of
antimicrobial resistance and transference of resistance genes from
animal to human strains is rising (Salyers et al., 2004; Mathur and
Singh, 2005; Devirgiliis et al., 2013). The potential risk of resis-
tance generation and transmission led to the ban of the use of
antibiotics as growth promoters in the European Union since year
2006. Although the relative contribution of foodborne transmis-
sion to antimicrobial resistance in humans remains unknown, it
does exist and is likely to bemore substantial than currently appre-
ciated (Collignon and Angulo, 2006). Some studies suggest that
the majority of antibiotic-resistant Escherichia coli strains carried
by people may have been originated in food animals, particularly
from poultry (Johnson et al., 2006).
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In this context and to preserve the effectiveness of important
human drugs (Casewell et al., 2003) the FDA prohibited the use of
ﬂuoroquinolones in chickens and turkeys in the United States,
based on evidence that use of these antimicrobials in poultry
caused development of resistance of thermoﬁlic Campylobacter
species. These resistant strains can be transmitted to humans with
consequences to public health (Nelson et al., 2007). Selection of
resistance in non-pathogenic bacteria is another potential risk.
Some resistance genes may be present in non-pathogenic bac-
teria and then can be transferred to pathogenic microorganisms.
Fairchild et al. (2005) showed that the oral administration of tetra-
cycline did not induce signiﬁcant changes in the chicken cecal
bacterial community but they found that Enterococcus spp. sus-
ceptibility tests showed an increase on tetracycline MICs. These
bacteria were positive for resistance genes, tet(M), tet(L), tet(K),
and tet(O), which can be transferred to Campylobacter jejuni, con-
ferring tetracycline resistance. The authors suggested that complex
ecological and genetic factors could contribute to the preva-
lence and transfer of antibiotic resistance genes in the chicken
production environment.
Despite the inconvenience of adding AGP to feed, it is gener-
ally accepted that intensiﬁcation in modern poultry production
and the increase in related stressors, e.g., feed changes or diet
imbalances, may have different negative effects on animal health,
e. g., reduced immune functions, high exposed susceptible pop-
ulation (Pinchasov and Noy, 1993). This may predispose broilers
to colonization of the gastrointestinal tract by bacterial pathogens,
producing a threat to bird’s health and food safety. Removal of
antibiotic AGP from animal diets implies a tremendous pressure
on the livestock and poultry farmers, one of the main conse-
quences being a substantial increase in the incidence of infectious
diseases with the associated augment in the use of antibiotics for
therapy (Inborr, 2001; Casewell et al., 2003; Grave et al., 2006).
Salmonella spp., Campylobacter jejuni and Clostridium perfringens
are considered to be the most important emerging and increasing
threat for poultry and human health (Van Immerseel et al., 2004;
Humphrey et al., 2007). The challenge is to implement new alter-
natives without affecting the production performances of livestock
and also avoid the increasing of antimicrobial resistance.
Alternatives to AGPs had its origin in public health programs
where nutritional interventions such as probiotics and prebiotics
are used to ameliorate chronic human conditions such as inﬂam-
matory bowel disease (Guarner et al., 2002; Damaskos and Kolios,
2008) and irritable bowel syndrome (Fooks and Gibson, 2002).
Formulation of diets focused on speciﬁc effects on gut health is
becoming a reality in the monogastric animal industries because
the maintenance or enhancement of gut health is essential for
the welfare and productivity of animals when antibiotics are not
allowed in feed. In this scenario raw plant extracts and derived
tannins are showing promising results for food animal production
(Huyghebaert et al., 2011).
PLANT EXTRACTS AND TANNINS
Plants synthesize many aromatic substances, most of which are
secondary metabolites. In many cases, these substances serve
as plant defense mechanisms against predation. Some, such as
terpenoids, give plants their odors; others (quinones and tannins)
are responsible for plant pigment, others are responsible for plant
ﬂavor (e.g., the terpenoid capsaicin from chili peppers). Tannins
are water-soluble polyphenolic compounds of variable molecu-
lar weights abundantly found in nature which have the ability to
precipitate proteins (Spencer et al., 1988; Cowan, 1999). Tannins
can be classiﬁed into condensed and hydrolysable (Scalbert, 1991;
Haslam, 1996). Hydrolyzable tannins are based on gallic acid, usu-
ally as multiple esters with D-glucose, while the more numerous
condensed tannins (often called proanthocyanidins) are derived
from ﬂavonoid monomers. Current scientiﬁc evidence suggests
that there is signiﬁcant potential in the use of tannins to enhance
nutrition and animal health, particularly for ruminants such as
cattle (Frutos et al., 2004). Many studies of phenolic compounds
(resveratrol, quercetin, rutin, catechin, proanthocyanidins) have
beenpresent in the last few years,most of theseworkswere directed
to improvements of human health and they demonstrate that tan-
nins havemultiple biological activities, including cardioprotective,
anti-inﬂammatory, anti-carcinogenic, antiviral, and antibacterial
properties attributed mainly to their antioxidant and antiradical
activity (Frankel et al., 1993; Teissedre et al., 1996; Santos-Buelga
and Scalbert, 2000). Recent studies in veterinary medicine men-
tion that these effects are reﬂected in a better growth performance
in different species of food producer animals. Tannins are also able
to reduce the risk of livestock disease and transmission of zoonotic
pathogens in a sustainable and environmentally friendly manner.
Recent reports of the use of tannin in poultry show promising
results (Van Parys et al., 2010; Anderson et al., 2012; Redondo et al.,
2013b; Tosi et al., 2013).
HISTORICAL CONSIDERATION OF TANNINS AS
ANTI-NUTRITIONAL FACTORS
Traditional concepts in poultry nutrition consider tannins as
anti-nutritional factors. In contrast with the effect on ruminant
animals where tannins in the diet may have considerable nutri-
tional beneﬁts, tannins are generally considered undesirable in
simple-stomached animals feed. In monogastric farm animals
it is commonly accepted that dietary tannins reduce digestibil-
ity (in particular of crude protein) and consequently growth
performance (Treviño et al., 1992; Smulikowska et al., 2001). In
poultry, a considerable number of publications have shown the
anti-nutritional effects of tannins in chicken feeding; these sub-
stances induce a worsening of productive performances as a
consequence of decreasing voluntary feed intake and organic mat-
ter digestibility, especially the protein component (Barroga et al.,
1985; Longstaff and McNab, 1991; Garcia et al., 2004; Longstaff
and McNab, 2007).
Reports of anti-nutritional effects of tannins are mostly based
on assays performedwith relatively high concentrations of tannins
in feed, mainly using puriﬁed condensed tannins or plant with
excess of tannins as may be the tannic acid from sorghum grains.
These experiments showed adverse effects such as decreased nutri-
ent utilization, animal productivity, and death in certain animals.
This limited experimental information and the fact that tannins
act as a defense mechanism in plants against herbivores have been
the origin of the widespread concept that tannins are negative
for animals. However, it is now known that their beneﬁcial
or detrimental properties depend upon their chemical structure
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(generally associated with the plant origin) and dosage, besides
other factors such as animal species, the physiological state of the
animal and composition of the diet. More recent evidence suggest
that a moderate tannin level is able to improve both nutrition and
health status in monogastric animals.
IMPACT ON POULTRY PRODUCTIVE PERFORMANCE
Despite that tannins have been traditionally considered as anti-
nutritional factors, is it now known that these substances can be
beneﬁcial to poultry. However, as it previously mentioned, several
factors must be considered and evaluated such as the ﬁnal con-
centration in feed, the structure of the compounds, the applied
process during feed preparation, and plant factors, which may
affect ﬁnal tannin impact on birds digestive function and global
health (Hagerman and Butler, 1980). Studies with different puri-
ﬁed tannins conﬁrm that chemical properties, like astringent taste
and protein binding are variable among tannin extracts (Hofmann
et al., 2006). Schiavone et al. (2008) showed that the use of chest-
nut extract in poultry feeding does not inﬂuence feed digestibility,
carcass quality or nitrogen balance. In fact, it has a positive inﬂu-
ence in growth performance if included in the diet up to 0.2% (on
dry matter). Similarly Marzoni et al. (2005) studied the dietary
effects of quebracho tannins in growing pheasants and demon-
strated that the inclusion of 2% in feed did not affect growth
performances. Furthermore, some authors mention that adminis-
tration of chestnut tannins may change the droppings consistency,
resulting in ﬁrmer droppings in treated groups which positively
affect the litter status and thus improving the overall health status
and welfare of chickens in intensive production systems. More-
over, the chestnut fruit content of phenolics (gallic and ellagic
acid), which have been linked to various positive effects on human
health such as antioxidant activity, a decrease in the risk of cardio-
vascular diseases, anticancer mechanisms, and anti-inﬂammatory
properties (de Vasconcelos et al., 2010). Tannins also can be used
in combination with other AGPs alternatives, as probiotics, show-
ing a synergist effect in the promotion of gut health. A recent
work reported that chestnut extracts exhibited a surprising effect
in improving the tolerance to gastric transit of Lactobacilli, while
chestnut ﬁber mainly improved the tolerance to bile juice (Blaiotta
et al., 2013).
Although tannins can have beneﬁcial effects on the digestion
and therefore animal performance when incorporated into ani-
mal diets, their primary mode of action is often not sufﬁciently
known to explain the ﬁnal in vivo effects. Some authors suggest
that low concentration of tannins can improve palatability of feed
and raise performance of monogastrics by stimulating feed intake
(Windisch and Kroismayr, 2006). Others suggest that stimulation
of digestive secretions is often considered to be a core mode of
action (e.g. Lee et al., 2003). Nevertheless, antimicrobial proper-
ties seem to be the most relevant mode of action, especially in
young animals. In general terms, like AGPs, plant derived com-
poundswouldbe involved in themodulationof thehighly complex
interaction between microbiota and the gastrointestinal tract. The
resulting relief of the animal host from microbial activity and their
undesired products might be responsible for the lower immune
defense costs (Windisch and Kroismayr, 2006; Kroismayr et al.,
2008). However, the complexity of the interactions and dynamics
of the gut microbiota makes it very difﬁcult to deﬁne such effects
in quantitative terms.
IMPACT ON POULTRY HEALTH
Over the last few years, the dietary role of tannins is receiving
increasing interest as they may reduce the number of gastroin-
testinal parasites in mammals (Athanasiadou et al., 2000; Butter
et al., 2002; Min et al., 2005) and birds (Marzoni et al., 2005). Tan-
nins, such as condensed tannins from green tea or quebracho,
have proven to have antimicrobial activity (Sakanaka et al., 2000;
Elizondo et al., 2010) and affect gastrointestinal bacteria coloniza-
tion in chickens and pigs (Hara et al., 1995; Hara, 1997). Multiple
reports suggest the efﬁcacy of tannins or plant extracts in the
control of zoonotic pathogens like Campylobacter and Salmonella.
Campylobacter spp. is one of the leading sources of human
bacterial diarrhea worldwide, with Campylobacter jejuni and
Campylobacter coli representing the most frequently involved
species (Adak et al., 1995; Kapperud et al., 2003). One of the
main sources of infection is considered to be foods of poultry ori-
gin, intestinal carriage rate within individual ﬂocks often exceed
80% (Anderson et al., 2012). Before AGP banning in determined
countries an increase in the incidence of antimicrobial resis-
tance was observed in this food borne pathogen (Desmonts et al.,
2004). The antimicrobial activity of various hydrolysable and con-
densed tannin-rich extracts against Campylobacter jejuni reveals
that both types of tannins inhibit the growth of this bacterium
(Nohynek et al., 2006; Gutierrez-Banuelos et al., 2011; Anderson
et al., 2012). It has been observed that condensed tannins may be
less efﬁcient than hydrolysable tannins in controllingCampylobac-
ter jejuni when high concentrations of amino acids and soluble
proteins are present (Anderson et al., 2012). The efﬁcacy of adding
selected tannins to poultry feed to diminish the in vivo incidence
of Campylobacter spp., needs to be evaluated.
Salmonella serovar Enteritidis is one of the foodborne
pathogens most commonly associated with the consumption of
poultry products. Control strategies of the disease in humans are
based on reducing contamination during slaughter and Salmonella
Enteritidis load in birds. This was achieved with the use of AGP,
which generates residues in meat and eggs and favors the selection
of multi-resistant strains of Salmonella and other pathogens. Van
Parys et al. (2010) found that chestnut (Castanea sativa) derived
tannins were able to inhibit the in vitro growth of Salmonella
typhimurium, but had no effect on the excretion of the bacte-
ria in an infection model in pigs. Quebracho (Schinopsis lorentzii)
raw extract shows bacteriostatic effect on Salmonella Enteritidis in
vitro, andwhenused in an experimental infectionmodel inbroilers
it was able to reduce the excretion of the bacteria (Redondo et al.,
2013a). Similarly, Prosdócimo et al. (2010) found antibacterial
activity of quebracho against Salmonella Enteritidis and Salmonella
Gallinarum in vitro.
Clostridium perfringens is considered an important poultry
pathogen that is the causative agent of necrotic enteritis and sub-
clinical disease (Ficken and Wages, 1997). Both presentations of
the disease have important economic impact on poultry produc-
tion. This bacterium is an important example of antimicrobial
banning consequences. AGPs have long been effective in pre-
vention of necrotic enteritis in poultry ﬂocks and after AGPs
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withdrawal, the incidence of necrotic enteritis increased consid-
erably (Van Immerseel et al., 2004). Inhibitory effects of tannins
from different sources have been demonstrated. Previous report
shows that tannins derived from chestnut and quebracho have
in vitro antibacterial and antitoxin activities against Clostridium
perfringens and its toxins and that mixtures of both tannins main-
tain individual activities (Elizondo et al., 2010). Subsequent results
from this research group conﬁrm the in vivo effects of chestnut
and quebracho tannins in a broiler necrotic enteritis model reduc-
ing the incidence and severity of gross lesions and improving
the productive performance of broiler chickens (Redondo et al.,
2013b). This ﬁndings are reinforced by the results obtained from
other authors with chestnut tannin added to diet in an Eime-
ria spp./Clostridium perfringens co-infection model (Tosi et al.,
2013). Although chestnut tannins show strong bactericidal activ-
ity against Clostridium perfringens, most ingested tannin do not
remain in the feces because it is hydrolyzed and degraded in
the intestinal tract. In contrast, quebracho tannins are mainly
condensed with lower antibacterial ability but most of the admin-
istered tannins remain in the fecal material. Therefore, those
different abilities could be used to readily diminish the intestinal
Clostridium perfringens load by chestnut and avoiding the rein-
fection by controlling the environmental contamination (i.e. feces
and bedding) with quebracho tannins.
Different works reports the antiviral activity of some tannin
against animal viruses. Ueda et al. (2013) test condensed and
hydrolysable tannins from different sources against selected fam-
ilies of pathogenic animal virus and show that these compounds
have an unspeciﬁc neutralizing effect on enveloped virus. The
same group reports the induced aggregation of puriﬁed virions or
BSA through association of tannins with proteins. Another poten-
tial mechanism was reported in works using human virus, like
herpesvirus (Lin et al., 2011) and human immunodeﬁciency virus
(HIV-1), in the same the authors suggest that reduce viral activity
could be due to tannins binding to cell receptor like glycoproteins
or CD4, respectively. Although they are few, works with avian
viruses suggest that natural extracts containing speciﬁc tannins
could contribute to control viral infections. Lupini et al. (2009)
showed that both, chestnut and quebracho wood extracts, have
inhibitory effect on avian reovirus (retrovirus) and avian metap-
neumovirus (paramyxovirus) before virus absorption to cells. In
this work the author reports that chestnut and quebracho extracts
reduce the extracellular viral activity, proposing that extracellu-
lar effect may be due to an interaction between tannins and viral
proteins resulting in the inhibition of viral attachment and pen-
etration of the cell membrane, as mention before for other virus.
In the same work, they report a reduction in the intracellular
viral activity only by quebracho extract, and propose that the
main mechanism would be the inhibition of viral enzymes. The
higher intracellular activity of quebracho extract could be due to
the smaller size of tannins extracted from this plant that could
penetrate the cells as suggested by Moreira et al. (2005).
Although tannins or plant derived extracts demonstrated activ-
ity against viral (Lupini et al., 2009), bacterial (Tosi et al., 2013),
and protozoal diseases (Cejas et al., 2011), little is known about
the mechanisms of these compounds on antimicrobial effects
and growth promotion. Some of the explained modes of action
for antimicrobials may help to deﬁne tannins main mechanism.
Metabolism inhibition is onepossiblemechanism; Bae et al. (1993)
showed that condensed tannins frombirdfoot trefoil (Lotus cornic-
ulatus L.) were inhibitory to the endoglucanase activity of cellulose
digesting Fibrobacter succinogenes S85 in the rumen. This may be
applied to virulence factors as Elizondo suggests for Clostridium
perfringens toxins (2010). On the other hand, iron deprivation has
been suggested by some authors (Scalbert, 1991; Haslam, 1996;
Mila et al., 1996). Tannic acid works like a siderophore to chelate
iron from the medium, making it unavailable for the microorgan-
isms. Iron is essential for most pathogenic bacteria and tannic acid
shows three times more afﬁnity for iron than E. coli siderophores
(Chung et al., 1998).
One of the most accepted mechanisms of action of some plant
tissues in animal diet is the shifts in intestinal microbiota com-
position. As reported for different groups, Gram positive bacteria
seem to be more sensitive to plant extract with high tannins con-
tent (Nohynek et al., 2006; Engels et al., 2011). It is important to
remark that microbiota changes have more impact on younger
animals due to their constantly evolving microbiota. It is thought
to take until the sixth week of age to achieve a mature micro-
biota (Barnes et al., 1972). Regardless of the mode of action, the
chemical characteristics of the tannins are highly variable and
different types of tannins can be present in one plant extract.
Therefore, the origin of the plant extract added to the feed will
be determinant in the ﬁnal impact on microbiota and the animal
performance.
ECONOMICAL CONSIDERATION
Independently of the use of antimicrobials or any of the available
alternatives to AGP, increase of the productive performance and
animal welfare depends on the overall health status of broilers. A
complete and continuous observation of the ﬂock health status
and performance must be considered. It requires regular necrop-
sies, sampling, and identiﬁcation of pathogens, together with
periodic monitoring of productive parameters like feed intake and
weight gain, ﬂock uniformity and other conditions. This should
provide an overview of the productive costs and allow measure
the economic impact of a disease and choose cost-effective ther-
apeutic or prophylactic strategies. The return-on-investment for
alternatives to AGPs will depend on both the biological impact
and the dynamics of the market price. Withdraw of AGP from the
ﬂock may cause a decreased growth rate, higher morbidity, and
mortality; but the continuous use may led to increased condem-
nations due to residues in meat and derived products. In countries
where the use of AGP is still allowed is imperative to consider
the net economic effect of replacing them with alternative prod-
ucts that do not represent a threat to public health and leave no
residues in meat and derived products. It will depend on several
factors including impact effects on productive performance lev-
els and the cost of any alternative potential technologies adopted
to compensate for the termination of use of AGPs and may be
offset by the beneﬁts like access to more demanding markets or
differential marketing, as in the case of organic foods. In countries
where AGP are banned from poultry production, the negative
impact may be temporarily compensated by the use of ionophore
anticoccidials, which are excluded from regulation due to lack of
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reports of relations between these substances and others antimi-
crobials. Taking into consideration that recent ﬁeld investigations
have demonstrated that animal husbandry use of antimicrobial
agents increases the likelihood that domestic animal bacteria will
develop resistance or cross-resistance to drugs approved for use
in human medicine (Diarra et al., 2007; da Costa et al., 2013),
experience with others groups of antimicrobials suggest that these
chemicals are prompt to be removed from animal feed for the
same reasons as AGPs, it is important to develop adequate alterna-
tives to be used alone or combined with other control measures to
improve the gut health. Further work is needed to deﬁne standards
for the replacement of antibiotic compounds in poultry in terms of
product type, identiﬁcation of suppliers, poultry response criteria,
regulatory status and veterinary deﬁnition (Rosen, 2003).
CONCLUSION
The use of plant extracts appears as an attractive alternative to
the use of antimicrobial growth promoter factors. These natu-
ral products do not leave residues in poultry-derived products.
Also, plant extracts are complex substances with many bioactive
principles that would have fewer chances to induce resistance in
microorganisms.
Successful application of any of these extracts as feed additive
must ensure a product of consistent quality in enough quanti-
ties to improve poultry production at AGPs levels and fulﬁll the
actual requirements of poultry derived products consumers. If the
products are effective and can be acquired in enough quantities
to supply the poultry industry requirements, the decisive factor
for the successful application will be the cost and it should be
at least similar to those of the AGPs. Although numerous prod-
ucts available in market have been proved to be efﬁcient in the
ﬁeld (Graziani et al., 2006; Lupini et al., 2009; Elizondo et al., 2010;
Redondo et al., 2013b), many have less clear potential. Chestnut
(hydrolizable) and Quebracho (condennsed) tannins are probably
themost readily available commercial products that are being used
and cover those needs as well as there is an important number of
data supporting their usage.
The diversity of results presented in different papers show the
complexity of elucidating effects of plant extracts over a deter-
minedmicroorganismor disease in different animal hosts. Further
investigations needs to be done in order to describe the effects of
plant extracts onpathogenicmicroorganismaswell as in commen-
salmicrobiota and the impact of its use in animal production. This
knowledge would allow the development of new and innovative
products suitable to be incorporated in animal feed in order to
improve animal production without compromising public health.
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The growth-promoting effect of antibiotic growth promoters (AGPs) was correlated with the
decreased activity of bile salt hydrolase (BSH), an intestinal bacteria-produced enzyme that
exerts negative impact on host fat digestion and utilization. Consistent with this ﬁnding,
independent chicken studies have demonstrated that AGP usage signiﬁcantly reduced
population of Lactobacillus species, the major BSH-producers in the intestine. Recent
ﬁnding also demonstrated that some AGPs, such as tetracycline and roxarsone, display
direct inhibitory effect on BSH activity. Therefore, BSH is a promising microbiome target
for developing novel alternatives to AGPs. Speciﬁcally, dietary supplementation of BSH
inhibitor may promote host lipid metabolism and energy harvest, consequently enhancing
feed efﬁciency and body weight gain in food animals.
Keywords: antibiotic growth promoters, bile salt hydrolase, Lactobacilli
INTRODUCTION
Epidemiological studies have linked usage of antibiotic growth
promoters (AGPs) to the emergence of antibiotic resistant bacteria
(Wegener, 2003). Antibiotic-resistant bacteria as well as resis-
tance determinants can therefore spread from animals to humans,
compromising the effectiveness of antibiotics for treating human
infections and posing a serious threat to public health (Wegener,
2003). For this reason, Denmark banned all AGPs in 1998
and European Union member nations banned all AGPs in 2006
(Wegener, 2003; Dibner and Richards, 2005). Therefore, there is
a worldwide trend to limit AGP use in food animals (Turnidge,
2004; Dibner and Richards, 2005). Ending the use of AGPs cre-
ates challenges for the animal feed and feed additive industries.
Several products, such as probiotics, prebiotics, and organic acids
have been used to alter intestinal microbiota for improving ani-
mal health and production (Dibner andRichards, 2005). However,
limited data is available to justify the choice of speciﬁc bacterial
species or products for such microbiota manipulation. Examina-
tion of microbiota in response to AGP treatment would provide
insights into the modes of action of AGPs and facilitate the devel-
opment of more effective microbiota-based strategies for growth
promotion. Recent studies on the relationship betweenAGP usage
and gut microbiota strongly suggest that bile salt hydrolase (BSH)
is an important target through which microbiome composition
and function may impact host fat digestion and energy harvest.
RESPONSE OF INTESTINAL BSH ACTIVITY TO AGP
Clearly a connection has been made between AGP usage, growth
promotion, and intestinal bacterial populations, but the precise
mechanism is yet to be delineated as to how these all coincide.
Strides have been made in uncovering this mystery, however,
Abbreviations: AGP, antibiotic growth promoter; BSH, bile salt hydrolase; CBA,
conjugated bile acid.
and it has been shown that the growth-promoting effect of low-
dose antibiotics does coincide with a decrease in BSH activity
in the gut (Feighner and Dashkevicz, 1987; Knarreborg et al.,
2004; Guban et al., 2006). BSH produced by gut bacteria cat-
alyzes deconjugation of conjugated bile acids (CBAs, also referred
to as conjugated bile salts) in the intestine (Begley et al., 2006).
CBAs consist of a hydrophobic steroid core that is conjugated
with either glycine or taurine. Thus, the CBAs are amphipathic
and function as a more efﬁcient “biological detergent” than
unconjugated bile acids to emulsify and solubilize lipids for fat
digestion (Begley et al., 2006). Consequently, BSH activity has sig-
niﬁcant impact on host physiology by disturbing CBA-mediated
fat metabolism and endocrine functions (Begley et al., 2006;
Jones et al., 2008).
Feighner and Dashkevicz (1987) provided early evidence that
antibiotic feed additives affect the transformation potential and
hydrolysis activity of BSHs from intestinal contents of poultry.
By keying in on a more speciﬁc aspect of lipid metabolism,
Knarreborg et al. (2004) demonstrated an enhanced bioavail-
ability of α-tocopheryl (alpha-tocopherol) acetate in broilers
given AGPs, and this was attributed to a reduced concen-
tration of unconjugated bile salts. Furthermore, Guban et al.
(2006) correlated dietary supplementation of AGPs to improved
weight gain and fat digestibility in broilers, decreased popu-
lation levels of Lactobacillus salivarius, and a reduced pool of
deconjugated bile salts. Based on these discoveries, the growth-
promoting effect of AGPs likely is partly attributed to the
reduced BSH activity, and thus the improvement of host lipid
metabolism.
RESPONSE OF INTESTINAL MICROBIOTA TO AGP
With the aid of culture-independent molecular approaches, the
investigations of the effect of AGPs on intestinal microbiota have
been initiated in different food animals, including poultry and
swine, which greatly improves our understanding of intestinal
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microbiota changes in response to AGPs (Engberg et al., 2000;
Knarreborg et al., 2002; Collier et al., 2003; Dumonceaux et al.,
2006; Guban et al., 2006; Wise and Siragusa, 2007; Zhou
et al., 2007; Danzeisen et al., 2011; Kim et al., 2012; Lin et al.,
2013). As expected, oral administration of low-dose antibiotics
affected diversity and relative abundance of gut microbiota in
all these studies. However, based on the ﬁndings from these
molecular ecology studies, it is challenging to deﬁnitively link
speciﬁc bacterial populations to the enhanced growth perfor-
mance due to AGP usage. Interestingly, independent studies
(Engberg et al., 2000; Knarreborg et al., 2002; Dumonceaux
et al., 2006; Guban et al., 2006; Zhou et al., 2007; Danzeisen
et al., 2011; Lin et al., 2013) showed that AGP usage signiﬁ-
cantly reduced the population of Lactobacillus species, a major
bacterial choice for probiotics development; in particular, pop-
ulation of L. salivarius, the dominant lactic acid bacterium
present in the chicken intestine, was reduced in response to
AGP treatment. Since Lactobacillus populations are major BSH-
producers in small intestine (Begley et al., 2006), this inter-
estingly bacterial shift due to AGP usage is consistent with
the reduced BSH activity as described above. Taken together,
these studies indicate that the AGP-mediated body weight gain
in food animal is inversely related to the activity of BSH
enzymes and the abundance of corresponding Lactobacilli pro-
ducers.
CHARACTERISTICS OF BSH
Bacterial BSH is a member of the choloylglycine hydrolase family
of enzymes and is predominantly associated with gastrointestinal
bacteria of both humans and animals. Additionally, it is classiﬁed
as an N-terminal nucleophilic hydrolase and can recognize sub-
strate at both the amino acid conjugate or steroid nucleus (Patel
et al., 2010). BSH is particularly abundant in lactic acid fermenting
probiotic strains like Lactobacilli and Biﬁdobacteria (Begley et al.,
2006). BSH enzymes display either narrow or broad substrate
speciﬁcity; most BSH enzymes from lactic acid bacteria showed
higher catalytic abilities to hydrolyze glyco-CBAs than tauro-CBAs
(Begley et al., 2006). Despite recent signiﬁcant progress in the char-
acterization of diverse BSH enzymes, research on BSH is still in its
infancy (Patel et al., 2010). The natural functions of BSH enzymes
for bacteria themselves are still not clear (Begley et al., 2006). One
hypothesis is that BSH activity confers Lactobacilli tolerance to
bile in the intestine (Begley et al., 2006). However, there are con-
tradictory reports about the correlation between bile tolerance
and BSH activity in intestinal bacteria (Begley et al., 2006). For
example, production of BSH does not determine bile resistance
level in L. salivarius, the dominant Lactobacillus species present
in the chicken intestine (Fang et al., 2009). Regardless the natural
function of BSH for its bacterial producer, it has been increasingly
recognized that intestinal BSH plays an important role in host
lipid metabolism and energy harvest (Begley et al., 2006; Jones
et al., 2008). Recent probiotics studies have already shown that oral
administration of BSH-producing Lactobacilli could affect lipid
metabolism, consequently lowering cholesterol level in humans
(Jones et al., 2012), rats (Kumar et al., 2011), and pigs (De et al.,
1998), which is likelymediated throughBSH activity. In the future,
more functional, genomic, andmicrobiological studies are needed
to better understand the role of BSH in the symbiosis relationship
between gut microbiota and host.
PRODUCTION OF BSH BY PROBIOTICS: A NEGATIVE TRAIT FROM
ANIMAL PRODUCTION PERSPECTIVES?
It is no doubt that dietary probiotics, the normal commensal
microorganisms, could exert various beneﬁcial effects on food ani-
mals. However, probiotics do impose a variety of potential costs
(or detrimental effects) to the animal host as well, which include
the production of toxic metabolites, decreased fat digestibility
due to production of BSH, and the increase of mucus secretion
and gut epithelial cell turn-over (Gaskins et al., 2002; Dibner and
Richards, 2004, 2005). Due to such opposite impact of probi-
otics on the host, it is not surprising that inconsistent results
on growth performance of poultry have been observed following
probiotic administration (Perumalla et al., 2011). In particular,
results available from the literature on probiotic treatments often
appear to be contradictory. Lactobacilli have been amajor bacterial
choice for probiotic development in poultry. In general, dietary
probiotic supplementation in chicken increases intestinal pop-
ulations of Lactobacilli (Smirnov et al., 2005). Since Lactobacilli
are dominant BSH-producers in the intestine, dietary Lactobacilli
treatment may negatively affect lipid metabolism and energy har-
vest, consequently imposing negative impact on body weight gain.
Recently, two research groups (Mountzouris et al., 2010; Shariﬁ
et al., 2012) have reported that probiotic supplementation to diets
signiﬁcantly reduced body weight gain, fat digestibility, and feed
conversion in broilers; in these studies, two different commer-
cially available probiotics with a mixture of various organisms
(Protexin and PoultryStar) were used. Based on these ﬁndings,
the authors have proposed that the detrimental effects of the
probiotics on chicken growth are likely attributed to the produc-
tion of intestinal BSH by Lactobacilli (Mountzouris et al., 2010;
Shariﬁ et al., 2012). Therefore, overall beneﬁcial effects associated
with speciﬁc probiotics should be carefully evaluated. Under-
standing the science of potential negative traits of probiotics can
help us develop “negative-traits-mitigation” strategy (e.g., BSH
inhibitors) to optimize probiotic products for enhanced growth
performance of food animals and proﬁtability of feed additive
industry.
DISCOVERY OF BSH INHIBITORS
Based on the information reviewed above, BSH inhibitors are
promising alternatives to AGP for enhanced production of food
animals. This hypothesis has been partly supported by our recent
study (Wang et al., 2012) in which a BSH enzyme with broad
substrate speciﬁcity from a chicken L. salivarius strain was charac-
terized. Examination of a panel of dietary compounds identiﬁed
copper and zinc compounds as potent BSH inhibitor (Wang et al.,
2012); notably, copper and/or zinc have been used at high concen-
trations to aid in feed efﬁciency and growth promotion in poultry
(Ewing et al., 1998; Miles et al., 1998; Arias and Koutsos, 2006) and
swine (Smith et al., 1997; Hill et al., 2000; Armstrong et al., 2004).
However, long-term use of high doses of copper or zinc in animal
feed has raised some serious concerns, such as copper/zinc toxi-
cosis and environmental contamination. Therefore, discovery of
potent, safe, and cost-effective BSH inhibitors is highly warranted.
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In our recent study (Smith et al., 2014), a rapid and convenient
high-throughput screening (HTS) system was developed and has
been successfully used for identiﬁcation of BSH inhibitors. This
HTS strategy is based on the unique feature of BSH enzyme:
hydrolysis of soluble unconjugated bile salts by BSH generates
insoluble unconjugated bile salts that could form signiﬁcant pre-
cipitations (Smith et al., 2014). After optimizing various screening
conditions, a pilot HTS was performed using a small compound
library comprised of 2,240 diverse compounds, leading to the
identiﬁcation of several promising BSH inhibitors with poten-
tial as alternatives to AGPs, such as riboﬂavin and phenethyl
caffeate (Smith et al., 2014). In the future, larger scale HTS
may reveal more novel BSH inhibitors. In addition, compre-
hensive animal trials are needed to determine the effect of
“champion” BSH inhibitors on growth performance of food
animals.
Interestingly, this HTS study also identiﬁed a panel of antibi-
otics as BSH inhibitor, such as various tetracycline antibiotics
and roxarsone that have been widely used as AGPs in food ani-
mals (Smith et al., 2014). This unexpected ﬁnding suggests a new
mode of action of low-dose antibiotics for promoting animal
growth: some AGPs may exert their growth-promoting effect on
food animals by direct inhibition of intestinal BSH enzymes for
enhanced lipid metabolism and energy harvest. However, some
AGPs, such as bacitracin that has been widely used in poul-
try industry (Chapman and Johnson, 2002), only displayed low
or little inhibitory effect on BSH activity (Smith et al., 2014).
The study by Smith et al. (2014) further showed the complex-
ity of the modes of action of AGPs and provided new insights
into the interactions between low-dose antibiotics and gut
microbiome.
CONCLUSIONS AND FUTURE DIRECTIONS
Independent studies have shown the link between usage of AGPs
and reduced BSH activity as well as reduced population of some
Lactobacillus species, the major BSH-producers, in the intestine of
food animals. In light of these ﬁndings, BSH enzyme is a promis-
ing microbiome target for developing novel alternatives to AGPs
for enhancing the productivity and sustainability of food animals.
Recent characterization of a broad-spectrum BSH from L. salivar-
ius (Wang et al., 2012) and development of an efﬁcientHTS system
for discovery of BSH inhibitors (Smith et al., 2014) have laid a solid
foundation for us to develop BSH inhibitors-based feed additives
to replace AGPs. In addition, the ﬁndings from screening of BSH
inhibitors (Smith et al., 2014) suggest a new mode of action of
low-dose antibiotics (direct inhibition of intestinal BSH) for pro-
moting animal growth. In the future, large animal trials are needed
to determine the effects of BSH inhibitors on growth performance
of food animals. Given that research on BSH is still in its infancy,
research on BSH ecology of BSH enzymes in the intestine and
the role of BSH in host physiology is also highly warranted in the
future.
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Antimicrobial resistance is a growing public health challenge worldwide, with agricultural
use of antimicrobials being one major contributor to the emergence and dissemination
of antimicrobial resistance (AMR). Globally, most antimicrobials are used in industrial
food animal production, a major context for microbiomes encountering low-doses or
subtherapeutic-levels of antimicrobial agents from all mechanistic classes. This modern
practice exerts broad eco-evolutionary effects on the gut microbiome of food animals,
which is subsequently transferred to animal waste. This waste contains complex
constituents that are challenging to treat, including AMR determinants and low-dose
antimicrobials. Unconfined storage or land deposition of a large volume of animal
waste causes its wide contact with the environment and drives the expansion of the
environmental resistome through mobilome facilitated horizontal genet transfer. The
expanded environmental resistome, which encompasses both natural constituents and
anthropogenic inputs, can persist under multiple stressors from agriculture and may
re-enter humans, thus posing a public health risk to humans. For these reasons, this
review focuses on agricultural antimicrobial use as a laboratory for understanding low-dose
antimicrobials as drivers of resistome expansion, briefly summarizes current knowledge
on this topic, highlights the importance of research specifically on environmental microbial
ecosystems considering AMR as environmental pollution, and calls attention to the needs
for longitudinal studies at the systems level.
Keywords: agriculture, antimicrobials, metals, microbiome, resistome, mobilome, environmental pollution
INTRODUCTION
The intensive production of food animals is a major context for
microbiomes encountering low-doses or subtherapeutic-levels of
diverse classes of antimicrobial agents. For that reason, this review
focuses on food animal production as an important labora-
tory for understanding the eco- evolutionary (interactions and
intersection of ecology and evolutionary biology) mechanisms
involved in bacterial responses to low-dose, sub-therapeutic pres-
sures associated with antimicrobials. A majority of agricultural
antimicrobials are used as feed additives for growth promotion
in livestock and poultry (Silbergeld et al., 2008). This use began
in the 1940s in the US, soon after the initiation of large-scale
production of these drugs for clinical medicine. From the first
approvals to the present, the concentrations of growth promot-
ing antimicrobials (GPAs) in feeds have been stipulated by FDA
regulation to deliver sub-therapeutic doses. Redefining GPA use
as “therapeutic,” “non-therapeutic,” or “prophylactic” to com-
ply with regulations in some countries and guidance by the
US FDA does not change this condition from the microbial
perspective.
This paper will not discuss the hypothesized mechanisms by
which GPAs are asserted to increase growth and feed efficiency,
since a recent large study by the Perdue Company reported that
there were very small or non-significant differences in these out-
comes among poultry flocks consuming feeds with or without
GPAs (Engster et al., 2002; Graham et al., 2007). In contrast to
earlier studies, including those at Lederle (Stokstad and Jukes,
1958-1959), this is the only study conducted under empiri-
cal conditions in poultry production over the lifespan of the
animals.
GPA use employs agents from every mechanistic class and
currently exceeds all clinical uses in terms of the proportion
of total antimicrobial production in the US (Silbergeld et al.,
2008; FDA, 2011) and, until recently, in the EU (Teuber, 2001).
Information from other regions is not generally available, but
given the global expansion of poultry and livestock produc-
tion using methods similar to those first developed in the US
(Graham et al., 2008), it is likely that global use of antimicro-
bials in animal feeds is also significant (see Arriola, 2011 for
study of Peru). As a result, GPAs have had important impacts
on selection and dissemination of antimicrobial resistance (AMR)
worldwide through the food supply and environmental releases.
Moreover, because GPAs are utilized most commonly as mix-
tures in animal feeds, the gut microbiome of poultry or livestock
is exposed to multiple pressures acting on a range of molecular
mechanisms associated with resistance development (Davis et al.,
2011).
From early in the history of GPA use, it was recognized that
the gut microbiome of poultry was responding to selection for
resistance to drugs in feeds. Jukes acknowledged this as a truism,
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but discounted any potential risks for human health (1972).
With more concern, Starr and Reynolds (1951) reported that
Escherichia coli isolated from the gut microflora of poultry flocks
fed with streptomycin as a GPA were resistant to streptomycin,
as compared to isolates from unexposed flocks. Since that time,
numerous studies have documented associations between GPA
use and temporal and geographic trends in AMR prevalence in
animal wastes, food products, and human populations (docu-
mented most completely in studies in Denmark e.g., Aarestrup
et al., 2001; Wegener, 2003, also see review by Silbergeld et al.,
2008).
The use of molecular, genomic, and metagenomic meth-
ods to track AMR genes and AMR strains from food ani-
mal production has increased the strength of the evidence on
this connection. These methods have also clarified implica-
tions of intensive food animal production for human health,
demonstrating that the microbiomes of livestock and poultry
are reservoirs for AMR pathogens and that resistance deter-
minants can be transferred from these microbiomes to the
environment and eventually to humans (Hammerum, 2012).
This has been most recently demonstrated for livestock spe-
cific strains of methicillin resistant Staphylococcus aureus (van
Loo et al., 2007; Waters et al., 2011; Price et al., 2012) and
extraintestinal pathogenic E. coli, especially those phylogroups
associated with urinary tract infection in humans (Jakobsen
et al., 2010). Smet et al. (2011) reported that a plasmid car-
rying the blaTEM−52 gene encoding ESBL (extended-spectrum
β-lactamase) could be transferred from a poultry strain of E. coli
into human E. coli under simulated human caecal conditions. The
same ESBL genes (including blaTEM−52), ESBL-encoding plas-
mids and ESBL-producing E. coli strains have been observed in
poultry, chicken meat and humans (Leverstein-van Hall et al.,
2011).
This paper briefly summarizes current knowledge on this topic
and highlights the importance of research specifically on environ-
mental microbial ecosystems for understanding the evolution and
persistence of resistance associated with GPA use in agriculture.
This reflects the fact that many events related to the emergence of
AMR in agricultural settings occur in the context of interactions
between the gut microbiome of food animals, such as chickens
and pigs, and environmental microbiomes in those ecological
niches impacted by disposal of animal wastes. These wastes are
normally not treated prior to disposal and often contain AMR
bacteria and transmissible genetic elements assembling resistance
genes, as well as residual antimicrobials and their degradation
products.
CURRENT KNOWLEDGE
Over the past three decades, research has largely investigated the
agricultural setting for AMR emergence primarily for the purpose
of understanding the origin of AMR in food borne pathogens.
Relatively recently, non-food pathways and the role of the envi-
ronment have attracted increasing research attention. However,
incorporating this knowledge into studies of microbial ecology
and evolution as well as into studies of disease outbreaks and
attributable risk of infection by drug resistant bacteria is still
limited (Ashbolt et al., 2013).
ECO-EVOLUTIONARY CONSEQUENCES OF INDUSTRIAL
FOOD ANIMAL PRODUCTION ON THE GUT MICROBIOME OF
FOOD ANIMALS
Current methods and conditions in industrial food animal pro-
duction are quite different from traditional agronomy in terms of
intensity and density as well as the use of GPAs (Silbergeld et al.,
2008). These changes are likely to have affected animal gut micro-
biomes. Looft et al. (2012), using phylogenetic and metagenomic
approaches, found that 14 days’ exposure to subtherapeutic doses
of chlortetracycline, sulfamethazine, and penicillin induced shifts
in gut microbiota of pigs. These changes included an increase
in the prevalence of Proteobacteria (primarily in E. coli species)
and in the abundance and diversity of AMR genes specific to
and beyond those used GPAs, as well as selection for other genes
related to gene transfer, virulence, energy production, and energy
conversion. Population shifts were also observed in the gut micro-
biome of pigs receiving the GPA tylosin (Kim et al., 2012).
Using metagenomic pyrosequencing, Danzeisen et al. (2011)
reported that the GPA mixtures of virginiamycin/monensin or
tylosin/monensin enriched E. coli populations in the chicken
cecal microbiome, along with genes encoding transport systems,
type I fimbriae and type IV conjugative secretion systems. That
study did not detect significant differences in AMR gene occur-
rence between GPA treatment and control groups, which may not
represent the commercial poultry production conditions. While
AMR genes are present in the gutmicrobiome of free-range chick-
ens (Zhou et al., 2012), a diverse pool of AMR genes is found in
conventionally raised chickens (Qu et al., 2008; Zhou et al., 2012).
Themobilome (Siefert, 2009), a collection of all mobile genetic
elements (MGEs), is a functional component of the microbiome,
and plays an essential role in microbial ecology and evolution
by facilitating horizontal gene transfer among microorganisms
(Frost et al., 2005; Gillings, 2013). There are some reports on
impacts of GPAs on the animal gut mobilome (Danzeisen et al.,
2011; Looft et al., 2012), but studies at the systems level are still
rare. Antimicrobials, in addition to enriching preexisting AMR
genotypes and phenotypes and providing pressure for evolution-
ary selection for de novo mutations that favor survival (Gullberg
et al., 2011), also induce horizontal transfer of MGEs through
mechanisms such as bacterial SOS response (Beaber et al., 2003)
and translation attenuation (Wozniak and Waldor, 2010). Some
recent studies have identified the contributions of GPAs to phage-
mediated horizontal transfer of AMR genes in the animal gut
microbiome. Allen et al. (2011) reported that the GPA mixture
Aureomix 500 used in swine feed (containing chlortetracycline,
sulfamethazine and penicillin) led to significant population shifts
in both phage and bacterial communities, as well as induction
of prophages (one type of MGEs) in swine fecal microbiomes.
The altered phage metagenomes harbored multiple AMR genes
including genes for multidrug resistance. Bearson et al. (2014)
reported that the GPA carbadox induced phage mediated trans-
fer of virulence and resistance genes in Salmonella enterica serovar
Typhimurium, a human foodborne pathogen that frequently col-
onizes swine. More investigation is needed for other components
of the animal gut mobilome, such as the plasmidome (Kav et al.,
2012), before we can fully understand impacts of GPAs on the
entire mobilome within the animal gut microbiome.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy June 2014 | Volume 5 | Article 284 | 134
You and Silbergeld Agricultural use of antimicrobials and resistome expansion
ANIMAL WASTES: THE CONNECTOR BETWEEN THE GUT
MICROBIOME OF FOOD ANIMALS AND THE ENVIRONMENT
The gut microbiome of poultry and livestock raised in con-
finement is transferred into animal excreta, which include the
resistome and the mobilome. Also present in animal excreta are
unmetabolized GPAs (Kumar et al., 2005; Sarmah et al., 2006)
and active metabolites. Thus, the first nexus in the environmen-
tal pathway of the dissemination of animal husbandry originated
AMR is poultry house litter or cesspits that collect wastes in swine
barns (see Figure 1).
Within a confinement house, wastes (solid and liquid) accu-
mulate inputs from animal excreta and other residues like spilled
feed containing GPAs into a waste microbiome over the lifetime
of a flock or a herd, and often for a longer period when poul-
try houses are not routinely cleaned between each flock or when
septic impoundments are not emptied between herds (Volkova
et al., 2009). During this period, the microbiomes of chickens
and house litter interact and exchange organisms and resistance
FIGURE 1 | (A) (left) Pigs in confinement house (photo USDA). Note slatted
floor; wastes (including excreta and spilled feed) accumulate on this surface
and are periodically washed down into a cesspit below the building. (right)
A view of a swine production operation showing open cesspits that collect
drainage from animal houses; disposal of these wastes involves spraying of
liquids (photo S Wing). (B) (left) Chickens in a Maryland poultry house.
Flocks are housed directly on litter, which contains excreta (as evident from
the birds) as well as spilled feed. Litter is removed infrequently from poultry
houses (photo J Graham). (right) The lower Pocomoke River, with poultry
houses and land disposal of poultry waste (source: Integration and
Application Network, University of Maryland Center for Environmental
Sciences).
genes (Cressman et al., 2010; Shanmugasundaram et al., 2011).
Eco-evolutionary events in the litter microbiome have not been
carefully studied. But poultry litter is known to be a reservoir of
AMR bacteria and resistance determinants, resistance-encoding
MGEs and residual antimicrobials (Nandi et al., 2004; Furtula
et al., 2009; Graham et al., 2009a; Cheng et al., 2013).
Environmental dissemination of the food-animal-associated
microbiome and resistome occurs through waste holding and dis-
posal. Food animal wastes are first released to the environment
through on site storage (usually in open sheds for poultry or open
impoundments for swine) and then discharged into the environ-
ment more broadly by land application as shown in Figure 1.
The sites of land disposal may be close to or very distant from
the sites of poultry or swine production (Leibler et al., 2009).
Once released into the external environment either by unconfined
storage or by deposition on land, the microbial and chemical con-
stituents of animal wastes can be widely dispersedmainly through
dust, air, and water movement, as well as by animal movement
(flies, rodents, and wild birds) (Graham et al., 2009b).
Because of the intensity of food animal production in the US
and other countries, this constitutes a major source of all gut
microbiota being transferred to the environment (Silbergeld et al.,
2008). Unlike human biosolids, no treatment is required prior to
discharge of animal wastes, which are almost entirely (>90%)
disposed of onto land (Graham and Nachman, 2010). Storage
of poultry house litter or of swine waste, without specific com-
posting procedures, does not reduce the burden of pathogens
and AMR determinants (Gerba and Smith, 2005; Graham et al.,
2009a). More intensive composting, though more effective in
attenuating microbial loadings in wastes, does not significantly
reduce loadings of AMR genes (Storteboom et al., 2007). Even
multiple treatment lagoons are unable to completely remove
AMR genes (McKinney et al., 2010).
For these characteristics of animal wastes—complex con-
stituents, large volume, insufficient waste management, and
broad contact with the environment—the appropriate focus for
understanding the emergence and dissemination of AMR driven
by use of subtherapeutic GPAs in agriculture is in the interactions
between animal wastes and the environment. Intensive animal
production operations and associated environmental compart-
ments have been characterized as “genetic reactors” where new
genotypes and phenotypes of resistance can evolve through
genetic exchange and recombination, and re-enter humans and
animals (Baquero et al., 2008). We conceive of a series of dynamic
interactions between environmental microbiomes and the altered
gut microbiome of poultry flocks that is represented within poul-
try house waste, which in turn integrates microbial loadings from
multiple flocks within each house. This is shown in Figure 2
(Davis et al., 2011).
THE ENVIRONMENTAL MICROBIOME AND LOW-LEVEL
ANTIMICROBIAL PRESSURE FROM AGRICULTURE
The environment is both themain receptor for animal wastes con-
taining AMR determinants, particularly those on MGEs (Heuer
et al., 2011), and the locus of the natural resistome (D’Costa et al.,
2006, 2007) and mobilome (Siefert, 2009; Gillings, 2013) which
together constitute the genetic resources available to microbial
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FIGURE 2 | Conceptual framework for understanding flow of resistance genes and mobile genetic elements across microbiomes within food
animals, the environment, and human populations (based on Davis et al., 2011).
communities for surviving antimicrobial stress and the genetic
machinery to transfer these genetic resources among bacteria
within and among different microbial communities. The environ-
mental resistome, which encompasses both natural constituents
as well as inputs from anthropogenic activities like agriculture,
is relevant to human health as it can be a source of resistance
determinants found in human pathogens, particularly through
the mobilome (Forsberg et al., 2012; Perry and Wright, 2013).
There is ample evidence in the literature on the impacts of
intensive food animal production on the occurrence of AMR
in directly or indirectly affected environmental compartments
(including soils, sediments, and water) (reviewed by Joseph et al.,
2001; D’Costa et al., 2007; Ghosh and LaPara, 2007; Stine et al.,
2007; Silbergeld et al., 2008; Graham et al., 2009a; Martinez, 2009;
Knapp et al., 2010; Heuer et al., 2011; You et al., 2012, 2013; Gaze
et al., 2013; Jones et al., 2013; Wei et al., 2013). Using quantitative
methods such as real-time PCR and LC-MS/MS, correlations have
been demonstrated between the occurrence/abundance of AMR
genes and the extent of antimicrobial use or drug concentrations
in animal husbandry environments (Smith et al., 2004; Peak et al.,
2007; McKinney et al., 2010; Wu et al., 2010; Zhu et al., 2013).
These relationships may involve multiple mechanisms includ-
ing the simultaneous loading of both genes and drugs into the
ecosystem and/or in situ selection for AMR in the environment
due to inputs of antimicrobials, metals, and other residues. Until
recently it was thought that the concentrations of antimicrobial
compounds or their degradation products in the environment,
which usually range fromμg/kg tomg/kg in sediment or soil sam-
ples (Kemper, 2008), were not high enough to select for resistance.
However, laboratory studies have demonstrated that low concen-
trations of antimicrobials in the same range are sufficient to select
for resistance through several mechanisms (Kohanski et al., 2010;
Gullberg et al., 2011). A study involving both field and laboratory
research and coupled with modeling reported a selective and per-
sistent effect of sulfadiazine in pig manure on resistance genes in
soil microbiota (Heuer et al., 2008). Interactions between drugs
(and their degradation products) and the soil microbiome are
influenced by the physicochemical properties of each drug, which
affect their potential bioavailability in the environment such as
soils (Tolls, 2001; Hamscher et al., 2005; Kemper, 2008). Also
antimicrobials undergo biotic/abiotic degradation in the environ-
ment (Sarmah et al., 2006), and only some of the degradation
products exhibit antimicrobial potency (Halling-Sørensen et al.,
2002). Data on the bioavailability of agricultural antimicrobials
in situ are still missing (Heuer et al., 2011).
There are demonstrated links between agricultural antimi-
crobial use and expansion of the environmental resistome and
mobilome (reviewed by Nandi et al., 2004; Ghosh and LaPara,
2007; Heuer et al., 2008, 2011; Zhang et al., 2009; Allen et al.,
2010; Gaze et al., 2013; Zhu et al., 2013). A historical analysis
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of soil samples collected from 1940 to 2008 in the Netherlands
found an exponential increase of AMR genes in agricultural soils
(Knapp et al., 2010). Horizontal gene transfer largely contributes
to the proliferation and persistence of AMR genes in the environ-
ment. After being introduced into the environment microbiome,
animal-waste borne bacteria can transfer their AMR genes to
indigenous bacteria through conjugation due to the frequent
assembly of AMR genes on integrons, transposons and plasmids
in the animal waste microbiome (Andrews et al., 2004; Nandi
et al., 2004; Binh et al., 2008; Byrne-Bailey et al., 2011; Heuer
et al., 2011; Zhu et al., 2013). This process can be stimulated
by enhanced nutrient availability from animal wastes (van Elsas
et al., 2003). Even after AMR bacteria of the animal gut micro-
biome died, their AMR genes can persist and be taken up by
soil bacteria through transformation (Lorenz and Wackernagel,
1994) and thus proliferate in the environmental microbiome.
Positive correlations have been observed between the concentra-
tion of antimicrobials and the abundance of MGEs carrying AMR
genes in soil or water (Knapp et al., 2008; Zhu et al., 2013). But
it is unclear whether this is due to enhanced horizontal gene
transfer or selection on the recipient populations after transfer.
Longitudinal and systemic studies on the environmental resis-
tome and mobilome in response to agricultural stress are needed
to assess its broad impacts on microbial ecosystems.
We have studied the presence of drugs, resistant bacteria, resis-
tance genes, and resistance-encoding plasmids in soil microbiota
near a waste storage site at a concentrated poultry production
operation in the US in comparison to several sites within a pro-
tected state forest in the same region (You et al., 2012). Neither
tetracycline nor chlortetracycline was detected in the forest soil
samples, but measurable levels (<10μg/kg) were detected in
the farm samples from near the storage site. Farm samples also
contained a high proportion of tetracycline resistant bacteria as
compared to forest samples. Resistance genes (tetM, O and ermA,
B, C) as well as plasmids containing tetL were only detected in
farm soils. While tetL was found in both farm and forest sam-
ples, its prevalence was much higher in the former. In all of the
perspectives, soil from a less waste-affected site at the same con-
centrated poultry production operation showed no significant
difference from forest soil. These results are similar to those pub-
lished on soils impacted by swine wastes (Agerso et al., 2006;
Ghosh and LaPara, 2007). The results of our study suggested that
resistance could persist within the soil microbiome. A study by
Sengelov et al. (2003) reported persistence of resistant isolates for
300 days after application of swine wastes to soil. Another study by
Ghosh and LaPara (2007) reported that bacterial resistance levels
in soil with excessive application of swine manure were sustained
for at least 18 months.
In summary, poultry and livestock wastes are an important
anthropogenic source of antimicrobial pressure, at low levels,
for the microbiomes of hosts and environments. The ecologi-
cal and evolutionary events in the environmental microbiome
in response to animal waste inputs include interactions between
antimicrobials (also other chemicals as exemplified in the next
paragraph) and the environmental microbiome; interactions
between the waste microbiome and the environmental micro-
biome; and interactions between the environmental microbiome
and resistance genes in waste. These interactions are relevant
to the expansion and persistence of the resistome within the
environmental microbiome, which may in turn expose human
microbiomes through multiple pathways. Because of the complex
nature of these interactions and the diversity of environmental
microbiomes, studies at a systems level using advanced “omics”
methods are in particular need.
INTERACTING STRESSORS IN THE GUT AND
ENVIRONMENTAL MICROBIOMES–ANTIMICROBIALS AND
METALS
Feeds for food animals are complex mixtures of natural products
from both crop and animal sources, as well as recycled wastes
and other additives (Sapkota et al., 2007). As a result, there are
multiple potential stressors, in addition to GPAs, presented via
feeds to food animal gut microbiomes. These include metals that
are known to co-select for resistance in bacteria (Baker-Austin
et al., 2006). For example, arsenicals are used as coccidiostats and
growth promoters, copper and zinc are used as trace element sup-
plements, mercury is present as a contaminant in fish meal (a
major constituent of poultry feeds), as well as a range of metals
in industrial waste byproducts permitted as additives to animal
feeds (in the US). These metals are not metabolized (except in the
case of arsenic, where chicken gut microbiota metabolize roxar-
sone, an organoarsenical, into the more toxic form of inorganic
arsenic Stolz et al., 2007) and thus like antimicrobial drugs, they
are excreted into wastes (Garbarino et al., 2003; Jackson et al.,
2003) and transferred into soil through waste disposal (Gupta and
Charles, 1999; Rutherford et al., 2003).
Previous microbiological research under both laboratory and
field conditions have reported on interactions between these met-
als and antimicrobials in terms of co-selection for and co-transfer
of resistance among bacteria via MGEs containing both metal
and drug resistance genes (Bass et al., 1999; Baker-Austin et al.,
2006; Singer et al., 2006; Stepanauskas et al., 2006; Wright, 2007;
Tuckfield andMcArthur, 2008; Novo et al., 2013). Significant pos-
itive correlations were observed between tet genes and several
metals in a study of swine waste lagoons (McKinney et al., 2010),
and between total AMR genes and copper in a study of manure,
compost, and soils from swine farm (Zhu et al., 2013).
These interactions have extended to human health con-
cerns. There is evidence that exposure of human hosts to mer-
cury increases odds of their carrying antibiotic resistant E. coli
(Skurnik et al., 2010). It has been known for some time that
tcrB, a copper resistance gene, is transferrable and linked to genes
encoding macrolide and glycopeptide resistance (Hasman and
Aarestrup, 2002). This was recently confirmed independently by
two research groups (Amachawadi et al., 2013; Silveira et al.,
2014) who also showed that tcrB could be transferred by con-
jugation among enterococci from pigs, poultry, and cattle along
with resistance genes for erythromycin, tetracycline, vancomycin,
ampicillin, and gentamycin. Cavaco et al. (2011) reported that
cadmium and zinc drive co-selection for methicillin resistance
in Staphylococcus aureus through horizontal transfer of plasmids
containing genes for both methicillin and metal resistance (mec
and czr).
These findings indicate the need to consider interaction effects
of antimicrobials and other stressors within agricultural set-
tings in terms of driving AMR emergence and dissemination,
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particularly in light of the complex nature of manufactured feeds
utilized in food animal production.
CONCLUSIONS: ANTIMICROBIAL RESISTANCE IS A FORM
OF ENVIRONMENTAL POLLUTION
Resistance dissemination involves multiple microbiomes, each
having a complex ensemble of microbes, particularly in the
case of the environmental microbiome. These microbiomes are
encountering diverse interacting stressors, and gene flow occurs
through these microbiomes. Systems-biology approaches driven
by “omics” methods (Raes and Bork, 2008) can improve our
understanding of mechanisms of AMR development and per-
sistence. Meanwhile, the “eco-health” perspective that takes into
account linkages between ecosystems and health (Zinsstag et al.,
2011) can improve our health practices, in particular those prior
to human exposure.
An intriguing concept has been proposed, to consider AMR
as environmental pollution, most comprehensively explained by
Martinez (2009). There are some studies utilizing this concept
to track AMR genes in landscapes, most frequently in studies of
watersheds (Pei et al., 2006; Pruden et al., 2006). But this research,
important as it is, still does not fully exploit the importance of
the concept. If we think about “resistance” as a material thing,
not just a behavior of bacteria, we can consider how this mate-
rial behaves in environmental compartments such as water, soils,
and sediments. Because of the importance of the environment
as a locus for the emergence, persistence, and dissemination of
AMR, particularly in relevance to low level AMR pressure derived
from agriculture, this proposal merits further analysis at the the-
oretical level as well as more extensive field research in impacted
environments.
In thinking about resistance as a pollutant, we can consider
the approaches of environmental research in studying chemical
pollutants. In many respects, resistance genes have the same prop-
erties that we consider in evaluating pollutants like pesticides.
Three characteristics are important in environmental health:
hazard, persistence, and bioaccumulation. That is, does a sub-
stance in itself have properties that could seriously harm human
health, does the substance remain unchanged in the environment
without being broken down by natural processes, and finally is
the substance taken up by organisms such that its levels increase
over time in those species.
We can certainly say that an AMR gene is hazardous to
human health because when it is present in a pathogenic bac-
terial cell or population it can result in failure of medical treat-
ment of infection. Thus, resistance genes require incorporation
into an organism to express their hazard, which is not so dif-
ferent from thinking the conversion of mercury into methyl
mercury and its incorporation into fish. Low dose issues are
important in understanding the hazards of agricultural use of
antimicrobials since, similar to the hazards of some environ-
mental chemicals, the pressure for selection for resistance may
be more significant at lower doses (Vandenberg, 2014). This
has been shown for failures of clinical antimicrobial treatment
(Schentag et al., 2007).
The second characteristic of importance is persistence of resis-
tance genes in the environment, about which we know relatively
little. Resistance genes can survive in soils for long periods of
time (Heuer et al., 2011). One recent study demonstrated that
purified DNA from transplastomic plants encoding resistance to
streptomycin could be detected as long as 4 years after being
added into soils, and that these resistance genes could still be
taken up by bacteria and incorporated into their chromoso-
mal DNA for expression (Pontiroli et al., 2010). Persistence of
resistant phenotypes is complex. There are both theoretical and
empirical data to challenge the standard model of evolution-
ary selection for AMR or for susceptibility depending upon
the presence or absence of antimicrobial stress (Andersson and
Hughes, 2010). Theoretically, Levin and others have demon-
strated that there are two evolutionary “choices” for resistant
bacteria to adapt to the absence of stress when the expres-
sion of resistance exacts some cost to the bacterial popula-
tions in terms of physiological demands or reproductive rate
(Levin et al., 2000; Rozen et al., 2007). One “choice” is rever-
sion to susceptibility; the other choice is selection for a means
to reduce this cost. Both choices involve mutation either back
to the wild type gene or to a change in some other gene
that is associated with increased Malthusian fitness. The second
path may be a more adaptive strategy for microbial commu-
nities under continuous or periodic stress from antimicrobials,
as in an environment with inputs of antimicrobial drugs from
agriculture.
The third key characteristic of chemical pollutants in the
environment in terms of raising alerts is bioaccumulation and
biomagnification, or uptake and retention of chemicals in biota
and increase in concentration within ecosystems through food
chains. DNA (extracellular or intracellular) in the environ-
ment, like chemicals in the environment, can be accumulated
by bacteria through transformation (Lorenz and Wackernagel,
1994) and on hierarchical compositions of MGEs through inser-
tion (Frost et al., 2005). Biomagnification of a resistance gene
occurs within microbiomes by the expansion of bacterial pop-
ulations or MGEs carrying that gene. That is, (1) once a novel
gene is taken up and incorporated into a bacterial genome,
when that organism divides, its daughter cells each contain
the new gene, which is a highly efficient process of increas-
ing the total amount of that gene; or (2) once a novel gene is
inserted in a MGE, when the MGE invades a bacterial commu-
nity, diverse populations acquire the new gene through repeated
infections.
RESEARCH NEEDS
From this brief review, we can identify some important research
needs relevant to increasing our understanding of low dose
antimicrobial exposures (including but not limited to GPAs in
agriculture) in the context of microbial ecology and evolution.
These questions in many cases can best answered with longitu-
dinal studies using state of the art methods to interrogate the
microbiome and its constituent elements such as the resistome
and the mobilome. As noted by others, there is a critical lack of
such studies at the systems level that permit examining associa-
tions between changes in the environmental resistome and well
annotated changes in the drivers related to agricultural land use
(Singer et al., 2006; Shade et al., 2013).
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(1) What does it mean to expose the microbiome to multiple
antimicrobial and metal stressors at low doses?
(2) What does it mean to stress the gut microbiome continuously
over the lifetime and generations of food animals in terms of
resistance and other changes at the microbiome level?
(3) What events occur in food animal wastes in terms of expand-
ing the resistome? What is the contribution of the continued
presence of residual antimicrobials in wastes?
(4) What events occur in soils where food animal wastes are
repeatedly applied and in sediments impacted by agricultural
runoff? What is the contribution of the continued presence of
antimicrobials at low concentrations in soils and sediments?
(5) How long is the persistence of resistant bacteria in animal
wastes? How long is the persistence of resistance genes in the
soil or sediment ecosystem?
(6) How can we quantify the contribution of food animal pro-
duction using GPAs to the expansion of the environmental
and human host resistome/mobilome?
(7) What are the major pathways from environmental compart-
ments such as soils or sediments to humans; to what extent
do these pathways involve passage through the microbiomes
of wild or other domesticated animals?
(8) What are the most effective and efficient methods for study-
ing these events at the system level?
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The release of antibiotics (AB) into the environment poses several threats for human
health due to potential development of AB-resistant natural bacteria. Even though the
use of low-dose antibiotics has been promoted in health care and farming, significant
amounts of AB are observed in aquatic environments. Knowledge on the impact of AB
on natural bacterial communities is missing both in terms of spread and evolution of
resistance mechanisms, and of modifications of community composition and productivity.
New approaches are required to study the response of microbial communities rather than
individual resistance genes. In this study a chemostat-based experiment with 4 coexisting
bacterial strains has been performed to mimicking the response of a freshwater bacterial
community to the presence of antibiotics in low and high doses. Bacterial abundance
rapidly decreased by 75% in the presence of AB, independently of their concentration, and
remained constant until the end of the experiment. The bacterial community was mainly
dominated by Aeromonas hydrophila and Brevundimonas intermedia while the other two
strains, Micrococcus luteus and Rhodococcus sp. never exceed 10%. Interestingly, the
bacterial strains, which were isolated at the end of the experiment, were not AB-resistant,
while reassembled communities composed of the 4 strains, isolated from treatments
under AB stress, significantly raised their performance (growth rate, abundance) in the
presence of AB compared to the communities reassembled with strains isolated from the
treatment without AB. By investigating the phenotypic adaptations of the communities
subjected to the different treatments, we found that the presence of AB significantly
increased co-aggregation by 5–6 fold. These results represent the first observation of
co-aggregation as a successful strategy of AB resistance based on phenotype in aquatic
bacterial communities, and can represent a fundamental step in the understanding of the
effects of AB in aquatic ecosystems.
Keywords: antibiotic resistance, experimental ecology, aquatic bacteria, ecological interactions, aggregation
INTRODUCTION
The occurrence of antibiotics (AB) in aquatic environments is of
major concern because of potential spread of AB resistance and of
ecosystem alteration (Levy, 1992).
Natural AB are constantly produced by microorganisms and
their presence in the environment in very low concentrations was
largely underestimate as a potential key factor in controlling eco-
logical interactions (Gullberg et al., 2011). The increased use of
AB, and the production of new generations of semi-synthetic
AB raise even more concerns about their effect on the natu-
ral bacterial communities. Pharmaceuticals, including AB, are
only partially eliminated in wastewater treatment plants, there-
fore residual amounts can reach surface waters or groundwater,
where these bioactive compounds potentially impact on natu-
ral microbial communities (Hirsch et al., 1999; Czekalski et al.,
2012). AB load has been quantified for a number of water bod-
ies and water treatment plants all over the world, demonstrating
a strong correlation between human activities (urbanization,
farming) and the amount of AB released in the water (McArdell
et al., 2003). Although most water treatment plants can reduce by
an order of magnitude the concentrations of several AB by sorp-
tion transfer to sewage sludge (Giger et al., 2003), AB loads in the
range of 5–10μg L−1 have been detected in a number of rivers
in different highly anthropized areas around Europe in the last
decades (Richardson and Bowron, 1985; Hirsch et al., 1999; Giger
et al., 2003). The problem of AB in aquatic environments has been
rather underestimated with the consequence of a poor policy on
the control of the AB releases (Ternes, 1998; Sarmah et al., 2006)
resulting in the discovery of a number new AB resistances devel-
oped in aquatic environments (Baquero et al., 2008; Kümmerer,
2009).
Currently used bactericidal or bacteriostatic AB, which are
thus released in the environment, are grouped in three main
modes of antimicrobial action: ABs acting against the bacterial
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membrane or cell walls, (e.g., β-lactam), AB targeting protein
synthesis through the ribosomal subunits (e.g., tetracycline), and
ABs which interfere with the nucleic acid synthesis (e.g., fluo-
roquinolones) (Sengupta et al., 2013). These groups of AB are
nowadays considered within the principal contributors to emer-
gence and maintenance of new resistances within the natural
bacterial communities, resulting in direct risk for human health
(McArdell et al., 2003). A number of studies found large pools
of genes involved in the development of resistances to clinically
relevant AB within the complex bacterial communities of aquatic
and terrestrial environments (D’Costa et al., 2006; Pruden et al.,
2006), where horizontal gene transfer can promote their rapid
spread and maintenance. Resistances generally covered the whole
sets of AB tested, confirming the rapid adaptability of natural
communities, not only to the natural AB but also to new synthetic
ones: in 2005 the resistance of over 400 strains library isolated
from soils to natural erythromycin (introduced in 1952) was of
27% while the resistance against the semisynthetic telithromycin
(FDA approved in 2004) was already of 17% of the strains
(D’Costa et al., 2006). This leads to the consideration of envi-
ronmental bacterial communities exposed to anthropic impact as
significant repository of AB resistances.
A number of possible factors can promote the development of
a resistance to a specific AB in low dose, and bacterial communi-
ties usually exposed to high selection pressure in the environment,
developed peculiar features (e.g., broad phylogenetic diversity,
phenotypic plasticity, presence of peculiar strains within the
rare species, competition pressure favoring rapid evolution) that
makes them extremely feasible toward AB resistance spread.
Recently, ideal reservoirs of AB resistances in waters were iden-
tified by Drudge and coworkers (Drudge et al., 2012) in water
flocs, microparticles composed by a number of tens to thou-
sands of bacterial cells belonging to different species and even-
tually grown around an organic substrate, i.e., “marine snow”
(Alldredge and Silver, 1988) and “freshwater snow” (Grossart and
Simon, 1993). This can be attributed to the chemical richness of
the flocs themselves coupled to the proximity of bacterial pop-
ulation that lives aggregated around the particle. The flocs can
represent a barrier against AB penetration, reducing its concen-
tration toward the center of the aggregate, and at the same time,
because of proximity, can promote horizontal gene transfer and
thus enhance AB resistance spread within the clustered bacterial
community. These particular microenvironments are also well
studied in oceanography and theoretical ecology, as they repre-
sent ideal hot-spots for bacterial production and organic matter
degradation (Azam and Malfatti, 2007; Corno et al., 2013), with
enhanced ecological interactions between organisms and complex
food-webs in a spatially limited habitat.
It can be guessed that the presence of low doses of AB in waters,
promotes not only resistance but, as more immediate response,
other kinds of adaptations of the bacterial community, potentially
involving alterations of the fitness and of species composition,
with unpredictable effects on the stability of the system itself.
In order to deepen our knowledge on the ecological effects
of AB in natural water bodies, we performed the first exper-
imental study where different doses of AB triggered a natural
bacterial community under controlled laboratory conditions. The
bacterial community was designed in order to reproduce a very
simplified non-AB resistant freshwater planktonic community.
In continuous culture mimicking lake water conditions, bacteria
were exposed to a cocktail of three antibiotics chosen from the
most commonly used ones in Europe.Wemeasured bacterial pro-
ductivity and fitness, community composition, and phylogenetic
distribution. Furthermore, we tested the degree of adaptation
to AB of single strains and communities (i.e. acquisition of AB
resistance) in order to assess the ecological impact of AB in
concentrations comparable with anthropized waters in Central
Europe on the bacterial community.
MATERIALS AND METHODS
SELECTION OF ISOLATES AND ANTIMICROBIAL SUSCEPTIBILITY
TESTS
Four freshwater bacterial strains isolated from European lakes
have been used for this study: Aeromonas hydrophila strain
GC035, Brevundimonas intermedia strain GC044 andMicrococcus
luteus strain GC037 have been isolated from Lake Zurich
(Switzerland), while Rhodococcus sp. strain NO0007 has been iso-
lated from Lake Maggiore (Italy). Partial 16SrDNA sequences
of each strain are deposited in Genbank (accession nrs.
KJ409640-43). The community composed by the mixture
of these strains reproduces an extremely simplified bacterial
community of a classical deep European oligo-mesotrophic
lake: A. hydrophila (Gammaproteobacteria) and B. intermedia
(Alphaproteobacteria) are common in freshwater and in partic-
ular conditions can dominate lakes communities (Farmer et al.,
1992; Zwart et al., 2002), while M. luteus and Rhodococcus sp.
(Actinobacteria) despite rather frequently found in freshwaters
are always limited to very little numbers and non-significant
relative abundances (Newton et al., 2011).
The four strains were preliminary subjected to antimicrobial
susceptibility test to the AB further used in this study, namely
levofloxacin, tetracycline, and imipenem (Oxoid, Milan, Italy) by
disc diffusion method, according to the Clinical and Laboratory
Standards Institute CLSI (2008). Because published breakpoints
for the species used are missing, the interpretive standards of
the diameter zone were applied as follow: non-Enterobacteriaceae
or nonfastidious Gram-negative rods were used to interpret
the diameter zone values for B.intermedia and A. hydrophila;
Staphylococcus sp. for M. luteus, and Corynebacterium for
Rhodococcus sp. (CLSI, 2008 and EUCAST, 2014). The same pro-
cedures and interpretative standards were used for the determi-
nation of antimicrobial susceptibility of the four strains isolated
after the experiment in continuous culture.
CONTINUOUS CULTURE DESIGN
Bacterial strains were pre-cultivated for 3 days in Artificial Lake
Water medium (ALW, Zotina et al., 2003). Aliquots from each
pre-culture were then used to prepare the experimental commu-
nity, which was inoculated into the chemostat.
The main experiment was carried out in a one-stage contin-
uous cultures system consisting of 9 reactors (Figure 1); three
parallel chemostat vessels were run for each treatment (NO AB,
AB+, AB++). The chemostat was assembled in a climate cham-
ber (18 ± 1◦C) with a night-day period of 12 h and ran for
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy July 2014 | Volume 5 | Article 297 | 144
Corno et al. Aggregation favors resistance to antibiotics
FIGURE 1 | Continuous culture design. Substrate was continuously renewed (0.2 d-1) through peristaltic pumps, aeration (fine bubbling) was performed in
order to ensure a full mixing of the water in the vessel and to prevent the deposition of detritus.
25 days. The 9 vessels were filled with 750ml of ALW medium
enriched with 10mg glucose L−1 as the sole C-source. New
medium was continuously pumped in the vessels by a multi-
channel peristaltic pump (Watson-Marlow 205S) from three 20
L reservoirs, in order to achieve a dilution rate of D = 0.2 d−1.
The vessels were aerated from the bottom by fine bubbling with
sterile air (Figure 1).
AB impact on the bacteria was tested at different concentra-
tions of the same AB cocktail, composed by an equal mixture
of tetracycline (Sigma-Aldrich, CAS number 60548), imipenem
(Sigma-Adlrich, CAS 74431-23-5; β-lactam, subgroup carbapen-
ems), and levofloxacin (Sigma-Adlrich, CAS 100986854; fluoro-
quinolon) to a final concentration of 12.5μg AB L−1 (treatment
AB+), and of 125μg AB L−1 (treatment AB++). Treatment
NO AB, without antibiotics, was used as control. The AB mix-
tures were added directly to the AB+ and AB++ 20 L reservoirs.
Concentration AB+ mimes the natural concentration of AB in
polluted effluxes by waste water treatment plants in anthropized
areas in Central Europe (Kümmerer, 2009), while concentration
AB++ represent a concentration 10 times higher than the high-
est reported in nature. The selection of the three ABs used for
the cocktail is consistent with the major AB groups nowadays
consumed in Western countries (Food and Drug Administration
report 2011—FDA Annual Report on Antimicrobials Sold or
Distributed for Food-Producing Animals in 2011; UCM338170).
About 18ml of the assembled freshwater community was inoc-
ulated into each of the 9 reactors to obtain a final concentration
of 1.0 × 106 cells ml−1 (composed by 0.25 × 106 cells ml−1 of
each strain). After an acclimation of 48 h without dilution, the
systemwas switched on and the experiment started. Daily samples
(5ml/vessel) were collected for the analysis of bacterial abun-
dance; weekly samples (25ml/vessel) were taken for the analyses
of community composition and phenotypical distribution.
BACTERIAL ABUNDANCE AND PHENOTYPICAL DIVERSITY
Bacterial cell numbers were determined from 0.5ml
formalin-fixed (2% final concentration) samples stained
with 4′,6-diamidino-2-phenylindole (DAPI) (Porter and Feig,
1980), filtered onto 0.2μm polycarbonate filters, and counted by
epifluorescence microscopy (Axioplan, Zeiss). At least 400 bac-
terial cells were counted per sample. Different phenotypes were
classified on the base of the bacterial social behaviors: free living
single cells, microcolonies composed by few aggregated cells
(generally belonging to the same strain), and larger aggregates
composed by several clustered individuals belonging to different
species (Corno et al., 2013). Images for the sizing of aggregates
and microcolonies were captured with a DP72 high resolution
camera (Olympus) and evaluated by image analysis (ImagePro
Plus, Media Cybernetics).
Aggregates size was approximated by determining the maxi-
mal Feret dimension (Femax) of single cells cluster as detected on
DAPI stained filters. Aggregates were grouped into size classes
each 10μm. Cell clusters composed by at least 5 cells, with
Femax <10μm were considered as microcolonies. The relative
importance of the aggregated cells within the bacterial commu-
nity was obtain by the estimation of their average number for
aggregate for each size class, thenmediated to cover the aggregates
size distribution for each sample (Corno et al., 2013). In detail, the
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average cells number per aggregate was estimated by the median
values for the corresponding aggregate size class and the average
bacterial cell sizes, as obtained from epifluorescence microscopy.
The reliability of the estimation was tested by comparing the
organic carbon content of the bacterial community (estimated
per bacterial cell per strain according to Loferer-Krössbacher et al.
(1998) and the direct measurement of POC in the same sam-
ple. Briefly, the relative proportion of each strain in the sample,
the specific amount of C per cell of each strain, and the differ-
ence between the total measured POC and the POC in single free
living cells, were used to estimate the amount of C in the aggre-
gates, then related to the different size classes (Corno et al., 2013).
In order to reduce the potential approximation error in the dif-
ferent size classes we merged our results in the general group
“Aggregates.”
BACTERIAL COMMUNITY COMPOSITION
The composition of the bacterial community was analyzed by
catalyzed reporter deposition-fluorescence in situ hybridization
(CARD-FISH) coupled with fluorescence microscopy. Weekly
collected samples were fixed with freshly prepared buffered PFA
(1% final concentration) and then concentrated on 0.2μm poly-
carbonate filters (GTTP, Millipore). Filters were rinsed twice
with sterile phosphate buffered saline (PBS), air-dried and stored
at −20◦C until further processed. The following probes were
used to determine the relative proportions of specific bac-
terial populations: ALF968 for Alphaproteobacteria (Glöckner
et al., 1998), GAM42a (mixed with the corresponding competi-
tor probe) for Gammaproteobacteria (Manz et al., 1992), and
HGC69a for Actinobacteria (Roller et al., 1994). CARD-FISH
was performed according to Sekar et al. (2003). The relative
proportion of each strain was then counted by epifluorescence
microscopy. Actinobacteria were additionally subdivided within
the two strains used in this study, by visual recognition: while
Rhodococcus sp. cells are rods of different length, M. luteus
cell shape is always coccoid with constant dimensions, thus
they are morphological easily distinguishable by epifluorescence
microscope.
POST CONTINUOUS-CULTURE RE-ISOLATION AND ANALYSIS
At the end of the experiment, each bacterial strain was isolated
from each treatment on ALW agar plates in order to be tested
for potential acquired AB resistance. Rhodococcus sp. strain could
not be isolated from treatments AB+ and AB++; the clonal
strain of the inoculum was used instead. Purity of the isolated
strains was checked by CARD-FISH: only cultures with 100%
of positive hybridization rate were then used in further experi-
ments. Single cultures from the different isolates were tested for
antimicrobial susceptibility as described above. Single cultures
and re-assembled communities (composition is described below)
were also tested for growth in 96 well plates: 200μl culture in
ALW medium enriched with 20mg L−1 of Glc, inoculum con-
centration 1 x 106 bact ml−1 in triplicate for each experimental
treatment. For example, A. hydrophila isolated fromNOAB treat-
ment was inoculated in triplicate in NO AB, AB+, and AB++
wells. The disposition of the treatments and the distribution of
the strains in the plates was randomized. Bacterial communities
were re-assembled bymixing the strains in identical proportion to
reproduce the same initial conditions as in the chemostats. Plates
were incubated (same conditions than for the chemostat) for 48 h,
radially shaken for 30 s every 30min and growth was measured
every 24 h as optical density (OD) of each well with a plate reader
Glomax Multi-detection System (Promega) cleaned of the blank
signal and other potential noises.
STATISTICAL ANALYSES
In order to evaluate the significance of the difference in the
median values between groups the Wilcoxon-Mann-Whitney test
was applied. To test for statistical differences with the expected
median value within a single time series a t-test was performed,
after testing for normal distribution of the series. All analyses were
performed by using software JMP10 (SAS Institute Inc.).
RESULTS
ANTIMICROBIAL SUSCEPTIBILITY TESTS IN PRE AND POST TREATED
ISOLATES
The resistance antibiotypes of the four isolates—before and after
the continuous culture experiments—are shown in Table 1. All
strains resulted to be susceptible to the tested antibiotics with the
exception of B. intermedia which showed intermediate resistance
for levofloxacin. The correlation of the resistance antibiotypes
Table 1 | Results of antimicrobial susceptibility tests by disk diffusion
method.
Bacterial strains Zone diameter values in mm
(results)
IMP TET LEV
Aeromonas hydrophila GC035 34 (S) 28 (S) 34 (S)
A. hydrophila (NO AB) 33 (S) 29 (S) 33 (S)
A. hydrophila (AB+) 34 (S) 29 (S) 34 (S)
A. hydrophila (AB++) 34 (S) 29 (S) 34 (S)
Brevundimonas intermedia GC044 47 (S) 38 (S) 18 (I)
B. intermedia (NO AB) 47 (S) 38 (S) 18 (I)
B. intermedia (AB+) 47 (S) 38 (S) 18 (I)
B. intermedia (AB++) 47 (S) 38 (S) 18 (I)
Micrococcus luteus GC037 33 (S) 23 (S) 22 (S)
M. luteus (NO AB) 33 (S) 23 (S) 23 (S)
M. luteus (AB+) 33 (S) 23 (S) 23 (S)
M. luteus (AB++) 33 (S) 23 (S) 23 (S)
Rhodococcus sp. NO007 55 (S)* 40 (S) 26 (S)
Rhodococcus (NO) 55 (S)* 40 (S) 26 (S)
Zone diameter values of the four isolates before the experiments /first row for
each strain) and of those re-isolated from the 3 different treatments (NO AB,
AB+, and AB++). The results of the interpretation are indicated in brackets
(S, susceptible, R, Resistant, I, Intermediate; * values ≥ 55 are off scale). For
disk zone diameter interpretation CLSI (2008) and EUCAST (2014) standards
were used, considering the values for non-Enterobacteriaceae or nonfastid-
ious P.aeruginosa, S.aureus and Corynebacterium sp. for A. hydrophila and
B. intermedia, M. luteus and Rhodococcus sp., respectively.
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FIGURE 2 | Bacterial abundances in continuous culture vs. time. Overall
bacterial numbers are given as mean of three replicates (± SD) for each of
the three treatments.
allowed us to exclude potential pre-existing competitive advan-
tages for single strains once exposed to AB.
BACTERIAL ABUNDANCE AND COMMUNITY COMPOSITION
A steady community of about 4 × 106 bact ml−1 characterized
the treatment NO AB already from day 2, without significant
fluctuations through the whole experiment (P = 0.532), while in
treatments AB+ and AB++ the overall community abundance
rapidly reduced by 75% (to about 1 × 106 bact ml−1) indepen-
dently by the AB concentration, and remaining then constant to
the end of the experiment (Figure 2). No significant differences in
numbers were detected between the treatments AB+ and AB++
considering the period 4–24 days (P = 0.836).
Community composition did not have important variations
during the experiment after day 2 (Figure 3), either. The four
strains could be detected in every sample on each date, thus
extinction events were not detected for any AB concentration.
Communities resulted either dominated by A. hydrophila (AB+),
B. intermedia (AB++), or by an almost equal proportion of
the two strains (NO AB), that together always achieved a rela-
tive abundance over 90% of the total bacterial number. The two
Actinobacteria rapidly reduced from 50 to less than 10%, with a
relative predominance of Rhodococcus sp. in all the treatments.
PHENOTYPICAL DISTRIBUTION
The weekly assessment of the relative proportion of free living
single cells, microcolonies composed by a few cells (in average
up to 25), and larger cell aggregates (Figure S1) showed different
aggregational behavior of the bacterial community once exposed
to AB (Figure 4). Clustered cells (microcolonies and aggregates)
at the beginning of the experiment never exceed 10% of the over-
all community. In treatment NO AB their proportion constantly
decreased to less than 3%, while in treatments AB+ and AB++
they rapidly rose to 20-25%, keeping then constant up to the
end of the experiment. Again, there was a significant effect of the
AB (P<0.001 for both treatment comparison: NO AB vs. AB+
and vs. AB++), but no significant differences between the two
treatments with AB (P = 0.394).
FIGURE 3 | Relative proportion of each strain in continuous culture vs.
time. The relative proportion of each strain is given as mean of three
replicates at day (d) 0, 4, 13, 16, and 20, for each of the three treatments
(from top to bottom): NO AB, AB+, AB++.
RE-GROWTH OF ADAPTED STRAINS
Bacterial strains isolated from the different vessels at the end of
the continuous culture experiment were then tested for the devel-
opment of AB resistance, potentially acquired while exposed to
AB in the chemostat (Table 2). Zero or negative values between
time 24 and 48 in the newly isolated single culture demonstrated
that none of the three strains tested (B. intermedia, A. hydrophila,
and M. luteus) could grow when re-inoculated in AB enriched
media, independently by the AB concentration and by their treat-
ment of origin. At this stage it resulted impossible to recover
Rhodococcus sp. from the continuous culture treatments with AB,
where Rhodococcus sp. was present only within co-aggregates.
Rhodococcus sp. already demonstrated a very slow growth on agar,
then, it is likely that in plates it suffered the competition by
most growth-effective strains, and thus got outcompeted. For this
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FIGURE 4 | Relative proportion of cells clustered in continuous culture
vs. time. The relative proportion of aggregated cells is given as mean of
three replicates (± SD) for each of the three treatments.
reason and for consistency, in the post-continuous cultures exper-
iments we used the same Rhodococcus sp. strain we used at the
beginning of the experiment for the inoculum in the chemostat.
These results are supported by the susceptibility confirmed
with disk diffusion methods after the continuous culture exper-
iment (Table 1). At the same time all strains responded positively
to the growth in NO AB medium, without significant differences
between the same strains isolated from different treatments.
The re-assembled communities, composed by an equal mix-
ture of the strains isolated at the end of the continuous cul-
ture experiment, performed as expected in treatments NO AB,
again without significant differences between communities iso-
lated from different treatments with or without AB. In contrast,
a significant growth of the communities composed by strains
exposed to AB during the continuous culture experiment was
detected when those were grown in presence of AB (Figure 5).
The acquired adaptation observed in these communities is con-
firmed by the concomitant failure of communities from the NO
AB treatment that, once exposed to AB, did not grow as the sin-
gle strains that composed them. Also in this respect, the impact
of AB caused a comparable response independently by the AB
concentration in the medium.
DISCUSSION
The assessment of the overall sub-lethal (or the sub-inhibitory)
concentration of antibiotics for a natural bacterial community is
basically impossible, as too many bacterial species and even sub-
species can have different sensitivity to different AB. Moreover,
the sensitivity of the different species composing the community
can change in time and space with changing ecological param-
eters, community composition, and evolutionary history. At the
same time, recent studies demonstrated that the response to AB
in low concentrations by bacterial communities in anthropized
open waters, or in waste water treatments, can significantly dif-
fer from the response of those in clinical environments (Gagneux
et al., 2006).
Table 2 | Growth of re-isolated strains and reassembled communities.
Growth T24–T48 (Absolute OD values)
Bacterial strains/communities NO AB AB+ AB++
Brevundimonas (NO AB) 0.083 0.023 0.009
Aeromonas (NO AB) 0.068 −0.011 0.005
Micrococcus (NO AB) 0.040 −0.019 −0.003
Rhodococcus (NO AB) 0.020 −0.007 0.008
Brevundimonas (AB+) 0.049 0.036 0.002
Aeromonas (AB+) 0.054 −0.009 0.004
Micrococcus (AB+) 0.047 −0.011 −0.002
Brevundimonas (AB++) 0.056 0.011 0.016
Aeromonas (AB++) 0.050 0.013 0.005
Micrococcus (AB++) 0.022 −0.003 0.002
Community (NO AB) 0.112 −0.001 0.002
Community (AB+) 0.103 0.032 0.042
Community (AB++) 0.104 0.056 0.046
Differences in optical density (OD) between growth time 24 and 48 h of bacte-
rial cultures isolated from the different treatments at the end of the continuous
cultures and of the relative mixed reassembled communities. In brackets it
is mentioned the origin of the strain/community, while bold numbers indicate
statistically significant growth (P < 0.01, student t-test).
The design of a simplified bacterial community, tested under
experimentally controlled conditions, reduces the complexity of
the natural environment and allows speculations at the com-
munity level, excluding a number of ecological interactions (i.e.,
viral lysis, predation) that would exponentially increase the num-
ber of variables to be taken into account (Horn˘ák and Corno,
2012), reducing our possibility to correctly evaluate the actual
effect of the AB in the system. The four strains we selected
for this study rather well represent a model community of a
large Central European lake, with strains common in every
water body and sometimes very abundant (A. hydrophila and
B. intermedia) and others less successful in waters but anyway
almost always represented within the “rare biosphere” (sensu
Pedros-Alio, 2007).
The impact of AB was immediately clear in terms of productiv-
ity of the system (Figure 2) but, interestingly, the concentration of
AB was not causing significant differences in this respect, whereas
it resulted in a different selection in terms of bacterial community
composition (BCC; Figure 3). In detail, the fitness of the bacterial
community, measured in number of new cells produced (thus, for
a chemostat, in cells abundance) was highly affected by the pres-
ence of AB, and the reduction in bacterial number (about 75%
in treatments AB+ and AB++) was independent from the AB
concentration. This result is not in accordance with the general
theory, stating that being in low concentrations, the impact of
AB in natural environment is negligible (Waksman, 1961). In this
respect, a number of studies (reviewed by Sengupta et al., 2013)
demonstrated a clear impact of low doses of AB in nature while
our study demonstrated that AB can have an impact on the pro-
ductivity of natural bacterial communities not only when in low
doses, but that this impact can be comparable to higher dosages,
raising our concerns for the release of AB into nature.
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FIGURE 5 | Growth of the reassembled communities. Growth of
communities reassembled (RAs comm) from the experimental strains at the
end of the continuous culture treatments, and preferentially re-exposed to
each experimental condition (NO AB, AB+, AB++). Values are in optical
density (OD) of each sample, and are given as mean of three replicates
(± SD) for each of the treatments.
Remarkably, the reduction of fitness had only a limited cor-
respondence with alterations of the overall ecological success of
the single strains (Figure 3). The two strains, A. hydrophila and
B. intermedia, which dominated the community without AB, still
kept having a clear supremacy also in presence of AB. Moreover
the “rare” Actinobacteria did not gain any advantage by the
reduction of potential competition for resources. A. hydrophila
appeared to be the most successful strain in communities NO AB
and AB+, while at higher AB dosage B. intermedia resulted to
be the most abundant genotype. This can be related to a inter-
mediate susceptibility of B. intermedia to levofloxacin in high
dosages, or to a significant increment of the inhibitory activity of
AB toward A. hydrophila. In any case, the modifications occurred
in the BCC demonstrated that, despite the buffering capabilities
of mixed bacterial communities can limit the impact of exter-
nal factors, the presence of AB, even in low concentration, can
modify the structure of the bacterial community. Reduced resis-
tance and potential reduced resilience of the bacterial community
can promote the success of allochtonous bacterial strains (e.g.,
pathogens, enhanced when AB are the disturbing factor) which
would otherwise be eliminated by the means of competition.
Although modifications in the genotypic composition of the
community were only partially affected by the presence of AB,
the phenotypic distribution drastically changed. When exposed
to AB the bacterial community switched from a free living single
cells dominated community (treatment NO AB) to communi-
ties where almost 1 bacterial cell out of 3 clustered in aggregates
with other cells (Figure 4). Since the experiment was conducted
in a continuous culture system, with a constant efflux, this incre-
ment in proportion within the community has to be related to
an effective clustering activity, thus in a significant competitive
advantage for clustered cells in comparison to the free living ones.
Large co-aggregates composed by up to 500 cells belonging to 2–4
different strains, as well as smaller microcolonies composed by
only one strain rapidly appeared in presence of AB and, again,
their proportion was comparable in treatments exposed to dif-
ferent AB concentrations. It can be speculated that the resistance
strategy developed in our system by typical freshwater strains is
based on the formation of aggregates, that ensure a AB free envi-
ronment for the cells embedded into them, and that this strategy
is thus equally efficient at AB+ and AB++ antibiotic concentra-
tions. Co-aggregates and microcolonies represent a well-studied
phenotype (or a specific “social behavior”) in planktonic bac-
teria: aggregation can protect bacteria from predation (Corno
and Jürgens, 2008), from starvation (Hahn et al., 2000), and can
reduce competition and raise the productivity (Blom et al., 2010),
thus preserves diversity and reduces the extinction risk in some
peculiar cases (Horn˘ák and Corno, 2012).
Comparable to biofilms on surfaces (Costerton et al., 1999),
bacteria forming aggregates are surrounded by different forms of
self-synthetized hydrated exopolymeric matrix effectively reduc-
ing the diffusion of the AB because of to the reduced permeability
of the aggregate itself. Co-aggregation is thus a fast-developing
winning strategy for planktonic bacteria once exposed to AB
in low to intermediate concentrations, by forming particular
niches where, possibly, the effect of AB is reduced by dilution,
and the competition for resources can be less limiting (Corno
et al., 2013). Similar observations have been recently published
by Haaber et al. (2012) on pure cultures of S. aureus: under AB
stress the formation of large clusters was accompanied by an
increment in productivity. The authors found direct evidences
of an increase in tolerance toward stressors like AB for S. aureus
once aggregated. A very similar conclusion can be reached by
our study on a more complex bacterial community, where treat-
ments exposed to AB selected for bacteria with enhanced ten-
dency toward aggregation, thus less sensitive to antimicrobials. It
would be reasonable to consider the aggregational state, already
present in reduced proportion at the beginning of the experi-
ment mainly as microcolonies, not as an acquired feature, but
simply a most competitive state in presence of AB. Nevertheless,
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our results on the growth of recombined communities (Figure 5)
show that communities reassembled with strains from treatments
AB+ and AB++ perform significantly better than the one from
NO AB treatment, once re-exposed to AB. The first reassembled
communities somehow kept a “memory,” possibly because they
were isolated from cells belonging to aggregates. This observation
implies that in nature, where clustering formation is common
for many aquatic bacterial strains, aggregation can be a “ready
to use” phenotypical adaptation for bacterial communities once
exposed to AB in low concentrations, and that these microenvi-
ronments should deserve a deeper and more focused attention
in the research of AB resistances in aquatic ecosystems. In the
96-wells plate we could test the short-term response in presence
of AB of re-isolated strains and re-assembled communities from
AB treatments: the difference in the growth curves of the re-
assembled communities from treatments with AB in comparison
with those of the “non-adapted” ones were already highly signifi-
cant after 48 h from the beginning of the incubation. While the
latter dropped in abundance, the “adapted” communities were
still in exponential growth. We do not consider the enhanced OD
values recorded for the “adapted” communities as an evidence
for potential resistance but as a confirmation that the adapta-
tion observed was due to coexistence of the different strains, and
that it is an acquired feature. We can speculate that the observed
differences in OD are given by aggregate formation, as we did
not measured the phenotypical composition of the communities
within the wells. Our opinion is that after the initial spin of the
bacterial growth due to the fresh amount of organic C available,
the AB had its impact on the less adapted communities, and the
difference become evident after 48 h. A similar trend in growth
has been detected in chemostat, too. In comparison to the analy-
ses of communities in chemostat, with OD in wells there is a loss
in the power of the analysis, excluding the possibility for a dis-
crimination between active and inactive cells: the missed growth
ofmany cultures after 48 h could be accounted to a stable commu-
nity, but also to a stable number of inactive cells, thus to a dead
community.
Finally, the composition of almost the totality of the aggre-
gates we observed in this study was multispecific. Not only, single
strains isolated from treatments under AB pressure, did not per-
form better than the control strains once exposed to AB, while
the same strains in the reassembled communities did. We can
thus suggest that only through multispecific co-aggregation the
community gains an advantage against the antimicrobial action.
The complexity of the interactions within the clustered cells raised
enormously, resulting in the formation of a specific microenvi-
ronment where, through proximity and species interactions, the
resistance of the single bacterial cells against AB rose.
We can thus suggest co-aggregates as ideal environments for
fast adaptations to AB presence in aquatic systems. Our results,
following the observations of Costerton et al. (1999) of biofilms
as ideal environments for the development of AB resistances and
pathogen preservation in clinical environments, and of Drudge
et al. (2012) on the enhanced ability for aquatic bacteria to share
AB resistance genes in flocs compared open waters, highlight the
importance of aggregational states in the understanding of the
ecology of aquatic ecosystems exposed to AB.
AB contamination of global water supplies is raising, increas-
ing the risk of the development of clinically important AB
resistance in these environments in the close future, with this
study we offer one of the first attempts to get deeper into the
ecology of bacterial communities exposed antimicrobials in low
doses.
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In a recent publication by Leski et al.
(2013), the authors reported the occur-
rence of multidrug-resistant tet(X)-
containing bacterial strains in a hospital in
Sierra Leone. Among 52 clinical isolates,
11 (21%) have been confirmed tet(X)-
positive. All the positive strains have been
isolated from urinary tract infections
and identified as Enterobacter cloa-
cae, Comamonas testosteroni, Escherichia
coli, Klebsiella pneumoniae, Delftia aci-
dovorans, Enterobacter sp., and other
members of Enterobacteriaceae and
Pseudomonadaceae (Leski et al., 2013).
The need for careful monitoring of
tet(X) dissemination is dictated by the
fact that the enzyme encoded by the gene,
a flavin-dependent monooxygenase, is
capable of degrading almost all tetra-
cyclines, including the third-generation
tetracycline, tigecycline (the minocycline
derivative 9-tert-butyl-glycylamido-
minocycline) (Yang et al., 2004; Moore
et al., 2005). The US FDA approved tige-
cycline in 2005, and its use in the EU was
authorized in 2006. Its use is approved
for complicated skin and intra-abdominal
infections as well as community-acquired
pneumonia (http://www.accessdata.
fda.gov/drugsatfda_docs/label/2010/02182
1s021lbl.pdf). The antibiotic is very
efficient in treatment of a number of
infections, including those resistant to the
first- and second-generation tetracyclines
(Bertrand and Dowzicky, 2012). Despite
being considered as a drug of last resort,
its use is steadily increasing, at least in the
US (Huttner et al., 2012).
Although tigecycline resistance has not
been tested at the time of isolation (Leski
et al., 2013), the high frequency of tet(X)
encountered in clinical samples signifies a
worrying trend. In the previous analysis of
the occurrence and phylogeny of the tet(X)
genes it has been established that these
genes can be detected in environmental
DNAs and isolates as well as commensal
bacteria (Aminov, 2009). Further studies
have not spotted any expansion beyond
these ecological niches. The presence of
tet(X) has been detected in the human
gut bacteria (de Vries et al., 2011), intesti-
nal Bacteroides strains (Bartha et al.,
2011), sewage treatment plants (Zhang
and Zhang, 2011), and an oxytetracycline
production wastewater treatment system
(Liu et al., 2012). But now tet(X) is
detected in a variety of clinical isolates and
accepted human pathogens (Leski et al.,
2013). The tet(X) sequences from this
study have been added to the previous
dataset (Aminov, 2009), and the phyloge-
netic tree has been recomputed (Figure 1).
It is not surprising to see a tight cluster-
ing, with a 100% bootstrap support, of the
tet(X) sequences from Enterobacteriaceae
bacterium SL1 and Delftia sp. SL20 with
the known tet(X) genes, given the high
similarity of sequences within the cluster
that exceeds 99%.
It is important to note here that there
is no access to tigecycline (Tygacil®, Pfizer
Inc.) in the hospital where tet(X)-positive
samples were collected nor it is avail-
able through the independent pharmacies
and hospital dispensaries operating in the
area (Leski et al., 2013). Still, 87% of
pharmacies dispense the “older” tetracy-
clines without prescription. As the authors
suggest, this selective pressure of con-
tinuous application of tetracyclines may
serve to maintain and spread tet(X) and
other tetracycline resistance genes into
pathogenic microbiota. Also, the prob-
ability of co-selection cannot be ruled
out. The authors indicated the presence
of mobile genetic elements in some iso-
lates, and 10 out of 11 isolates appeared
to be harboring multidrug resistance
determinants.
In animal production systems,
the penetration of tet(X) into the
pathogens happened earlier. This can
be demonstrated with the example of
Riemerella anatipestifer, a causative agent
of septicaemia anserum exsudativa (Segers
et al., 1993). Septicaemia leads to major
economic losses in duck production (Ryll
et al., 2001; Sarver et al., 2005) but it
also affects other bird species (Sandhu
and Rimler, 1997; Hess et al., 2013).
The R. anatipestifer strain, resistant to
ampicillin, chloramphenicol, gentam-
icin, amikacin, tetracycline, nalidixic
acid, and trimethoprim/sulfamethoxazole,
was isolated in 2005 from waterfowl in
Taiwan (Chen et al., 2010). It carries
pRA0511 plasmid, which, in addition to
two chloramphenicol acetyltransferases
and a multi-drug ABC transporter per-
mease/ATPase, also encodes TetX. The
gene sequence has been incorporated into
the existing dataset (Aminov, 2009) and
recomputed (Figure 1). Similar to the
genes from human pathogens, the gene
from the poultry pathogen is confidently
grouped into the tet(X) cluster. Three
genomic sequences of R. anatipestifer,
published (Yuan et al., 2011) or available
as database entries (GenBank accession
numbers CP003787 and CP004020), also
carry chromosomally encoded genes sim-
ilar to tet(X) (Figure 1). Interestingly,
four other strains of R. anatipestifer, for
which genome sequences are available
(Mavromatis et al., 2011; Zhou et al., 2011;
Wang et al., 2012; Yuan et al., 2013), have
not yet acquired tet(X). No information
regarding antibiotic use practices at sam-
pling sites where R. anatipestifer strains
have been isolated is available in the cited
publications.
It seems that the use of even ‘older’
antibiotics may contribute to the resis-
tance to newer antibiotics. There is no
access to the third-generation tetracycline,
tigecycline (Tygacil®, Pfizer Inc.), in the
areas sampled in Sierra Leone (Leski et al.,
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FIGURE 1 | Neighbor-joining tree of the tet(X) and flavin
monooxygenase-encoding genes. Numbers above each node show the
percentage of tree configurations that occurred during 1000 bootstrap trials.
The scale bar is in fixed nucleotide substitutions per sequence position.
GenBank accession numbers of nucleotide sequences used in this analysis
are given in parenthesis.
2013). It is also highly unlikely that this
expensive new antibiotic is used in duck
production, most likely these are the first-
generation tetracyclines. Thus the conclu-
sion is that the selective pressure by older
antibiotics drives the resistance to a newer
antibiotic and contributes to the dissemi-
nation of this resistance to pathogens.
The flavoprotein monooxygenase
group of enzymes is found in many
metabolic pathways involved in the
region-specific hydroxylation of organic
substrates in all three domains of life
(Harayama et al., 1992). Based on
sequence similarity and 3D structural
data, the enzymes are divided into six
classes (van Berkel et al., 2006). Class
A enzymes, to which TetX belongs, are
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generally involved in the degradation
of phenolic compounds by ortho- or
para-hydroxylation of the aromatic ring
(Moonen et al., 2002).
Bacteria that carry these genes are
omnipresent and can be encountered
in a variety of ecosystems, including
soil, aquatic ecosystems, and intestinal
tract; some are opportunistic pathogens.
Accordingly, the range of biochemi-
cal reactions performed by this class
of enzymes is quite broad, and they
may play an important role in the
global carbon and nitrogen cycles (Chen
et al., 2011; Wang and Shao, 2012).
Interestingly, the range of metabolic activ-
ities expressed by these enzymes also
includes the modification of many antibi-
otics. Besides the tetracylines discussed
here, this range is extended to such struc-
turally different antibiotics as rifampin
(Andersen et al., 1997), mithramycin
(Prado et al., 1999), griseorhodin (Li
and Piel, 2002), chromomycin (Menendez
et al., 2004), and auricin (Novakova et al.,
2005).
The genetic context of flavin monooxy-
genase genes has been discussed earlier
(Aminov, 2009). In brief, the majority of
the genes analysed is almost uniformly
associated with mobile genetic elements,
including the plasmid-encoded tet(X) dis-
cussed here (Chen et al., 2010). The genes
in this class are also highly incongru-
ent with taxonomic positioning suggesting
horizontal gene transfer events. They are
also subject to frequent duplication events,
which are partially illustrated here with
the paralogous genes from Flavobacterium
johnsoniae UW101 and Pedobacter sp.
BAL39 (Figure 1).
The case of flavin monooxygenases is
a vivid example demonstrating enormous
adaptability of bacteria: they can freely
move their protective armours amongst
a variety of ecological compartments in
response to yet another challenge, this
time inflicted by humans in the form of
antibiotic selective pressure. The global
microbiota has been dealing with envi-
ronmental challenges for billions of years
to become sophisticated genetic engineers
moving genes around with ease (Aminov,
2011). Combined with the readily avail-
able massive metabolic resources of the
environmental metagenome, the micro-
biota seem capable of countering any
kind of environmental or anthropogenic
assault.
We are living in a fascinating era with
technological advancements that allow us
to see almost instantaneously the evolu-
tionary events leading to the emergence
of novel pathogens armed with resistance
mechanisms against the most advanced
antibiotics that we have been able to
design. We should not underestimate the
enormous genetic flexibility and the vast
metabolic capabilities of the environmen-
tal microbiota. Based on our technical
capabilities and knowledge acquired dur-
ing the antibiotic era (Aminov, 2010), we
have to make every effort, at every level
possible, to preserve the power of antibi-
otics. Taking a bystander position in this
situation is not acceptable.
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The discovery of antibiotics heralded the start of a “Golden Age” in the history of
medicine. Over the years, the use of antibiotics extended beyond medical practice into
animal husbandry, aquaculture and agriculture. Now, however, we face the worldwide
threat of diseases caused by pathogenic bacteria that are resistant to all existing major
classes of antibiotic, reflecting the possibility of an end to the antibiotic era. The
seriousness of the threat is underscored by the severely limited production of new
classes of antibiotics. Evolution of bacteria resistant to multiple antibiotics results from the
inherent genetic capability that bacteria have to adapt rapidly to changing environmental
conditions. Consequently, under antibiotic selection pressures, bacteria have acquired
resistance to all classes of antibiotics, sometimes very shortly after their introduction.
Arguably, the evolution and rapid dissemination of multiple drug resistant genes en-masse
across microbial pathogens is one of the most serious threats to human health. In this
context, effective surveillance strategies to track the development of resistance to multiple
antibiotics are vital to managing global infection control. These surveillance strategies are
necessary for not only human health but also for animal health, aquaculture and plant
production. Shortfalls in the present surveillance strategies need to be identified. Raising
awareness of the genetic events that promote co-selection of resistance to multiple
antimicrobials is an important prerequisite to the design and implementation of molecular
surveillance strategies. In this review we will discuss how lateral gene transfer (LGT),
driven by the use of low-dose antibiotics in animal husbandry, has likely played a significant
role in the evolution of multiple drug resistance (MDR) in Gram-negative bacteria and has
complicated molecular surveillance strategies adopted for predicting imminent resistance
threats.
Keywords: multi drug resistance, lateral gene transfer, bacterial genomes, complex resistance loci, Antimicrobial
growth promotion
INTRODUCTION
Antibiotics are central to modern medical and veterinary prac-
tice. However, the effectiveness of existing antibiotics in both
medical and veterinary practice is under threat due to the rapid
rise of multiple drug resistance (MDR) (Gootz, 2010). The 2014
World Health Organisation (WHO) Global report on surveil-
lance of antimicrobial resistance makes this point clear—“A post-
antibiotic era—in which common infections and minor injuries
can kill—far from being an apocalyptic fantasy, is instead a very
real possibility for the 21st century.” (WHO, 2014). This possi-
bility was illustrated by antibiotic treatment failure in the 2011
epidemic in Germany in which enteroaggregative Escherichia coli
(EAHEC) O104:H4 caused a large outbreak of acute gastroen-
teritis and haemolytic uremic syndrome. EAHEC O104:H4 is an
example of a newly emerged pathogen that possesses novel com-
binations of acquired antibiotic resistance genes and virulence
factors. In the case of EAHEC O104:H4 an enteroaggregative
E. coli had acquired a stx2 shiga toxin gene, a characteristic feature
of enterohaemorrhagic E. coli genomes, via a bacteriophage (Grad
et al., 2013); a plasmid encoded CTX-M-15 gene (encoding the
antibiotic resistance factor, extended-spectrum beta-lactamase)
(Kunne et al., 2012); and a chromosomally-located complex
antibiotic resistance gene cluster, identified recently as the region
of divergence 1 (Frank et al., 2011; Januszkiewicz et al., 2011;
Ahmed et al., 2012; Radosavljevic et al., 2014). The extensively
antibiotic resistant E. coli clonal group ST131 is similarly a glob-
ally emergent pathogen with novel combinations of acquired
antibiotic resistance genes and virulence factors (Johnson et al.,
2010; Andersen et al., 2013; Banerjee and Johnson, 2013; Price
et al., 2013). Since 2011 there has been an increase in the num-
ber of reports describing hybrid E. coli genomes with a repertoire
of virulence and resistance genes, complicating precise pathotype
allocations (Bielaszewska et al., 2014; Prager et al., 2014; Toval
et al., 2014). However, it is difficult to determine whether the
increased number of reports equates to an increasing rate in the
emergence of these novel pathogens. It could simply mean that
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the increase in reports of novel pathogens is due to the growing
affordability of, and improvements in, whole genome sequenc-
ing technologies and molecular diagnostics that enable rapid and
accurate identification of emerging clones. However, increasing
emergence of novel strains is also likely- given the rapid rise in
human population, increased demands on food production and
the speed by which people and commodities move globally. Either
way, the suite of acquired resistance genes these novel pathogens
harbor clearly indicates the significant role played by Lateral Gene
Transfer (LGT) in shaping these genomes. Antibiotic resistance
genes have a propensity to cluster on mobile elements and con-
sequently a single LGT event can result in resistance to multiple
antibiotic classes (Toleman and Walsh, 2011). Notably also, these
trends are not restricted to Gram-negative pathogens but apply
additionally to Gram-positive genomes.
Antibiotic resistance existed in nature long before the dis-
covery of antibiotics 70 years ago. For example, genes encoding
resistance to β–lactam(s), tetracycline and glycopeptide antibi-
otics have been identified from ancient metagenomic samples of
30,000 years old Beringian permafrost sediments (D’Costa et al.,
2011). Controlling the spread of antibiotic resistance into diverse
pathogens, and particularly multidrug resistance, requires better
use of currently available antibiotics. It is insufficient to rely on
the development of new antibiotics or antibiotic adjuncts. More
effective use of existing antibiotics can be guided by molecular
surveillance of microbiomes.
It is now clear that multiple distinct antibiotic resistance genes
forming complex resistance gene loci (CRL) in MDR bacterial
genomes were likely acquired from disparate backgrounds. Many
MDR bacteria resulting in hospital infections carry genes encod-
ing resistance to antibiotics used frequently in food animal pro-
duction or resistance genes that have been acquired from aquatic
and soil environments (Szczepanowski et al., 2009; Popowska and
Krawczyk-Balska, 2013; Wibberg et al., 2013). This is not sur-
prising given that New Generation DNA sequencing has revealed
a vast repertoire of drug resistance determinants across diverse
microbiomes (Forsberg et al., 2012). It has, however, largely gone
unnoticed, because of the way in which molecular surveillance is
carried out differentially in hospital and veterinary microbiology
laboratories.
Screening procedures in hospital and veterinary laborato-
ries are quite justifiably influenced by the urgent need to
deal with an infectious threat; thus screening is carried out
on the basis of resistance to the set of antibiotics that are
of relevance to the respective unit. This means, for exam-
ple, that although mercury resistance transposons are one of
the largest carriers of multiple antibiotic resistance genes, vet-
erinary and clinical hospital microbiology laboratories do not
screen for mercury resistance. Focused surveillance approaches
have thus resulted in an underestimated view of the real prob-
lem of antibiotic resistance. In recognition of the importance
of fully understanding the problem of antibiotic resistance,
recent WHO and UK government reports have advocated a
“one health” approach that uses genomic surveillance of both
clinical and food animal isolates (Department of Heath and
Department for Environment Food and Rural Affairs, 2013;
WHO, 2014).
The disparate reservoirs of drug resistance determinants raises
important questions regarding the extent of transmissibility of the
pool of resistance genes and the range of bacteria that can acquire
them as a consequence of LGT. This review will give an overview
of antibiotic resistance gene reservoirs with particular focus on
the reservoirs in food animals, soil and water resulting from the
in-feed use of large quantities of sub-therapeutic doses of antibi-
otics as growth promoting agents in food animal husbandry. It
will highlight a significant gap in our knowledge regarding the
evolution of MDR in bacteria: the range of factors that trig-
ger the selection and mobilization of antibiotic-resistance genes
from environmental reservoirs into clinically-relevant organisms.
The complexity of the evolution of MDR in bacteria has myriad
implications, including, for example, for the choice of alterna-
tive food animal growth promoters other than in-feed antibi-
otics. This review will point to considerations relevant to this
choice.
AN ASSESSMENT OF THE REPERTOIRE OF RESISTANCE
GENES AND EFFECTS OF LOW DOSE ANTIBIOTICS
ANTIBIOTIC RESISTANCE GENES PRESENT IN DISPARATE RESERVOIRS
The antibiotic resistance genes that accumulate in the genomes
of bacteria are likely to have their origins in disparate reser-
voirs, a conclusion arrived at in several independent recent studies
on the evolution of MDR (Aminov, 2011; Amos et al., 2014;
Guerra et al., 2014; Hsu et al., 2014; Ojer-Usoz et al., 2014)
and evidenced also by the widespread dissemination of various
antibiotic resistance genes, including those encoding resistance
to extended spectrum β-lactamases in birds and other wildlife
species (Costa et al., 2008; Poeta et al., 2008; Simoes et al., 2010).
Aquatic and soil environments serve as sinks of older gener-
ation antibiotics including sulphonamides, tetracycline, amoxi-
cillin, ampicillin and trimethoprim (Boxall, 2004; Monteiro and
Boxall, 2009). The pools of antibiotic resistance genes available
for dissemination (known as the “resistome”) are enriched by
veterinary and agricultural practices, human sewage and hospi-
tal waste (Tennstedt et al., 2005; Galvin et al., 2010; Heuer et al.,
2011; Wellington et al., 2013; Hsu et al., 2014; Ojer-Usoz et al.,
2014).
Genes imparting antibiotic resistance move within bacterial
population(s) through LGT, independent of the linear “parent
to progeny” descent (Tennstedt et al., 2005; Stokes and Gillings,
2011). The genes can be from a wide “gene pool” and can
be transmitted between closely and distantly related species.
Examples in which LGT plays a significant role in the evolu-
tion of important multi-resistant pathogenic bacterial genomes
include, but are not restricted to, E. coli, Pseudomonas aerugi-
nosa, and Vibrio cholerae. Notably, these organisms can survive
in a range of environmental niches outside of the human body,
including fomites in hospitals, soil and aquatic environments.
Consequently, there exists diverse niche-adapted pools of micro-
bial communities that can provide opportunities for the sampling
and exchange of genetic information. Further, these opportu-
nities are likely to be influenced significantly by the ecology of
the niche-adapted microbial communities (Heuer et al., 2009,
2011; Galvin et al., 2010; Forsberg et al., 2012; Wellington et al.,
2013).
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FOOD ANIMALS, SOIL, AND WATER ARE IMPORTANT RESERVOIRS OF
ANTIBIOTIC RESISTANCE GENES
Reservoirs of antibiotic resistance genes that are increasingly
recognized as important are the gastrointestinal tract of food
animals, soil and water. This is because of the practice of using
sub-therapeutic doses of antibiotics to promote the growth of
food animals and the prophylactic use of antibiotics to prevent
disease in food animals. A significant percentage of adminis-
tered antibiotics are excreted in animal waste. Un-metabolized
antibiotics concentrate in animal waste ponds and, depend-
ing on their chemical composition, partition to different frac-
tions during the wastewater treatment processes (Kolpin et al.,
2002; Ghosh and Lapara, 2007; Watanabe et al., 2010; Cheng
et al., 2013; Li et al., 2013). Thus, antibiotics enter into envi-
ronments/ecosystems where bacteria pathogenic to humans may
also survive (Sarmah et al., 2006). The antibiotics used with
food animals for growth promotion and prophylactically include
a set of FDA (FDA, 2011) approved drugs, recognized by the
World Health Organization as important to treat human dis-
eases (Table 1) (Aarestrup et al., 2008). Further, the quantities
of antibiotics administered to food animals are very large. In
Australia, in the period 2005 to 2010, 98% of veterinary antibi-
otics sold were for use in food animals. Only approximately 43%
were sold for therapeutic or prophylactic purposes (no distinc-
tion could be drawn between “therapeutic” and “prophylactic”
uses as it was difficult for those surveyed to estimate the pro-
portions of products used for these purposes). This means that,
on average, for the surveyed period, sales of antimicrobials for
growth promotion averaged 35.3 tons; in 2005–2006 this was as
much as 47.2 tons (APVMA, 2014). Importantly, a large propor-
tion of the antimicrobials sold (almost 77%), were administered
in feed.
The practice of using sub-therapeutic doses of antibiotics to
promote growth of food animals became widespread following
initial studies of the effect of antibiotics on the growth of broiler
chickens (Elam et al., 1953; Jacobs et al., 1953; Izat et al., 1990;
Dibner and Richards, 2005; Castanon, 2007). Antibiotics are used
for growth promotion in doses lower than the recommended
minimum effective concentrations (MEC) for therapeutic pur-
poses but often at concentrations greater than the minimum
inhibitory concentration (MIC) of specific drug/microbe combi-
nations (Berrang et al., 2007; Alexander et al., 2008; Mirzaagha
et al., 2011; Holman and Chenier, 2013). The practice of using
antibiotics to promote growth of food animals has been banned
in several countries in Europe due to concerns over the devel-
opment and spread of antimicrobial resistance (Gilbert, 2011;
Maron et al., 2013).
IMPACT OF SUB-INHIBITORY CONCENTRATIONS OF ANTIBIOTICS ON
BACTERIA
The practice raises concerns over the development and spread
of antimicrobial resistance because sub-inhibitory concentrations
of antibiotics can enhance LGT (Barr et al., 1986; Torres et al.,
1991; Stevens et al., 1993); potentially act as signal transduction
molecules (Romero et al., 2011) in the transition from plank-
tonic to biofilm phase during the process of monomicrobial and
polymicrobial biofilm formations,(Bagge et al., 2004; Hoffman
et al., 2005); and globally modulate transcriptional activity. Sub-
therapeutic doses of β-lactam antibiotics has been shown to
enhance the rate of conjugative plasmid transfer (Barr et al., 1986)
and tetracycline has been implicated in driving the lateral transfer
of integrative conjugative elements (Torres et al., 1991; Stevens
et al., 1993). Conjugative transfer of single-stranded (ss) DNA
(the mechanism by which plasmids are transferred from donor
to recipient cells) induces the bacterial SOS response, which in
turn up-regulates expression of the integron integrase resulting
in the capture or exchange of resistance genes in Gram-negative
pathogens (Baharoglu et al., 2010). Integron-mediated gene shuf-
fling events in V. cholerae and E. coli were elevated significantly
(4.5-fold and 37-fold increase respectively) in response to antibi-
otic mediated stress, which in turn triggered the SOS response.
In addition, the study also reported up-regulation of the fre-
quency of integron-associated excision/shuffling of gene-cassettes
by 141-fold in V. cholera and 340-fold in E. coli, in a SOS response
mediated event. In a recent study, Zhu et al. (2013) demonstrated
the presence and relative abundance (an increase of 198-fold on
average) of 149 antibiotic resistance genes (of 244 included in the
study) conferring resistance to common in-feed and veterinary
antibiotics used in the swine farming industry in China within
36 metagenomic samples extracted from compost, manure and
soil. The study also provided evidence of abundance and enrich-
ment of common transposase genes [identified in the course of a
previous study (Aziz et al., 2010)] known to be frequently associ-
ated with antibiotic resistance genes. The conclusions of the study
included a statement of the likely roles played by the subset of
mobile elements in LGT of resistance genes in China (Zhu et al.,
2013).
In a pioneering transcriptome analyses study, Goh et al. pro-
vided direct evidence of the global modulation of transcriptional
activity of genes in Salmonella enterica serovar Typhimurium in
the presence of sub-inhibitory concentrations of antibiotics like
erythromycin (used as Antimicrobial growth promoters or AGP
for poultry and swine) and rifampicin (Goh et al., 2002). Further
gene-expression studies have now presented data on the influ-
ence of sub-inhibitory concentrations of antibiotics on the global
transcriptome of genes related to virulence (Subrt et al., 2011),
colonization (Bagge et al., 2004), motility, SOS stress response
(inducible DNA repair system) and biofilm formation (Kaplan
et al., 2012) for many important human pathogens (Davies et al.,
2006). Notably, stress responses have been shown to enhance bac-
terial adaptation through increased mutation and LGT (Aertsen
and Michiels, 2006; Baharoglu and Mazel, 2011).
LGT OF RESISTANCE GENES AND CO-SELECTION OF OTHER
RESISTANCE DETERMINANTS BY THE FORMATION OF
COMPLEX RESISTANCE LOCI
COMPLEX RESISTANCE GENE LOCI—MULTIPLE ANTIBIOTIC
RESISTANCE GENES AND MOBILE ELEMENTS
Genes that encode resistance to antibiotics often appear clustered
in the genomes of many bacteria, forming CRL (Parkhill et al.,
2001; Szczepanowski et al., 2005, 2009; Tennstedt et al., 2005; Roy
Chowdhury et al., 2009, 2011; Venturini et al., 2010; Toleman and
Walsh, 2011). In addition to antibiotic resistance genes, the CRL
possess diverse mobile genetic elements (predominantly insertion
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Table 1 | List of FDA approved Antibiotic classes and countries still using them in growth promotion, associated resistance genes and genetic
scaffolds that laterally co-mobilize them with other antibiotic and metal resistance genes.
Antibiotic classes:
specific examples
Countries still using
them
Associated resistance
genes
Association of genes with
mobile elements
Examples of
co-resistances
Penicillins: amoxicillin,
ampicillin
United States (Mathers
et al., 2011), Sudan
(Eltayb et al., 2012)
blaTEM genes blaTEM genes transposons
(Bailey et al., 2011) and
plasmids (Cain et al., 2010)
Lead, cadmium, zinc and
chromium (Yamina et al.,
2012)
mer genes; mercury
(Mcintosh et al., 2008)
Glycopeptides: avoparcin,
vancomycin
Mexico (Maron et al.,
2013)
van genes van genes [transposons
(Jensen et al., 1999; Leavis
et al., 2003) and plasmids
(Zhu et al., 2010, 2013)]
tcrB gene; copper (Hasman
and Aarestrup, 2002)
Macrolides:
erythromycin, tylosin,
tilmicosin, kitasamycin,
oleandomycin
United States (Kim et al.,
2012), Australia (Hughes
and Heritage, 2004),
Mexico (Maron et al.,
2013)
erm gene cluster
CmeABC multi-drug
efflux pump (Lin et al.,
2007)
erm gene cluster
[transposons (Li et al., 2011;
Ramos et al., 2012) and
plasmids (Wendlandt et al.,
2014)]
erm genes; tetracycline and
streptogramin (Ramos
et al., 2012)
tcrB gene; copper (Hasman
and Aarestrup, 2002)
Streptogramins:
virginiamycin,
quinupristin-dalfopristin
United States (Kieke
et al., 2006), Australia
(Hughes and Heritage,
2004), Mexico (Maron
et al., 2013)
vatD and vatE
erm gene cluster
satA (Hammerum et al.,
1998)
varS (Lee et al., 1999;
Kieke et al., 2006)
vatD and vatE plasmids
(Allignet and El Solh, 1999)
erm gene cluster
[transposons (Li et al., 2011;
Ramos et al., 2012) and
plasmids (Wendlandt et al.,
2014)]
erm genes; macrolide and
tetracycline (Ramos et al.,
2012)
Sulfonamides:
sulfisoxazole,
sulfadimethoxine,
sulfamethazine
Sudan (Eltayb et al.,
2012), United States
(APUA, 2010)
sul genes sul genes [transposons
(Cain et al., 2010), plasmids
(Wu et al., 2010) and clinical
class 1 integrons (Stokes
and Hall, 1989; Wu et al.,
2010)]
czcA gene; zinc, cadmium
and cobalt (Stokes et al.,
2006; Gillings et al., 2008)
mer genes; mercury
(Mcintosh et al., 2008)
Tetracyclines:
chlortetracycline,
oxytetracycline,
doxycycline
United States (Cox and
Popken, 2010; Mathers
et al., 2011), China (Wu
et al., 2010), Sudan
(Eltayb et al., 2012)
tet genes tet genes [transposons
(Schmitt et al., 1979; Ramos
et al., 2012) and plasmids
(Han et al., 2012; Wendlandt
et al., 2014)]
erm genes; macrolide and
streptogramin (Ramos
et al., 2012)
mer genes; mercury
(Mcintosh et al., 2008)
Polypeptides: bacitracin Mexico (Maron et al.,
2013)
rgpA-F, mbrA-D (Tsuda
et al., 2002)
bcr
bcr [plasmids (Tremblay and
Archambault, 2013)]
Amphenicols:
chloramphenicol
China (Li et al., 2013) cmlA
floR
fexA and fexB
cfr
cat gene
cat gene [transposons,
(Cain and Hall, 2012),
plasmids (Mcintosh et al.,
2008) and integrons (Bunny
et al., 1995)]
mer genes; mercury
(Mcintosh et al., 2008)
elements, transposons and integrons) clustered either in inde-
pendently replicating units, like plasmids, or in genomic islands
within the bacterial chromosome. Mobile elements facilitate dis-
semination of CRL within bacteria. Acquisition of a CRL by any
bacterium thus provides a survival mechanism to it when exposed
to an entire range of antimicrobial agents. CRL evolve rapidly,
especially within Gram-negative bacteria, and they generally con-
tain hotspots where additional resistance genes can accumulate.
Lateral transfer of genes within the gastrointestinal tracts of
humans and food animals, and in reservoirs where environmental
bacteria mix with bacteria derived from anthropogenic activities
(sewage, hospital waste and food production animal waste) signif-
icantly contribute to these evolutionary processes (Forsberg et al.,
2012). Although mobile genetic elements are a key component
of CRL, there is currently limited understanding of the different
types of mobile genetic element(s) that may contribute to: (1)
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the spread of CRL; (2) the diversity of resistance gene reservoirs
that can be utilized by the mobile elements to form CRL and (3)
the mechanisms by which resistance genes assemble on laterally
mobile segments of DNA.
INTEGRONS ARE MOBILE ELEMENTS ASSOCIATED WITH CRL AND
FOUND IN DIVERSE BACTERIA
Integrons represent a group of genetic elements that are most
commonly found in association with CRL and have been impli-
cated in the rapid evolution of multi-drug resistance within
Gram-negative pathogens (Martinez et al., 2013). Based on the
amino acid sequences of the integrase/recombinase gene intI
(Recchia and Hall, 1995) integrons can be differentiated into
several classes, all of which are found in diverse microbial com-
munities (Marquez et al., 2008). Classes 1–3 are most frequently
associated with the dissemination of MDR within Gram-negative
bacteria, although recently class 1 integrons have also been iden-
tified in Gram-positive bacteria (Nandi et al., 2004; Shi et al.,
2006; Xu et al., 2010, 2011). Exchange of resistance genes within
different classes of integrons (from diverse bacteria) has been
reported in a range of microbial communities (Labbate et al.,
2008; Roy Chowdhury et al., 2009). The role of class 1 integrons
in the evolution of MDR within hospitals is most comprehen-
sively documented (Djordjevic et al., 2013; Martinez et al., 2013),
although they are also frequently reported from environmental
bacteria (Holmes et al., 2003; Stokes et al., 2006). Functionally, a
class 1 integron is a two-component site-specific gene recombina-
tion system. Structurally a class 1 integron comprises an integrase
gene and a tandem array of a variable number of independently
acquired mobile genes. The independently mobile units of a class
1 integron are called “gene cassettes” and are made up of a
promoter-less open reading frame and a recombination site. Class
1 integrons most frequently contain multiple gene cassettes, in
structures called “cassette arrays,” that can be expressed from a
single promoter (Stokes and Hall, 1989) in an operon-like man-
ner. Exchange/insertion/deletion of gene cassettes (by the process
of site-specific recombination) and expression of these genes
enables their host to exhibit multiple “acquired” resistance phe-
notypes simultaneously and relatively quickly (on an evolutionary
time scale).
A key component of the integron integrase is the integrase
promoter (Pint) (Stokes and Hall, 1989). The regulation and
expression of the integron integrase is an adaptive response to
stress, including that induced by sub-lethal dosages of antibiotics
in any environment (Guerin et al., 2009). Hocquet et al. described
a metronidazole induced cassette rearrangement in a class 1 inte-
gron that resulted in the formation of a fused gcuF1-blaOXA−28
cassette, which subsequently led to the expression of the fused
β-lactamase gene and ceftazidime resistance in a P. aeruginosa iso-
late (Hocquet et al., 2012). A LexA binding site is found conserved
across the vast majority of integrase genes, indicating the likeli-
hood of bacterial SOS mediated up-regulation of most integron
integrases (Guerin et al., 2009). Importance of the LexA bind-
ing site has been experimentally demonstrated in Vibrio spp. and
E. coli (Guerin et al., 2009).
Class 1 integrons isolated from clinical samples, are predomi-
nantly linked to the Tn3 family of transposons, particularly Tn21
(Liebert et al., 1999) and Tn1696 (Partridge et al., 2001), which in
turn harbor clustered mercury resistance genes. Class 1 integrons
also have a propensity of targeting resolution sites of plasmids or
other transposons on plasmid backbones (Kholodii et al., 1995;
Minakhina et al., 1999). Thus, in addition to carrying genes con-
ferring MDR, class 1 integrons also associate with other mobile
elements, which independently carry other combinations of resis-
tance genes to form laterally mobile resistance scaffolds (Parkhill
et al., 2001; Szczepanowski et al., 2005; Tennstedt et al., 2005;
Wibberg et al., 2013).
CO-SELECTION AND TRANSFER OF ANTIBIOTIC AND OTHER
RESISTANCE GENES—THE ROLE OF PLASMIDS
Plasmids play a central role in the lateral transfer of CRL
within both closely and distantly related Gram-negative bacteria.
Identical CRL are frequently seen piggy-backing on different plas-
mid backbones isolated from different hosts, supporting the role
of plasmids in the transfer of drug resistance loci. Such events are
best exemplified by plasmids carrying identical complex Tn21-
associated MDR regions (Tennstedt et al., 2005; Szczepanowski
et al., 2009; Venturini et al., 2013). Recent examples of such
plasmids with complex resistance loci isolated from waste water
treatment plants include IncF plasmids pRSB225 (Wibberg et al.,
2013) and pRSB107 (Szczepanowski et al., 2005) and the series of
IncP-1 plasmids reviewed recently by Popowska and Krawczyk-
Balska (2013). Although isolated from waste water treatment
plants, all these plasmids and a set of 140 plasmids described
in a recent plasmid metagenomic study by Szczepanowski et al.
clearly indicate that the resistance gene pool within the CRL on
the plasmids are an admixture of genes that have originated from
different bacterial communities (Szczepanowski et al., 2009).
The co-selection of antibiotic resistance genes by plasmids
containing transposons with genes encoding resistance to heavy
metals (such as mercury, cadmium, copper, and zinc) adds to the
complexity of the evolution of laterally mobile clustered resistance
regions (Seiler and Berendonk, 2012). This is particularly so when
considering food animals and their environments (e.g. soil and
water) as reservoirs of antibiotic resistance determinants; met-
als like copper and zinc, all of which are often used in animal
husbandry for growth promotion (Jacob et al., 2010). This phe-
nomenon of co-selection of resistance genes on plasmids increase
the opportunity for microbial populations, that proliferate both
in the gastrointestinal tracts of mammals and that survive in soil
and aquatic environments, to act as major conduits in the flow of
resistance genes between these reservoirs.
Plasmids pO26-CRL, pO26-CRL125 (isolated from an entero-
hemorrhagic E. coli specimen from a human with bloody diar-
rhea) and pO111-CRL115 (isolated from a bovine source in
Australia) are examples of plasmids with identical clustered
antibiotic and metal resistance genes that have been identified
recently by our group (Venturini et al., 2010, 2013). The CRL in
these plasmids are characterized by a Tn21-associated class 1 inte-
gron truncated by the presence of a composite IS26 transposon,
Tn6026 (Cain et al., 2010). Composite transposons, another type
of mobile element frequently associated with CRL, are defined as
segments of DNA bounded by two related insertion elements (or
IS elements). DNA segments between two IS elements mobilize
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intervening genes as a single unit. Composite transposons there-
fore have the ability to capture and mobilize random pieces of
DNA from many diverse genetic locations, promoting genetic
diversity. In relation to evolution ofMDR, composite transposons
can allow the movement of clustered antibiotic resistance genes
from one bacterial genome to another through the capture of such
genes into bacteriophages or conjugative plasmids that can then
move readily between bacteria. Tn6026 is an example of a com-
posite transposon, which consists of two independently mobile
composite transposons, Tn6029 and Tn4352 (Cain et al., 2010;
Martinez et al., 2013). Collectively the CRL (described above as
Tn6026) confers resistance to ampicillin, kanamycin, neomycin,
streptomycin, sulfathiazole and trimethoprim. Similar structures,
consisting of Tn6029 derivatives and essentially consisting of the
same group of resistance genes have been described in plas-
mids such as pASL01a, which circulates in commensal E. coli in
the human population in West Africa (Labar et al., 2012), and
pHCM1, from a human E. coli isolate from a patient living in
the Mekong Delta in Vietnam (Parkhill et al., 2001). However, the
group of plasmids described by us, pO26-CRL, pO26-CRL125,and
pO111-CRL115, is a clear example of plasmid mediated LGT of
CRL between animal and human reservoirs in recent times.
IncA/C plasmids can provide conjugative functions in trans
to mobilize integrative elements such as Salmonella Genomic
Island 1 (SGI1) (Douard et al., 2010). SGI1 harbors genes encod-
ing resistance to seven antibiotics (ampicillin, chlorampheni-
col, florphenicol, streptomycin, spectinomycin, tetracycline and
sulphonamides). The resistance genes are clustered on a 13-kb
class 1 integron, In104, embedded within a 42.4-kb genomic
island embedded between thdF and yidY genes (Boyd et al., 2001;
Levings et al., 2005). SGI1 is widely dispersed among a range of
S. enterica serovars and Proteus mirabilus (Levings et al., 2005,
2006, 2007; Djordjevic et al., 2009; Le Hello et al., 2011, 2012),
clearly indicating the lateral transfer of the element within bacte-
ria occupying disparate hosts. A structurally similar CRL is also
found in SGI2 described initially from a S. enterica serovar Emek
strain in Australia. Major differences between SGI1 and SGI2 are
in the physical location of the class 1 integron on the genomic
backbone and in the different set of resistance gene cassettes
seen associated with the integron found in SGI2. The integron,
known as InEmek is a close variant of In104 seen in SGI1 (Levings
et al., 2008) and the entire island shows characteristic features that
mobilize SGI1.
NOVEL STRATEGIES AND ALTERNATIVES TO IN-FEED
ANTIBIOTICS
The growing knowledge of how LGT drives the evolution of MDR
in bacteria and the importance of disparate pools of resistance
genes has implications for the use of antibiotics as growth pro-
moters in food animals, suggesting a need for novel alternatives
to in-feed antibiotics. These alternatives should, in development,
pay regard to: (1) the potential dangers for increasing evolu-
tion of MDR in bacteria when altering the microbial ecology
of the gut (as most currently used growth promoters appear
to do) (Dibner and Richards, 2005); and (2) consideration of
questioning the effectiveness of in-feed antibiotics as growth pro-
moters (Bengtsson and Wierup, 2006). Kim et al. conducted a
comparative fecal microbiome study on two separate porcine
populations, one of which was given a diet supplemented with
the macrolide tylosin (a commonly used AGP), while the other
group represented the control (Kim et al., 2012), i.e., did not
receive tylosin, and reported the flux of microbial communi-
ties within them over a period of time. The fecal microbiome
of each group was determined, which initially showed a promi-
nent shift in microbial content for all species detected, proving
that AGPs such as tylosin alter the native intestinal flora, result-
ing in less competition for nutrients and ultimately leading to
the desired growth promoting effects. However, this study also
showed that fecal microbiomes from the control group eventually
became indistinguishable to those of the tylosin-fed group, offer-
ing an air of redundancy to the use of AGPs with respect to health
and welfare of the animals. An important aspect of this study was
that it was conducted in two separate farm settings, instead of
the common choice among similar studies of an infectious dis-
ease isolation facility, making the results more comparable and
applicable to the pig-farming industry.
Any alternative strategy for growth promotion in food animals
over antibiotics needs to consider the growing understanding of
the triggers for lateral transfer of CRL and the warning provided
by evidenced movement of CRL between disparate bacterial hosts
as consequences of administration of sub-inhibitory dosages of
antibiotics. Controlling the spread of antibiotic resistance is not
so simple as banning non-therapeutic in-feed antibiotics and
using anything else as a growth promoter. This is clearly demon-
strated by the problems associated with the use of heavy metals
as growth promoters in relation to lateral co-transfer of associ-
ated antibiotic resistance genes. Further, an ideal alternative to
in-feed AGPs should ideally meet the definition for feed addi-
tives set by The Official Journal of the European Union (Council
Directive 89/107/EEC). The derivative clearly states “any sub-
stance not normally consumed as a food in itself and not normally
used as a characteristic ingredient of food whether or not it has
nutritive value, the intentional addition of which to food for
a technological purpose in the manufacture, processing, prepa-
ration, treatment, packaging, transport or storage of such food
results, or may be reasonably expected to result, in it or its by-
products becoming directly or indirectly a component of such
foods” (Council Directive 89/107/EEC). With respect to farming
and animal husbandry, the novel additive should ideally improve
the characteristics of the feed itself as well as dairy and deli prod-
ucts derived from the receiving animal. They should increase
the efficiency of animal performance and welfare via the gastro-
intestinal microbiota and satisfy the nutritional requirements of
the animal. Additionally, the additive should not adversely impact
the environment or human/animal health. From this perspec-
tive, it is questionable whether the environmental accumulation
of minerals, such as zinc oxide (often used as an alternative to
in-feed antibiotics), is worth the positive effects of growth pro-
motion and prophylaxis for conditions such as E. coli mediated
post-weaning diarrhea in piglets (Pluske, 2013).
A diverse range of options, which could possibly minimize or
ideally alleviate forces that drive lateral transfer of resistance genes
within the gut microbiome, have been proposed as alternatives
of AGPs including, but not limited to, enzymes, nutraceuticals,
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amino acids and plant extracts (Askbrant et al., 1994; Hill et al.,
2000; Barrerra et al., 2004; Schone et al., 2006; Muhl and Liebert,
2007; Nortey et al., 2007; Ragland et al., 2007; Jacela et al., 2008).
These have shown varying outcomes in the promotion of growth
in different animals (Supplementary Table 1). Therefore, it is
most likely that a combination of these substitutes may serve
as a better alternative that could account for all benefits and
functions of in-feed antibiotics than any individual substance
tested for the purpose. This idea was investigated within poul-
try by Ohimain and Ofongo (2012). They reported the effects of
using a mixture of probiotics, prebiotics and enzymes as a dietary
supplement in poultry. The probiotics and prebiotics had a syner-
gistic effect, while the enzymes enhanced digestibility of the feed,
increasing the amount of nutrients available for absorption. The
combined effect improved digestive health in the chickens and
consequently protected them against common microbial diseases
such as enteritis (Ohimain and Ofongo, 2012). Probiotics, on the
other hand, have been documented to prevent inflammation in
the gut, reduce the incidence of meat contamination and pro-
mote growth, proving a propitious alternative to AGPs (Patterson
and Burkholder, 2003). Use of non-pathogenic E. coli probiotics
in combination with a low-protein diet in a porcine model was
shown to reduce mucosal populations of pathogenic E. coli K88,
subsequently decreasing the incidence of post-weaning diarrhea.
These effects were attributed to the production of colicin by some
bacteria introduced via the probiotic product (Bhandari et al.,
2010) as well as the unavailability of protein normally utilized
by the pathogenic E. coli for energy production. A similar study
used a low-protein diet with the addition of essential amino acids
(Heo et al., 2008) and described similar results. Further develop-
ment of such strategies would assist in controlling the spread of
antibiotic resistance, as well as reduce appearance of medical con-
ditions such as post-weaning diarrhea in piglets, a major cause of
economic hardship in swine production (Pluske, 2013).
One of the main problems of developing alternatives to in-
feed AGPs is that the mechanism of action of AGPs is still largely
unknown. No general consensus for the mechanism of action
of AGP exists, however, several hypotheses have been proposed
and evaluated, including: (1) reduction in total bacterial load as
a consequence of administrated antibiotics; (2) reduction in the
number of pathogenic bacteria resulting in better animal health;
and (3) manipulation of the gut microflora in a way that natu-
ral immune and metabolic responses balance resulting in healthy
animals (Dibner and Richards, 2005). Like existing alternatives
to in-feed antibiotics, proposed novel alternatives tend to have a
mechanism of action which directly affects the composition and
quantity of bacteria within the animal’s gastrointestinal system,
suggesting a link between commensal bacteria and growth per-
formance. The effects of AGP on porcine and broiler chicken
intestinal microbiomes have been reported (Collier et al., 2003;
Dumonceaux et al., 2006), as well as the positive effects of the
change in composition of these microbiomes in response to in-
feed antibiotics. These studies mirror those reported by Kim et al.,
as well as provide evidence to the hypothesis of this mode of
action. Collier et al. and Dumonceaux et al. also identified bac-
terial composition within specific regions of the gastro-intestinal
tract, and in doing so created a link between the alterations of
bacterial communities most affected by the antibiotics and areas
of the intestine most involved in nutrient absorption.
Several reports have linked the use of AGPs (Feighner and
Dashkevicz, 1987; Knarreborg et al., 2004; Guban et al., 2006) to
the reduction in activity of intestinal bile salt hydrolase (BSH).
This enzyme directly affects lipid metabolism within the host
and is produced by bacteria that occur naturally in the gut. The
observation led to a new avenue of research into factors that tar-
get bacterial products rather than the bacteria themselves. Based
strictly on an in vitro study, Wang et al. (2012) proposed the use
of bile salt inhibitors as growth performance enhancers (Wang
et al., 2012). Whether BSH inhibitors would adequately function
in an in vivo model is still unclear. Zinc and copper, (com-
mon feed additives for increasing feed efficiency and promoting
growth), were shown to cause inhibition of BSH and improve
lipid metabolism. There are likely to be a number of non-metal
BSH inhibitors, so this research path, with further studies into
non-environmentally contaminating compounds, is a promising
replacement for in-feed antibiotics.
CONCLUDING REMARKS
Laterally acquired DNA is a major driver of genome plasticity
and poses problems for the reliable identification and classi-
fication of emerging pathogens, a necessary pre-requisite for
using molecular surveillance as a tool for guiding effective use of
existing antibiotics. For many years microbiological and molec-
ular epidemiological surveillance studies within the veterinary
and hospital environments have focused on characterizing their
own targeted bacteria and antibiotic resistance profiles rather
than taking a larger “one health” view of microbial resistance.
Consequently, the molecular structures and CRL scaffolds that
laterally mobilize drug resistance determinants between com-
munities have been relatively under-studied. The sequences of
plasmids; transposons; integrons insertion elements; genomic
islands and other mobile elements need to be comprehended
fully to unravel the real complexity of the problem. MDR evolves
where antibiotics are used heavily, irrespective of whether it is
in human clinical environments, food animal production set-
tings, aquaculture or horticulture. Genetic phenomena like LGT
inextricably links genes from disparate reservoirs to form CRL.
These concepts, although increasingly recognized by the scientific
community are not clearly communicated to the general public.
Raised awareness of the complexity and far reaching implications
associated with antibiotic resistance and a “one health” approach
are critical for a global, sustained effort needed to alleviate the
serious threat posed by multiple antibiotic resistant infectious
agents. Molecular surveillance strategies embracing a “one health”
approach are expected to provide a better understanding of how
the genes flow throughmicrobial communities and therefore pro-
vide a platform to more accurately predict and contain imminent
threats posed by MDR bacteria.
One of the major challenges going forward is to stem the use of
antibiotics and seek effective alternatives in our food production
industries because antibiotic resistance gene reservoirs associated
with food animals contribute to the evolution of MDR bacte-
ria. One starting point for this is the development of alternatives
to in-feed AGPs. This development should include studies that
www.frontiersin.org August 2014 | Volume 5 | Article 394 | 162
Roy Chowdhury et al. Subtle interplay within the bacterial resistome
incorporate a full range of animals within the farming industry,
as intestinal microbiomes are likely to differ between species. It
should further include new approaches to gauge the effects of
probiotics and alternate in-feed growth promoters.
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